nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,days_since_update
NCT04381052,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-06,NA,NA,2021-09-17,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-23,Actual,"May 18, 2020",Actual,2020-05-18,September 2021,2021-09-30,"March 12, 2021",Actual,2021-03-12,"February 3, 2021",Actual,2021-02-03,NA,Interventional,NA,,Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-Controlled Safety and Dose-Finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Completed,NA,Phase 2,1,Actual,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Coded data will be shared with New York University (NYU) Langone for the purpose of statistical analysis and scientific reporting.,2021-10-17T08:25:34Z,2021-10-17T08:25:34Z,43
NCT04381000,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2020-06-30,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,"June 10, 2020",Actual,2020-06-10,"May 29, 2020",Actual,2020-05-29,NA,Interventional,NA,,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,The Impact of Quarantine and the Effectiveness of Telerehabilitation in Patients With Chronic Pain During COVID-19 Pandemic.,Completed,NA,N/A,170,Actual,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:25:34Z,2021-10-17T08:25:34Z,487
NCT04380961,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-07-13,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-14,Actual,"April 24, 2020",Actual,2020-04-24,July 2021,2021-07-31,"June 24, 2021",Actual,2021-06-24,"April 9, 2021",Actual,2021-04-09,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease",Completed,NA,Phase 2,212,Actual,"Janssen Pharmaceutica N.V., Belgium",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-10-17T08:25:35Z,2021-10-17T08:25:35Z,109
NCT04380909,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-08-23,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"May 6, 2020",Actual,2020-05-06,August 2021,2021-08-31,"July 29, 2021",Actual,2021-07-29,"July 29, 2021",Actual,2021-07-29,NA,Interventional,ROCO,,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,Randomized Controlled Trial (RCT) to Evaluate the Efficacy of an Internet-based Self-help Program for People With Psychological Distress Due to Covid-19,Completed,NA,N/A,107,Actual,University of Bern,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:35Z,2021-10-17T08:25:35Z,68
NCT04380688,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,2021-08-19,NA,2021-09-08,2020-05-07,2020-05-08,Actual,2021-09-08,2021-09-13,Actual,NA,NA,NA,2021-09-08,2021-09-13,Actual,"June 13, 2020",Actual,2020-06-13,September 2021,2021-09-30,"November 16, 2020",Actual,2020-11-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,CALAVI US,,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,62,Actual,AstraZeneca,"Improvements in BSC (use of corticosteroids and antivirals) have led to a substantial reduction in mortality and morbidity in patients hospitalized with COVID-19, which, in turn, minimizes the impact that additional treatment regimens can have on patient prognosis and recovery. In addition, variability in patient population and the performance of BSC across the globe poses challenges to demonstrate benefit.",2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",2021-10-17T08:25:37Z,2021-10-17T08:25:37Z,52
NCT04380519,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-06,NA,NA,2020-09-28,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"April 23, 2020",Actual,2020-04-23,September 2020,2020-09-30,"July 24, 2020",Actual,2020-07-24,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),"An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)",Completed,NA,Phase 2/Phase 3,372,Actual,R-Pharm,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:25:40Z,2021-10-17T08:25:40Z,397
NCT04379661,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-05,NA,NA,2021-01-07,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"May 7, 2020",Actual,2020-05-07,January 2021,2021-01-31,"August 31, 2020",Actual,2020-08-31,"July 7, 2020",Actual,2020-07-07,NA,Interventional,NA,,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,SUNLIGHT Study: Online Support Groups for Multiple Sclerosis (MS) to Address COVID-19,Completed,NA,N/A,32,Actual,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:47Z,2021-10-17T08:25:47Z,296
NCT04379531,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-30,NA,NA,2020-06-10,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"May 22, 2020",Actual,2020-05-22,"May 22, 2020",Actual,2020-05-22,NA,Interventional,LDCTiP,,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Low-dose Computed Tomography in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,NA,N/A,230,Actual,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:51Z,2021-10-17T08:25:51Z,507
NCT04379271,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-01,NA,NA,2021-04-23,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-26,Actual,"June 11, 2020",Actual,2020-06-11,April 2021,2021-04-30,"February 23, 2021",Actual,2021-02-23,"January 12, 2021",Actual,2021-01-12,NA,Interventional,NA,,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)","A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19",Completed,NA,Phase 2/Phase 3,223,Actual,Immunic AG,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:25:53Z,2021-10-17T08:25:53Z,190
NCT04379037,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-05,NA,NA,2021-06-01,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-04,Actual,"June 27, 2020",Actual,2020-06-27,June 2021,2021-06-30,"November 1, 2020",Actual,2020-11-01,"September 1, 2020",Actual,2020-09-01,NA,Interventional,NA,,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Completed,NA,N/A,50,Actual,Nemechek Technologies,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:55Z,2021-10-17T08:25:55Z,151
NCT04378803,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-04,NA,NA,2020-08-14,2020-05-04,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-17,Actual,"May 13, 2020",Actual,2020-05-13,August 2020,2020-08-31,"August 4, 2020",Actual,2020-08-04,"August 4, 2020",Actual,2020-08-04,NA,Interventional,NA,,Mindfulness Training for Seniors,Mindfulness Training for Older Adults During the COVID-19 Pandemic,Completed,NA,N/A,53,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:57Z,2021-10-17T08:25:57Z,442
NCT04378712,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-29,NA,NA,2020-05-13,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"January 21, 2020",Actual,2020-01-21,May 2020,2020-05-31,"March 23, 2020",Actual,2020-03-23,"March 23, 2020",Actual,2020-03-23,NA,Interventional,NA,,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),"Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial",Completed,NA,N/A,90,Actual,Guangzhou Institute of Respiratory Disease,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:25:58Z,2021-10-17T08:25:58Z,535
NCT04377789,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-01,NA,NA,2021-02-17,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"March 20, 2020",Actual,2020-03-20,February 2021,2021-02-28,"August 31, 2020",Actual,2020-08-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19,Completed,NA,N/A,447,Actual,Kanuni Sultan Suleyman Training and Research Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:26:06Z,2021-10-17T08:26:06Z,255
NCT04377711,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-05,NA,NA,2021-08-10,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-16,Actual,"June 8, 2020",Actual,2020-06-08,August 2021,2021-08-31,"January 5, 2021",Actual,2021-01-05,"January 5, 2021",Actual,2021-01-05,NA,Interventional,NA,,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection",Completed,NA,Phase 3,400,Actual,Covis Pharma S.Ã .r.l.,,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:26:06Z,2021-10-17T08:26:06Z,81
NCT04376814,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-03,NA,NA,2020-06-12,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-12,2020-06-16,Actual,"March 29, 2020",Actual,2020-03-29,May 2020,2020-05-31,"May 25, 2020",Actual,2020-05-25,"April 5, 2020",Actual,2020-04-05,NA,Interventional,NA,,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,"The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study",Completed,NA,N/A,40,Actual,Baqiyatallah Medical Sciences University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:26:13Z,2021-10-17T08:26:13Z,505
NCT04376684,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-04,NA,NA,2021-09-10,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-14,Actual,"May 28, 2020",Actual,2020-05-28,September 2021,2021-09-30,"August 16, 2021",Actual,2021-08-16,"July 15, 2021",Actual,2021-07-15,NA,Interventional,OSCAR,,Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease,"A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease",Completed,NA,Phase 2,1156,Actual,GlaxoSmithKline,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2021-10-17T08:26:15Z,2021-10-17T08:26:15Z,50
NCT04375397,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-04,NA,NA,2021-07-07,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"June 6, 2020",Actual,2020-06-06,July 2021,2021-07-31,"June 8, 2021",Actual,2021-06-08,"May 10, 2021",Actual,2021-05-10,NA,Interventional,iNSPIRE,,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE),Completed,NA,Phase 2,46,Actual,AbbVie,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.",Requests for access to individual participant data from ibrutinib clinical studies conducted by AbbVie can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu,http://yoda.yale.edu/,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2021-10-17T08:26:26Z,2021-10-17T08:26:26Z,115
NCT04375098,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-03,NA,NA,2020-09-12,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-12,2020-09-16,Actual,"May 4, 2020",Actual,2020-05-04,September 2020,2020-09-30,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial,Completed,NA,Phase 2,58,Actual,Pontificia Universidad Catolica de Chile,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:26:29Z,2021-10-17T08:26:29Z,413
NCT04374526,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-02,NA,NA,2021-05-27,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-05-28,Actual,"May 27, 2020",Actual,2020-05-27,May 2020,2020-05-31,"May 26, 2021",Actual,2021-05-26,"May 26, 2021",Actual,2021-05-26,NA,Interventional,LIFESAVER,,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Early transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression.,Completed,NA,Phase 2/Phase 3,29,Actual,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:26:34Z,2021-10-17T08:26:34Z,156
NCT04374032,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-30,NA,NA,2020-12-23,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"May 1, 2020",Actual,2020-05-01,December 2020,2020-12-31,"November 3, 2020",Actual,2020-11-03,"October 7, 2020",Actual,2020-10-07,NA,Interventional,NA,,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,"An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTENÂ® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection",Completed,NA,Phase 2/Phase 3,120,Actual,Bosnalijek D.D,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:26:38Z,2021-10-17T08:26:38Z,311
NCT04374149,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-20,NA,NA,2021-03-24,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"April 30, 2020",Actual,2020-04-30,March 2021,2021-03-31,"December 1, 2020",Actual,2020-12-01,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,"Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)",Completed,NA,Phase 2,20,Actual,Prisma Health-Upstate,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:26:37Z,2021-10-17T08:26:37Z,220
NCT04373291,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-01,NA,NA,2021-10-07,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-08,Actual,"May 18, 2020",Actual,2020-05-18,October 2021,2021-10-31,"October 1, 2021",Actual,2021-10-01,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial,Completed,NA,Phase 3,1293,Actual,Bandim Health Project,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,When follow-up has been completed and the dataset have been closed,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,2021-10-17T08:26:45Z,2021-10-17T08:26:45Z,23
NCT04371367,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-29,NA,NA,2021-05-26,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"April 27, 2020",Actual,2020-04-27,May 2021,2021-05-31,"March 30, 2021",Actual,2021-03-30,"March 30, 2021",Actual,2021-03-30,NA,Interventional,FORCE,,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )","A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia",Completed,NA,Phase 2,208,Actual,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:03Z,2021-10-17T08:27:03Z,157
NCT04371029,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-28,NA,NA,2021-06-04,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"April 28, 2020",Actual,2020-04-28,June 2021,2021-06-30,"December 9, 2020",Actual,2020-12-09,"September 9, 2020",Actual,2020-09-09,NA,Interventional,COVISLEEP,,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Completed,NA,N/A,17,Actual,"University Hospital, Bordeaux",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:05Z,2021-10-17T08:27:05Z,148
NCT04370262,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-27,NA,NA,2020-12-10,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-10,2020-12-11,Actual,"April 7, 2020",Actual,2020-04-07,December 2020,2020-12-31,"September 7, 2020",Actual,2020-09-07,"September 7, 2020",Actual,2020-09-07,NA,Interventional,NA,,Multi-site Adaptive Trials for COVID-19,"A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,233,Actual,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:27:12Z,2021-10-17T08:27:12Z,324
NCT04369378,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,NA,NA,2021-08-27,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"August 19, 2020",Actual,2020-08-19,August 2021,2021-08-31,"August 26, 2021",Actual,2021-08-26,"April 28, 2021",Actual,2021-04-28,NA,Interventional,NA,,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Completed,NA,N/A,103,Actual,Lake Erie College of Osteopathic Medicine,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Upon publication of findings,Upon written request to corresponding author on publication,NA,Yes,"De-identified participant data will be reported as individual data points, as well as means +/- SD or medians with quartiles.",2021-10-17T08:27:20Z,2021-10-17T08:27:20Z,64
NCT04367662,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-16,NA,NA,2020-06-05,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 9, 2020",Actual,2020-04-09,June 2020,2020-06-30,"May 14, 2020",Actual,2020-05-14,"May 14, 2020",Actual,2020-05-14,NA,Interventional,COVID'HEMOS,,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Completed,NA,N/A,99,Actual,"University Hospital, Rouen",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:35Z,2021-10-17T08:27:35Z,512
NCT04366960,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,NA,NA,2021-06-07,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-08,Actual,"May 14, 2020",Actual,2020-05-14,June 2021,2021-06-30,"May 25, 2021",Actual,2021-05-25,"May 25, 2021",Actual,2021-05-25,NA,Interventional,X-Covid 19,,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients: Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial,Completed,NA,Phase 3,189,Actual,Niguarda Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:27:41Z,2021-10-17T08:27:41Z,145
NCT04366947,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-23,NA,NA,2020-12-17,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-19,Actual,"April 14, 2020",Actual,2020-04-14,December 2020,2020-12-31,"October 30, 2020",Actual,2020-10-30,"September 20, 2020",Actual,2020-09-20,NA,Interventional,NA,,Intravascular Access in Suspected/Confirmed COVID-19 Patient,Comparison of Intraosseous Versus Intravenous Access in Suspected/Confirmed COVID-19 Patient in Prehospital Setting,Completed,NA,N/A,60,Actual,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,the investigators will decide after study finishing,2021-10-17T08:27:41Z,2021-10-17T08:27:41Z,317
NCT04366297,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-23,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"January 12, 2020",Actual,2020-01-12,April 2020,2020-04-30,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Intraosseous Versus Intravenous Access During COVID-19 Patients Performed by Paramedics Wearing Level C Personal Protective Equipment. A Multi-center Prospective Randomized Crossover Single-blinded Simulation Trial,Completed,NA,N/A,41,Actual,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,the investigators will add data into manuscript,2021-10-17T08:27:47Z,2021-10-17T08:27:47Z,551
NCT04365972,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,NA,NA,2020-05-06,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic: An Open Pilot Trial,Completed,NA,N/A,20,Actual,Tel Aviv University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:50Z,2021-10-17T08:27:50Z,542
NCT04365608,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,NA,NA,2020-12-17,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-19,Actual,"March 20, 2020",Actual,2020-03-20,December 2020,2020-12-31,"December 10, 2020",Actual,2020-12-10,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Safety and Efficacy of Endotracheal Intubation by Paramedics in Suspected/Confirmed COVID-19 Patients Under Cardiac Arrest Using Vie Scope Laryngoscope,Completed,NA,N/A,90,Actual,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after manuscript publishing,NA,NA,Yes,NA,2021-10-17T08:27:53Z,2021-10-17T08:27:53Z,317
NCT04365153,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,2021-04-05,NA,2021-04-13,2020-04-24,2020-04-28,Actual,2021-04-13,2021-04-15,Actual,NA,NA,NA,2021-04-13,2021-04-15,Actual,"April 24, 2020",Actual,2020-04-24,April 2021,2021-04-30,"April 1, 2021",Actual,2021-04-01,"February 2, 2021",Actual,2021-02-02,NA,Interventional,NA,,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened Inflammation,Completed,NA,Phase 2,45,Actual,The Cleveland Clinic,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:57Z,2021-10-17T08:27:57Z,200
NCT04365127,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,NA,NA,2021-01-25,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"April 27, 2020",Actual,2020-04-27,January 2021,2021-01-31,"August 20, 2020",Actual,2020-08-20,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Progesterone for the Treatment of COVID-19 in Hospitalized Men,"A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men",Completed,NA,Phase 1,40,Actual,Cedars-Sinai Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:27:58Z,2021-10-17T08:27:58Z,278
NCT04373161,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-30,NA,NA,2020-05-05,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"March 20, 2020",Actual,2020-03-20,May 2020,2020-05-31,"April 22, 2020",Actual,2020-04-22,"April 22, 2020",Actual,2020-04-22,NA,Interventional,NA,,Home Pulse Oximeter Use in Patients With COVID-19,Utilizing Home Pulse Oximetry for Patients With COVID-19 To Monitor Disease Progression,Completed,NA,N/A,209,Actual,Swedish Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:26:46Z,2021-10-17T08:26:46Z,543
NCT04372589,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,NA,NA,2021-07-26,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"May 20, 2020",Actual,2020-05-20,January 2021,2021-01-31,"May 17, 2021",Actual,2021-05-17,"May 17, 2021",Actual,2021-05-17,NA,Interventional,ATTACC,,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC), in Collaboration With Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4)",Completed,NA,Phase 2/Phase 3,1200,Actual,University of Manitoba,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:26:52Z,2021-10-17T08:26:52Z,96
NCT04371965,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-29,NA,NA,2020-10-23,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"September 1, 2020",Actual,2020-09-01,July 2020,2020-07-31,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,KILLER,,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19","Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2",Completed,NA,Phase 2,24,Actual,Poitiers University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:26:57Z,2021-10-17T08:26:57Z,372
NCT04371419,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-28,2021-05-28,NA,2021-07-24,2020-04-28,2020-05-01,Actual,2021-07-24,2021-07-27,Actual,NA,NA,NA,2021-07-24,2021-07-27,Actual,"May 13, 2020",Actual,2020-05-13,July 2021,2021-07-31,"May 26, 2020",Actual,2020-05-26,"May 24, 2020",Actual,2020-05-24,NA,Interventional,NA,Any intervention was indeed an arm that included each sub arm of different types of message that we tested against a control and pre-specified in our study protocol and analysis plan to combine arms for analysis.,COVID-19 Health Messaging to Underserved Communities,COVID-19 Health Messaging to Underserved Communities,Completed,NA,N/A,14267,Actual,"National Bureau of Economic Research, Inc.","Participants' behavior was not directly observed, outcomes were measured immediately postintervention in May 2020, and online recruitment may not be representative.",17,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Generally, social scientists post code and de-identified data when the findings are published","To be determined, if published alongside the paper data and code may be gated.",NA,Yes,"Generally, economists will post code and de-identified data when the findings are published",2021-10-17T08:27:01Z,2021-10-17T08:27:01Z,98
NCT04370886,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-28,NA,NA,2020-05-28,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"April 30, 2020",Actual,2020-04-30,April 2020,2020-04-30,"May 10, 2020",Actual,2020-05-10,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19,Completed,NA,N/A,456517,Actual,Guangzhou Blood Center,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:27:07Z,2021-10-17T08:27:07Z,520
NCT04370782,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-26,NA,NA,2020-12-08,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-09,Actual,"April 28, 2020",Actual,2020-04-28,December 2020,2020-12-31,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting,Completed,NA,Phase 4,18,Actual,"St. Francis Hospital, New York",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:08Z,2021-10-17T08:27:08Z,326
NCT04368377,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-23,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"April 23, 2020",Actual,2020-04-23,"April 23, 2020",Actual,2020-04-23,NA,Interventional,PIC-19,,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol,Completed,NA,Phase 2,5,Actual,University of Milan,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:29Z,2021-10-17T08:27:29Z,550
NCT04367831,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-27,NA,NA,2021-09-27,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"May 2, 2020",Actual,2020-05-02,September 2021,2021-09-30,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,IMPROVE,,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID),Completed,NA,Phase 4,94,Actual,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:34Z,2021-10-17T08:27:34Z,33
NCT04367545,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-27,NA,NA,2020-11-04,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,"May 17, 2020",Actual,2020-05-17,"May 17, 2020",Actual,2020-05-17,NA,Interventional,MolCOVID,,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Completed,NA,N/A,130,Actual,"University Hospital, Rouen",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:36Z,2021-10-17T08:27:36Z,360
NCT04366141,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,NA,NA,2021-02-23,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-24,Actual,"May 1, 2020",Actual,2020-05-01,February 2021,2021-02-28,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box,The Impact of a Barrier Enclosure on Endotracheal Intubation Duration and First Pass Attempt - A Randomized Controlled Trial,Completed,NA,N/A,100,Actual,University of British Columbia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:48Z,2021-10-17T08:27:48Z,249
NCT04365738,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-26,NA,NA,2020-04-26,2020-04-26,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"March 11, 2020",Actual,2020-03-11,April 2020,2020-04-30,"April 26, 2020",Actual,2020-04-26,"April 10, 2020",Actual,2020-04-10,NA,Interventional,NA,,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection: Prospective Randomized Controlled Trial,Completed,NA,N/A,270,Actual,Istanbul Bilgi University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:27:52Z,2021-10-17T08:27:52Z,552
NCT04365699,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-25,2021-09-01,NA,2021-09-10,2020-04-25,2020-04-28,Actual,2021-09-10,2021-09-16,Actual,NA,NA,NA,2021-09-10,2021-09-16,Actual,"April 8, 2020",Actual,2020-04-08,September 2021,2021-09-30,"January 31, 2021",Actual,2021-01-31,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NA,,Cardiovascular Effects of COVID-19,A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection,Completed,NA,Phase 2,81,Actual,NYU Langone Health,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Beginning 9 months and ending 36 months following article publication,Requests may be directed to Stuart.Katz@nyulangone.org.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to Stuart.Katz@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2021-10-17T08:27:52Z,2021-10-17T08:27:52Z,50
NCT04364594,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-22,NA,NA,2020-07-22,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-23,Actual,"March 26, 2020",Actual,2020-03-26,July 2020,2020-07-31,"May 30, 2020",Actual,2020-05-30,"April 24, 2020",Actual,2020-04-24,NA,Interventional,COVID-T,,COVID-19 Search in Conjunctival Cells,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Diagnostic Targets for Customized Medicine.,Completed,NA,N/A,50,Actual,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will be available immediately after the statistical analysis of the results and will remain available for at least 1 year,On request by e-mail,NA,Yes,"Study Protocol approved by Ethical Committee, informed consent, clinical study report, will be available",2021-10-17T08:28:02Z,2021-10-17T08:28:02Z,465
NCT04364022,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-23,NA,NA,2021-04-09,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-12,Actual,"April 23, 2020",Actual,2020-04-23,April 2021,2021-04-30,"March 24, 2021",Actual,2021-03-24,"March 24, 2021",Actual,2021-03-24,NA,Interventional,COPEP,,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland: an Open-label Cluster Randomized Trial,Completed,NA,Phase 3,326,Actual,"University Hospital, Geneva",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:28:07Z,2021-10-17T08:28:07Z,204
NCT04363749,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-20,NA,NA,2021-08-27,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"April 27, 2020",Actual,2020-04-27,August 2021,2021-08-31,"January 11, 2021",Actual,2021-01-11,"January 11, 2021",Actual,2021-01-11,NA,Interventional,CRC-COVID,,COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities,Do Respiratory Control Center Anomalies Explain the Lack of Respiratory Sensations Perceptions Observed in Patients Affected by COVID-19 ?,Completed,NA,N/A,50,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:10Z,2021-10-17T08:28:10Z,64
NCT04363736,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-21,2021-07-30,NA,2021-08-26,2020-04-24,2020-04-27,Actual,2021-08-26,2021-08-30,Actual,NA,NA,NA,2021-08-26,2021-08-30,Actual,"May 5, 2020",Actual,2020-05-05,August 2021,2021-08-31,"August 12, 2020",Actual,2020-08-12,"August 12, 2020",Actual,2020-08-12,NA,Interventional,MARIPOSA,,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,"A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia",Completed,NA,Phase 2,97,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-10-17T08:28:10Z,2021-10-17T08:28:10Z,65
NCT04363593,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,NA,NA,2020-12-09,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-09,2020-12-10,Actual,"May 4, 2020",Actual,2020-05-04,December 2020,2020-12-31,"November 16, 2020",Actual,2020-11-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,ROCOCO,,Serology COVID-19 From the Cornwall Hospital Union,Serology COVID-19 From the Cornwall Hospital Union,Completed,NA,N/A,2587,Actual,Centre Hospitalier de Cornouaille,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:28:12Z,2021-10-17T08:28:12Z,325
NCT04362813,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,2021-07-30,2021-02-08,2021-08-12,2020-04-24,2020-04-27,Actual,2021-08-12,2021-08-16,Actual,2021-08-12,2021-08-16,Actual,2021-08-12,2021-08-16,Actual,"April 30, 2020",Actual,2020-04-30,August 2021,2021-08-31,"December 22, 2020",Actual,2020-12-22,"September 16, 2020",Actual,2020-09-16,NA,Interventional,CAN-COVID,"While patient flow and baseline measure tables show 454 participants enrolled, only 451 randomized. 3 were ""mis-randomized"" i.e. assigned a randomization number in error and not treated.",Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,"Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)",Completed,NA,Phase 3,454,Actual,Novartis,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-10-17T08:28:18Z,2021-10-17T08:28:18Z,79
NCT04362358,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-21,NA,NA,2021-09-24,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-27,Actual,"July 20, 2020",Actual,2020-07-20,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"September 1, 2021",Actual,2021-09-01,NA,Interventional,REST,,Online Cognitive Behavioral Therapy (CBT) for Stress Disorders in Health Workers Involved in the Care of Patients During the Covid-19 Epidemic,Efficacy of an Online Cognitive Behavioral Therapy (CBT) Programme Aiming at Reducing the Stress of Health Workers Involved in the Care of Patients During the Covid-19 Epidemic: a Randomized-controlled Trial,Completed,NA,N/A,156,Actual,"University Hospital, Strasbourg, France",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:22Z,2021-10-17T08:28:22Z,36
NCT04362137,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-22,2021-04-15,NA,2021-10-07,2020-04-22,2020-04-24,Actual,2021-05-28,2021-06-02,Actual,NA,NA,NA,2021-10-07,2021-10-11,Actual,"May 2, 2020",Actual,2020-05-02,October 2021,2021-10-31,"October 17, 2020",Actual,2020-10-17,"October 17, 2020",Actual,2020-10-17,NA,Interventional,RUXCOVID,,Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Completed,NA,Phase 3,432,Actual,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-10-17T08:28:24Z,2021-10-17T08:28:24Z,23
NCT04361474,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-22,NA,NA,2021-08-02,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"May 18, 2020",Actual,2020-05-18,August 2021,2021-08-31,"June 25, 2021",Actual,2021-06-25,"November 24, 2020",Actual,2020-11-24,NA,Interventional,COVIDORL,,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,Completed,NA,Phase 3,120,Actual,Fondation Ophtalmologique Adolphe de Rothschild,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:30Z,2021-10-17T08:28:30Z,89
NCT04359251,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"March 5, 2020",Actual,2020-03-05,April 2020,2020-04-30,"March 25, 2020",Actual,2020-03-25,"March 25, 2020",Actual,2020-03-25,NA,Interventional,NA,,Different PEEP Settings of COVID-19 Induced ARDS,Avoiding High PEEP in COVID-19 Induced ARDS: a Multi-center Study,Completed,NA,N/A,20,Actual,"Southeast University, China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:48Z,2021-10-17T08:28:48Z,557
NCT04359875,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-18,NA,NA,2021-04-07,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-12,Actual,"April 30, 2020",Actual,2020-04-30,April 2021,2021-04-30,"December 31, 2020",Actual,2020-12-31,"June 30, 2020",Actual,2020-06-30,NA,Interventional,COVIQuest,,A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment,Does a Systematic Phone-call by a Medical Student/General Practitioner Team in Patients Suffering From a Chronic Condition During the COVID-19 Containment Period Impact One-month Hospitalization's Rate in France? A Cluster Randomized Trial,Completed,NA,N/A,22000,Actual,"University Hospital, Tours",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,1 year,email,NA,Yes,"One-month-data can be shared, whereas 6-month data are not legally sharable (electronic health records).",2021-10-17T08:28:43Z,2021-10-17T08:28:43Z,206
NCT04359810,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-21,NA,NA,2021-05-16,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-16,2021-05-18,Actual,"April 21, 2020",Actual,2020-04-21,May 2021,2021-05-31,"December 30, 2020",Actual,2020-12-30,"December 30, 2020",Actual,2020-12-30,NA,Interventional,NA,,Plasma Therapy of COVID-19 in Severely Ill Patients,"A Phase 2, Multi-Center, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19",Completed,NA,Phase 2,223,Actual,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,The data-sharing plans for this study will be made available at a later date.,2021-10-17T08:28:43Z,2021-10-17T08:28:43Z,167
NCT04359797,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-20,NA,NA,2021-08-28,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-28,2021-08-31,Actual,"April 27, 2020",Actual,2020-04-27,August 2021,2021-08-31,"January 17, 2021",Actual,2021-01-17,"December 17, 2020",Actual,2020-12-17,NA,Interventional,NA,,COVID-19 Patient Positioning Pragmatic Trial,Pragmatic Trial Exploring Impact of Patient Positioning in the Management of Patients Infected With COVID-19: Supine vs. Prone,Completed,NA,N/A,503,Actual,Vanderbilt University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.,Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee.,NA,Yes,Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.,2021-10-17T08:28:43Z,2021-10-17T08:28:43Z,63
NCT04359095,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2021-08-04,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-12,Actual,"August 18, 2020",Actual,2020-08-18,August 2021,2021-08-31,"June 30, 2021",Actual,2021-06-30,"March 20, 2021",Actual,2021-03-20,NA,Interventional,NA,,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial,Completed,NA,Phase 2/Phase 3,650,Actual,Universidad Nacional de Colombia,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,As soon we have checked the quality of data of recruited participants,Approved by the monitor committee of the study,NA,Yes,Communicating trial results and data to be able to combine data from multiple studies (live SR),2021-10-17T08:28:50Z,2021-10-17T08:28:50Z,87
NCT04358783,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-21,NA,NA,2021-05-24,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-24,2021-05-26,Actual,"April 27, 2020",Actual,2020-04-27,May 2021,2021-05-31,"May 1, 2021",Actual,2021-05-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,COP-COVID-19,,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,"Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia",Completed,NA,Phase 2,31,Actual,Hospital Universitario Dr. Jose E. Gonzalez,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:28:53Z,2021-10-17T08:28:53Z,159
NCT04358081,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,2021-03-08,NA,2021-10-07,2020-04-20,2020-04-22,Actual,2021-03-08,2021-03-17,Actual,NA,NA,NA,2021-10-07,2021-10-11,Actual,"May 1, 2020",Actual,2020-05-01,October 2021,2021-10-31,"July 27, 2020",Actual,2020-07-27,"July 27, 2020",Actual,2020-07-27,NA,Interventional,NA,Full Analysis Set (FAS) was comprised of all participants to whom study treatment had been assigned by randomization excluding one mis-randomized participant.,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,"A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease",Completed,NA,Phase 3,20,Actual,Novartis,"Only 20 participants of the initially planned 444 were randomized; and one of those was mis-randomized (so total of 19 participants). Due to this limited number of participants, study objectives could not be evaluated as planned. Results for select efficacy and for safety were summarized based in the information collected up to the eCRF database lock on 13-Aug-2020.",3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-10-17T08:28:58Z,2021-10-17T08:28:58Z,23
NCT04357340,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2020-05-30,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"April 2, 2020",Actual,2020-04-02,May 2020,2020-05-31,"May 30, 2020",Actual,2020-05-30,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Efficacy of Pulmonary Physiotherapy on Hospitalized Patients With Novel Coronavirus 2019 Pneumonia,Completed,NA,N/A,40,Actual,Tehran University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Beginning 3 months and ending 12 months following article publication,Researchers who provide an approved methodologically proposal in the same purpose,NA,Yes,"Individual participant data that underline the results reported in this article, after de-identification",2021-10-17T08:29:05Z,2021-10-17T08:29:05Z,518
NCT04357327,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2020-11-02,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,"July 31, 2020",Actual,2020-07-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19): a Diagnostic Accuracy Study,Completed,NA,N/A,122,Actual,UniversitÃ  degli Studi dell'Insubria,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Data will be available at the end of the study, once statistical analyses is conducted",Contact Principal Investigator,NA,Yes,"We could provide anamnestic, clinical and serological data of each participant at the end of the study, or at least at the end of the first phase.",2021-10-17T08:29:05Z,2021-10-17T08:29:05Z,362
NCT04356937,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-19,2021-06-23,NA,2021-07-23,2020-04-19,2020-04-22,Actual,2021-07-23,2021-07-27,Actual,NA,NA,NA,2021-07-23,2021-07-27,Actual,"April 20, 2020",Actual,2020-04-20,July 2021,2021-07-31,"August 27, 2020",Actual,2020-08-27,"July 13, 2020",Actual,2020-07-13,NA,Interventional,NA,All randomized patients,Efficacy of Tocilizumab on Patients With COVID-19,Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19,Completed,NA,Phase 3,243,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,Request for IPD can be submitted to PI for review,2021-10-17T08:29:08Z,2021-10-17T08:29:08Z,99
NCT04355962,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,NA,NA,2021-07-16,2020-04-19,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-16,2021-07-19,Actual,"April 23, 2020",Actual,2020-04-23,July 2021,2021-07-31,"July 16, 2021",Actual,2021-07-16,"June 25, 2021",Actual,2021-06-25,NA,Interventional,NA,,Sevoflurane in COVID-19 ARDS (SevCov),Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial,Completed,NA,Phase 3,68,Actual,University of Zurich,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:17Z,2021-10-17T08:29:17Z,106
NCT04355936,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-17,NA,NA,2020-12-23,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"May 19, 2020",Actual,2020-05-19,December 2020,2020-12-31,"November 30, 2020",Actual,2020-11-30,"November 2, 2020",Actual,2020-11-02,NA,Interventional,NA,,Telmisartan for Treatment of COVID-19 Patients,Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial,Completed,NA,Phase 4,400,Actual,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:29:17Z,2021-10-17T08:29:17Z,311
NCT04355728,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2021-02-25,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-01,Actual,"April 25, 2020",Actual,2020-04-25,February 2021,2021-02-28,"October 31, 2020",Actual,2020-10-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,,Use of UC-MSCs for COVID-19 Patients,Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS),Completed,NA,Phase 1/Phase 2,24,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:19Z,2021-10-17T08:29:19Z,247
NCT04351542,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2020-04-15,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"March 6, 2020",Actual,2020-03-06,April 2020,2020-04-30,"April 12, 2020",Actual,2020-04-12,"April 6, 2020",Actual,2020-04-06,NA,Interventional,NA,,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Ayurveda for Flu-like Illness During the Covid 19 Outbreak: Non Randomised Single-blind Controlled Trial,Completed,NA,N/A,32,Actual,Aarogyam UK,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:29:56Z,2021-10-17T08:29:56Z,563
NCT04359290,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2021-08-23,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"July 1, 2020",Actual,2020-07-01,November 2020,2020-11-30,"July 30, 2021",Actual,2021-07-30,"December 31, 2020",Actual,2020-12-31,NA,Interventional,RuXoCoil,,Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,"Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study",Completed,NA,Phase 2,15,Actual,Philipps University Marburg Medical Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,3 Months after publication,Central server,NA,Yes,Study protocol will be provided after publication,2021-10-17T08:28:48Z,2021-10-17T08:28:48Z,68
NCT04358939,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-16,NA,NA,2021-04-15,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-15,2021-04-19,Actual,"April 27, 2020",Actual,2020-04-27,January 2021,2021-01-31,"February 21, 2021",Actual,2021-02-21,"February 21, 2021",Actual,2021-02-21,NA,Interventional,NA,,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome,Completed,NA,N/A,405,Actual,"University Hospital, Tours",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available immediately following publication and ending in 5 years.,Contact with the corresponding author.,NA,Yes,Individual participant data after de-identification can be obtained by contacting the corresponding author.,2021-10-17T08:28:51Z,2021-10-17T08:28:51Z,198
NCT04358926,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-21,NA,NA,2021-02-01,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-03,Actual,"April 30, 2020",Actual,2020-04-30,November 2020,2020-11-30,"November 1, 2020",Actual,2020-11-01,"October 15, 2020",Actual,2020-10-15,NA,Interventional,HBOTCOVID19,,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Completed,NA,N/A,30,Actual,Assaf-Harofeh Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,Within 1 month of request,Specific requests,NA,Yes,Sharing upon specific requests will be considered,2021-10-17T08:28:51Z,2021-10-17T08:28:51Z,271
NCT04358614,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-19,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"April 7, 2020",Actual,2020-04-07,"April 5, 2020",Actual,2020-04-05,NA,Interventional,NA,,Baricitinib Therapy in COVID-19,Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact,Completed,NA,Phase 2/Phase 3,12,Actual,Hospital of Prato,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:54Z,2021-10-17T08:28:54Z,557
NCT04358549,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-16,NA,2021-09-30,2021-09-30,2020-04-21,2020-04-24,Actual,NA,NA,NA,2021-09-30,2021-10-05,Actual,2021-09-30,2021-10-05,Actual,"April 17, 2020",Actual,2020-04-17,September 2021,2021-09-30,"October 30, 2020",Actual,2020-10-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,"Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir Compared to Standard of Care in Hospitalized Subjects With COVID-19",Completed,NA,Phase 2,50,Actual,"Fujifilm Pharmaceuticals U.S.A., Inc.",,2,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:54Z,2021-10-17T08:28:54Z,30
NCT04357860,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-20,NA,NA,2021-07-06,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-07,Actual,"April 28, 2020",Actual,2020-04-28,April 2020,2020-04-30,"April 6, 2021",Actual,2021-04-06,"March 9, 2021",Actual,2021-03-09,NA,Interventional,SARICOR,,Clinical Trial of Sarilumab in Adults With COVID-19,Clinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome,Completed,NA,Phase 2,120,Actual,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,After the end of the trial.,Contact uicec@imibic.org,NA,Yes,All the information will be published and it will be available in open access.,2021-10-17T08:29:01Z,2021-10-17T08:29:01Z,116
NCT04357808,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2021-02-10,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 13, 2020",Actual,2020-04-13,February 2021,2021-02-28,"December 4, 2020",Actual,2020-12-04,"November 30, 2020",Actual,2020-11-30,NA,Interventional,SARCOVID,,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection,Completed,NA,Phase 2,30,Actual,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:29:01Z,2021-10-17T08:29:01Z,262
NCT04357782,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-17,NA,NA,2020-12-21,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-21,2020-12-23,Actual,"April 16, 2020",Actual,2020-04-16,December 2020,2020-12-31,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Interventional,AVoCaDO,,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,"Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial",Completed,NA,Phase 1/Phase 2,20,Actual,Hunter Holmes Mcguire Veteran Affairs Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:02Z,2021-10-17T08:29:02Z,313
NCT04357444,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-10,NA,NA,2021-10-01,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"October 23, 2020",Actual,2020-10-23,April 2021,2021-04-30,"April 5, 2021",Actual,2021-04-05,"November 2, 2020",Actual,2020-11-02,NA,Interventional,LILIADE-COVID,,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,Completed,NA,Phase 2,30,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:29:04Z,2021-10-17T08:29:04Z,29
NCT04355637,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2021-09-21,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"April 21, 2020",Actual,2020-04-21,September 2021,2021-09-30,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia,Completed,NA,Phase 4,120,Actual,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:29:20Z,2021-10-17T08:29:20Z,39
NCT04354870,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-16,2021-09-29,NA,2021-10-04,2020-04-16,2020-04-21,Actual,2021-10-04,2021-10-06,Actual,NA,NA,NA,2021-10-04,2021-10-06,Actual,"April 3, 2020",Actual,2020-04-03,October 2021,2021-10-31,"October 1, 2020",Actual,2020-10-01,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,,COVID-19 PrEP HCW HCQ Study,Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2,Completed,NA,Phase 2,130,Actual,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,Study internal to NYU at this time,2021-10-17T08:29:26Z,2021-10-17T08:29:26Z,26
NCT04354610,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2021-09-30,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"April 27, 2020",Actual,2020-04-27,January 2021,2021-01-31,"March 26, 2021",Actual,2021-03-26,"December 19, 2020",Actual,2020-12-19,NA,Interventional,Nancy-CovH-AKI,,Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,Prediction of Acute Heart or Kidney Injury With Cardiovascular-renal Biomarkers in Patients Hospitalised for Severe or Critical Covid-19 Infection,Completed,NA,N/A,73,Actual,"Central Hospital, Nancy, France",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:29:28Z,2021-10-17T08:29:28Z,30
NCT04354155,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2021-07-19,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"June 2, 2020",Actual,2020-06-02,July 2021,2021-07-31,"June 4, 2021",Actual,2021-06-04,"June 4, 2021",Actual,2021-06-04,NA,Interventional,NA,,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,Completed,NA,Phase 2,40,Actual,Johns Hopkins All Children's Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:32Z,2021-10-17T08:29:32Z,103
NCT04353596,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2021-02-25,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-02,Actual,"April 20, 2020",Actual,2020-04-20,February 2021,2021-02-28,"February 24, 2021",Actual,2021-02-24,"February 16, 2021",Actual,2021-02-16,NA,Interventional,ACEI-COVID,,Stopping ACE-inhibitors in COVID-19,Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial,Completed,NA,Phase 4,216,Actual,Medical University Innsbruck,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:29:36Z,2021-10-17T08:29:36Z,247
NCT04353336,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2021-07-29,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-02,Actual,"March 23, 2020",Actual,2020-03-23,July 2021,2021-07-31,"July 1, 2020",Actual,2020-07-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,,Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Completed,NA,Phase 2/Phase 3,194,Actual,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:39Z,2021-10-17T08:29:39Z,93
NCT04353284,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-16,NA,NA,2021-10-06,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-08,Actual,"June 9, 2020",Actual,2020-06-09,October 2021,2021-10-31,"April 22, 2021",Actual,2021-04-22,"March 3, 2021",Actual,2021-03-03,NA,Interventional,NA,,Camostat Mesylate in COVID-19 Outpatients,"The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients: An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial",Completed,NA,Phase 2,74,Actual,Yale University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:39Z,2021-10-17T08:29:39Z,24
NCT04352959,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2021-02-10,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 27, 2020",Actual,2020-04-27,February 2021,2021-02-28,"December 11, 2020",Actual,2020-12-11,"December 11, 2020",Actual,2020-12-11,NA,Interventional,BBCovid,,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,"COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study",Completed,NA,N/A,176,Actual,Claude Bernard University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:29:42Z,2021-10-17T08:29:42Z,262
NCT04351763,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2021-08-30,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-05,Actual,"May 20, 2020",Actual,2020-05-20,August 2021,2021-08-31,"June 5, 2021",Actual,2021-06-05,"May 25, 2021",Actual,2021-05-25,NA,Interventional,ReCOVery-SIRIO,,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Completed,NA,Phase 2/Phase 3,804,Actual,Nicolaus Copernicus University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:29:53Z,2021-10-17T08:29:53Z,61
NCT04351295,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2021-08-04,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"April 20, 2020",Actual,2020-04-20,August 2021,2021-08-31,"September 28, 2020",Actual,2020-09-28,"September 28, 2020",Actual,2020-09-28,NA,Interventional,NA,,Efficacy of Faviprevir in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment,Completed,NA,Phase 2/Phase 3,92,Actual,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:58Z,2021-10-17T08:29:58Z,87
NCT04351243,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2021-04-02,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-05,Actual,"April 12, 2020",Actual,2020-04-12,April 2021,2021-04-30,"April 1, 2021",Actual,2021-04-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),"A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)",Completed,NA,Phase 2,227,Actual,Kinevant Sciences GmbH,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:58Z,2021-10-17T08:29:58Z,211
NCT04350723,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2021-10-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"June 10, 2020",Actual,2020-06-10,October 2021,2021-10-31,"July 17, 2021",Actual,2021-07-17,"July 17, 2021",Actual,2021-07-17,NA,Interventional,COVI-PRONE,,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 COVID-19 (COVI-PRONE),Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Completed,NA,N/A,400,Actual,St. Joseph's Healthcare Hamilton,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:04Z,2021-10-17T08:30:04Z,16
NCT04350593,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2021-09-13,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-14,Actual,"April 22, 2020",Actual,2020-04-22,September 2021,2021-09-30,"June 11, 2021",Actual,2021-06-11,"March 31, 2021",Actual,2021-03-31,NA,Interventional,DARE-19,,Dapagliflozin in Respiratory Failure in Patients With COVID-19,"An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19",Completed,NA,Phase 3,1250,Actual,Saint Luke's Health System,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:06Z,2021-10-17T08:30:06Z,47
NCT04350580,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,NA,NA,2021-08-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-14,2021-08-19,Actual,"April 11, 2020",Actual,2020-04-11,August 2021,2021-08-31,"February 20, 2021",Actual,2021-02-20,"November 20, 2020",Actual,2020-11-20,NA,Interventional,ICAR,,Polyvalent Immunoglobulin in COVID-19 Related ARds,Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections,Completed,NA,Phase 3,146,Actual,Centre Hospitalier St Anne,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:06Z,2021-10-17T08:30:06Z,77
NCT04350736,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2021-06-29,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-07-01,Actual,"April 23, 2020",Actual,2020-04-23,June 2021,2021-06-30,"July 1, 2020",Actual,2020-07-01,"June 24, 2020",Actual,2020-06-24,NA,Interventional,NA,,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19","A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Completed,NA,Phase 1,54,Actual,Theravance Biopharma,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2021-10-17T08:30:04Z,2021-10-17T08:30:04Z,123
NCT04350320,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2021-01-11,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"April 30, 2020",Actual,2020-04-30,January 2021,2021-01-31,"December 30, 2020",Actual,2020-12-30,"October 20, 2020",Actual,2020-10-20,NA,Interventional,COL-COVID,,Trial to Study the Benefit of Colchicine in Patients With COVID-19,"Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria.",Completed,NA,Phase 3,102,Actual,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:09Z,2021-10-17T08:30:09Z,292
NCT04350281,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2020-07-27,2020-04-13,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"April 9, 2020",Actual,2020-04-09,July 2020,2020-07-31,"July 7, 2020",Actual,2020-07-07,"July 1, 2020",Actual,2020-07-01,NA,Interventional,NA,,Double Therapy With IFN-beta 1b and Hydroxychloroquine,"An Open-label Randomized Controlled Trial on Interferon Î²-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection",Completed,NA,Phase 2,60,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:09Z,2021-10-17T08:30:09Z,460
NCT04349592,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-12,NA,NA,2021-02-21,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-21,2021-02-23,Actual,"April 14, 2020",Actual,2020-04-14,February 2021,2021-02-28,"August 30, 2020",Actual,2020-08-30,"August 14, 2020",Actual,2020-08-14,NA,Interventional,NA,,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Completed,NA,N/A,456,Actual,Hamad Medical Corporation,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:15Z,2021-10-17T08:30:15Z,251
NCT04349631,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-06,NA,NA,2021-07-02,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-07,Actual,"April 22, 2020",Actual,2020-04-22,March 2021,2021-03-31,"May 1, 2021",Actual,2021-05-01,"November 24, 2020",Actual,2020-11-24,NA,Interventional,NA,,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,"A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease",Completed,NA,Phase 2,56,Actual,Hope Biosciences,,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:15Z,2021-10-17T08:30:15Z,120
NCT04349410,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-11,NA,NA,2020-11-10,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"April 11, 2020",Actual,2020-04-11,October 2020,2020-10-31,"September 14, 2020",Actual,2020-09-14,"September 14, 2020",Actual,2020-09-14,NA,Interventional,FMTVDM,,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Completed,NA,Phase 2/Phase 3,1800,Actual,The Camelot Foundation,,11,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,This will depend upon the availability of staff given the multi-nation approach to this project.,Expressed request through email as listed.,NA,Yes,Data will be made available through electronic request from approved individuals and institutions.,2021-10-17T08:30:17Z,2021-10-17T08:30:17Z,354
NCT04349098,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2020-12-23,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"April 17, 2020",Actual,2020-04-17,December 2020,2020-12-31,"October 5, 2020",Actual,2020-10-05,"October 5, 2020",Actual,2020-10-05,NA,Interventional,Coronavirus,,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection,Completed,NA,Phase 2,202,Actual,Karyopharm Therapeutics Inc,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:30:19Z,2021-10-17T08:30:19Z,311
NCT04349241,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2020-06-24,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-24,2020-06-25,Actual,"April 18, 2020",Actual,2020-04-18,June 2020,2020-06-30,"June 20, 2020",Actual,2020-06-20,"June 1, 2020",Actual,2020-06-01,NA,Interventional,FAV-001,,Efficacy and Safety of Favipiravir in Management of COVID-19,Efficacy and Safety of Favipiravir in Management of COVID-19,Completed,NA,Phase 3,100,Actual,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:18Z,2021-10-17T08:30:18Z,493
NCT04348435,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2021-08-19,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"May 14, 2020",Actual,2020-05-14,March 2021,2021-03-31,"July 30, 2021",Actual,2021-07-30,"July 9, 2021",Actual,2021-07-09,NA,Interventional,NA,,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19",Completed,NA,Phase 2,55,Actual,Hope Biosciences,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:26Z,2021-10-17T08:30:26Z,72
NCT04348305,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-11,NA,NA,2021-09-20,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"April 17, 2020",Actual,2020-04-17,September 2021,2021-09-30,"September 8, 2021",Actual,2021-09-08,"September 10, 2020",Actual,2020-09-10,NA,Interventional,COVID STEROID,,Hydrocortisone for COVID-19 and Severe Hypoxia,Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial,Completed,NA,Phase 3,30,Actual,Scandinavian Critical Care Trials Group,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Immediate sharing of protocol, SAP and ICF. CSR will be shared no later than 6 months after last-patient-last-visit",Contact to the trial management committee,http://www.cric.nu/covid-steroid-trial/,Yes,Fully de-identified IPD will be shared after the approval by the the trial management committee,2021-10-17T08:30:27Z,2021-10-17T08:30:27Z,40
NCT04347382,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-11,NA,NA,2020-11-09,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"April 30, 2020",Actual,2020-04-30,November 2020,2020-11-30,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,HNS-COVID-PK,,Honey & Nigella Sativa Trial Against COVID-19,"The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Pakistan",Completed,NA,Phase 3,313,Actual,Sheikh Zayed Federal Postgraduate Medical Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:35Z,2021-10-17T08:30:35Z,355
NCT04347031,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2021-01-26,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"April 8, 2020",Actual,2020-04-08,January 2021,2021-01-31,"November 20, 2020",Actual,2020-11-20,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,"An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC ""Farmzashita"" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19",Completed,NA,Phase 2/Phase 3,320,Actual,Burnasyan Federal Medical Biophysical Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:30:38Z,2021-10-17T08:30:38Z,277
NCT04346927,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2021-03-24,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-26,Actual,"August 10, 2020",Actual,2020-08-10,March 2021,2021-03-31,"November 30, 2020",Actual,2020-11-30,"October 10, 2020",Actual,2020-10-10,NA,Interventional,COVID-19,,Telerehabilitation for Patients Diagnosed With Coronavirus,Investigation of the Effects of Exercise Using Telerehabilitation in Patients Diagnosed With Coronavirus (COVID-19) and Followed at Home,Completed,NA,N/A,30,Actual,Istinye University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:38Z,2021-10-17T08:30:38Z,220
NCT04346693,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,NA,NA,2021-10-05,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-13,Actual,"April 8, 2020",Actual,2020-04-08,October 2021,2021-10-31,"November 20, 2020",Actual,2020-11-20,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,,An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug in Patients With Severe and Critical Manifestations of SARS-COVID-19,An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19),Completed,NA,Phase 3,320,Actual,Burnasyan Federal Medical Biophysical Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:40Z,2021-10-17T08:30:40Z,25
NCT04346628,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-10,NA,NA,2021-04-19,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-04-19,2021-04-20,Actual,"July 12, 2020",Actual,2020-07-12,April 2021,2021-04-30,"April 16, 2021",Actual,2021-04-16,"April 16, 2021",Actual,2021-04-16,NA,Interventional,NA,,Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,"A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19",Completed,NA,Phase 2,149,Actual,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,No current plan to share individual participant data (IPD).,2021-10-17T08:30:41Z,2021-10-17T08:30:41Z,194
NCT04346420,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,NA,NA,2020-06-05,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 9, 2020",Actual,2020-04-09,June 2020,2020-06-30,"May 1, 2020",Actual,2020-05-01,"May 1, 2020",Actual,2020-05-01,NA,Interventional,NA,,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Impact of the Double-Trunk Mask on Oxygenation Titration in Patients With COVID-19,Completed,NA,N/A,12,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:30:43Z,2021-10-17T08:30:43Z,512
NCT04346017,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2021-09-28,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"March 20, 2020",Actual,2020-03-20,September 2021,2021-09-30,"November 23, 2020",Actual,2020-11-23,"November 23, 2020",Actual,2020-11-23,NA,Interventional,NA,,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome,Completed,NA,N/A,63,Actual,Brugmann University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:46Z,2021-10-17T08:30:46Z,32
NCT04345653,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,2021-04-01,NA,2021-05-10,2020-04-13,2020-04-14,Actual,2021-05-05,2021-05-10,Actual,NA,NA,NA,2021-05-10,2021-05-12,Actual,"April 14, 2020",Actual,2020-04-14,May 2021,2021-05-31,"May 10, 2021",Actual,2021-05-10,"June 5, 2020",Actual,2020-06-05,NA,Interventional,NA,High risk healthcare providers,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers",Completed,NA,Phase 2,48,Actual,Hackensack Meridian Health,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:50Z,2021-10-17T08:30:50Z,173
NCT04345419,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-11,NA,NA,2021-07-29,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-02,Actual,"June 16, 2020",Actual,2020-06-16,July 2021,2021-07-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,,Remdesivir Efficacy in Coronavirus Disease,Remdesivir in COVID-19 Treatment: A Randomised Trial,Completed,NA,Phase 2/Phase 3,200,Actual,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:52Z,2021-10-17T08:30:52Z,93
NCT04344587,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,NA,NA,2021-06-02,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-02,2021-06-03,Actual,"April 23, 2020",Actual,2020-04-23,June 2021,2021-06-30,"May 7, 2021",Actual,2021-05-07,"May 7, 2021",Actual,2021-05-07,NA,Interventional,APPEX-19,,Awake Prone Position for Early Hypoxemia in COVID-19,Awake Prone Position for Early Hypoxemia in COVID-19,Completed,NA,N/A,305,Actual,Boston University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:59Z,2021-10-17T08:30:59Z,150
NCT04344379,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-27,NA,NA,2021-07-31,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-31,2021-08-03,Actual,"April 17, 2020",Actual,2020-04-17,July 2021,2021-07-31,"June 18, 2020",Actual,2020-06-18,"June 18, 2020",Actual,2020-06-18,NA,Interventional,PREP-COVID,,Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,Randomized Multicenter Study Evaluating the Efficacy of Azithromycin and Hydroxychloroquine in the Prevention of SARS-CoV-2 Infection in the Hospital Population Exposed to Virus,Completed,NA,Phase 3,122,Actual,Assistance Publique - HÃ´pitaux de Paris,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:01Z,2021-10-17T08:31:01Z,91
NCT04344210,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2020-10-11,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-11,2020-10-14,Actual,"April 17, 2020",Actual,2020-04-17,October 2020,2020-10-31,"September 20, 2020",Actual,2020-09-20,"September 20, 2020",Actual,2020-09-20,NA,Interventional,NA,,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial,Completed,NA,N/A,149,Actual,Federal University of Rio Grande do Sul,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:31:02Z,2021-10-17T08:31:02Z,384
NCT04343092,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-05,2020-06-11,NA,2020-11-02,2020-04-08,2020-04-13,Actual,2020-11-02,2020-11-04,Actual,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 18, 2020",Actual,2020-04-18,November 2020,2020-11-30,"June 1, 2020",Actual,2020-06-01,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial),Completed,NA,Phase 1,16,Actual,University of Baghdad,"small sample size; single center design, and short time for the study",1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:12Z,2021-10-17T08:31:12Z,362
NCT04340557,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-06,2021-05-20,NA,2021-05-24,2020-04-08,2020-04-09,Actual,2021-05-24,2021-05-26,Actual,NA,NA,NA,2021-05-24,2021-05-26,Actual,"March 27, 2020",Actual,2020-03-27,May 2021,2021-05-31,"June 13, 2020",Actual,2020-06-13,"June 13, 2020",Actual,2020-06-13,NA,Interventional,NA,,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection,Completed,NA,Phase 4,31,Actual,Sharp HealthCare,"The generalizability is limited by small size of the study population, unblinded design, and all the subjects being screened from three hospitals in close proximity in one geographic area in Southern California.",2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:33Z,2021-10-17T08:31:33Z,159
NCT04338841,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-05,NA,NA,2020-09-22,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-23,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"June 17, 2020",Actual,2020-06-17,"June 17, 2020",Actual,2020-06-17,NA,Interventional,HOME-CoV,,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With Confirmed or Probable SARS-CoV-2 Infection. A Before and After Implementation of a Consensus Help-decision Making Rule Study,Completed,NA,N/A,3133,Actual,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:50Z,2021-10-17T08:31:50Z,403
NCT04330586,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,NA,NA,2021-06-19,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-19,2021-06-24,Actual,"April 1, 2020",Actual,2020-04-01,June 2021,2021-06-30,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19,Completed,NA,Phase 2,68,Actual,Korea University Guro Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:17Z,2021-10-17T08:33:17Z,133
NCT04337541,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-02,NA,NA,2020-07-29,2020-04-05,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-08-03,Actual,"April 2, 2020",Actual,2020-04-02,July 2020,2020-07-31,"June 2, 2020",Actual,2020-06-02,"June 2, 2020",Actual,2020-06-02,NA,Interventional,NA,,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,NA,N/A,6000,Actual,"Rigshospitalet, Denmark",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:04Z,2021-10-17T08:32:04Z,458
NCT04346446,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2020-06-11,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-12,Actual,"April 20, 2020",Actual,2020-04-20,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"May 30, 2020",Actual,2020-05-30,NA,Interventional,NA,,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial,Completed,NA,Phase 2,29,Actual,"Institute of Liver and Biliary Sciences, India",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:30:42Z,2021-10-17T08:30:42Z,506
NCT04346199,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-09,2021-09-08,NA,2021-09-15,2020-04-14,2020-04-15,Actual,2021-09-08,2021-09-13,Actual,NA,NA,NA,2021-09-15,2021-09-17,Actual,"June 12, 2020",Actual,2020-06-12,September 2021,2021-09-30,"November 17, 2020",Actual,2020-11-17,"November 17, 2020",Actual,2020-11-17,NA,Interventional,CALAVI,,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,177,Actual,AstraZeneca,"Improvements in BSC (use of corticosteroids and antivirals) have led to a substantial reduction in mortality and morbidity in patients hospitalized with COVID-19, which, in turn, minimizes the impact that additional treatment regimens can have on patient prognosis and recovery. In addition, variability in patient population and the performance of BSC across the globe poses challenges to demonstrate benefit.",2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.,2021-10-17T08:30:44Z,2021-10-17T08:30:44Z,45
NCT04345614,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2021-07-30,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-03,Actual,"April 8, 2020",Actual,2020-04-08,July 2021,2021-07-31,"July 30, 2021",Actual,2021-07-30,"June 28, 2021",Actual,2021-06-28,NA,Interventional,NA,,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,"A Randomized Double Blind, Placebo-Controlled Study of Auxora for the Treatment of Severe COVID-19 Pneumonia (CARDEA)",Completed,NA,Phase 2,284,Actual,"CalciMedica, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:50Z,2021-10-17T08:30:50Z,92
NCT04345549,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"February 26, 2020",Actual,2020-02-26,April 2020,2020-04-30,"March 30, 2020",Actual,2020-03-30,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Ayurveda Self-Management for Flu Like Symptoms in People Self-Isolated for 7 Days During the Coronavirus Disease 2019 (COVID-19) Outbreak,Completed,NA,N/A,18,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:30:51Z,2021-10-17T08:30:51Z,568
NCT04345523,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-02,NA,NA,2021-05-12,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-13,Actual,"April 3, 2020",Actual,2020-04-03,May 2021,2021-05-31,"April 5, 2021",Actual,2021-04-05,"February 5, 2021",Actual,2021-02-05,NA,Interventional,ConPlas-19,,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients,"Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients",Completed,NA,Phase 2,350,Actual,Puerta de Hierro University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research,The investigator who proposed to use the data will have access to the data upon reasonable request.,NA,Yes,"PD that underlie the results reported in this article, after deidenficiation (text, tables, figures, and appendices) will be shared. The data will be available after main report is published.",2021-10-17T08:30:51Z,2021-10-17T08:30:51Z,171
NCT04345276,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-10,NA,NA,2020-06-01,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"March 18, 2020",Actual,2020-03-18,March 2020,2020-03-31,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,10,Actual,Huoshenshan Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:30:53Z,2021-10-17T08:30:53Z,516
NCT04344080,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-09,NA,NA,2021-06-30,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-30,2021-07-02,Actual,"April 1, 2020",Actual,2020-04-01,June 2021,2021-06-30,"April 28, 2021",Actual,2021-04-28,"April 10, 2021",Actual,2021-04-10,NA,Interventional,CYTOCOV-19,,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Completed,NA,N/A,24,Actual,UniversitÃ¤tsklinikum Hamburg-Eppendorf,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:03Z,2021-10-17T08:31:03Z,122
NCT04344041,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-09,NA,NA,2021-04-29,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-04-30,Actual,"April 15, 2020",Actual,2020-04-15,April 2021,2021-04-30,"January 14, 2021",Actual,2021-01-14,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Completed,NA,Phase 3,260,Actual,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:31:03Z,2021-10-17T08:31:03Z,184
NCT04344015,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-09,NA,NA,2021-05-07,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-07,2021-05-10,Actual,"April 13, 2020",Actual,2020-04-13,May 2021,2021-05-31,"June 2, 2020",Actual,2020-06-02,"June 2, 2020",Actual,2020-06-02,NA,Interventional,NA,,COVID-19 Plasma Collection,Collection of COVID-19 Convalescent Plasma,Completed,NA,N/A,206,Actual,Thomas Jefferson University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:31:04Z,2021-10-17T08:31:04Z,176
NCT04343989,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-09,NA,NA,2021-05-11,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 31, 2020",Actual,2020-03-31,May 2021,2021-05-31,"March 12, 2021",Actual,2021-03-12,"February 3, 2021",Actual,2021-02-03,NA,Interventional,NA,,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Completed,NA,Phase 2,180,Actual,NYU Langone Health,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,Upon reasonable request by an investigator who proposes to use the data.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2021-10-17T08:31:04Z,2021-10-17T08:31:04Z,172
NCT04343768,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,NA,NA,2020-05-02,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-02,2020-05-05,Actual,"April 9, 2020",Actual,2020-04-09,May 2020,2020-05-31,"April 27, 2020",Actual,2020-04-27,"April 27, 2020",Actual,2020-04-27,NA,Interventional,COVIFERON,,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,NA,Phase 2,60,Actual,Shahid Beheshti University of Medical Sciences,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,One year after the publication of the results in a journal.,"Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question.",NA,Yes,"One year after the publication of the results in a journal, Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question can have access to data and supporting information.",2021-10-17T08:31:06Z,2021-10-17T08:31:06Z,546
NCT04343729,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-09,NA,NA,2021-07-21,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-28,Actual,"April 18, 2020",Actual,2020-04-18,July 2021,2021-07-31,"October 20, 2020",Actual,2020-10-20,"June 16, 2020",Actual,2020-06-16,NA,Interventional,MetCOVID,,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,"Efficacy of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.",Completed,NA,Phase 2,416,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after study publication.,upon formal request.,NA,Yes,all patient data will be shared after study publication,2021-10-17T08:31:06Z,2021-10-17T08:31:06Z,101
NCT04343651,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,NA,NA,2021-09-28,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"April 1, 2020",Actual,2020-04-01,September 2021,2021-09-30,"September 20, 2021",Actual,2021-09-20,"July 21, 2020",Actual,2020-07-21,NA,Interventional,NA,,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)",Completed,NA,Phase 2,86,Actual,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:31:07Z,2021-10-17T08:31:07Z,32
NCT04343261,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,2020-09-01,NA,2020-09-22,2020-04-08,2020-04-13,Actual,2020-09-15,2020-09-17,Actual,NA,NA,NA,2020-09-22,2020-09-24,Actual,"April 10, 2020",Actual,2020-04-10,September 2020,2020-09-30,"August 13, 2020",Actual,2020-08-13,"July 23, 2020",Actual,2020-07-23,NA,Interventional,NA,,Convalescent Plasma in the Treatment of COVID 19,Convalescent Plasma in the Treatment of COVID 19,Completed,NA,Phase 2,48,Actual,Saint Francis Care,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:10Z,2021-10-17T08:31:10Z,403
NCT04342728,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,NA,NA,2021-02-12,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-16,Actual,"April 8, 2020",Actual,2020-04-08,February 2021,2021-02-28,"February 11, 2021",Actual,2021-02-11,"December 30, 2020",Actual,2020-12-30,NA,Interventional,COVIDAtoZ,,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",Completed,NA,N/A,214,Actual,The Cleveland Clinic,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:31:15Z,2021-10-17T08:31:15Z,260
NCT04342663,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,2021-07-01,NA,2021-07-07,2020-04-08,2020-04-13,Actual,2021-07-07,2021-07-09,Actual,NA,NA,NA,2021-07-07,2021-07-09,Actual,"April 10, 2020",Actual,2020-04-10,July 2021,2021-07-31,"December 12, 2020",Actual,2020-12-12,"August 20, 2020",Actual,2020-08-20,NA,Interventional,STOP COVID,,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,NA,Phase 2,152,Actual,Washington University School of Medicine,It was a small study and was conducted within a single geographic area; there was a small number of end point events; it is possible that the differences in clinical deterioration may have been a reflection of the comparative baseline distributions of O2 saturation rather than an effect of treatment; the method of measuring the most severe baseline symptom over time did not appear to provide valid data; the follow-up was short; the 7-point scale created for this study has not been validated.,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:31:15Z,2021-10-17T08:31:15Z,115
NCT04342650,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-04,NA,NA,2021-08-02,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-09,Actual,"April 8, 2020",Actual,2020-04-08,July 2020,2020-07-31,"June 8, 2020",Actual,2020-06-08,"May 14, 2020",Actual,2020-05-14,NA,Interventional,CloroCOVID19II,,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,"Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial",Completed,NA,Phase 2,152,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after study publication,Upon formal request to researchers.,NA,Yes,all patient data will be shared after study publication,2021-10-17T08:31:16Z,2021-10-17T08:31:16Z,89
NCT04341584,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2021-01-29,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2021-01-29,2021-02-01,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"July 25, 2020",Actual,2020-07-25,"May 10, 2020",Actual,2020-05-10,NA,Interventional,CORIMUNO-ANA,,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,"CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19",Completed,NA,Phase 2,161,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:31:24Z,2021-10-17T08:31:24Z,274
NCT04340050,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2020-12-23,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-28,Actual,"April 10, 2020",Actual,2020-04-10,December 2020,2020-12-31,"December 23, 2020",Actual,2020-12-23,"December 23, 2020",Actual,2020-12-23,NA,Interventional,NA,,COVID-19 Convalescent Plasma,Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center,Completed,NA,Early Phase 1,10,Actual,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database,NA,NA,Yes,We will share individual participant data that is de-identified available to all qualified investigators,2021-10-17T08:31:39Z,2021-10-17T08:31:39Z,311
NCT04339712,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,NA,NA,2021-01-08,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"April 2, 2020",Actual,2020-04-02,January 2021,2021-01-31,"January 8, 2021",Actual,2021-01-08,"December 1, 2020",Actual,2020-12-01,NA,Interventional,ESCAPE,,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial,Completed,NA,Phase 2,102,Actual,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:42Z,2021-10-17T08:31:42Z,295
NCT04338958,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2021-08-12,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"April 22, 2020",Actual,2020-04-22,August 2021,2021-08-31,"July 15, 2021",Actual,2021-07-15,"July 15, 2021",Actual,2021-07-15,NA,Interventional,RuxCoFlam,,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation,Completed,NA,Phase 2,193,Actual,University of Jena,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:49Z,2021-10-17T08:31:49Z,79
NCT04338009,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,2021-01-28,NA,2021-04-07,2020-04-07,2020-04-08,Actual,2021-04-07,2021-04-09,Actual,NA,NA,NA,2021-04-07,2021-04-09,Actual,"March 31, 2020",Actual,2020-03-31,April 2021,2021-04-30,"August 20, 2020",Actual,2020-08-20,"August 20, 2020",Actual,2020-08-20,NA,Interventional,REPLACECOVID,,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019,Completed,NA,N/A,152,Actual,University of Pennsylvania,"Limitations of the study include (1) small sample size; (2) we did not control participant ACEI or ARB dosing or other medication exposures during the trial; (3) Although outcome adjudicators were masked to the randomly assigned groups when determining clinical endpoints, providers caring for the patients were aware of the group the patient was assigned to. It is possible that the open-label nature of the study might have introduced information bias or influenced provider behavior.",2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Not making it available,2021-10-17T08:31:59Z,2021-10-17T08:31:59Z,206
NCT04337996,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,NA,NA,2021-01-25,2020-04-03,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-26,Actual,"July 13, 2020",Actual,2020-07-13,January 2021,2021-01-31,"January 13, 2021",Actual,2021-01-13,"January 13, 2021",Actual,2021-01-13,NA,Interventional,TRODVID-19,,Dynamic Evaluation of COVID-19 Diagnostic Tests,Dynamic Evaluation of COVID-19 Diagnostic Tests,Completed,NA,N/A,8,Actual,Tourcoing Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:00Z,2021-10-17T08:32:00Z,278
NCT04337918,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-06,NA,NA,2021-02-08,2020-04-06,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"May 8, 2020",Actual,2020-05-08,February 2021,2021-02-28,"February 2, 2021",Actual,2021-02-02,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NOCOVID,,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,"Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection",Completed,NA,Phase 2,143,Actual,Sanotize Research and Development corp.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:01Z,2021-10-17T08:32:01Z,264
NCT04347174,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,NA,NA,2021-01-25,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"April 30, 2020",Actual,2020-04-30,January 2021,2021-01-31,"August 21, 2020",Actual,2020-08-21,"August 10, 2020",Actual,2020-08-10,NA,Interventional,NA,,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection,Completed,NA,N/A,40,Actual,Cadila Pharnmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:37Z,2021-10-17T08:30:37Z,278
NCT04335851,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-02,NA,NA,2020-06-04,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-09,Actual,"April 6, 2020",Actual,2020-04-06,June 2020,2020-06-30,"June 3, 2020",Actual,2020-06-03,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,,Video-Based Exercises and Well-Being During Social Isolation,Effectiveness of Video-Based Exercises on Physical and Emotional Well-Being During COVID-19 Induced Social Isolation,Completed,NA,N/A,68,Actual,Biruni University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:19Z,2021-10-17T08:32:19Z,513
NCT04335279,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,NA,NA,2020-11-26,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"April 9, 2020",Actual,2020-04-09,November 2020,2020-11-30,"July 24, 2020",Actual,2020-07-24,"June 3, 2020",Actual,2020-06-03,NA,Interventional,SPIN-CHAT,,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,A Partially Nested RCT to Evaluate the Effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to Reduce Anxiety Among At-Risk Scleroderma Patients,Completed,NA,N/A,172,Actual,Lady Davis Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,12 months after the collection of the primary outcome,Approval of proposed purpose for data access,NA,Yes,Upon request,2021-10-17T08:32:25Z,2021-10-17T08:32:25Z,338
NCT04335136,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,2021-06-07,NA,2021-07-29,2020-04-03,2020-04-06,Actual,2021-07-29,2021-08-02,Actual,NA,NA,NA,2021-07-29,2021-08-02,Actual,"April 30, 2020",Actual,2020-04-30,July 2021,2021-07-31,"December 26, 2020",Actual,2020-12-26,"December 26, 2020",Actual,2020-12-26,NA,Interventional,APN01-COVID-19,All randomized patients who received at least 1 dose of investigational medicinal product (IMP).,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Completed,NA,Phase 2,185,Actual,Apeiron Biologics,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:32:26Z,2021-10-17T08:32:26Z,93
NCT04335123,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,NA,NA,2021-05-06,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,"April 4, 2020",Actual,2020-04-04,May 2021,2021-05-31,"August 17, 2020",Actual,2020-08-17,"June 21, 2020",Actual,2020-06-21,NA,Interventional,NA,,Study of Open Label Losartan in COVID-19,An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19,Completed,NA,Phase 1,34,Actual,University of Kansas Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,Beginning 3 months and ending 5 years following article publication,"Proposals should be directed to msalathe@kumc.edu. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)",2021-10-17T08:32:27Z,2021-10-17T08:32:27Z,177
NCT04334928,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-02,NA,NA,2021-09-15,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"April 15, 2020",Actual,2020-04-15,September 2021,2021-09-30,"July 11, 2021",Actual,2021-07-11,"February 25, 2021",Actual,2021-02-25,NA,Interventional,EPICOS,,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo,Completed,NA,Phase 3,1002,Actual,Plan Nacional sobre el Sida (PNS),,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:31Z,2021-10-17T08:32:31Z,45
NCT04334876,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-02,2021-07-19,NA,2021-09-10,2020-04-02,2020-04-06,Actual,2021-09-10,2021-09-16,Actual,NA,NA,NA,2021-09-10,2021-09-16,Actual,"April 1, 2020",Actual,2020-04-01,September 2021,2021-09-30,"January 1, 2021",Actual,2021-01-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,COVID-Antibody,,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers and Candidacy for Convalescent Plasma Therapy/Prophylaxis,Completed,NA,N/A,571,Actual,Indiana University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:31Z,2021-10-17T08:32:31Z,50
NCT04334850,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-02,NA,NA,2021-07-31,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-31,2021-08-03,Actual,"April 20, 2020",Actual,2020-04-20,July 2021,2021-07-31,"June 23, 2021",Actual,2021-06-23,"December 20, 2020",Actual,2020-12-20,NA,Interventional,MultiCov,,Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,"Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial",Completed,NA,N/A,194,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:31Z,2021-10-17T08:32:31Z,91
NCT04334434,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-02,NA,NA,2021-01-30,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-01-30,2021-02-03,Actual,"July 30, 2020",Actual,2020-07-30,January 2021,2021-01-31,"December 15, 2020",Actual,2020-12-15,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Investigation Of The Effectiveness Of The Telerehabilitation Applied To Individuals Over The Age Of 65 Who Experience Social Isolation At Houses Due To The Coronavirus (Covid-19) Pandemic,Completed,NA,N/A,30,Actual,Istanbul University-Cerrahpasa,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:35Z,2021-10-17T08:32:35Z,273
NCT04334044,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,NA,NA,2021-07-05,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-05,2021-07-07,Actual,"September 1, 2020",Actual,2020-09-01,July 2021,2021-07-31,"April 30, 2021",Actual,2021-04-30,"April 12, 2021",Actual,2021-04-12,NA,Interventional,NA,,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib,Completed,NA,Phase 1/Phase 2,77,Actual,Grupo Cooperativo de HemopatÃ­as Malignas,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:39Z,2021-10-17T08:32:39Z,117
NCT04333225,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,2021-08-02,NA,2021-08-18,2020-04-02,2020-04-03,Actual,2021-08-18,2021-08-20,Actual,NA,NA,NA,2021-08-18,2021-08-20,Actual,"April 3, 2020",Actual,2020-04-03,May 2020,2020-05-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures,Completed,NA,Phase 2,221,Actual,Baylor Research Institute,"Due to the off-label use of HCQ, we were not able to incorporate randomization in our design.
The outcome of CLI was based on self-reported symptoms, which is prone to bias.
The trial may be under-powered as recruitment was forced to stop early at 221 instead of 360 because of the demand for and subsequent shortage of HCQ in March 2020.
Our study participants were young and healthy compared to other prophylaxis trials, which may partially explain the low rates of COVID-19.",2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:46Z,2021-10-17T08:32:46Z,73
NCT04332835,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,NA,NA,2020-11-25,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"August 8, 2020",Actual,2020-08-08,November 2020,2020-11-30,"November 15, 2020",Actual,2020-11-15,"October 31, 2020",Actual,2020-10-31,NA,Interventional,CP-COVID-19,,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study","Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Completed,NA,Phase 2/Phase 3,92,Actual,Universidad del Rosario,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:53Z,2021-10-17T08:32:53Z,339
NCT04332991,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,2021-02-09,NA,2021-03-12,2020-03-31,2020-04-03,Actual,2021-03-12,2021-03-17,Actual,NA,NA,NA,2021-03-12,2021-03-17,Actual,"April 2, 2020",Actual,2020-04-02,March 2021,2021-03-31,"July 23, 2020",Actual,2020-07-23,"June 19, 2020",Actual,2020-06-19,NA,Interventional,ORCHID,,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,NA,Phase 3,479,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:32:49Z,2021-10-17T08:32:49Z,232
NCT04332380,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-30,NA,NA,2020-08-12,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-17,Actual,"May 1, 2020",Actual,2020-05-01,August 2020,2020-08-31,"July 28, 2020",Actual,2020-07-28,"July 28, 2020",Actual,2020-07-28,NA,Interventional,CP-COVID-19,,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Completed,NA,Phase 2,10,Actual,Universidad del Rosario,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:59Z,2021-10-17T08:32:59Z,444
NCT04331899,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-27,2021-04-08,NA,2021-05-19,2020-04-01,2020-04-02,Actual,2021-04-19,2021-04-22,Actual,NA,NA,NA,2021-05-19,2021-05-21,Actual,"April 25, 2020",Actual,2020-04-25,May 2021,2021-05-31,"May 6, 2021",Actual,2021-05-06,"August 14, 2020",Actual,2020-08-14,NA,Interventional,COVID-Lambda,,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,"A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19",Completed,NA,Phase 2,120,Actual,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,The datasets generated and analyzed during the current study are permanently available in the Stanford Digital Repository,Full access,https://purl.stanford.edu/hc972ys6733,Yes,Sharing of generated and analyzed datasets.,2021-10-17T08:33:04Z,2021-10-17T08:33:04Z,164
NCT04331834,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,NA,NA,2021-02-15,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-16,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"December 31, 2020",Actual,2020-12-31,"June 25, 2020",Actual,2020-06-25,NA,Interventional,PrEP_COVID,,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,"Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Multicentre, Double-Blinded Randomized Controlled Trial",Completed,NA,Phase 3,275,Actual,Barcelona Institute for Global Health,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:04Z,2021-10-17T08:33:04Z,257
NCT04331795,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,NA,NA,2021-03-05,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-03-05,2021-03-09,Actual,"April 4, 2020",Actual,2020-04-04,March 2021,2021-03-31,"June 5, 2020",Actual,2020-06-05,"June 5, 2020",Actual,2020-06-05,NA,Interventional,COVIDOSE,,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis,Completed,NA,Phase 2,32,Actual,University of Chicago,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:05Z,2021-10-17T08:33:05Z,239
NCT04331600,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-30,NA,NA,2021-02-10,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,"December 17, 2020",Actual,2020-12-17,"December 17, 2020",Actual,2020-12-17,NA,Interventional,NA,,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,"Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications",Completed,NA,Phase 4,16,Actual,Wroclaw Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:08Z,2021-10-17T08:33:08Z,262
NCT04331366,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,2021-02-05,NA,2021-02-16,2020-03-31,2020-04-02,Actual,2021-02-05,2021-02-10,Actual,NA,NA,NA,2021-02-16,2021-02-18,Actual,"April 8, 2020",Actual,2020-04-08,February 2021,2021-02-28,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,GO2 PEEP,,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,NA,N/A,2,Actual,Emory University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:10Z,2021-10-17T08:33:10Z,256
NCT04330638,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,NA,NA,2021-09-28,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"April 3, 2020",Actual,2020-04-03,September 2021,2021-09-30,"April 12, 2021",Actual,2021-04-12,"December 18, 2020",Actual,2020-12-18,NA,Interventional,COV-AID,,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome",Completed,NA,Phase 3,342,Actual,"University Hospital, Ghent",,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:16Z,2021-10-17T08:33:16Z,32
NCT04329533,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,NA,NA,2020-11-11,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"April 13, 2020",Actual,2020-04-13,November 2020,2020-11-30,"November 1, 2020",Actual,2020-11-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Effects of a Mobile Meditation App on Stress During COVID-19 Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial,Completed,NA,N/A,101,Actual,University of Arizona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:26Z,2021-10-17T08:33:26Z,353
NCT04328961,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,NA,NA,2020-10-27,2020-03-29,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"March 31, 2020",Actual,2020-03-31,October 2020,2020-10-31,"October 8, 2020",Actual,2020-10-08,"September 24, 2020",Actual,2020-09-24,NA,Interventional,NA,,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study",Completed,NA,Phase 2/Phase 3,829,Actual,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2021-10-17T08:33:30Z,2021-10-17T08:33:30Z,368
NCT04328493,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-27,NA,NA,2021-05-20,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-24,Actual,"April 7, 2020",Actual,2020-04-07,May 2021,2021-05-31,"September 10, 2020",Actual,2020-09-10,"September 10, 2020",Actual,2020-09-10,NA,Interventional,VICO,,The Vietnam Chloroquine Treatment on COVID-19,A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam,Completed,NA,Phase 2,10,Actual,"Oxford University Clinical Research Unit, Vietnam",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:34Z,2021-10-17T08:33:34Z,163
NCT04328480,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-30,NA,NA,2021-04-26,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-27,Actual,"April 17, 2020",Actual,2020-04-17,April 2021,2021-04-30,"April 26, 2021",Actual,2021-04-26,"April 25, 2021",Actual,2021-04-25,NA,Interventional,COLCOVID,,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,The ECLA PHRI COLCOVID Trial,Completed,NA,Phase 3,1279,Actual,Estudios ClÃ­nicos Latino AmÃ©rica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:34Z,2021-10-17T08:33:34Z,187
NCT04328467,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-27,2021-06-25,NA,2021-06-30,2020-03-30,2020-03-31,Actual,2021-06-25,2021-06-30,Actual,NA,NA,NA,2021-06-30,2021-07-02,Actual,"April 6, 2020",Actual,2020-04-06,June 2021,2021-06-30,"July 13, 2020",Actual,2020-07-13,"July 13, 2020",Actual,2020-07-13,NA,Interventional,NA,,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1483,Actual,University of Minnesota,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:33:34Z,2021-10-17T08:33:34Z,122
NCT04327388,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,2021-04-28,NA,2021-05-11,2020-03-26,2020-03-31,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 28, 2020",Actual,2020-03-28,May 2021,2021-05-31,"September 2, 2020",Actual,2020-09-02,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,Analysis was performed on randomized population.,Sarilumab COVID-19,"An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",Completed,NA,Phase 3,420,Actual,Sanofi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-17T08:33:44Z,2021-10-17T08:33:44Z,172
NCT04326920,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-24,NA,NA,2021-03-01,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-02,Actual,"March 24, 2020",Actual,2020-03-24,March 2021,2021-03-31,"February 26, 2021",Actual,2021-02-26,"September 28, 2020",Actual,2020-09-28,NA,Interventional,SARPAC,,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (LeukineÂ®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.",Completed,NA,Phase 4,80,Actual,"University Hospital, Ghent",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:49Z,2021-10-17T08:33:49Z,243
NCT04325906,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,NA,NA,2021-04-21,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-23,Actual,"April 2, 2020",Actual,2020-04-02,April 2021,2021-04-30,"February 21, 2021",Actual,2021-02-21,"January 26, 2021",Actual,2021-01-26,NA,Interventional,NA,,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS,Completed,NA,N/A,222,Actual,Rush University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:58Z,2021-10-17T08:33:58Z,192
NCT04324528,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-25,NA,NA,2021-03-11,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-15,Actual,"March 27, 2020",Actual,2020-03-27,March 2021,2021-03-31,"January 27, 2021",Actual,2021-01-27,"January 27, 2021",Actual,2021-01-27,NA,Interventional,CYCOV,,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Completed,NA,N/A,34,Actual,University Hospital Freiburg,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:34:10Z,2021-10-17T08:34:10Z,233
NCT04324489,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-25,NA,NA,2020-05-01,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-05,Actual,"March 6, 2020",Actual,2020-03-06,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 16, 2020",Actual,2020-04-16,NA,Interventional,NA,,DAS181 for Severe COVID-19: Compassionate Use,DAS181 for Severe COVID-19: Compassionate Use,Completed,NA,N/A,4,Actual,Renmin Hospital of Wuhan University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:34:10Z,2021-10-17T08:34:10Z,547
NCT04323527,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-19,NA,NA,2021-08-02,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-09,Actual,"March 23, 2020",Actual,2020-03-23,August 2021,2021-08-31,"June 7, 2020",Actual,2020-06-07,"May 7, 2020",Actual,2020-05-07,NA,Interventional,CloroCOVID19,,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,"Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial",Completed,NA,Phase 2,278,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,after study publication,upon request to researchers,NA,Yes,all patient data will be shared after study publication,2021-10-17T08:34:18Z,2021-10-17T08:34:18Z,89
NCT04321421,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,NA,NA,2020-05-27,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"March 17, 2020",Actual,2020-03-17,May 2020,2020-05-31,"May 7, 2020",Actual,2020-05-07,"April 28, 2020",Actual,2020-04-28,NA,Interventional,COV19-PLASMA,,Hyperimmune Plasma for Critical Patients With COVID-19,Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19,Completed,NA,N/A,49,Actual,Foundation IRCCS San Matteo Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,will be decided,2021-10-17T08:34:39Z,2021-10-17T08:34:39Z,521
NCT04321278,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,NA,NA,2021-01-15,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-20,Actual,"March 28, 2020",Actual,2020-03-28,March 2020,2020-03-31,"June 14, 2020",Actual,2020-06-14,"June 14, 2020",Actual,2020-06-14,NA,Interventional,NA,,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients,Completed,NA,Phase 3,440,Actual,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:34:40Z,2021-10-17T08:34:40Z,288
NCT04320953,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-21,NA,NA,2020-04-15,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"April 9, 2020",Actual,2020-04-09,"March 26, 2020",Actual,2020-03-26,NA,Interventional,NA,,Non-contact Endoscopy at Covid-19 Outbreak,Non-contact Endoscopy at Covid-19 Outbreak,Completed,NA,N/A,5,Actual,Changhai Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:34:43Z,2021-10-17T08:34:43Z,563
NCT04320615,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,2021-06-23,NA,2021-06-28,2020-03-23,2020-03-25,Actual,2021-06-28,2021-06-30,Actual,NA,NA,NA,2021-06-28,2021-06-30,Actual,"April 3, 2020",Actual,2020-04-03,June 2021,2021-06-30,"July 28, 2020",Actual,2020-07-28,"June 24, 2020",Actual,2020-06-24,NA,Interventional,COVACTA,,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 3,452,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform https://vivli.org.
Further details on Roche's criteria for eligible studies are available here: https://vivli.org.
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm",2021-10-17T08:34:47Z,2021-10-17T08:34:47Z,124
NCT04318431,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-20,NA,NA,2020-07-08,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-09,Actual,"April 14, 2020",Actual,2020-04-14,July 2020,2020-07-31,"June 1, 2020",Actual,2020-06-01,"May 12, 2020",Actual,2020-05-12,NA,Interventional,COVILLE,,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,"Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care.",Completed,NA,N/A,605,Actual,Centre Hospitalier Intercommunal Creteil,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:35:08Z,2021-10-17T08:35:08Z,479
NCT04317040,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-19,2021-09-28,NA,2021-10-13,2020-03-19,2020-03-20,Actual,2021-10-13,2021-10-15,Estimate,NA,NA,NA,2021-10-13,2021-10-15,Estimate,"April 24, 2020",Actual,2020-04-24,October 2021,2021-10-31,"October 20, 2020",Actual,2020-10-20,"October 20, 2020",Actual,2020-10-20,NA,Interventional,SAC-COVID,All randomized participants.,CD24Fc (MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007),"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment",Completed,NA,Phase 3,234,Actual,"OncoImmune, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-10-17T08:35:20Z,2021-10-17T08:35:20Z,17
NCT04315298,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-15,2021-07-23,NA,2021-09-16,2020-03-17,2020-03-19,Actual,2021-09-16,2021-09-23,Actual,NA,NA,NA,2021-09-16,2021-09-23,Actual,"March 18, 2020",Actual,2020-03-18,September 2021,2021-09-30,"September 2, 2020",Actual,2020-09-02,"July 24, 2020",Actual,2020-07-24,NA,Interventional,NA,,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19",Completed,NA,Phase 2/Phase 3,1912,Actual,Regeneron Pharmaceuticals,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All IPD that underlie publicly available results will be considered for sharing,2021-10-17T08:35:37Z,2021-10-17T08:35:37Z,44
NCT04313023,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-16,NA,NA,2021-09-01,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"June 9, 2020",Actual,2020-06-09,September 2021,2021-09-30,"July 31, 2021",Actual,2021-07-31,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,Completed,NA,Phase 2,217,Actual,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:36:08Z,2021-10-17T08:36:08Z,59
NCT04312997,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-16,NA,NA,2021-07-14,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-07-14,2021-07-16,Actual,"June 16, 2020",Actual,2020-06-16,July 2021,2021-07-31,"July 2, 2021",Actual,2021-07-02,"July 2, 2021",Actual,2021-07-02,NA,Interventional,NA,,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Completed,NA,Phase 2,101,Actual,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:36:08Z,2021-10-17T08:36:08Z,108
NCT04312009,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-13,NA,NA,2021-08-16,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-18,Actual,"April 13, 2020",Actual,2020-04-13,August 2021,2021-08-31,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,Completed,NA,Phase 2,205,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:36:16Z,2021-10-17T08:36:16Z,75
NCT04313127,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-15,NA,NA,2021-08-02,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"March 16, 2020",Actual,2020-03-16,May 2020,2020-05-31,"February 20, 2021",Actual,2021-02-20,"January 20, 2021",Actual,2021-01-20,NA,Interventional,CTCOVID-19,,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old",Completed,NA,Phase 1,108,Actual,CanSino Biologics Inc.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available beginning 3 months and ending one year following article publication,"Data access requests will be reviewed by the sponsorï¼Œinvestigator and collaborators on the basis of scientific merit. To gain access, data requestors will need to sign a data access agreement.",http://www.jshealth.com/,Yes,"We support data sharing of the individual participant data. The individual participant data that underlie the results reported in this article, after deidentiï¬cation (text, tables, figures, and appendixes) will be shared. Individual participant data will be available beginning 3 months and ending one year following article publication. Supporting clinical documents including study protocol, statistical analysis plan (SAP), and the informed consent form (ICF) will be available immediately following publication for at least one year. Supporting clinical documents access information will be available at http://www.jshealth.com/. Researchers who provide a scientifically sound proposal will be allowed to access to the individual participant data. Proposals should be directed to jszfc@vip.sina.com or cw0226@foxmail.com.",2021-10-17T08:36:07Z,2021-10-17T08:36:07Z,89
NCT04311177,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-13,NA,NA,2021-09-17,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-24,Actual,"April 9, 2020",Actual,2020-04-09,September 2021,2021-09-30,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,Completed,NA,Phase 2,162,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:36:23Z,2021-10-17T08:36:23Z,43
NCT04311697,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-14,NA,NA,2021-09-05,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-05,2021-09-13,Actual,"May 15, 2020",Actual,2020-05-15,September 2021,2021-09-30,"February 22, 2021",Actual,2021-02-22,"February 22, 2021",Actual,2021-02-22,NA,Interventional,COVID-AIV,,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure,Completed,NA,Phase 2/Phase 3,196,Actual,"NeuroRx, Inc.",,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Currently available,Public access,NA,Yes,NeuroRx will share study protocol and statistical analysis plan upon request by qualified researchers,2021-10-17T08:36:19Z,2021-10-17T08:36:19Z,55
NCT04308668,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-11,2021-04-26,NA,2021-05-11,2020-03-11,2020-03-16,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 17, 2020",Actual,2020-03-17,May 2021,2021-05-31,"May 20, 2020",Actual,2020-05-20,"May 20, 2020",Actual,2020-05-20,NA,Interventional,COVID-19 PEP,,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1312,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,at time of publication,To be publicly provided. Please register at the website to receive the dataset.,https://covidpep.umn.edu/data,Yes,De-identified dataset will be available within 1 month of publication.,2021-10-17T08:36:47Z,2021-10-17T08:36:47Z,172
NCT04306055,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-08,NA,NA,2020-04-09,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 13, 2020",Actual,2020-03-13,April 2020,2020-04-30,"April 3, 2020",Actual,2020-04-03,"March 13, 2020",Actual,2020-03-13,NA,Interventional,NA,,Blood Donor Recruitment During Epidemic of COVID-19,"Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China",Completed,NA,N/A,19491,Actual,Guangzhou Blood Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:37:10Z,2021-10-17T08:37:10Z,569
NCT04303299,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-24,NA,NA,2021-08-28,2020-03-08,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-28,2021-09-02,Actual,"August 19, 2020",Actual,2020-08-19,August 2021,2021-08-31,"August 28, 2021",Actual,2021-08-28,"August 28, 2021",Actual,2021-08-28,NA,Interventional,FIGHT-COVID-19,,Fight COVID-19 Trial,"A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19",Completed,NA,Phase 3,320,Actual,Rajavithi Hospital,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:37:35Z,2021-10-17T08:37:35Z,63
NCT04304053,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-05,NA,NA,2020-06-26,2020-03-07,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-26,2020-06-30,Actual,"March 18, 2020",Actual,2020-03-18,June 2020,2020-06-30,"June 15, 2020",Actual,2020-06-15,"June 15, 2020",Actual,2020-06-15,NA,Interventional,HCQ4COV19,,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study),Completed,NA,Phase 3,2300,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,30 days after start of treatment,Open access for everybody,http://www.estudicovid19.org,Yes,Open access,2021-10-17T08:37:27Z,2021-10-17T08:37:27Z,491
NCT04292899,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-28,2020-12-15,NA,2020-12-15,2020-02-28,2020-03-03,Actual,2020-12-15,2020-12-31,Actual,NA,NA,NA,2020-12-15,2020-12-31,Actual,"March 6, 2020",Actual,2020-03-06,December 2020,2020-12-31,"June 30, 2020",Actual,2020-06-30,"April 9, 2020",Actual,2020-04-09,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment.
Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into part B of the study and received at least 1 dose of study treatment.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe COVID-19,Completed,NA,Phase 3,4891,Actual,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-10-17T08:39:05Z,2021-10-17T08:39:05Z,319
NCT04292730,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-28,2020-12-15,NA,2021-01-21,2020-02-28,2020-03-03,Actual,2021-01-21,2021-01-26,Actual,NA,NA,NA,2021-01-21,2021-01-26,Actual,"March 15, 2020",Actual,2020-03-15,January 2021,2021-01-31,"June 26, 2020",Actual,2020-06-26,"April 29, 2020",Actual,2020-04-29,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment or completed the Day 1 visit (SOC only group).
Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into Part B of the study and received at least 1 dose of study drug.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment,Completed,NA,Phase 3,1113,Actual,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-10-17T08:39:08Z,2021-10-17T08:39:08Z,282
NCT04291729,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-27,NA,NA,2020-04-09,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 17, 2020",Actual,2020-02-17,March 2020,2020-03-31,"March 19, 2020",Actual,2020-03-19,"March 19, 2020",Actual,2020-03-19,NA,Interventional,NA,,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Ganovoï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,11,Actual,The Ninth Hospital of Nanchang,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:39:20Z,2021-10-17T08:39:20Z,569
NCT04288102,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-24,NA,NA,2020-08-18,2020-02-25,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"March 5, 2020",Actual,2020-03-05,August 2020,2020-08-31,"July 9, 2020",Actual,2020-07-09,"May 12, 2020",Actual,2020-05-12,NA,Interventional,NA,,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),"A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients",Completed,NA,Phase 2,100,Actual,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"After approval from the steering committee and the Human Genetic Resources Administration of China, this trial data can be shared with qualifying researchers who submit a proposal with a valuable research question. A contract should be signed.",2021-10-17T08:39:52Z,2021-10-17T08:39:52Z,438
NCT04280705,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-20,2020-09-16,NA,2020-12-05,2020-02-20,2020-02-21,Actual,2020-09-22,2020-09-25,Actual,NA,NA,NA,2020-12-05,2020-12-09,Actual,"February 21, 2020",Actual,2020-02-21,April 2020,2020-04-30,"May 21, 2020",Actual,2020-05-21,"May 21, 2020",Actual,2020-05-21,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,1062,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:41:02Z,2021-10-17T08:41:02Z,329
NCT04276688,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-11,NA,NA,2020-04-13,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"February 10, 2020",Actual,2020-02-10,April 2020,2020-04-30,"March 31, 2020",Actual,2020-03-31,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection",Completed,NA,Phase 2,127,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:41:38Z,2021-10-17T08:41:38Z,565
NCT04276987,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-16,NA,NA,2020-09-03,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-07,Actual,"February 15, 2020",Actual,2020-02-15,September 2020,2020-09-30,"July 31, 2020",Actual,2020-07-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia,Completed,NA,Phase 1,24,Actual,Ruijin Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Starting 6 months after publication,NA,NA,Yes,all IPD that underlie results in a publication,2021-10-17T08:41:35Z,2021-10-17T08:41:35Z,422
NCT04275245,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-06,NA,NA,2021-04-07,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-09,Actual,"February 3, 2020",Actual,2020-02-03,April 2021,2021-04-30,"March 9, 2020",Actual,2020-03-09,"March 9, 2020",Actual,2020-03-09,NA,Interventional,NA,,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,"Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia",Completed,NA,Phase 1/Phase 2,17,Actual,Tang-Du Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:41:50Z,2021-10-17T08:41:50Z,206
NCT04275414,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-14,NA,NA,2020-09-10,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"February 15, 2020",Actual,2020-02-15,February 2020,2020-02-29,"May 2, 2020",Actual,2020-05-02,"April 5, 2020",Actual,2020-04-05,NA,Interventional,BEST-CP,,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Effecacy and Safety of Bevacizumab in Severe Patients With Covid-19: a Pilot Study (BEST-CP),Completed,NA,Phase 2,27,Actual,Qilu Hospital of Shandong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:41:48Z,2021-10-17T08:41:48Z,415
NCT04273321,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-15,NA,NA,2020-05-08,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"February 14, 2020",Actual,2020-02-14,April 2020,2020-04-30,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,,Efficacy and Safety of Corticosteroids in COVID-19,Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails,Completed,NA,N/A,86,Actual,Beijing Chao Yang Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:42:09Z,2021-10-17T08:42:09Z,540
NCT04260594,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-06,NA,NA,2021-09-06,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"February 8, 2020",Actual,2020-02-08,September 2021,2021-09-30,"December 30, 2020",Actual,2020-12-30,"March 12, 2020",Actual,2020-03-12,NA,Interventional,NA,,Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus,"Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).",Completed,NA,Phase 4,236,Actual,Ruijin Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:44:14Z,2021-10-17T08:44:14Z,54
NCT04261517,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-06,NA,NA,2020-04-09,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 6, 2020",Actual,2020-02-06,April 2020,2020-04-30,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,NA,Phase 3,30,Actual,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:44:06Z,2021-10-17T08:44:06Z,569
NCT04252885,"ClinicalTrials.gov processed this data on October 15, 2021",2020-01-30,NA,NA,2020-06-29,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"January 28, 2020",Actual,2020-01-28,June 2020,2020-06-30,"May 31, 2020",Actual,2020-05-31,"April 30, 2020",Actual,2020-04-30,NA,Interventional,ELACOI,,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection",Completed,NA,Phase 4,86,Actual,Guangzhou 8th People's Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:45:27Z,2021-10-17T08:45:27Z,488
NCT04244591,"ClinicalTrials.gov processed this data on October 15, 2021",2020-01-23,NA,NA,2020-06-13,2020-01-25,2020-01-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-13,2020-06-16,Actual,"January 26, 2020",Actual,2020-01-26,February 2020,2020-02-29,"April 13, 2020",Actual,2020-04-13,"April 13, 2020",Actual,2020-04-13,NA,Interventional,NA,,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,"Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial",Completed,NA,Phase 2/Phase 3,80,Actual,Peking Union Medical College Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:46:47Z,2021-10-17T08:46:47Z,504
NCT04516564,"ClinicalTrials.gov processed this data on October 18, 2021",2020-08-13,NA,NA,2021-10-15,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-18,Estimate,"September 29, 2020",Actual,2020-09-29,October 2021,2021-10-31,"June 18, 2021",Actual,2021-06-18,"March 4, 2021",Actual,2021-03-04,NA,Interventional,NA,,"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AK119 in Healthy Subjects",Completed,NA,Phase 1,29,Actual,Akeso,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-19T08:28:55Z,2021-10-19T08:28:55Z,15
NCT04388826,"ClinicalTrials.gov processed this data on October 18, 2021",2020-05-13,NA,NA,2021-10-14,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-18,Estimate,"June 18, 2020",Actual,2020-06-18,October 2021,2021-10-31,"August 13, 2021",Actual,2021-08-13,"December 18, 2020",Actual,2020-12-18,NA,Interventional,NA,,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,"Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)",Completed,NA,Phase 2,39,Actual,Veru Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-19T08:29:28Z,2021-10-19T08:29:28Z,16
NCT04345991,"ClinicalTrials.gov processed this data on October 18, 2021",2020-04-10,NA,NA,2021-10-15,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-18,Estimate,"April 15, 2020",Actual,2020-04-15,October 2021,2021-10-31,"May 28, 2021",Actual,2021-05-28,"May 28, 2021",Actual,2021-05-28,NA,Interventional,CORIPLASM,,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - CORIMUNO-CORIPLASM : EFFICACY OF CONVALESCENT PLASMA TO TREAT SARS-COV2 INFECTED PATIENTS,Completed,NA,Phase 2,120,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-19T08:29:36Z,2021-10-19T08:29:36Z,15
NCT05042141,"ClinicalTrials.gov processed this data on October 19, 2021",2021-09-08,NA,NA,2021-10-16,2021-09-09,2021-09-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-16,2021-10-19,Estimate,"July 28, 2021",Actual,2021-07-28,September 2021,2021-09-30,"September 12, 2021",Actual,2021-09-12,"August 11, 2021",Actual,2021-08-11,NA,Interventional,KOVIR,,Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR),A Study to Evaluate the Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients Without Symptoms of Acute Respiratory Distress,Completed,NA,N/A,66,Actual,Sunstar Joint Stock Company,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-20T09:38:56Z,2021-10-20T09:38:56Z,14
NCT04806074,"ClinicalTrials.gov processed this data on October 19, 2021",2021-03-17,NA,NA,2021-10-14,2021-03-17,2021-03-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-19,Estimate,"August 14, 2020",Actual,2020-08-14,October 2021,2021-10-31,"September 6, 2021",Actual,2021-09-06,"December 6, 2020",Actual,2020-12-06,NA,Interventional,NA,,FOODLIT-Trial: Digital Behaviour Change Intervention to Improve Food Literacy Amidst the COVID-19 Pandemic,FOODLIT-Trial: Protocol of a Randomised Controlled Digital Intervention to Promote Food Literacy and Food Sustainability Behaviours in Adults Using the Health Action Process Approach (HAPA) and the Behaviour Change Techniques Taxonomy (BCTT) During the COVID-19 Pandemic,Completed,NA,N/A,215,Actual,"ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-20T09:41:08Z,2021-10-20T09:41:08Z,16
NCT04355767,"ClinicalTrials.gov processed this data on October 19, 2021",2020-04-17,2021-10-13,NA,2021-10-15,2020-04-17,2020-04-21,Actual,2021-10-15,2021-10-19,Estimate,NA,NA,NA,2021-10-15,2021-10-19,Estimate,"August 11, 2020",Actual,2020-08-11,October 2021,2021-10-31,"March 29, 2021",Actual,2021-03-29,"March 29, 2021",Actual,2021-03-29,NA,Interventional,C3PO,,Convalescent Plasma in Outpatients With COVID-19,Clinical-trial of COVID-19 Convalescent Plasma in Outpatients,Completed,NA,Phase 3,511,Actual,Stanford University,This study did not meet its maximum sample size of 900 participants due to a planned interim analysis that indicated that it was unlikely that there would be a difference in the rate of disease progression between the two groups if continued to the planned sample size.,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Data will be available indefinitely.,"Data requests will be managed by National Heart, Lung, and Blood Institute (NHLBI).",https://biodatacatalyst.nhlbi.nih.gov/,Yes,The complete de-identified patient data set will be shared.,2021-10-20T09:43:46Z,2021-10-20T09:43:46Z,15
NCT04927182,"ClinicalTrials.gov processed this data on October 20, 2021",2021-06-14,NA,NA,2021-10-19,2021-06-14,2021-06-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-20,Estimate,"October 15, 2020",Actual,2020-10-15,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 30, 2021",Actual,2021-09-30,NA,Interventional,NA,,Impact of Moderate Exercise Training on Vitals and Peak VO2 in Different Age Categories of Adult in COVID-19.,Impact of Moderate Exercise Training on Vitals and Peak VO2 in Different Age Categories of Adult in COVID-19.,Completed,NA,N/A,102,Actual,Riphah International University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-21T09:52:51Z,2021-10-21T09:52:51Z,11
NCT04790851,"ClinicalTrials.gov processed this data on October 20, 2021",2021-03-08,NA,NA,2021-10-12,2021-03-08,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-20,Estimate,"March 10, 2021",Actual,2021-03-10,October 2021,2021-10-31,"September 5, 2021",Actual,2021-09-05,"September 5, 2021",Actual,2021-09-05,NA,Interventional,NA,,Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4,"A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Beijing) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)",Completed,NA,Phase 4,1133,Actual,China National Biotec Group Company Limited,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-21T09:53:40Z,2021-10-21T09:53:40Z,18
NCT04726098,"ClinicalTrials.gov processed this data on October 20, 2021",2021-01-23,NA,NA,2021-10-19,2021-01-26,2021-01-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-20,Estimate,"January 15, 2021",Actual,2021-01-15,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"August 31, 2021",Actual,2021-08-31,NA,Interventional,HIGHLOWDEXA,,Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19,Efficacy of Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19,Completed,NA,Phase 4,198,Actual,Hospital Clinico Universitario de Santiago,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-21T09:54:07Z,2021-10-21T09:54:07Z,11
NCT04701502,"ClinicalTrials.gov processed this data on October 21, 2021",2021-01-04,NA,NA,2021-10-20,2021-01-07,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"November 9, 2020",Actual,2020-11-09,November 2020,2020-11-30,"February 15, 2021",Actual,2021-02-15,"February 15, 2021",Actual,2021-02-15,NA,Interventional,NA,,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Completed,NA,Phase 2,60,Actual,Catalysis SL,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-22T09:37:18Z,2021-10-22T09:37:18Z,10
NCT04980534,"ClinicalTrials.gov processed this data on October 21, 2021",2021-07-26,NA,NA,2021-10-20,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"January 8, 2021",Actual,2021-01-08,July 2021,2021-07-31,"September 15, 2021",Actual,2021-09-15,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,,Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip,Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip,Completed,NA,N/A,80,Actual,Catalysis SL,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-22T09:35:25Z,2021-10-22T09:35:25Z,10
NCT04400305,"ClinicalTrials.gov processed this data on October 21, 2021",2020-05-21,NA,NA,2021-10-19,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-21,Estimate,"May 20, 2020",Actual,2020-05-20,October 2021,2021-10-31,"August 30, 2021",Actual,2021-08-30,"August 30, 2021",Actual,2021-08-30,NA,Interventional,COVID-19,,"""Increasing Physical Activity in Canadian Adults Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""","""Increasing Physical Activity in Canadian Adults Who Have Been Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""",Completed,NA,N/A,37,Actual,University of Victoria,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-22T09:38:49Z,2021-10-22T09:38:49Z,11
NCT05089045,"ClinicalTrials.gov processed this data on October 22, 2021",2021-10-11,NA,NA,2021-10-21,2021-10-21,2021-10-22,Estimate,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-22,Estimate,"August 31, 2021",Actual,2021-08-31,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 16, 2021",Actual,2021-09-16,NA,Interventional,NA,,Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity,A Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant New Coronavirus Vaccine (CHO Cells) After Vaccination With Two Inactivated Vaccine in Healthy People Aged 18 and Above,Completed,NA,N/A,360,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-25T08:55:23Z,2021-10-25T08:55:23Z,9
NCT04347954,"ClinicalTrials.gov processed this data on October 21, 2021",2020-04-13,2021-10-15,NA,2021-10-19,2020-04-13,2020-04-15,Actual,2021-10-19,2021-10-21,Estimate,NA,NA,NA,2021-10-19,2021-10-21,Estimate,"August 15, 2020",Actual,2020-08-15,October 2021,2021-10-31,"December 13, 2020",Actual,2020-12-13,"December 13, 2020",Actual,2020-12-13,NA,Interventional,NA,Participants who received the allocated intervention and completed the study; participants with negative PCR nasal swab results at baseline or incomplete data were excluded.,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers,Completed,NA,Phase 1/Phase 2,47,Actual,Stanford University,The study did not meet its accrual goal of 45 participants with analyzable data.,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-22T09:39:05Z,2021-10-22T09:39:05Z,11
NCT04874766,"ClinicalTrials.gov processed this data on October 25, 2021",2021-04-23,NA,NA,2021-10-19,2021-05-02,2021-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-25,Estimate,"May 28, 2021",Actual,2021-05-28,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"July 15, 2021",Actual,2021-07-15,NA,Interventional,NA,,The Effects of Wearing a Face Mask During Exercise in Youth Hockey Players During COVID-19,The Effects of Wearing a Face Mask on Exercise Tolerance in Children's Hockey During the COVID-19 Pandemic,Completed,NA,N/A,26,Actual,University of Saskatchewan,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-26T08:53:54Z,2021-10-26T08:53:54Z,11
NCT04710199,"ClinicalTrials.gov processed this data on October 25, 2021",2021-01-05,NA,NA,2021-10-15,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-25,Estimate,"February 23, 2021",Actual,2021-02-23,April 2021,2021-04-30,"July 8, 2021",Actual,2021-07-08,"July 8, 2021",Actual,2021-07-08,NA,Interventional,COVIMAR,,Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19),Proof-of-concept Trial to Evaluate the Safety and Efficacy of Maraviroc in Severe Acute Respiratory Syndrome (SARS) Coronavirus-2 (CoV-2) Infected Patients Hospitalized for COVID-19,Completed,NA,Phase 2,44,Actual,FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-26T08:54:58Z,2021-10-26T08:54:58Z,15
NCT05079308,"ClinicalTrials.gov processed this data on October 26, 2021",2021-09-08,NA,NA,2021-10-18,2021-10-14,2021-10-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"March 1, 2021",Actual,2021-03-01,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,,"Clinical Trial on the Efficacy of Different Masks With and Without a Peripheral Sealing Device, Against Covid-19","Clinical Trial on the Level of Respiratory Protection of Surgical Face Masks and Filtering Face Pieces (FFP2), With and Without a Peripheral Sealing Device, Against Covid-19",Completed,NA,N/A,210,Actual,University of the Balearic Islands,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-27T11:13:52Z,2021-10-27T11:13:52Z,12
NCT04853836,"ClinicalTrials.gov processed this data on October 26, 2021",2021-04-16,NA,NA,2021-10-24,2021-04-20,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-24,2021-10-26,Estimate,"November 15, 2020",Actual,2020-11-15,October 2021,2021-10-31,"October 1, 2021",Actual,2021-10-01,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,,Olfactory Disfunction and Co-ultraPEALut,Olfactory Disfunction After COVID-19: Conventional Therapy Versus Intervention Treatment With Co-ultraPEALut,Completed,NA,Phase 4,200,Actual,University Of Perugia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,request to PI,NA,Yes,"Shared, only anonymized data directly requested to PI",2021-10-27T11:16:29Z,2021-10-27T11:16:29Z,6
NCT04657809,"ClinicalTrials.gov processed this data on October 26, 2021",2020-12-02,NA,NA,2021-10-25,2020-12-02,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"October 1, 2020",Actual,2020-10-01,October 2021,2021-10-31,"March 20, 2021",Actual,2021-03-20,"February 18, 2021",Actual,2021-02-18,NA,Interventional,NA,,Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia,"""Insulin Fast Dissolving Film for Intranasal Delivery Via Olfactory Region, a Promising Approach for the Treatment of Anosmia in COVID 19 Patients: Design, In-vitro Characterization and Clinical Evaluation.""",Completed,NA,Phase 2,40,Actual,Deraya University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-27T11:17:43Z,2021-10-27T11:17:43Z,5
NCT04655638,"ClinicalTrials.gov processed this data on October 26, 2021",2020-12-03,NA,NA,2021-10-25,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"February 10, 2021",Actual,2021-02-10,October 2021,2021-10-31,"October 25, 2021",Actual,2021-10-25,"September 22, 2021",Actual,2021-09-22,NA,Interventional,COVID-HIGH,,HFNT vs. COT in COVID-19,High-Flow Nasal Therapy Versus Conventional Oxygen Therapy in Patients With COVID-19: A Randomized Controlled Trial (The COVID-HIGH Trial),Completed,NA,N/A,364,Actual,Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-27T11:17:44Z,2021-10-27T11:17:44Z,5
NCT04504240,"ClinicalTrials.gov processed this data on October 26, 2021",2020-08-06,NA,NA,2021-10-23,2020-08-06,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-23,2021-10-26,Estimate,"August 1, 2020",Actual,2020-08-01,October 2021,2021-10-31,"April 15, 2021",Actual,2021-04-15,"April 15, 2021",Actual,2021-04-15,NA,Interventional,NA,,Role of Famotidine in the Clinical Improvement of COVID-19 Patients.,Role of Famotidine in the Clinical Recovery and Symptomatic Improvement of COVID-19 Patients.,Completed,NA,Phase 3,208,Actual,Chattogram General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-27T11:18:42Z,2021-10-27T11:18:42Z,7
NCT04444700,"ClinicalTrials.gov processed this data on October 26, 2021",2020-06-22,NA,NA,2021-10-25,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"July 4, 2020",Actual,2020-07-04,October 2021,2021-10-31,"October 14, 2021",Actual,2021-10-14,"May 10, 2021",Actual,2021-05-10,NA,Interventional,RAPID-BRAZIL,,A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic,UtilizaÃ§Ã£o da Enoxaparina em Dose Anticoagulante em Pacientes Hospitalizados Com sÃ­ndrome respiratÃ³ria Aguda Grave Por COVID-19,Completed,NA,Phase 3,465,Actual,University of Sao Paulo General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-27T11:19:01Z,2021-10-27T11:19:01Z,5
NCT04435379,"ClinicalTrials.gov processed this data on October 26, 2021",2020-06-16,NA,NA,2021-10-25,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"June 18, 2020",Actual,2020-06-18,October 2021,2021-10-31,"October 12, 2021",Actual,2021-10-12,"October 12, 2021",Actual,2021-10-12,NA,Interventional,NA,,Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in the SARS-CoV-2 Pandemic by Modulating the Immune System",Completed,NA,Phase 3,2038,Actual,Vakzine Projekt Management GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is uncertainty whether the European Union General Data Protection Regulation allows dissemination of individual participant data to other researchers. Some reasons why the EU Regulation would not allow this are the lack of suitable safeguards when personal data are transferred to any researcher asking for it and the impairment of the rights of the subjects for erasure of their data once they are disseminated.,2021-10-27T11:19:03Z,2021-10-27T11:19:03Z,5
NCT04429854,"ClinicalTrials.gov processed this data on October 26, 2021",2020-06-09,NA,NA,2021-10-18,2020-06-09,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"May 2, 2020",Actual,2020-05-02,October 2021,2021-10-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,DAWN-Plasma,,Donated Antibodies Working Against nCoV,"A Randomized, Open-label, Adaptive, Proof-of-concept Clinical Trial of Donated Antibodies Working Against With COVID-19: DAWN-PLASMA",Completed,NA,Phase 2,483,Actual,Universitaire Ziekenhuizen Leuven,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-27T11:19:05Z,2021-10-27T11:19:05Z,12
NCT04387760,"ClinicalTrials.gov processed this data on October 26, 2021",2020-05-09,NA,NA,2021-10-25,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"August 11, 2020",Actual,2020-08-11,August 2021,2021-08-31,"April 7, 2021",Actual,2021-04-07,"March 6, 2021",Actual,2021-03-06,NA,Interventional,NA,,Favipiravir vs Hydroxychloroquine vs Control in COVID -19,Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial,Completed,NA,Phase 2,150,Actual,Royal College of Surgeons in Ireland - Medical University of Bahrain,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,"Dr Manaf will act as the data custodian and is responsible for the storage, handling and quality of the study data.
Data will be collected in the case report form to allow for cross referencing to check validity.
Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point). A label stating the date after which the documents can be destroyed will be placed on the inside front cover of the case notes of trial participants.",Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2021-10-27T11:19:16Z,2021-10-27T11:19:16Z,5
NCT04362085,"ClinicalTrials.gov processed this data on October 26, 2021",2020-04-20,NA,NA,2021-10-22,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-26,Estimate,"May 11, 2020",Actual,2020-05-11,October 2021,2021-10-31,"October 14, 2021",Actual,2021-10-14,"May 10, 2021",Actual,2021-05-10,NA,Interventional,NA,,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG),Completed,NA,Phase 3,465,Actual,Unity Health Toronto,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-27T11:19:27Z,2021-10-27T11:19:27Z,8
NCT04356534,"ClinicalTrials.gov processed this data on October 26, 2021",2020-04-15,NA,NA,2021-10-25,2020-04-17,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"April 19, 2020",Actual,2020-04-19,July 2020,2020-07-31,"July 9, 2020",Actual,2020-07-09,"June 15, 2020",Actual,2020-06-15,NA,Interventional,NA,,Convalescent Plasma Trial in COVID -19 Patients,Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial,Completed,NA,N/A,40,Actual,Royal College of Surgeons in Ireland - Medical University of Bahrain,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Dr Manaf will act as the data custodian and is responsible for the storage, handling and quality of the study data.
Data will be collected in the case report form to allow for cross referencing to check validity.
Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point). A label stating the date after which the documents can be destroyed will be placed on the inside front cover of the case notes of trial participants.",Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2021-10-27T11:19:27Z,2021-10-27T11:19:27Z,5
NCT04631705,"ClinicalTrials.gov processed this data on October 26, 2021",2020-11-10,NA,NA,2021-10-23,2020-11-14,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-23,2021-10-26,Estimate,"December 14, 2020",Actual,2020-12-14,October 2021,2021-10-31,"September 23, 2021",Actual,2021-09-23,"September 23, 2021",Actual,2021-09-23,NA,Interventional,NA,,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation,A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,Completed,NA,Phase 1/Phase 2,45,Actual,University of Cologne,,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-27T11:17:54Z,2021-10-27T11:17:54Z,7
NCT05096026,"ClinicalTrials.gov processed this data on October 27, 2021",2021-10-25,NA,NA,2021-10-26,2021-10-26,2021-10-27,Estimate,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"March 29, 2021",Actual,2021-03-29,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"May 20, 2021",Actual,2021-05-20,NA,Interventional,NA,,Effect of Electronic and Mail Outreach From Primary Care Physicians for COVID-19 Vaccination Among Elderly Patients,Effect of Electronic and Mail Outreach From Primary Care Physicians for COVID-19 Vaccination Among Elderly Patients,Completed,NA,N/A,8287,Actual,Kaiser Permanente,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"December 1, 2022 through December 1, 2024","Deidentified data will be shared on submission of a protocol approved by the Kaiser Permanente Northern California Institutional Review Board or Research Determination Official, and contingent on appropriate data sharing agreement being completed.",NA,Yes,"Deidentified data will be shared on submission of a protocol approved by the Kaiser Permanente Northern California Institutional Review Board or Research Determination Official, and contingent on appropriate data sharing agreement being completed.",2021-10-28T09:06:47Z,2021-10-28T09:06:47Z,4
NCT04960228,"ClinicalTrials.gov processed this data on October 27, 2021",2021-06-30,NA,NA,2021-10-26,2021-07-09,2021-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"July 30, 2021",Actual,2021-07-30,October 2021,2021-10-31,"September 13, 2021",Actual,2021-09-13,"September 13, 2021",Actual,2021-09-13,NA,Interventional,NA,,Exploring Changes in COVID-19 Vaccination Intentions by Prompting Altruistic Motives Using a Video Intervention,Enhancing COVID-19 Vaccination Intentions by Eliciting Prosocial Altruistic Motives: Evaluating the Efficacy of a Brief Video-Based Intervention,Completed,NA,N/A,1623,Actual,Sir Mortimer B. Davis - Jewish General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Consent form, data collection method, and organizational policy means only aggregated data will be shared with other researchers.",2021-10-28T09:09:49Z,2021-10-28T09:09:49Z,4
NCT04646044,"ClinicalTrials.gov processed this data on October 27, 2021",2020-11-14,NA,NA,2021-10-26,2020-11-24,2020-11-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"November 13, 2020",Actual,2020-11-13,October 2021,2021-10-31,"May 18, 2021",Actual,2021-05-18,"May 11, 2021",Actual,2021-05-11,NA,Interventional,NA,,A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19,"A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Mild COVID-19",Completed,NA,Phase 1,30,Actual,Nektar Therapeutics,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-28T09:12:14Z,2021-10-28T09:12:14Z,4
NCT04507256,"ClinicalTrials.gov processed this data on October 27, 2021",2020-08-07,NA,NA,2021-10-26,2020-08-07,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"August 18, 2020",Actual,2020-08-18,October 2021,2021-10-31,"October 19, 2021",Actual,2021-10-19,"October 19, 2021",Actual,2021-10-19,NA,Interventional,NA,,AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19,"A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD7442 in Healthy Adults",Completed,NA,Phase 1,60,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",2021-10-28T09:13:13Z,2021-10-28T09:13:13Z,4
NCT04410549,"ClinicalTrials.gov processed this data on October 27, 2021",2020-05-21,NA,NA,2021-10-26,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"June 1, 2020",Actual,2020-06-01,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 30, 2021",Actual,2021-09-30,NA,Interventional,NA,,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Optical Coherence Tomography for Microvascular Lung Vessels Obstructive Thromboinflammatory Syndrome Assessment in Patients With COVID-19: an Exploratory Study,Completed,NA,N/A,13,Actual,IRCCS San Raffaele,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-28T09:14:02Z,2021-10-28T09:14:02Z,4
NCT05012267,"ClinicalTrials.gov processed this data on October 28, 2021",2021-08-11,NA,NA,2021-10-27,2021-08-17,2021-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"March 25, 2021",Actual,2021-03-25,October 2021,2021-10-31,"October 27, 2021",Actual,2021-10-27,"October 27, 2021",Actual,2021-10-27,NA,Interventional,OmeLEtte,,Duration of Prone Position in the Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).,OptiMal pronE Position LEnghT in Patients With acuTE Respiratory Distress Syndrome Due to COVID-19.,Completed,NA,N/A,61,Actual,Hospital Universitario 12 de Octubre,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-29T09:11:11Z,2021-10-29T09:11:11Z,3
NCT04418947,"ClinicalTrials.gov processed this data on October 28, 2021",2020-05-29,2021-10-25,NA,2021-10-26,2020-06-02,2020-06-05,Actual,2021-10-26,2021-10-28,Estimate,NA,NA,NA,2021-10-26,2021-10-28,Estimate,"June 15, 2020",Actual,2020-06-15,October 2021,2021-10-31,"July 17, 2020",Actual,2020-07-17,"July 17, 2020",Actual,2020-07-17,NA,Interventional,NA,,Project Resurgence Communication Trial,Comparison of the Effectiveness of Communication Strategies on the Return to In-Person Visits to a Medical Center After the Emergence of COVID-19: A Randomized Trial,Completed,NA,N/A,11120,Actual,University of Pennsylvania,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-29T09:15:18Z,2021-10-29T09:15:18Z,4
NCT04497324,"ClinicalTrials.gov processed this data on October 28, 2021",2020-07-31,NA,NA,2021-10-20,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"September 21, 2020",Actual,2020-09-21,March 2021,2021-03-31,"April 17, 2021",Actual,2021-04-17,"April 17, 2021",Actual,2021-04-17,NA,Interventional,NA,,PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19,PERUCONPLASMA: Randomized Clinical Trial to Evaluate Safety and Efficacy of the Use of Convalescent Plasma in Hospitalized Patients With COVID-19,Completed,NA,Phase 2,100,Actual,Universidad Peruana Cayetano Heredia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-29T09:15:03Z,2021-10-29T09:15:03Z,10
NCT04484207,"ClinicalTrials.gov processed this data on October 28, 2021",2020-07-21,2021-10-12,NA,2021-10-26,2020-07-21,2020-07-23,Actual,2021-10-26,2021-10-28,Estimate,NA,NA,NA,2021-10-26,2021-10-28,Estimate,"July 6, 2020",Actual,2020-07-06,October 2021,2021-10-31,"October 26, 2020",Actual,2020-10-26,"October 20, 2020",Actual,2020-10-20,NA,Interventional,NA,,Addressing COVID-19 Mental Health Problems Among US Veterans,Addressing COVID-19 Mental Health Problems Among US Veterans,Completed,NA,N/A,172,Actual,"Research Foundation for Mental Hygiene, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,two months,Co-Is,NA,Yes,"Data will be shared as needed with investigators, IRB etc. A plan will be determined in the short future",2021-10-29T09:15:07Z,2021-10-29T09:15:07Z,4
NCT04414241,"ClinicalTrials.gov processed this data on October 28, 2021",2020-06-01,NA,NA,2021-10-20,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"June 25, 2020",Actual,2020-06-25,June 2020,2020-06-30,"November 23, 2020",Actual,2020-11-23,"November 23, 2020",Actual,2020-11-23,NA,Interventional,NA,,Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19,"Hydroxychloroquine to Prevent SARS-CoV-2 Infection Among Healthcare Workers: Randomized Controlled, Open-label, Phase 3 Clinical Trial",Completed,NA,Phase 3,68,Actual,Universidad Peruana Cayetano Heredia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-29T09:15:19Z,2021-10-29T09:15:19Z,10
NCT04399356,"ClinicalTrials.gov processed this data on October 28, 2021",2020-05-19,NA,NA,2021-10-27,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"October 1, 2020",Actual,2020-10-01,October 2021,2021-10-31,"August 19, 2021",Actual,2021-08-19,"April 20, 2021",Actual,2021-04-20,NA,Interventional,NA,,Niclosamide for Mild to Moderate COVID-19,Niclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19),Completed,NA,Phase 2,73,Actual,Tufts Medical Center,,2,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-29T09:15:23Z,2021-10-29T09:15:23Z,3
NCT05080179,"ClinicalTrials.gov processed this data on October 15, 2021",2021-10-12,NA,NA,2021-10-13,2021-10-13,2021-10-15,Estimate,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-15,Estimate,"December 11, 2020",Actual,2020-12-11,October 2021,2021-10-31,"January 28, 2021",Actual,2021-01-28,"January 28, 2021",Actual,2021-01-28,NA,Interventional,NA,,Impact of Nudges on Downloads of COVID-19 Exposure Notification Smartphone Apps: A Randomized Trial,The Interactive Effect of Social Norm and Self (vs. Others) Benefit Nudges on Downloads of COVID-19 Exposure Notification Smartphone Apps: A Randomized Trial,Completed,NA,N/A,39937,Actual,University of Pennsylvania,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:40:01Z,2021-10-17T06:40:01Z,17
NCT05077306,"ClinicalTrials.gov processed this data on October 15, 2021",2021-10-08,NA,NA,2021-10-12,2021-10-12,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-14,Actual,"April 15, 2021",Actual,2021-04-15,October 2021,2021-10-31,"June 30, 2021",Actual,2021-06-30,"May 15, 2021",Actual,2021-05-15,NA,Interventional,MADC-19,,Receptive Music Therapy on Anxiety and Vital Parameters in Hospitalized Covid-19 Patients.,Effect of Musical Listening on Anxiety and Depression in Patients Hospitalized for Covid-19: a Randomized Controlled Trial,Completed,NA,N/A,40,Actual,Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:40:31Z,2021-10-17T06:40:31Z,18
NCT05075304,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-22,NA,NA,2021-10-08,2021-10-08,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-12,Actual,"February 21, 2020",Actual,2020-02-21,August 2021,2021-08-31,"April 14, 2020",Actual,2020-04-14,"April 14, 2020",Actual,2020-04-14,NA,Interventional,NA,,"A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients","A Phase Ib, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BDB-001 Injection in Patients With Novel Coronavirus (2019-nCoV) Infection",Completed,NA,Phase 1,18,Actual,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:40:53Z,2021-10-17T06:40:53Z,22
NCT05054114,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-21,NA,NA,2021-09-23,2021-09-21,2021-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-29,Actual,"December 21, 2020",Actual,2020-12-21,September 2021,2021-09-30,"September 2, 2021",Actual,2021-09-02,"May 25, 2021",Actual,2021-05-25,NA,Interventional,NA,,"Study of the Use of Nasal IFN-Î³ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19","Prospective Randomized Open-label Comparative Study of the Use of Intranasal Form of Interferon Gamma Human Recombinant in Patients for the Prevention of Acute Respiratory Viral Infections, Including COVID-19",Completed,NA,N/A,630,Actual,SPP Pharmaclon Ltd.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:43:47Z,2021-10-17T06:43:47Z,37
NCT05045989,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-06,NA,NA,2021-09-15,2021-09-09,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-22,Actual,"April 1, 2021",Actual,2021-04-01,September 2021,2021-09-30,"July 31, 2021",Actual,2021-07-31,"July 31, 2021",Actual,2021-07-31,NA,Interventional,RB-TPP,,Process Evaluation of a Residence-Based SARS-CoV-2 Testing Participation Pilot,Mixed-methods Process Evaluation of a Residence-Based SARS-CoV-2 Testing Participation Pilot on a UK University Campus During the COVID-19 Pandemic.,Completed,NA,N/A,152,Actual,University of Nottingham,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The datasets generated and/or analysed during the current study are not publicly available due to risk of identification of participants and service providers but are available from the corresponding author on reasonable request.,2021-10-17T06:44:53Z,2021-10-17T06:44:53Z,45
NCT05037448,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-24,NA,NA,2021-08-31,2021-08-31,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-08,Actual,"August 17, 2020",Actual,2020-08-17,March 2021,2021-03-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,,Exploring Telehealth to Deliver Me & My Wishes During Coronavirus-19,Me & My Wishes: An Efficacy Trial of Long Term Care Residents With Alzheimer's Using Videos to Communicate Care Preferences With Caregivers,Completed,NA,N/A,17,Actual,University of Utah,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:46:05Z,2021-10-17T06:46:05Z,60
NCT05037253,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-25,NA,NA,2021-09-06,2021-09-06,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"October 30, 2020",Actual,2020-10-30,August 2021,2021-08-31,"May 30, 2021",Actual,2021-05-30,"May 30, 2021",Actual,2021-05-30,NA,Interventional,NA,,COVID-19 Morbidity in Healthcare Workers and Vitamin D Supplementation,The Effect of Vitamin D Supplementation in Reducing COVID-19 Morbidity Among Healthcare Workers,Completed,NA,Phase 4,128,Actual,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:46:07Z,2021-10-17T06:46:07Z,54
NCT05037240,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-03,NA,NA,2021-09-06,2021-09-06,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"January 12, 2021",Actual,2021-01-12,September 2021,2021-09-30,"May 25, 2021",Actual,2021-05-25,"April 6, 2021",Actual,2021-04-06,NA,Interventional,NA,,Quercetin in the Prevention of Covid-19 Infection,"Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of an Oral Nutritional Supplement Based on Quercetin in the Prevention of Covid-19 Infection for a Duration of 3 Months",Completed,NA,N/A,80,Actual,Azienda di Servizi alla Persona di Pavia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:46:07Z,2021-10-17T06:46:07Z,54
NCT05035550,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-12,NA,NA,2021-09-02,2021-09-02,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"February 4, 2021",Actual,2021-02-04,September 2021,2021-09-30,"May 5, 2021",Actual,2021-05-05,"May 5, 2021",Actual,2021-05-05,NA,Interventional,NA,,Effects of Open-label Placebos on COVID-related Psychological Health,"Effects of Open-label Placebos Administered Through Telehealth on COVID-related Stress, Anxiety, and Depression",Completed,NA,N/A,64,Actual,Michigan State University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,IPD will be available one year after publication,IPD will be available upon request.,NA,Yes,The investigators plan to share the IPD used in the analysis for manuscript submission.,2021-10-17T06:46:20Z,2021-10-17T06:46:20Z,58
NCT05021588,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-16,NA,NA,2021-08-23,2021-08-23,2021-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-25,Actual,"April 12, 2020",Actual,2020-04-12,August 2021,2021-08-31,"September 10, 2020",Actual,2020-09-10,"August 2, 2020",Actual,2020-08-02,NA,Interventional,SARS-CoV-2,,Steroid and Anticoagulant Therapy in covid19,Challenges in Steroid and Anticoagulant Therapy in Severe COVID-19 Pneumonia: A Prospective Study,Completed,NA,N/A,123,Actual,Assiut University,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:48:15Z,2021-10-17T06:48:15Z,68
NCT05021016,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-19,NA,NA,2021-08-26,2021-08-19,2021-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-27,Actual,"November 19, 2020",Actual,2020-11-19,August 2021,2021-08-31,"January 30, 2021",Actual,2021-01-30,"January 30, 2021",Actual,2021-01-30,NA,Interventional,NA,,Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above,"An Open Study of the Safety, Reactogenicity and Immunogenicity of the Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), With the Involvement of Volunteers Aged 60 Years and Above (Phase III-IV)",Completed,NA,Phase 3,150,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:48:20Z,2021-10-17T06:48:20Z,65
NCT05018065,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-23,NA,NA,2021-08-24,2021-08-23,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-27,Actual,"May 1, 2020",Actual,2020-05-01,January 2021,2021-01-31,"December 30, 2020",Actual,2020-12-30,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,,Sexual Functions and Covid-19,Evaluation of Women's Sexual Functions After Having Covid-19,Completed,NA,N/A,101,Actual,Gaziosmanpasa Research and Education Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:48:43Z,2021-10-17T06:48:43Z,67
NCT05019287,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-03,NA,NA,2021-08-28,2021-08-22,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-28,2021-09-02,Actual,"April 17, 2021",Actual,2021-04-17,August 2021,2021-08-31,"June 9, 2021",Actual,2021-06-09,"May 21, 2021",Actual,2021-05-21,NA,Interventional,NA,,Menstrual Blood Stem Cells in Severe Covid-19,"Safety and Efficacy Study of Allogeneic Human Menstrual Blood Stem Cells Secretome to Treat Severe Covid-19 Patients, Clinical Trial Phase I&II",Completed,NA,Phase 1/Phase 2,29,Actual,Avicenna Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:48:33Z,2021-10-17T06:48:33Z,63
NCT05017493,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-04,NA,NA,2021-08-16,2021-08-16,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-24,Actual,"July 1, 2020",Actual,2020-07-01,August 2021,2021-08-31,"February 8, 2021",Actual,2021-02-08,"December 7, 2020",Actual,2020-12-07,NA,Interventional,NA,,"Treatment of Covid-19 With a Herbal Compound, Xagrotin","Treatment of Early-Stage Covid-19 With a Herbal Compound, Xagrotin",Completed,NA,Phase 1/Phase 2,539,Actual,Biomad AS,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:48:49Z,2021-10-17T06:48:49Z,75
NCT05010876,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-16,NA,NA,2021-08-17,2021-08-17,2021-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"February 4, 2021",Actual,2021-02-04,August 2021,2021-08-31,"June 21, 2021",Actual,2021-06-21,"June 13, 2021",Actual,2021-06-13,NA,Interventional,AntagoBrad-Cov,,Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).,Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).,Completed,NA,Phase 2,44,Actual,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T06:49:42Z,2021-10-17T06:49:42Z,74
NCT05007600,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-05,NA,NA,2021-08-12,2021-08-12,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-16,Actual,"February 1, 2021",Actual,2021-02-01,August 2021,2021-08-31,"July 30, 2021",Actual,2021-07-30,"July 1, 2021",Actual,2021-07-01,NA,Interventional,NA,,Online Interactive Courses on Loneliness and Quality of Life of Older Adults,Investigating the Effectiveness of Online Interactive Courses on Loneliness and Quality of Life of Older Adults in the Community During COVID-19 Pandemic: A Pilot Study and a Randomized Controlled Trial,Completed,NA,N/A,89,Actual,National Cheng Kung University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:50:12Z,2021-10-17T06:50:12Z,79
NCT05007496,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-11,NA,NA,2021-08-16,2021-08-12,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-20,Actual,"April 14, 2021",Actual,2021-04-14,August 2021,2021-08-31,"May 31, 2021",Actual,2021-05-31,"May 31, 2021",Actual,2021-05-31,NA,Interventional,NA,,"Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19","Phase II Randomized Double Blind Clinical Trial Three Preventive Vaccine Formulations Consisting of Autologous Dendritic Cells and Lymphocytes Incubated With Different Quantities of Spike Protein Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Not Proven Actively Infected or Never Infected With COVID-19",Completed,NA,Phase 2,145,Actual,"Aivita Biomedical, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T06:50:13Z,2021-10-17T06:50:13Z,75
NCT05004753,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-26,NA,NA,2021-09-01,2021-08-11,2021-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-09,Actual,"September 30, 2020",Actual,2020-09-30,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,,A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects,"A Prospective, Randomized, Multi-center, Open Label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg Capsule in Treatment of Adult Subjects With COVID-19",Completed,NA,Phase 4,120,Actual,Mateon Therapeutics,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:50:35Z,2021-10-17T06:50:35Z,59
NCT05001542,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-28,NA,NA,2021-10-05,2021-08-05,2021-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-07,Actual,"May 31, 2021",Actual,2021-05-31,October 2021,2021-10-31,"August 30, 2021",Actual,2021-08-30,"August 30, 2021",Actual,2021-08-30,NA,Interventional,VR,,Digital Interventions for Detection and Reduction of Moral Distress,"Could Digital Interventions Help Understand And ""Flatten The Curve"" Of Distress Due To Moral Injury Among Health Care Workers During The COVID Pandemic?",Completed,NA,N/A,15,Actual,Unity Health Toronto,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:51:02Z,2021-10-17T06:51:02Z,25
NCT04998708,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-08,NA,NA,2021-08-08,2021-08-08,2021-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-08,2021-08-10,Actual,"December 1, 2020",Actual,2020-12-01,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,,Relaxation Exercise in Patients With COVID-19,An Integrated Relaxation Protocol Improves Immune Biomarkers and Reduces COVID-19 Severity and Progression in Patients With COVID-19,Completed,NA,N/A,30,Actual,Beni-Suef University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T06:51:25Z,2021-10-17T06:51:25Z,83
NCT04998253,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-19,NA,NA,2021-08-09,2021-08-07,2021-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-13,Actual,"October 1, 2020",Actual,2020-10-01,August 2021,2021-08-31,"May 15, 2021",Actual,2021-05-15,"November 30, 2020",Actual,2020-11-30,NA,Interventional,COVID-19,,Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2,A Randomized Pilot Clinical Trial of the Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction of Sevoflurane in Patient's Whit ARDS Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2),Completed,NA,Early Phase 1,24,Actual,Unidad Temporal COVID-19 en Centro Citibanamex,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:51:29Z,2021-10-17T06:51:29Z,82
NCT04993547,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-04,NA,NA,2021-08-05,2021-08-05,2021-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-06,Actual,"March 31, 2021",Actual,2021-03-31,March 2021,2021-03-31,"June 10, 2021",Actual,2021-06-10,"June 9, 2021",Actual,2021-06-09,NA,Interventional,NA,,Cluster-RCT Collective Nasopharyngeal COVID-19 Testing Amongst Pupils,Peers' and Parent's Presence During Collective Nasopharyngeal COVID-19 Testing Amongst Pupils: A Cluster-Randomized Controlled Trial,Completed,NA,N/A,952,Actual,"University Hospital, Ghent",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:52:09Z,2021-10-17T06:52:09Z,86
NCT04992000,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-29,NA,NA,2021-08-05,2021-07-29,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-12,Actual,"June 1, 2020",Actual,2020-06-01,August 2021,2021-08-31,"December 1, 2020",Actual,2020-12-01,"September 1, 2020",Actual,2020-09-01,NA,Interventional,NA,,Self-Care of Hypertension Among Older Adults During COVID-19,Self-Care of Hypertension of Older Adults During COVID-19 Lockdown Period: A Randomized Controlled Trial,Completed,NA,N/A,120,Actual,"Near East University, Turkey",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:52:22Z,2021-10-17T06:52:22Z,86
NCT04990830,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-29,NA,NA,2021-08-03,2021-08-03,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-05,Actual,"February 3, 2021",Actual,2021-02-03,August 2021,2021-08-31,"May 21, 2021",Actual,2021-05-21,"April 21, 2021",Actual,2021-04-21,NA,Interventional,NA,,Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia,Early Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia: A Phase IIb Trial,Completed,NA,Phase 2/Phase 3,80,Actual,Istanbul University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Data sharing will be decided on a later date depending on completion of further study Phases,2021-10-17T06:52:32Z,2021-10-17T06:52:32Z,88
NCT04729491,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-25,NA,NA,2021-01-25,2021-01-25,2021-01-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-28,Actual,"June 30, 2020",Actual,2020-06-30,June 2020,2020-06-30,"October 7, 2020",Actual,2020-10-07,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,,EAT-DUTA AndroCoV Trial,Early Antiandrogen Treatment (EAT) With Dutasteride for COVID-19 (EAT-DUTA AndroCoV Trial),Completed,NA,Phase 2/Phase 3,138,Actual,Corpometria Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:30:29Z,2021-10-17T07:30:29Z,278
NCT04981379,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-26,NA,NA,2021-07-26,2021-07-26,2021-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-29,Actual,"November 16, 2020",Actual,2020-11-16,June 2021,2021-06-30,"February 16, 2021",Actual,2021-02-16,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NA,,Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment,"Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment",Completed,NA,Phase 3,1120,Actual,Health Institutes of Turkey,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:53:55Z,2021-10-17T06:53:55Z,96
NCT04980508,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-26,NA,NA,2021-07-26,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-28,Actual,"February 20, 2021",Actual,2021-02-20,July 2021,2021-07-31,"May 30, 2021",Actual,2021-05-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,,Effects of COVID-19 on Cavernous Smooth Muscle,COVID-19 Can Cause Cavernous Smooth Muscle Damage: Investigation of the Effects of COVID-19 on Cavernous Smooth Muscle by Corpus Cavernosum Electromyography,Completed,NA,N/A,29,Actual,Ankara Yildirim BeyazÄ±t University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:54:02Z,2021-10-17T06:54:02Z,96
NCT04972864,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-15,NA,NA,2021-07-21,2021-07-21,2021-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"March 1, 2021",Actual,2021-03-01,July 2021,2021-07-31,"July 18, 2021",Actual,2021-07-18,"July 18, 2021",Actual,2021-07-18,NA,Interventional,NA,,Effects of Respiratory Muscle Training in Patients With Post COVID-19,Effects of Respiratory Muscle Training in Patients With Post COVID-19,Completed,NA,N/A,24,Actual,Gazi University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:55:07Z,2021-10-17T06:55:07Z,101
NCT04977921,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-17,NA,NA,2021-07-22,2021-07-22,2021-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-27,Actual,"January 17, 2021",Actual,2021-01-17,July 2021,2021-07-31,"May 30, 2021",Actual,2021-05-30,"May 15, 2021",Actual,2021-05-15,NA,Interventional,EDU,,Lab Skills Nursing Education Into Effective Clinical Practice During COVID-19: Elsevier Clinical Skill Platform,An Authentic Solution to Translate Lab Skills Nursing Education Into Effective Clinical Practice During COVID-19: Elsevier Clinical Skill Platform,Completed,NA,N/A,50,Actual,Beni-Suef University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,data analysis completed July writing paper on August publish paper on September,2021-10-17T06:54:23Z,2021-10-17T06:54:23Z,100
NCT04973488,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-20,NA,NA,2021-07-20,2021-07-20,2021-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-22,Actual,"July 25, 2020",Actual,2020-07-25,July 2021,2021-07-31,"January 10, 2021",Actual,2021-01-10,"January 10, 2021",Actual,2021-01-10,NA,Interventional,NA,,Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients,Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients,Completed,NA,Phase 2/Phase 3,38,Actual,"University of Medicine and Pharmacy ""Victor Babes"" Timisoara",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will become available at 6 months after registering the study. It will be available for 36 months,"Data will be shared with interested researchers, contact: novacescu_alex@yahoo.com",NA,Yes,"We plan on sharing treatment protocol, demographic data of the study cohort, primary outcomes, secondary outcomes, miscellaneous data, treatment scheme, statystical data",2021-10-17T06:55:01Z,2021-10-17T06:55:01Z,102
NCT04962906,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-08,NA,NA,2021-08-18,2021-07-13,2021-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-20,Actual,"July 5, 2021",Actual,2021-07-05,July 2021,2021-07-31,"August 15, 2021",Actual,2021-08-15,"August 5, 2021",Actual,2021-08-05,NA,Interventional,NA,,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes,"Randomised Phase II Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes (rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV).",Completed,NA,Phase 2,192,Actual,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T06:56:30Z,2021-10-17T06:56:30Z,73
NCT04962022,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-10,NA,NA,2021-10-11,2021-07-10,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Actual,"July 20, 2021",Actual,2021-07-20,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 30, 2021",Actual,2021-09-30,NA,Interventional,NA,,Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants,"COVID-19: A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF PF-07321332/RITONAVIR IN HEALTHY PARTICIPANTS",Completed,NA,Phase 1,12,Actual,Pfizer,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-17T06:56:37Z,2021-10-17T06:56:37Z,19
NCT04958863,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-30,NA,NA,2021-07-09,2021-07-09,2021-07-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"January 1, 2021",Actual,2021-01-01,July 2021,2021-07-31,"June 30, 2021",Actual,2021-06-30,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,,Impact of Facemasks on Running During COVID-19 Pandemic,Running and Facemasks During COVID-19 Pandemic: a Randomized Crossover Trial,Completed,NA,N/A,18,Actual,Fundacion Clinica Valle del Lili,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:57:04Z,2021-10-17T06:57:04Z,113
NCT04957940,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-06,NA,NA,2021-09-26,2021-07-07,2021-07-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-26,2021-09-28,Actual,"July 5, 2021",Actual,2021-07-05,September 2021,2021-09-30,"September 26, 2021",Actual,2021-09-26,"September 20, 2021",Actual,2021-09-20,NA,Interventional,NA,,Lipid Emulsion Infusion and COVID-19 Patients,Fish-Oil-Based Lipid Emulsion Infusion (FOBLE): Could Early Use Provide a Potential Therapy to Stop Moderate Cases of COVID-19 Diseased Patient's Shift to ICU?,Completed,NA,Phase 3,74,Actual,Assiut University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T06:57:11Z,2021-10-17T06:57:11Z,34
NCT04957017,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-04,NA,NA,2021-07-07,2021-07-07,2021-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-09,Actual,"August 15, 2020",Actual,2020-08-15,July 2021,2021-07-31,"June 10, 2021",Actual,2021-06-10,"January 25, 2021",Actual,2021-01-25,NA,Interventional,NA,,Effect of Hand-Washing Training in Covid-19,"Effect of Training on Given to Women With Chronic Disease on Hand-Washing Behaviours, Attitudes and Nutrition During the Covid-19 Pandemic",Completed,NA,N/A,90,Actual,Mehmet Akif Ersoy University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,There is not plan.,2021-10-17T06:57:18Z,2021-10-17T06:57:18Z,115
NCT04954118,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-04,NA,NA,2021-07-07,2021-07-07,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"March 20, 2020",Actual,2020-03-20,July 2021,2021-07-31,"September 30, 2020",Actual,2020-09-30,"March 20, 2020",Actual,2020-03-20,NA,Interventional,NA,,A Different Use of The Aerosol Box in COVID-19 Patients; Internal Jugular Vein Cannulation,Use of Aerosol Box for Ultrasound-guided Internal Jugular Vein Cannulation in COVID-19 Patients; Single Center Experience,Completed,NA,N/A,40,Actual,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:57:42Z,2021-10-17T06:57:42Z,115
NCT04953234,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-04,NA,NA,2021-07-04,2021-07-04,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-04,2021-07-07,Actual,"February 23, 2021",Actual,2021-02-23,July 2021,2021-07-31,"April 26, 2021",Actual,2021-04-26,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,,"Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge","A Pilot, Open-Label Study of NovoTTF-100L (TTFields, 150Hz) in Hospitalized Patients With COVID-19 and Continued Treatment After Hospitalization",Completed,NA,N/A,10,Actual,NovoCure Ltd.,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T06:57:51Z,2021-10-17T06:57:51Z,118
NCT04951349,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-30,NA,NA,2021-07-01,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-06,Actual,"January 21, 2021",Actual,2021-01-21,July 2021,2021-07-31,"May 30, 2021",Actual,2021-05-30,"May 30, 2021",Actual,2021-05-30,NA,Interventional,NA,,Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.,"Phase 2b Clinical Trial to Evaluate the Tolerability and Efficacy in Reducing the Nasal Viral Load of SARS-CoV-2 of Benzalkonium Chloride 0.0065% (GX-03), in the Form of Nasal Ointment, in Patients Infected With COVID -19, and Evaluation of Its Tolerability in Health Care Providers, as a Preventive of Nasal Colonization, Complementary to Personal Protective Equipment",Completed,NA,Phase 2,85,Actual,Turn Therapeutics,,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,Within 30 days of announcement of study completion.,By official request for qualified use.,NA,Yes,NA,2021-10-17T06:58:06Z,2021-10-17T06:58:06Z,121
NCT04945811,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-29,NA,NA,2021-06-29,2021-06-29,2021-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-06-30,Actual,"April 1, 2020",Actual,2020-04-01,June 2021,2021-06-30,"May 30, 2021",Actual,2021-05-30,"May 15, 2021",Actual,2021-05-15,NA,Interventional,NA,,Role of Interleukin-6 and Procalcitonin as Novel Inflammatory Biomarkers in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta,Role of Interleukin-6 and Procalcitonin in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta,Completed,NA,N/A,100,Actual,"Combined Military Hospital, Pakistan",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T06:58:52Z,2021-10-17T06:58:52Z,123
NCT04942990,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-21,NA,NA,2021-06-29,2021-06-21,2021-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-07-01,Actual,"April 1, 2021",Actual,2021-04-01,June 2021,2021-06-30,"June 21, 2021",Actual,2021-06-21,"June 21, 2021",Actual,2021-06-21,NA,Interventional,NA,,The Effectiveness of Calistenic Exercise Training in Adolescents,The Effectiveness of Calistenic Exercise Training in Adolescents Receiving Online Education During COVID-19 Pandemic,Completed,NA,N/A,38,Actual,Baskent University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:59:15Z,2021-10-17T06:59:15Z,123
NCT04942392,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-23,NA,NA,2021-06-24,2021-06-24,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-28,Actual,"September 4, 2020",Actual,2020-09-04,June 2021,2021-06-30,"December 3, 2020",Actual,2020-12-03,"December 3, 2020",Actual,2020-12-03,NA,Interventional,NA,,Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic,Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic: A Feasibility Study,Completed,NA,N/A,33,Actual,UmeÃ¥ University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:59:20Z,2021-10-17T06:59:20Z,128
NCT04936503,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-02,NA,NA,2021-06-22,2021-06-22,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-23,Actual,"June 18, 2020",Actual,2020-06-18,June 2021,2021-06-30,"March 2, 2021",Actual,2021-03-02,"March 2, 2021",Actual,2021-03-02,NA,Interventional,ASCCOVID19,,Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19,Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19,Completed,NA,N/A,984,Actual,"University Hospital, Bordeaux",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:00:12Z,2021-10-17T07:00:12Z,130
NCT04935515,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-20,NA,NA,2021-06-22,2021-06-22,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-23,Actual,"April 15, 2021",Actual,2021-04-15,June 2021,2021-06-30,"June 6, 2021",Actual,2021-06-06,"May 9, 2021",Actual,2021-05-09,NA,Interventional,NA,,C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.,C Reactive Protein Based Early Intervention for Home Quarantined COVID -19 Patients to Avoid Complications and Hospitalization.,Completed,NA,N/A,25,Actual,UR Anoop Research Group,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:00:21Z,2021-10-17T07:00:21Z,130
NCT04935502,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-14,NA,NA,2021-09-17,2021-06-21,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-23,Actual,"March 15, 2021",Actual,2021-03-15,September 2021,2021-09-30,"August 30, 2021",Actual,2021-08-30,"August 30, 2021",Actual,2021-08-30,NA,Interventional,NA,,Home Based Exercises With and Without Posture and Ergonomics Training Among Students During COVID-19,Effects of Home Based Exercises With and Without Posture and Ergonomics Training on Pain and Physical Activity Level Among Students With Musculoskeletal Pain Due to COVID-19 Pandemic: A Randomised Controlled Trial,Completed,NA,N/A,216,Actual,Riphah International University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:00:21Z,2021-10-17T07:00:21Z,43
NCT04933864,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-15,NA,NA,2021-06-21,2021-06-21,2021-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"April 24, 2020",Actual,2020-04-24,June 2021,2021-06-30,"July 30, 2020",Actual,2020-07-30,"May 20, 2020",Actual,2020-05-20,NA,Interventional,NA,,COVID-19 Treatment Using Methylene Blue and Photodynamic Therapy,The Clinical Trial of Methylene Blue Application Combined With Photodynamic Therapy for Treatment of SARS-CoV-2 Infected Patients,Completed,NA,Phase 1,60,Actual,I.M. Sechenov First Moscow State Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The Local Ethics Committee of I.M. Sechenov First Moscow State Medical University did not give permission to provide individual participant data.,2021-10-17T07:00:34Z,2021-10-17T07:00:34Z,131
NCT04932369,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-12,NA,NA,2021-08-29,2021-06-12,2021-06-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-29,2021-09-02,Actual,"March 1, 2020",Actual,2020-03-01,August 2021,2021-08-31,"March 1, 2021",Actual,2021-03-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,"The Effect of Emotion Regulation Training on Anxiety, in College Students in Egypt","The Effect of Emotion Regulation Training on Anxiety, in College Students in Egypt During COVID-19 Lockdown",Completed,NA,N/A,200,Actual,British University In Egypt,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:00:46Z,2021-10-17T07:00:46Z,62
NCT04926428,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-13,NA,NA,2021-06-16,2021-06-13,2021-06-15,Actual,NA,NA,NA,NA,NA,NA,2021-06-16,2021-06-21,Actual,"December 25, 2020",Actual,2020-12-25,June 2021,2021-06-30,"March 30, 2021",Actual,2021-03-30,"March 30, 2021",Actual,2021-03-30,NA,Interventional,NA,,In Situ Thrombolysis With tPA and Inflow Perfusion Analysis in Patient With Severe Covid-19 Infection,In Situ Thrombolysis With tPA and Inflow Lung Perfusion Analysis in Patient With Severe Covid-19 Infection,Completed,NA,N/A,15,Actual,Grupo Mexicano para el Estudio de la Medicina Intensiva,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,3 months up to 5 years after completion,"proposal should be directed to gmemiinv@gmails.com, to gain access, requestor will need to sign a data access agreement",NA,Yes,IPD will be shared by petition.,2021-10-17T07:01:38Z,2021-10-17T07:01:38Z,136
NCT04922905,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-09,NA,NA,2021-06-09,2021-06-09,2021-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-11,Actual,"April 2, 2020",Actual,2020-04-02,June 2021,2021-06-30,"April 2, 2021",Actual,2021-04-02,"May 7, 2020",Actual,2020-05-07,NA,Interventional,NS-COV,,Nervous System Symptoms Associated With COVID 19,Nervous System Symptoms Associated With COVID 19 : NS-COV,Completed,NA,N/A,99,Actual,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:02:10Z,2021-10-17T07:02:10Z,143
NCT04920773,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-06,NA,NA,2021-06-09,2021-06-09,2021-06-10,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-10,Actual,"May 3, 2021",Actual,2021-05-03,June 2021,2021-06-30,"June 6, 2021",Actual,2021-06-06,"May 21, 2021",Actual,2021-05-21,NA,Interventional,NA,,Community-based Post-exposure Prophylaxis for COVID-19,Community-based Post-exposure Prophylaxis for COVID-19: Results and Implications of Ayurveda Practice Guidelines,Completed,NA,N/A,216,Actual,NMP Medical Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:02:28Z,2021-10-17T07:02:28Z,143
NCT04916574,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-03,NA,NA,2021-06-07,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-09,Actual,"March 20, 2021",Actual,2021-03-20,June 2021,2021-06-30,"June 3, 2021",Actual,2021-06-03,"March 28, 2021",Actual,2021-03-28,NA,Interventional,NA,,Clinical Trial of BioBlock COVID-19 Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum,Clinical Trial of Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum,Completed,NA,N/A,16,Actual,Icosagen Cell Factory,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:03:08Z,2021-10-17T07:03:08Z,145
NCT04915820,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-28,NA,NA,2021-09-10,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-14,Actual,"May 29, 2021",Actual,2021-05-29,September 2021,2021-09-30,"September 9, 2021",Actual,2021-09-09,"September 9, 2021",Actual,2021-09-09,NA,Interventional,NA,,Iron and COVID-19 Vaccine Response,Iron and Vaccine-preventable Viral Disease,Completed,NA,N/A,121,Actual,Jomo Kenyatta University of Agriculture and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:03:14Z,2021-10-17T07:03:14Z,50
NCT04910932,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-01,NA,NA,2021-09-21,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"June 10, 2021",Actual,2021-06-10,September 2021,2021-09-30,"September 14, 2021",Actual,2021-09-14,"September 14, 2021",Actual,2021-09-14,NA,Interventional,NA,,"Effects of Breathing Exercises on Fear of COVID-19, Anxiety, Sleep and Quality of Life During the COVID-19 Pandemic","Effects of Breathing Exercises on Fear of COVID-19, Anxiety, Sleep and Quality of Life During the COVID-19 Pandemic",Completed,NA,N/A,50,Actual,Izmir Bakircay University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:03:57Z,2021-10-17T07:03:57Z,39
NCT04910230,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-24,NA,NA,2021-06-01,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"March 1, 2020",Actual,2020-03-01,June 2021,2021-06-30,"April 2, 2020",Actual,2020-04-02,"April 2, 2020",Actual,2020-04-02,NA,Interventional,NA,,Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19,Efficiency and Safety of Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19: A Randomized Clinical Trial,Completed,NA,N/A,24,Actual,Shenyang Northern Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:04:03Z,2021-10-17T07:04:03Z,151
NCT04909918,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-30,NA,NA,2021-09-04,2021-05-30,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-04,2021-09-08,Actual,"May 28, 2021",Actual,2021-05-28,September 2021,2021-09-30,"August 20, 2021",Actual,2021-08-20,"August 15, 2021",Actual,2021-08-15,NA,Interventional,NA,,Impact of Steroids on Inflammatory Response in Covid-19,The Impact of Dexamethasone Versus Methylprednisolone Upon Neutrophil/Lymphocyte Ratio (NLR) in COVID-19 Diseased Patients Admitted in ICU,Completed,NA,Phase 3,60,Actual,Assiut University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:04:05Z,2021-10-17T07:04:05Z,56
NCT04904510,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-19,NA,NA,2021-05-25,2021-05-25,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-27,Actual,"November 20, 2020",Actual,2020-11-20,May 2021,2021-05-31,"March 9, 2021",Actual,2021-03-09,"March 9, 2021",Actual,2021-03-09,NA,Interventional,NA,,Evaluation of the INDICAIDâ„¢ COVID-19 Rapid Antigen Test,Evaluation of the INDICAIDâ„¢ COVID-19 Rapid Antigen Test in Symptomatic Populations and Asymptomatic Community Testing,Completed,NA,N/A,22994,Actual,"University of California, Los Angeles",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T07:04:52Z,2021-10-17T07:04:52Z,158
NCT04900129,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-18,NA,NA,2021-05-23,2021-05-23,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-23,2021-05-25,Actual,"December 1, 2020",Actual,2020-12-01,May 2021,2021-05-31,"December 30, 2020",Actual,2020-12-30,"December 30, 2020",Actual,2020-12-30,NA,Interventional,NA,,"Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study","Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study",Completed,NA,Phase 1,43,Actual,Sher-E-Bangla Medical College,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:05:30Z,2021-10-17T07:05:30Z,160
NCT04898088,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-21,NA,NA,2021-05-21,2021-05-21,2021-05-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-24,Actual,"January 1, 2020",Actual,2020-01-01,May 2021,2021-05-31,"September 30, 2020",Actual,2020-09-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,REPAIR,,A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients,A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients,Completed,NA,N/A,30,Actual,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:05:50Z,2021-10-17T07:05:50Z,162
NCT04894409,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-16,NA,NA,2021-05-18,2021-05-18,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-20,Actual,"April 24, 2020",Actual,2020-04-24,May 2021,2021-05-31,"September 29, 2020",Actual,2020-09-29,"June 30, 2020",Actual,2020-06-30,NA,Interventional,COVID-19,,Evaluation of Silver Nanoparticles for the Prevention of COVID-19,"Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2",Completed,NA,N/A,231,Actual,"Cluster de Bioeconomia de Baja California, A.C",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:06:22Z,2021-10-17T07:06:22Z,165
NCT04890509,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-17,NA,NA,2021-10-13,2021-05-17,2021-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-14,Actual,"October 20, 2020",Actual,2020-10-20,October 2021,2021-10-31,"May 25, 2021",Actual,2021-05-25,"May 25, 2021",Actual,2021-05-25,NA,Interventional,NA,,A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients,"A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients",Completed,NA,Phase 2,115,Actual,BerGenBio ASA,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Beginning 3 months and ending 5 years following article publication,"Proposal should be directed to HYPERLINK ""mailto:clinical@bergenbio.com"" clinical@bergenbio.com. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in the article, after deidentification [text, tables, figures and appendices].",2021-10-17T07:06:55Z,2021-10-17T07:06:55Z,17
NCT04883203,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-20,NA,NA,2021-05-10,2021-05-10,2021-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,"April 22, 2020",Actual,2020-04-22,May 2021,2021-05-31,"October 31, 2020",Actual,2020-10-31,"September 30, 2020",Actual,2020-09-30,NA,Interventional,COVID-VITD,,The Effect of Vitamin D Supplementation on COVID-19 Recovery,The Effect of Vitamin D Supplementation on Recovery Delays for Non Severe COVID-19 Cases,Completed,NA,Phase 3,130,Actual,University of Monastir,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:07:59Z,2021-10-17T07:07:59Z,173
NCT04880135,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-06,NA,NA,2021-09-17,2021-05-06,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-20,Actual,"March 1, 2021",Actual,2021-03-01,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"August 30, 2021",Actual,2021-08-30,NA,Interventional,NA,,Supervised Versus Home Based Exercises Neck and Low Back Pain Among Students Due to Quarantine During COVID-19,Effects of Supervised Versus Home Based Stretching and Strengthening Exercise Program on Neck Pain and Back Pain Among University Students Due to Quarantine During COVID-19: A Randomised Controlled Trial,Completed,NA,N/A,404,Actual,Riphah International University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:08:25Z,2021-10-17T07:08:25Z,43
NCT04880122,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-05,NA,NA,2021-05-06,2021-05-06,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,"August 1, 2020",Actual,2020-08-01,May 2021,2021-05-31,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,,Dried Blood Spots for SARS-CoV-2 Serology (COVID-19).,Comparison of Dried Blood Spots and Venous Blood for the Detection of SARS-CoV-2 2 Antibodies in a Population of Nursing Home Residents.,Completed,NA,N/A,440,Actual,University Ghent,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:08:25Z,2021-10-17T07:08:25Z,177
NCT04878809,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-28,NA,NA,2021-06-17,2021-05-04,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-18,Actual,"April 22, 2021",Actual,2021-04-22,June 2021,2021-06-30,"June 17, 2021",Actual,2021-06-17,"June 17, 2021",Actual,2021-06-17,NA,Interventional,NA,,"Rapid Screening Circuit of COVID 19 in Schools, Pilot Study","Rapid Screening Circuit of COVID 19 in Schools, Pilot Study",Completed,NA,N/A,153,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:08:36Z,2021-10-17T07:08:36Z,135
NCT04876560,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-27,NA,NA,2021-05-05,2021-05-05,2021-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"March 11, 2020",Actual,2020-03-11,May 2021,2021-05-31,"April 15, 2021",Actual,2021-04-15,"October 10, 2020",Actual,2020-10-10,NA,Interventional,CDSS,,Implementation of a CDSS in Oncology Patients During COVID-19,"The Use of Clinical Decision Support Systems (CDSS) to Provide Nutritional Care to Breast Cancer Patients During the COVID-19 Pandemic: a Randomised Controlled, Pilot Trial",Completed,NA,N/A,44,Actual,"Iaso Maternity Hospital, Athens, Greece",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:08:58Z,2021-10-17T07:08:58Z,178
NCT04872075,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-29,NA,NA,2021-07-12,2021-04-29,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-13,Actual,"May 26, 2021",Actual,2021-05-26,July 2021,2021-07-31,"June 13, 2021",Actual,2021-06-13,"June 13, 2021",Actual,2021-06-13,NA,Interventional,SPRING,,Study on Prevention of SARS-CoV-2 Transmission During a Large Indoor Gathering Event,Study on Prevention of SARS-CoV-2 Transmission During a Large Indoor Gathering Event,Completed,NA,N/A,6678,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:09:36Z,2021-10-17T07:09:36Z,110
NCT04871633,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-11,NA,NA,2021-05-02,2021-05-02,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-04,Actual,"August 1, 2020",Actual,2020-08-01,May 2021,2021-05-31,"December 30, 2020",Actual,2020-12-30,"November 15, 2020",Actual,2020-11-15,NA,Interventional,NA,,Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore,Effectiveness of Remedesvir in SARS-CoV2 Patients Presenting at Mayo Hospital Lahore,Completed,NA,N/A,66,Actual,King Edward Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:09:40Z,2021-10-17T07:09:40Z,181
NCT04869072,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-08,NA,NA,2021-04-27,2021-04-27,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-05-03,Actual,"April 29, 2020",Actual,2020-04-29,April 2021,2021-04-30,"March 30, 2021",Actual,2021-03-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,CPT-ZHP,,Convalescent Plasma Therapy - Zurich Protocol,"A Phase i, Open-label, Single-centre Clinical Study to Evaluate Safety and Efficacy of Passive Immunization of High-risk SARS-CoV-2 Positive Patients With Convalescent Plasma Therapy",Completed,NA,Phase 1,30,Actual,University of Zurich,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:10:04Z,2021-10-17T07:10:04Z,186
NCT04867265,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-26,NA,NA,2021-06-02,2021-04-28,2021-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-02,2021-06-03,Actual,"May 3, 2021",Actual,2021-05-03,June 2021,2021-06-30,"June 2, 2021",Actual,2021-06-02,"June 2, 2021",Actual,2021-06-02,NA,Interventional,MOVERESP,,Mouth-to-mouth Ventilation Efficiency Through Breathable Self-sterilizing Respirator During BLS in COVID-19 Pandemic,Mouth-to-mouth Ventilation Efficiency Through Breathable Self-sterilizing Respirator During BLS in COVID-19 Pandemic: a Crossover Simulation-based Study,Completed,NA,N/A,104,Actual,Brno University Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:10:20Z,2021-10-17T07:10:20Z,150
NCT04867226,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-25,NA,NA,2021-06-19,2021-04-28,2021-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-19,2021-06-22,Actual,"May 8, 2021",Actual,2021-05-08,June 2021,2021-06-30,"June 18, 2021",Actual,2021-06-18,"June 18, 2021",Actual,2021-06-18,NA,Interventional,NA,,Effectiveness of Colchicine Among Patients With COVID-19 Infection,Effectiveness of Colchicine Among Patients With COVID-19 Infection,Completed,NA,Phase 2,100,Actual,Hawler Medical University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:10:20Z,2021-10-17T07:10:20Z,133
NCT04864015,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-27,NA,NA,2021-10-07,2021-04-27,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-08,Actual,"March 17, 2021",Actual,2021-03-17,October 2021,2021-10-31,"June 30, 2021",Actual,2021-06-30,"May 15, 2021",Actual,2021-05-15,NA,Interventional,NA,,COVID-19 Aerosol in EGD Using a Droplet Reduction Mouthpiece,COVID-19: a Study About Aerosol Formation During Gastroscopy With a Adjusted Mouthpiece for Droplet Reduction,Completed,NA,N/A,80,Actual,Universitaire Ziekenhuizen Leuven,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,We won't share individual participant data,2021-10-17T07:10:48Z,2021-10-17T07:10:48Z,23
NCT04861298,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-25,NA,NA,2021-09-03,2021-04-25,2021-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-08,Actual,"January 11, 2021",Actual,2021-01-11,April 2021,2021-04-30,"August 29, 2021",Actual,2021-08-29,"August 29, 2021",Actual,2021-08-29,NA,Interventional,NA,,Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early COVID-19 Symptoms at Home,Study to Investigate the Benefits of Dietary Supplement Quercetin for COVID-19,Completed,NA,N/A,100,Actual,King Edward Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:11:11Z,2021-10-17T07:11:11Z,57
NCT04860258,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-22,NA,NA,2021-10-01,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"April 22, 2021",Actual,2021-04-22,January 2021,2021-01-31,"September 21, 2021",Actual,2021-09-21,"September 21, 2021",Actual,2021-09-21,NA,Interventional,NA,,"A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities for COVID-19","COVID-19: A Phase 3 Multicenter Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Above With Co-morbidities",Completed,NA,Phase 3,129,Actual,CureVac AG,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:11:20Z,2021-10-17T07:11:20Z,29
NCT04859244,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-19,NA,NA,2021-08-07,2021-04-21,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-07,2021-08-10,Actual,"January 1, 2021",Actual,2021-01-01,April 2021,2021-04-30,"August 1, 2021",Actual,2021-08-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,NA,,First-in-Human Study of Orally Administered GS-441524 for COVID-19,"First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of Orally Administered GS-441524 in a Healthy Human Volunteer",Completed,NA,Phase 1,1,Actual,Copycat Sciences LLC,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,Within 6 months after publication,Materials available upon request,NA,Yes,All collected IPD,2021-10-17T07:11:29Z,2021-10-17T07:11:29Z,84
NCT04859023,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-22,NA,NA,2021-05-03,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-06,Actual,"February 22, 2021",Actual,2021-02-22,May 2021,2021-05-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,AutoCoV,,Comparison of Strategies Based on RT-PCR or Antigenic Test for the Screening of SARS-CoV-2 Infection (COVID-19).,Comparison of Strategies Based on RT-PCR or Antigenic Test for the Screening of SARS-CoV-2 Infection in General Population Using Self-samples (COVID-19).,Completed,NA,N/A,10000,Actual,Centre Hospitalier Universitaire de Saint Etienne,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:11:30Z,2021-10-17T07:11:30Z,180
NCT04854941,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-07,NA,NA,2021-04-21,2021-04-21,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-22,Actual,"December 10, 2020",Actual,2020-12-10,April 2021,2021-04-30,"April 10, 2021",Actual,2021-04-10,"March 10, 2021",Actual,2021-03-10,NA,Interventional,NA,,Efficacy of Probiotics in the Treatment of Hospitalised Patients With Novel Coronavirus Infection,"Efficacy of Probiotics (Lactobacillus Rhamnosus, Bifidobacterium Bifidum, Bifidobacterium Longum Subsp. Infantis and Bifidobacterium Longum) in the Treatment of Hospitalised Patients With Novel Coronavirus Infection",Completed,NA,N/A,200,Actual,I.M. Sechenov First Moscow State Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The provision of data is prohibited by Local Ethical Committee and is possible upon receipt of an official request addressed to the principal investigator,2021-10-17T07:12:07Z,2021-10-17T07:12:07Z,192
NCT04853901,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-01,NA,NA,2021-04-17,2021-04-17,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-17,2021-04-22,Actual,"July 27, 2020",Actual,2020-07-27,April 2021,2021-04-30,"March 1, 2021",Actual,2021-03-01,"January 1, 2021",Actual,2021-01-01,NA,Interventional,NA,,Remdesivir Efficacy In Management Of COVID-19 Patients,Remdesivir Efficacy In Management Of COVID-19 Patients,Completed,NA,Phase 3,77,Actual,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:12:15Z,2021-10-17T07:12:15Z,196
NCT04851821,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-06,NA,NA,2021-07-26,2021-04-18,2021-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"January 4, 2021",Actual,2021-01-04,July 2021,2021-07-31,"June 30, 2021",Actual,2021-06-30,"May 30, 2021",Actual,2021-05-30,NA,Interventional,Quercetix,,The Effectiveness of Phytotherapy in SARS-COV2(COVID-19),The Effectiveness of Phytotherapy in the Treatment of SARS-COV2 (COVID-19),Completed,NA,Phase 1,80,Actual,HÃ´pital Universitaire Sahloul,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,In the publication of the article,we will publish the Access criteria after the final Statistical analysis,NA,Yes,Statistical analysis Plan can be shared in supplimentary data,2021-10-17T07:12:32Z,2021-10-17T07:12:32Z,96
NCT04845971,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-17,NA,NA,2021-09-07,2021-04-14,2021-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"November 5, 2020",Actual,2020-11-05,April 2021,2021-04-30,"June 30, 2021",Actual,2021-06-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,COral-MAF1,,Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia,Phase II Clinical Trial Evaluating Efficacy and Safety of Oral Immunotherapy With Third Generation Gc Protein Derived Macrophage Activating Factor (GcMAF) in Hospitalized Patients With COVID-19 Pneumonia: the COral-MAF1 Trial,Completed,NA,Phase 2,97,Actual,Ospedale del Mare,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"This is a multicenter trial. However, we reserve the possibility of enrolling further COVID-19 Hospital Units that are interested in participating in the trial, in order to get the correct sample size as needed for the study.Thus, if needed, we'll share IPD with the involved research centers.",2021-10-17T07:13:26Z,2021-10-17T07:13:26Z,53
NCT04845880,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-13,NA,NA,2021-04-13,2021-04-13,2021-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-15,Actual,"October 1, 2020",Actual,2020-10-01,April 2021,2021-04-30,"April 1, 2021",Actual,2021-04-01,"March 1, 2021",Actual,2021-03-01,NA,Interventional,NA,,SARS Cov_2 Incidence of Healthy Health Workers,Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 Patients in Our Hospital,Completed,NA,N/A,182,Actual,Baskent University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:13:26Z,2021-10-17T07:13:26Z,200
NCT04844710,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-12,NA,NA,2021-04-12,2021-04-12,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-14,Actual,"September 1, 2020",Actual,2020-09-01,April 2021,2021-04-30,"November 20, 2020",Actual,2020-11-20,"November 15, 2020",Actual,2020-11-15,NA,Interventional,NA,,The Effects of Acupuncture in Overcoming Inflammatory Response to COVID-19 Mild-moderate Symptoms,The Effects of Combined Treatment of Acupuncture Intervention & Standard of Care on Laboratory and Clinical Outcomes in Hospitalized COVID-19 Patients With Mild-Moderate Symptoms,Completed,NA,N/A,22,Actual,Indonesia University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:13:36Z,2021-10-17T07:13:36Z,201
NCT04841681,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-06,NA,NA,2021-04-08,2021-04-08,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-12,Actual,"June 7, 2020",Actual,2020-06-07,April 2021,2021-04-30,"August 26, 2020",Actual,2020-08-26,"August 25, 2020",Actual,2020-08-25,NA,Interventional,NA,,Video-based Psychotherapy for COVID-19 Patients in Isolation Ward in Jakarta,Effectiveness of Video-based Psychotherapy in Reducing Distress in Patients With COVID-19 Treated in a Hospital Isolation Ward in Jakarta,Completed,NA,N/A,42,Actual,Indonesia University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,1 month after publication.,"The data will be available through request to Petrin Redayani Lukman MD as the contact person, e-mail ptrn1010@yahoo.com.",NA,Yes,We plan to share the data of participants' (identities will be initials only) demographic data and SUDS score before and after watching the video.,2021-10-17T07:14:03Z,2021-10-17T07:14:03Z,205
NCT04834856,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-06,NA,NA,2021-09-07,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"April 1, 2021",Actual,2021-04-01,September 2021,2021-09-30,"August 20, 2021",Actual,2021-08-20,"August 20, 2021",Actual,2021-08-20,NA,Interventional,NA,,"Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients","A Phase 2a Open Label, Non-comparative, Single Dose Escalation Study to Evaluate the Dynamics of Viral Clearance, Pharmacokinetics and Tolerability of Ensovibep in Patients With Symptomatic COVID-19 Disease",Completed,NA,Phase 2,12,Actual,Molecular Partners AG,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:15:00Z,2021-10-17T07:15:00Z,53
NCT04834739,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-10,NA,NA,2021-08-23,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"January 4, 2021",Actual,2021-01-04,January 2021,2021-01-31,"April 30, 2021",Actual,2021-04-30,"March 28, 2021",Actual,2021-03-28,NA,Interventional,NA,,Comparison of Functional Capacities of Healthcare Workers With and Without Covid-19,Comparison of Functional Capacities of Healthcare Workers With and Without Covid-19,Completed,NA,N/A,60,Actual,Gaziosmanpasa Research and Education Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:15:01Z,2021-10-17T07:15:01Z,68
NCT04834726,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-06,NA,NA,2021-08-30,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"April 29, 2021",Actual,2021-04-29,August 2021,2021-08-31,"July 6, 2021",Actual,2021-07-06,"June 4, 2021",Actual,2021-06-04,NA,Interventional,NA,,COVID-19 Vaccine Text Outreach,Pragmatic Trial of COVID Vaccine Text Outreach Interventions,Completed,NA,N/A,19554,Actual,University of Pennsylvania,,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:15:02Z,2021-10-17T07:15:02Z,61
NCT04830943,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-24,NA,NA,2021-04-01,2021-04-01,2021-04-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-05,Actual,"August 1, 2020",Actual,2020-08-01,April 2021,2021-04-30,"March 30, 2021",Actual,2021-03-30,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,,Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia,The Effectiveness of Cerebrolycin for Treatment of Post-covid Olfactory and Gustatory Dysfunctions: A Pilot Study,Completed,NA,Phase 4,100,Actual,Assiut University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:15:34Z,2021-10-17T07:15:34Z,212
NCT04822285,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-26,NA,NA,2021-03-26,2021-03-26,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-03-30,Actual,"January 22, 2020",Actual,2020-01-22,March 2021,2021-03-31,"March 21, 2021",Actual,2021-03-21,"April 22, 2020",Actual,2020-04-22,NA,Interventional,Triaging,,Effect Psychological Triaging Intervention on Students' Psychological Distress and Resilience Capacity,Psychological Triaging Intervention: Rescue From Psychological Distress and Improving Senior Nursing Students' Resilience Capacity During COVID-19 Crisis,Completed,NA,N/A,64,Actual,Alexandria University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:16:49Z,2021-10-17T07:16:49Z,218
NCT04820803,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-23,NA,NA,2021-07-01,2021-03-26,2021-03-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-07,Actual,"February 3, 2021",Actual,2021-02-03,March 2021,2021-03-31,"June 30, 2021",Actual,2021-06-30,"April 29, 2021",Actual,2021-04-29,NA,Interventional,NA,,Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load in Patients With COVID-19,PILOT CLINICAL TRIAL TO ASSESS THE IMPACT OF ORAL INTERVENTION WITH CETIL PYRIDINIUM CHLORIDE TO REDUCE THE VIRAL LOAD OF SARS-CoV-2,Completed,NA,N/A,80,Actual,Instituto de InvestigaciÃ³n Sanitaria AragÃ³n,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:17:05Z,2021-10-17T07:17:05Z,121
NCT04816942,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-12,NA,NA,2021-03-24,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"April 23, 2020",Actual,2020-04-23,March 2021,2021-03-31,"October 12, 2020",Actual,2020-10-12,"July 21, 2020",Actual,2020-07-21,NA,Interventional,NA,,Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt,Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt,Completed,NA,Phase 3,102,Actual,"Ministry of Health and Population, Egypt",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:17:38Z,2021-10-17T07:17:38Z,220
NCT04816656,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-24,NA,NA,2021-03-25,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-26,Actual,"August 3, 2020",Actual,2020-08-03,March 2021,2021-03-31,"March 22, 2021",Actual,2021-03-22,"February 1, 2021",Actual,2021-02-01,NA,Interventional,COVID-ONCO,,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,Completed,NA,N/A,43,Actual,Jessa Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:17:40Z,2021-10-17T07:17:40Z,219
NCT04817332,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-25,NA,NA,2021-08-12,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-17,Actual,"June 5, 2020",Actual,2020-06-05,August 2021,2021-08-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,STOP-COVID19,,STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19,A Randomised Double-blind Placebo-controlled Trial of Brensocatib (INS1007) in Patients With Severe COVID-19,Completed,NA,Phase 3,406,Actual,University of Dundee,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:17:34Z,2021-10-17T07:17:34Z,79
NCT04816084,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-19,NA,NA,2021-03-24,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"November 5, 2020",Actual,2020-11-05,March 2021,2021-03-31,"March 15, 2021",Actual,2021-03-15,"December 1, 2020",Actual,2020-12-01,NA,Interventional,SERUR,,SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes,SERUR : Etude sÃ©rologique COVID-19 (Anti-SARS CoV 2) du Personnel de l'UniversitÃ© de Reims Champagne-Ardenne,Completed,NA,N/A,389,Actual,UniversitÃ© de Reims Champagne-Ardenne,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:17:45Z,2021-10-17T07:17:45Z,220
NCT04815057,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-11,NA,NA,2021-04-11,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-11,2021-04-14,Actual,"November 2, 2020",Actual,2020-11-02,April 2021,2021-04-30,"March 8, 2021",Actual,2021-03-08,"November 23, 2020",Actual,2020-11-23,NA,Interventional,NA,,The Effects of Wellness Training Given to Fifth Grade Students During the Covid-19 Epidemic Period,The Effects of Wellness Education Given to 5th Grade Students During the Covid-19 Pandemic Process on Their Quality of Life and Physical Activity,Completed,NA,N/A,176,Actual,Saglik Bilimleri Universitesi,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:17:54Z,2021-10-17T07:17:54Z,202
NCT04813497,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-21,NA,NA,2021-07-19,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"February 5, 2021",Actual,2021-02-05,July 2021,2021-07-31,"July 19, 2021",Actual,2021-07-19,"July 19, 2021",Actual,2021-07-19,NA,Interventional,NA,,Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members,Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members: Protocol for an Interventional Cohort Study in 2020-2021,Completed,NA,N/A,4000,Actual,Grand HÃ´pital de Charleroi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:18:07Z,2021-10-17T07:18:07Z,103
NCT04813770,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-23,NA,NA,2021-05-05,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"April 6, 2021",Actual,2021-04-06,May 2021,2021-05-31,"April 26, 2021",Actual,2021-04-26,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,Completed,NA,N/A,1113,Actual,University of Glasgow,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,On publication of the study results for a period of ten years.,Data will be made publicly available.,NA,Yes,Anonymised individual level study data will be shared via the University of Glasgow's repository Enlighten: Research Data.,2021-10-17T07:18:05Z,2021-10-17T07:18:05Z,178
NCT04810728,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-16,NA,NA,2021-04-17,2021-03-20,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-04-17,2021-04-20,Actual,"June 20, 2020",Actual,2020-06-20,April 2021,2021-04-30,"January 30, 2021",Actual,2021-01-30,"December 4, 2020",Actual,2020-12-04,NA,Interventional,NA,,Efficacy of Psidii Guava's Extract For COVID-19,Efficacy of Psidii Guava's Extract For Mild And Symptomless Coronavirus Disease-19 (COVID-19),Completed,NA,Phase 3,90,Actual,Faculty of Medicine Baiturrahmah University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:18:30Z,2021-10-17T07:18:30Z,196
NCT04810065,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-19,NA,NA,2021-09-27,2021-03-19,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"March 29, 2021",Actual,2021-03-29,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"July 29, 2021",Actual,2021-07-29,NA,Interventional,ss,,SingStrong: Strong Lungs Through Song - Long COVID-19 Study,SingStrong: Strong Lungs Through Song,Completed,NA,N/A,30,Actual,University of Limerick,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:18:35Z,2021-10-17T07:18:35Z,33
NCT04808284,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-16,NA,NA,2021-10-13,2021-03-18,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-14,Actual,"August 10, 2021",Actual,2021-08-10,October 2021,2021-10-31,"October 11, 2021",Actual,2021-10-11,"October 11, 2021",Actual,2021-10-11,NA,Interventional,NA,,Neuromodulation in COVID-19 Patients,Neuromodulation in COVID-19 Patients,Completed,NA,Phase 1/Phase 2,60,Actual,D'Or Institute for Research and Education,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:18:51Z,2021-10-17T07:18:51Z,17
NCT04808921,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-18,NA,NA,2021-04-05,2021-03-18,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"January 9, 2021",Actual,2021-01-09,April 2021,2021-04-30,"January 28, 2021",Actual,2021-01-28,"January 18, 2021",Actual,2021-01-18,NA,Interventional,NA,,Performance Evaluation of SARS-COV-2 (Covid-19) Antigen Rapid Test,Rapid Diagnostic Test for Detection of SARS-CoV-2 Antigen,Completed,NA,N/A,151,Actual,"Sky Medical Supplies & Equipments, LLC",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:18:45Z,2021-10-17T07:18:45Z,208
NCT04805684,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-15,NA,NA,2021-03-17,2021-03-17,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-18,Actual,"January 1, 2021",Actual,2021-01-01,March 2021,2021-03-31,"March 5, 2021",Actual,2021-03-05,"March 5, 2021",Actual,2021-03-05,NA,Interventional,NA,,Different Lung Ultrasound Imaging Protocols in COVID-19 Pneumonia,Comparison of Two Different Lung Ultrasound Imaging Protocols in COVID -19 Pneumonia,Completed,NA,N/A,59,Actual,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:19:12Z,2021-10-17T07:19:12Z,227
NCT04801888,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-15,NA,NA,2021-07-23,2021-03-15,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"March 23, 2021",Actual,2021-03-23,March 2021,2021-03-31,"May 28, 2021",Actual,2021-05-28,"May 28, 2021",Actual,2021-05-28,NA,Interventional,NA,,Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine,A Study to Evaluate the Safety and Immunogenicity of Concomitant Administration of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) With Quadrivalent Influenza Vaccine in Adults Aged From 18 to 59 Years,Completed,NA,Phase 4,480,Actual,"Sinovac Biotech Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:19:44Z,2021-10-17T07:19:44Z,99
NCT04797936,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-08,NA,NA,2021-03-12,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-03-12,2021-03-15,Actual,"May 1, 2020",Actual,2020-05-01,March 2021,2021-03-31,"January 8, 2021",Actual,2021-01-08,"December 19, 2020",Actual,2020-12-19,NA,Interventional,NA,,BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19,"A Randomized, Open-label, Multicentre, Comparative Study of Therapeutic Efficacy, Safety, and Tolerability of BNO 1030 Extract, in the Treatment of Mild Forms of COVID-19",Completed,NA,Phase 4,133,Actual,Ivano-Frankivsk National Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:20:19Z,2021-10-17T07:20:19Z,232
NCT04796064,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-10,NA,NA,2021-03-11,2021-03-11,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-12,Actual,"March 30, 2020",Actual,2020-03-30,March 2021,2021-03-31,"December 15, 2020",Actual,2020-12-15,"November 5, 2020",Actual,2020-11-05,NA,Interventional,NA,,Low Versus High-Intensity Aerobic Training in Community-dwelling Older Men With Post-COVID 19 (SARS-CoV-2) Sarcopenia,Comparative Effectiveness Study of Low Versus High-Intensity Aerobic Training in Community-dwelling Older Men With Post-COVID 19 Sarcopenia,Completed,NA,N/A,76,Actual,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:20:34Z,2021-10-17T07:20:34Z,233
NCT04794400,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-10,NA,NA,2021-06-05,2021-03-10,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-05,2021-06-09,Actual,"February 4, 2021",Actual,2021-02-04,June 2021,2021-06-30,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,,The Application of a Mask in Patients With Severe Covid-19 Already Treated With High-flow Nasal Cannula.,The Application of a Mask in Patients With Severe Covid-19 Already Treated With High-flow Nasal Cannula.,Completed,NA,N/A,18,Actual,Region Skane,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:20:49Z,2021-10-17T07:20:49Z,147
NCT04793243,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-03,NA,NA,2021-03-09,2021-03-09,2021-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"August 17, 2020",Actual,2020-08-17,March 2021,2021-03-31,"October 24, 2020",Actual,2020-10-24,"October 10, 2020",Actual,2020-10-10,NA,Interventional,NA,,Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico,Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico: Clinical Correlation and Effect of Its Supplementation,Completed,NA,N/A,42,Actual,University of Guadalajara,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:21:02Z,2021-10-17T07:21:02Z,235
NCT04789525,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-05,NA,NA,2021-03-09,2021-03-08,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"March 10, 2020",Actual,2020-03-10,March 2021,2021-03-31,"December 25, 2020",Actual,2020-12-25,"October 1, 2020",Actual,2020-10-01,NA,Interventional,NA,,Physical Training and Diet for Childhood Obesity,"Clinical (BMI & MRI) and Biochemical (Adiponectin, Leptin, TNF-Î± & IL-6) Effects of High-intensity Aerobic Training With High Protein Diet in Childhood Obesity Following COVID-19 Infection",Completed,NA,N/A,76,Actual,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:21:33Z,2021-10-17T07:21:33Z,235
NCT04788355,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-05,NA,NA,2021-03-06,2021-03-06,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-06,2021-03-09,Actual,"July 1, 2020",Actual,2020-07-01,March 2021,2021-03-31,"December 23, 2020",Actual,2020-12-23,"November 15, 2020",Actual,2020-11-15,NA,Interventional,NA,,Prevention of Complications (SARS-CoV-2): Clinical Study,Hydroxychloroquine and Apixaban: Analysis of Physiological Parameters for the Prevention of Complications in Patients With Infection With the New Coronavirus (Covid-19). A Randomized Clinical Trial,Completed,NA,Phase 3,176,Actual,Universidade do Vale do Sapucai,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:21:43Z,2021-10-17T07:21:43Z,238
NCT04784897,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-03,NA,NA,2021-08-11,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-13,Actual,"February 22, 2021",Actual,2021-02-22,August 2021,2021-08-31,"July 30, 2021",Actual,2021-07-30,"July 1, 2021",Actual,2021-07-01,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19",Completed,NA,Phase 2,120,Actual,"Innovation Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:22:13Z,2021-10-17T07:22:13Z,80
NCT04784481,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-20,NA,NA,2021-04-22,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-26,Actual,"September 20, 2020",Actual,2020-09-20,April 2021,2021-04-30,"January 18, 2021",Actual,2021-01-18,"December 20, 2020",Actual,2020-12-20,NA,Interventional,IVER-Leve,,Ivermectin Reproposing for Mild Stage COVID-19 Outpatients,Ivermectin Reproposing for COVID-19 Treatment in Outpatients With Mild Stage,Completed,NA,Phase 1/Phase 2,254,Actual,"Ministry of Public Health, Argentina",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,N/D,2021-10-17T07:22:17Z,2021-10-17T07:22:17Z,191
NCT04782700,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-25,NA,NA,2021-06-17,2021-03-03,2021-03-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-18,Actual,"April 1, 2021",Actual,2021-04-01,June 2021,2021-06-30,"June 8, 2021",Actual,2021-06-08,"June 8, 2021",Actual,2021-06-08,NA,Interventional,NA,,P-Co-Li (Pulmonary Covid-19 Study),P-CO-Li (Pulmonary Covid-19 Longterm Intervention Study),Completed,NA,N/A,6,Actual,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:22:32Z,2021-10-17T07:22:32Z,135
NCT04771585,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-26,NA,NA,2021-08-25,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-26,Actual,"March 29, 2021",Actual,2021-03-29,August 2021,2021-08-31,"August 20, 2021",Actual,2021-08-20,"August 20, 2021",Actual,2021-08-20,NA,Interventional,QUELLE,,Quantification of Exhaled Particles to Identify Airborne Transmission Risks of COVID-19,Quantification of Exhaled Particles to Identify Airborne Transmission Risks of SARS-Co-V-2,Completed,NA,N/A,30,Actual,Fraunhofer-Institute of Toxicology and Experimental Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:24:07Z,2021-10-17T07:24:07Z,66
NCT04771559,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-17,NA,NA,2021-08-01,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-01,2021-08-03,Actual,"March 1, 2021",Actual,2021-03-01,August 2021,2021-08-31,"July 1, 2021",Actual,2021-07-01,"June 1, 2021",Actual,2021-06-01,NA,Interventional,NA,,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients,Completed,NA,N/A,1500,Actual,Bezmialem Vakif University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:24:08Z,2021-10-17T07:24:08Z,90
NCT04772859,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-13,NA,NA,2021-09-23,2021-02-24,2021-02-26,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-27,Actual,"February 1, 2021",Actual,2021-02-01,September 2021,2021-09-30,"July 16, 2021",Actual,2021-07-16,"July 16, 2021",Actual,2021-07-16,NA,Interventional,NA,,Evaluation of an Online Lifestyle Intervention in Mexican School Children During COVID-19 Pandemic,Evaluation of a 4-month Online Lifestyle Intervention on the BMI Z-score of Mexican School Children During COVID-19 Pandemic: Randomized Controlled Pilot Trial,Completed,NA,N/A,54,Actual,Universidad de Sonora,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:23:57Z,2021-10-17T07:23:57Z,37
NCT04771013,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-24,NA,NA,2021-05-14,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-18,Actual,"February 10, 2021",Actual,2021-02-10,May 2021,2021-05-31,"May 14, 2021",Actual,2021-05-14,"May 14, 2021",Actual,2021-05-14,NA,Interventional,NA,,Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras,"A Single-arm, Open-Label, Phase II Clinical Study to Evaluate the Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras",Completed,NA,Phase 2,22,Actual,Universidad CatÃ³lica de Honduras,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Beginning 3 months and ending 5 years following article publication.,"Investigators whose proposed use of the data has been approved by an independent review committee (""learned intermediary"") identified for this purpose.
For individual participant data meta-analysis.",NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2021-10-17T07:24:12Z,2021-10-17T07:24:12Z,169
NCT04769999,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-13,NA,NA,2021-02-22,2021-02-22,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-25,Actual,"June 4, 2020",Actual,2020-06-04,December 2020,2020-12-31,"October 30, 2020",Actual,2020-10-30,"October 16, 2020",Actual,2020-10-16,NA,Interventional,CALM-ED,,Computer Assisted Lessening of Intrusive Memories in the Emergency Department,"Reducing Intrusive Memories of Work-Related Traumatic Events, Including Events During the COVID-19 Pandemic, in NHS Staff Using a Brief Cognitive Task Intervention",Completed,NA,N/A,14,Actual,University of Oxford,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:24:21Z,2021-10-17T07:24:21Z,250
NCT04767477,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-21,NA,NA,2021-10-04,2021-02-22,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"March 28, 2021",Actual,2021-03-28,October 2021,2021-10-31,"September 10, 2021",Actual,2021-09-10,"August 31, 2021",Actual,2021-08-31,NA,Interventional,NA,,Telerehabilitation and Face-to-face Rehabilitation on COVID-19 Survivors,Telerehabilitation and Face-to-face Rehabilitation on Tolerance to Exercise and Quality of Life of COVID-19 Survivors: a Study Protocol,Completed,NA,N/A,26,Actual,Universidade Federal de Pernambuco,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:24:42Z,2021-10-17T07:24:42Z,26
NCT04765839,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-02,NA,NA,2021-07-28,2021-02-19,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-30,Actual,"February 12, 2021",Actual,2021-02-12,July 2021,2021-07-31,"April 3, 2021",Actual,2021-04-03,"April 3, 2021",Actual,2021-04-03,NA,Interventional,CERC,,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With Minority Populations,Completed,NA,N/A,74,Actual,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:24:57Z,2021-10-17T07:24:57Z,94
NCT04762628,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-11,NA,NA,2021-08-06,2021-02-18,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-09,Actual,"October 27, 2020",Actual,2020-10-27,August 2021,2021-08-31,"August 6, 2021",Actual,2021-08-06,"July 5, 2021",Actual,2021-07-05,NA,Interventional,SaiseiCovUKR,,"Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients","Randomized Trial to Assess the Efficacy and Safety of Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Addition to the Standard of Care (SOC) Compared SOC in the Treatment of Hospitalized With COVID-19 Patients Who Not Requiring the Mechanical Ventilation",Completed,NA,N/A,600,Actual,Saisei Pharma,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be indefinitely available for requesting,Reasonable request to investigators,NA,Yes,The data will be shared via ISARIC COVID-19 Clinical Database.,2021-10-17T07:25:27Z,2021-10-17T07:25:27Z,85
NCT04762173,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-15,NA,NA,2021-07-09,2021-02-18,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"November 6, 2020",Actual,2020-11-06,July 2021,2021-07-31,"May 31, 2021",Actual,2021-05-31,"May 31, 2021",Actual,2021-05-31,NA,Interventional,NA,,Self-Help for Stress Related to COVID-19,Self-Help for Stress Related to COVID-19,Completed,NA,N/A,585,Actual,Penn State University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:25:31Z,2021-10-17T07:25:31Z,113
NCT04761874,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-15,NA,NA,2021-04-19,2021-02-17,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-19,2021-04-22,Actual,"December 1, 2019",Actual,2019-12-01,April 2021,2021-04-30,"September 29, 2020",Actual,2020-09-29,"June 29, 2020",Actual,2020-06-29,NA,Interventional,TELECAST-CSC,,Telestroke at Comprehensive Stroke Center During the COVID-19 Pandemic,TELEstroke to CAre for STroke Patients at a Comprehensive Stroke Center During the COVID-19 Pandemic,Completed,NA,N/A,296,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:25:33Z,2021-10-17T07:25:33Z,194
NCT04758299,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-12,NA,NA,2021-05-21,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"March 13, 2021",Actual,2021-03-13,May 2021,2021-05-31,"April 30, 2021",Actual,2021-04-30,"April 15, 2021",Actual,2021-04-15,NA,Interventional,NA,,Understanding Communications Included With COVID-19 (Corona Virus Disease of 2019) Home Testing Kits,At Home Self-testing Kits for SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) : A Randomized Trial Assessing How Consumers Interpret and Act on Test Results,Completed,NA,N/A,360,Actual,Carnegie Mellon University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:26:09Z,2021-10-17T07:26:09Z,162
NCT04758286,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-11,NA,NA,2021-02-16,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"July 1, 2020",Actual,2020-07-01,February 2021,2021-02-28,"February 11, 2021",Actual,2021-02-11,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,Anesthetic & Surgical Protocol for Emergency Surgeries During the Era of COVID-19,Protocol for Anesthesia for Emergency Surgery,Completed,NA,N/A,209,Actual,Benha University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,after publishing,email,NA,Yes,The study protocol may be shared,2021-10-17T07:26:09Z,2021-10-17T07:26:09Z,256
NCT04757818,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-16,NA,NA,2021-07-13,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-19,Actual,"February 17, 2021",Actual,2021-02-17,July 2021,2021-07-31,"June 3, 2021",Actual,2021-06-03,"May 25, 2021",Actual,2021-05-25,NA,Interventional,CPC COVID,,"Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 (COVID-19) in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%.","Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%",Completed,NA,N/A,118,Actual,Dentaid SL,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:26:13Z,2021-10-17T07:26:13Z,109
NCT04751474,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-08,NA,NA,2021-04-18,2021-02-08,2021-02-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-18,2021-04-20,Actual,"February 1, 2021",Actual,2021-02-01,April 2021,2021-04-30,"March 31, 2021",Actual,2021-03-31,"March 1, 2021",Actual,2021-03-01,NA,Interventional,NA,,"The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction","The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction of Intensive Care Nurses During the COVID-19 Pandemic : A Randomized Controlled Study",Completed,NA,N/A,93,Actual,Saglik Bilimleri Universitesi,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:27:10Z,2021-10-17T07:27:10Z,195
NCT04750317,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-10,NA,NA,2021-02-11,2021-02-10,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-15,Actual,"May 11, 2020",Actual,2020-05-11,February 2021,2021-02-28,"September 1, 2020",Actual,2020-09-01,"August 1, 2020",Actual,2020-08-01,NA,Interventional,TOFA-COV-2,,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,Completed,NA,Phase 2,414,Actual,I.M. Sechenov First Moscow State Medical University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:27:21Z,2021-10-17T07:27:21Z,261
NCT04749121,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-04,NA,NA,2021-02-09,2021-02-09,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-11,Actual,"April 1, 2020",Actual,2020-04-01,February 2021,2021-02-28,"February 5, 2021",Actual,2021-02-05,"February 5, 2021",Actual,2021-02-05,NA,Interventional,NA,,Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators,"Impact of Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators (VJR-NMU) Respirator Performances, Structural Integrity and Sterility During COVID -19 Pandemic:",Completed,NA,N/A,20,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Plan to share in protocol.io,2021-10-17T07:27:31Z,2021-10-17T07:27:31Z,263
NCT04748536,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-01,NA,NA,2021-04-22,2021-02-08,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-26,Actual,"January 29, 2021",Actual,2021-01-29,February 2021,2021-02-28,"April 5, 2021",Actual,2021-04-05,"April 5, 2021",Actual,2021-04-05,NA,Interventional,NA,,Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers,"A Randomised, Double-blind, Placebo-controlled, Parallel Group Study in Healthy Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of IRL201104 to Support a Future COVID-19 Patient Study",Completed,NA,Phase 1,18,Actual,Revolo Biotherapeutics,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:27:35Z,2021-10-17T07:27:35Z,191
NCT04747158,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-27,NA,NA,2021-02-25,2021-02-08,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-02,Actual,"August 10, 2020",Actual,2020-08-10,February 2021,2021-02-28,"January 10, 2021",Actual,2021-01-10,"December 10, 2020",Actual,2020-12-10,NA,Interventional,TPCC,,COVID-19 Convalescent Plasma Therapy,COVID-19 Convalescent Plasma Therapy,Completed,NA,Phase 2/Phase 3,350,Actual,Universidad Nacional de AsunciÃ³n,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The investigators will publish the results to compare data with other studies with COVID-19 convalescent plasma patients,2021-10-17T07:27:48Z,2021-10-17T07:27:48Z,247
NCT04747132,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-06,NA,NA,2021-02-08,2021-02-08,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"July 20, 2020",Actual,2020-07-20,February 2021,2021-02-28,"November 16, 2020",Actual,2020-11-16,"October 20, 2020",Actual,2020-10-20,NA,Interventional,NA,,Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency,Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency,Completed,NA,N/A,110,Actual,"Universidad Iberoamericana A.C., Mexico",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:27:48Z,2021-10-17T07:27:48Z,264
NCT04746365,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-06,NA,NA,2021-02-08,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"December 6, 2020",Actual,2020-12-06,February 2021,2021-02-28,"February 6, 2021",Actual,2021-02-06,"January 31, 2021",Actual,2021-01-31,NA,Interventional,IRICT,,Ivermectin Role in Covid-19 Clinical Trial,"Ivermectin Role in Severe Covid-19 Treatment; a Double-blinded, Randomized Clinical Trial",Completed,NA,Phase 4,300,Actual,Elaraby Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T07:27:54Z,2021-10-17T07:27:54Z,264
NCT04745442,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-08,NA,NA,2021-02-08,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"April 27, 2020",Actual,2020-04-27,February 2021,2021-02-28,"January 15, 2021",Actual,2021-01-15,"December 20, 2020",Actual,2020-12-20,NA,Interventional,NA,,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Completed,NA,Phase 2,48,Actual,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The information will be provided after the results are published in a journal.,Upon request to uicec@imibic.org,NA,Yes,NA,2021-10-17T07:28:01Z,2021-10-17T07:28:01Z,264
NCT04739410,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-02,NA,NA,2021-02-03,2021-02-03,2021-02-04,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-04,Actual,"May 1, 2020",Actual,2020-05-01,February 2021,2021-02-28,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Completed,NA,Phase 4,50,Actual,FMH College of Medicine and Dentistry,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,as soon as i will have time to respond,NA,NA,Yes,"whatever is needed, will share if needed at any time",2021-10-17T07:28:56Z,2021-10-17T07:28:56Z,269
NCT04734561,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-31,NA,NA,2021-09-29,2021-01-30,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-09-30,Actual,"February 8, 2021",Actual,2021-02-08,September 2021,2021-09-30,"September 29, 2021",Actual,2021-09-29,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,,Effects of Respiratory Muscle Training in People Who Have Had COVID-19 Disease,"Effects of Respiratory Muscle Training on Quality of Life, Physical and Pulmonary Function and Psychological Status in Patients Who Have Had COVID-19 Disease",Completed,NA,N/A,88,Actual,Universidad Complutense de Madrid,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:29:43Z,2021-10-17T07:29:43Z,31
NCT04734886,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-10,NA,NA,2021-10-14,2021-01-30,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"November 27, 2020",Actual,2020-11-27,September 2021,2021-09-30,"September 13, 2021",Actual,2021-09-13,"September 13, 2021",Actual,2021-09-13,NA,Interventional,NA,,The Effect of Probiotic Supplementation on SARS-CoV-2 Antibody Response After COVID-19,Exploratory Study on the Effects of Probiotic Supplementation on SARS-CoV-2 Antibody Response in Healthy Adults,Completed,NA,N/A,161,Actual,"Ã–rebro University, Sweden",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"IPD will not be shared, results will shared only on group-level",2021-10-17T07:29:40Z,2021-10-17T07:29:40Z,16
NCT04734171,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-29,NA,NA,2021-02-01,2021-02-01,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"April 2, 2020",Actual,2020-04-02,February 2021,2021-02-28,"April 16, 2020",Actual,2020-04-16,"April 16, 2020",Actual,2020-04-16,NA,Interventional,NA,,"Social Activity, Loneliness and Stigma During COVID-19 Outbreak","COVID-19 and Its Implications on Social Activity, Loneliness and Stigma",Completed,NA,N/A,1200,Actual,Columbia University,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:29:47Z,2021-10-17T07:29:47Z,271
NCT04733625,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-31,NA,NA,2021-01-31,2021-01-31,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-31,2021-02-02,Actual,"September 15, 2020",Actual,2020-09-15,January 2021,2021-01-31,"December 17, 2020",Actual,2020-12-17,"December 17, 2020",Actual,2020-12-17,NA,Interventional,NA,,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,Completed,NA,N/A,56,Actual,Kasr El Aini Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:29:51Z,2021-10-17T07:29:51Z,272
NCT04732819,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-27,2021-07-22,NA,2021-09-01,2021-01-29,2021-02-01,Actual,2021-09-01,2021-09-05,Actual,NA,NA,NA,2021-09-01,2021-09-05,Actual,"December 21, 2020",Actual,2020-12-21,September 2021,2021-09-30,"April 16, 2021",Actual,2021-04-16,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,"The overall number of baseline participants includes the number of residents and staff in each arm. The unit analyzed was nursing home facility. Baseline characteristics were obtained for residents and nursing home facilities, but not for staff.",Improving COVID-19 Vaccine Uptake in Nursing Homes,IMPACT-C: Improving Vaccine Uptake in Skilled Nursing Facilities,Completed,NA,N/A,23768,Actual,Brown University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,The IPD and supporting documentation will be available through the CDCC within 6 months of the completion of the trial.,"Staff and patient data will be aggregated at the level of the facility. This data will be shared with the RADx-UP CDCC, who plans to make a central database that will ultimately be publicly available.",NA,Yes,"Data will be aggregated at the level of the facility. We will provide aggregated data to the RADx-UP Coordination and Data Collection Center (CDCC); however, given the nature of this data it will not be identifiable or linkable. The CDCC will facilitate cross-site pooling of data, whenever possible, and create a publicly available dataset with this information.",2021-10-17T07:29:58Z,2021-10-17T07:29:58Z,59
NCT04730323,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-26,NA,NA,2021-01-28,2021-01-28,2021-01-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"May 12, 2020",Actual,2020-05-12,January 2021,2021-01-31,"June 12, 2020",Actual,2020-06-12,"June 12, 2020",Actual,2020-06-12,NA,Interventional,NA,,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,Completed,NA,Phase 4,93,Actual,FMH College of Medicine and Dentistry,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,"Whenever will be asked to, within few days",Only officials can access the data,NA,Yes,IPD can be shared with researchers in future too,2021-10-17T07:30:22Z,2021-10-17T07:30:22Z,275
NCT04728594,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-26,2021-07-16,NA,2021-07-22,2021-01-26,2021-01-28,Actual,2021-07-22,2021-07-26,Actual,NA,NA,NA,2021-07-22,2021-07-26,Actual,"January 15, 2021",Actual,2021-01-15,July 2021,2021-07-31,"January 20, 2021",Actual,2021-01-20,"January 17, 2021",Actual,2021-01-17,NA,Interventional,NA,"The baseline outcome measure was not applicable, since registration for vaccination was the outcome, and all participants were selected for not being registered.",Emails Promoting COVID-19 Vaccination Among Healthcare Workers,Evaluation of an Email Intervention Promoting COVID-19 Vaccination Among Healthcare Workers,Completed,NA,N/A,9566,Actual,Geisinger Clinic,"In the original ClinicalTrials record, the researchers preregistered that the study would examine primary and secondary outcomes after two days. This was extended to about three days, which was the time when the delayed control group was emailed. This altered timing was dictated by when the organization's marketing department was ready to send emails to the delayed control group.",3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will become available after publication of study results in a scientific journal and will be available as long as the Open Science Framework hosts the data.,The data on the Open Science Framework will be open to anyone requesting that information.,http://osf.io,Yes,Data with no personally identifiable information will be made available to other researchers on the Open Science Framework for transparency. This will include the essential data and code needed to replicate the analysis that yielded reported findings.,2021-10-17T07:30:37Z,2021-10-17T07:30:37Z,100
NCT04728802,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-27,2021-06-15,NA,2021-06-22,2021-01-27,2021-01-28,Actual,2021-06-15,2021-06-23,Actual,NA,NA,NA,2021-06-22,2021-06-24,Actual,"February 1, 2021",Actual,2021-02-01,June 2021,2021-06-30,"April 15, 2021",Actual,2021-04-15,"April 15, 2021",Actual,2021-04-15,NA,Interventional,NA,,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Completed,NA,Phase 3,645,Actual,"Applied Biology, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Available upon request after peer review and publication.,Available upon request at data@appliedbiology.com,NA,Yes,"Yes, study data sets will be made available upon request after peer review and publication.",2021-10-17T07:30:35Z,2021-10-17T07:30:35Z,130
NCT04724538,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-29,2021-05-02,NA,2021-07-04,2021-01-23,2021-01-26,Actual,2021-07-04,2021-07-07,Actual,NA,NA,NA,2021-07-04,2021-07-07,Actual,"October 15, 2020",Actual,2020-10-15,July 2021,2021-07-31,"March 15, 2021",Actual,2021-03-15,"February 10, 2021",Actual,2021-02-10,NA,Interventional,NA,,Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19,Inhalation Low Dose Radionuclide Therapy in Comprehensive Treatment of COVID-19 Viral Pneumonia,Completed,NA,Phase 1/Phase 2,25,Actual,National Medical Research Radiological Centre of the Ministry of Health of Russia,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:31:13Z,2021-10-17T07:31:13Z,118
NCT04723563,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-22,NA,NA,2021-09-03,2021-01-22,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-05,Actual,"February 22, 2021",Actual,2021-02-22,September 2021,2021-09-30,"August 23, 2021",Actual,2021-08-23,"August 23, 2021",Actual,2021-08-23,NA,Interventional,INHALE-HEP,,Nebulized Heparin for the Treatment of COVID-19,INHALEd Unfractionated HEParin for the Treatment of Hospitalized Patients With COVID-19 Pneumonia,Completed,NA,Phase 4,50,Actual,Frederick Health,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:31:22Z,2021-10-17T07:31:22Z,57
NCT04723524,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-22,NA,NA,2021-10-05,2021-01-22,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"September 22, 2020",Actual,2020-09-22,October 2021,2021-10-31,"August 23, 2021",Actual,2021-08-23,"August 23, 2021",Actual,2021-08-23,NA,Interventional,RCT,,Jinhua Qinggan Granules in the Treatment of COVID-19,"Multi-center, Randomized, Double Blind and Placebo Controlled Clinical Trial on the Effectiveness and Safety of Jinhua Qinggan Granules (JHQG) for the Treatment of COVID 19 Patients",Completed,NA,Phase 2,402,Actual,University of Karachi,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:31:22Z,2021-10-17T07:31:22Z,25
NCT04723290,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-21,NA,NA,2021-03-24,2021-01-21,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"June 20, 2020",Actual,2020-06-20,March 2021,2021-03-31,"December 31, 2020",Actual,2020-12-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,,COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020,SARS-CoV-2 Seroconversion Study Among GHdC Staff Members,Completed,NA,N/A,2817,Actual,Grand HÃ´pital de Charleroi,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"At this moment, there is no plan to share the results",2021-10-17T07:31:24Z,2021-10-17T07:31:24Z,220
NCT04720235,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-15,NA,NA,2021-04-09,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-12,Actual,"December 9, 2020",Actual,2020-12-09,January 2021,2021-01-31,"March 30, 2021",Actual,2021-03-30,"March 9, 2021",Actual,2021-03-09,NA,Interventional,NA,,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay Among Asymptomatic Subjects,Completed,NA,N/A,304,Actual,Lucira Health Inc,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:31:50Z,2021-10-17T07:31:50Z,204
NCT04719234,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-20,NA,NA,2021-01-21,2021-01-21,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"June 15, 2020",Actual,2020-06-15,January 2021,2021-01-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,,Lung Ultrasonography in COVID-19 Pneumonia,Comparison of Lung Ultrasonography Findings With Chest Computerized Tomography Results in Corona virÃ¼s (COVID-19) Pneumonia,Completed,NA,N/A,60,Actual,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:32:01Z,2021-10-17T07:32:01Z,282
NCT04715932,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-15,NA,NA,2021-07-08,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-08,2021-07-12,Actual,"February 18, 2021",Actual,2021-02-18,July 2021,2021-07-31,"June 7, 2021",Actual,2021-06-07,"May 25, 2021",Actual,2021-05-25,NA,Interventional,Hesperidin,,Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN),"A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Hesperidin Therapy on COVID-19 Symptoms: The Hesperidin Coronavirus Study (Hesperidin)",Completed,NA,Phase 2,216,Actual,Montreal Heart Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:32:31Z,2021-10-17T07:32:31Z,114
NCT04720794,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-13,NA,NA,2021-01-22,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-26,Actual,"September 25, 2020",Actual,2020-09-25,January 2021,2021-01-31,"October 20, 2020",Actual,2020-10-20,"October 20, 2020",Actual,2020-10-20,NA,Interventional,NA,,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay,Completed,NA,N/A,101,Actual,Lucira Health Inc,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:31:45Z,2021-10-17T07:31:45Z,281
NCT04716647,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-18,NA,NA,2021-01-19,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-20,Actual,"October 9, 2020",Actual,2020-10-09,January 2021,2021-01-31,"December 18, 2020",Actual,2020-12-18,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,,Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research,A Community-Based Participatory Research to Assess the Feasibility of Ayurveda Intervention in Patients With Mild-to-Moderate COVID-19,Completed,NA,N/A,28,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:32:25Z,2021-10-17T07:32:25Z,284
NCT04716556,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-14,NA,NA,2021-08-25,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-26,Actual,"July 16, 2020",Actual,2020-07-16,August 2021,2021-08-31,"May 31, 2021",Actual,2021-05-31,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa Due to SARS-CoV2 (TSUNAMI Study): a Multicenter Open Label Randomized Control Trial,Completed,NA,N/A,474,Actual,Istituto Superiore di SanitÃ ,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:32:26Z,2021-10-17T07:32:26Z,66
NCT04716426,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-18,2021-03-31,NA,2021-04-06,2021-01-18,2021-01-20,Actual,2021-04-06,2021-04-08,Actual,NA,NA,NA,2021-04-06,2021-04-08,Actual,"January 28, 2021",Actual,2021-01-28,April 2021,2021-04-30,"March 25, 2021",Actual,2021-03-25,"March 25, 2021",Actual,2021-03-25,NA,Interventional,NA,,APTâ„¢ T3X on the COVID-19 Contamination Rate,Use of APTâ„¢ T3X to Decrease the COVID-19 Contamination Rate in Humans,Completed,NA,N/A,100,Actual,University of Nove de Julho,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:32:27Z,2021-10-17T07:32:27Z,207
NCT04715607,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-12,NA,NA,2021-09-28,2021-01-15,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-30,Actual,"January 22, 2021",Actual,2021-01-22,September 2021,2021-09-30,"May 31, 2021",Actual,2021-05-31,"May 30, 2021",Actual,2021-05-30,NA,Interventional,NA,,"COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens","Comparison of Detection Rate of SARS-CoV-2 in Saliva, Oropharyngeal and Nasopharyngeal Specimens in a Public COVID-19 Test Setting",Completed,NA,N/A,27947,Actual,"Rigshospitalet, Denmark",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T07:32:34Z,2021-10-17T07:32:34Z,32
NCT04713878,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-09,NA,NA,2021-01-16,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-16,2021-01-20,Actual,"May 8, 2020",Actual,2020-05-08,January 2021,2021-01-31,"July 15, 2020",Actual,2020-07-15,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,A 8-Week Trial of Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,Completed,NA,N/A,21,Actual,Kanuni Sultan Suleyman Training and Research Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:32:49Z,2021-10-17T07:32:49Z,287
NCT04713111,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-08,NA,NA,2021-03-10,2021-01-14,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-03-10,2021-03-12,Actual,"May 4, 2020",Actual,2020-05-04,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,,Stress and Recovery in Frontline COVID-19 Workers,Stress and Recovery in Frontline Healthcare COVID-19 Workers: A Feasibility Study Using Wearable and Smartphone Devices,Completed,NA,N/A,383,Actual,4YouandMe,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Internal collaborative researchers will have access to all coded data during the full duration of the study. Consented participants' coded data will be available in the Synapse at Sage Bionetworks for selected researchers to access indefinitely, one year after study completion.","As coded study data will then exist among consenting participants in the Synapse at Sage Bionetworks in de-identified form, the electronic data files will be kept indefinitely. The Principal Investigator will be responsible for receipt and/or transmission of data as required.",NA,Yes,"Under the 4YouandMe open source model, we will make all data, findings, digital health applications and algorithms available in the public domain. Accordingly, de-identified data produced from this project will be shared broadly with qualified researchers (among participants who opt in) through Sage Bionetworks Synapse and will serve as an immense resource, reflecting a highly granular and high- dimensional map of physiological stress responses and knowledge surrounding inadvertent consequences of objective stress measurement. Only data from consenting participants will be shared through Sage Bionetworks Synapse. Additionally, Source code for the developed app will be made available as open source software on GitHub so it can be evolved for future work by others.",2021-10-17T07:32:55Z,2021-10-17T07:32:55Z,234
NCT04713553,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-15,NA,NA,2021-08-04,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"February 15, 2021",Actual,2021-02-15,August 2021,2021-08-31,"July 22, 2021",Actual,2021-07-22,"July 22, 2021",Actual,2021-07-22,NA,Interventional,NA,,"A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162b2 AGAINST COVID-19 IN HEALTHY PARTICIPANTS 12 THROUGH 50 YEARS OF AGE AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED COVID-19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50 YEARS OF AGE",Completed,NA,Phase 3,1530,Actual,BioNTech SE,,7,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-17T07:32:52Z,2021-10-17T07:32:52Z,87
NCT04712045,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-11,NA,NA,2021-01-13,2021-01-13,2021-01-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-15,Actual,"August 1, 2020",Actual,2020-08-01,January 2021,2021-01-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,RUPERT,,Rational Use of Personal Protective Equipment During COVID-19 Pandemic,Rational Use of Personal Protective Equipment: a Randomised Trial and Quality Improvement Intervention During COVID-19 Pandemic,Completed,NA,N/A,67,Actual,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:33:04Z,2021-10-17T07:33:04Z,290
NCT04710381,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-13,NA,NA,2021-07-20,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"February 1, 2021",Actual,2021-02-01,July 2021,2021-07-31,"June 2, 2021",Actual,2021-06-02,"June 2, 2021",Actual,2021-06-02,NA,Interventional,NA,,IMUNORÂ® Preparation in the Prevention of COVID-19,"Pilot, Monocentric, Phase-IV Clinical Trial Assessing the Clinical Effect of Peroral Immunomodulation Treatment Using the IMUNORÂ® Preparation in the Prevention of COVID-19 Disease",Completed,NA,Phase 4,56,Actual,University Hospital Ostrava,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is no plan to make individual participant data available to other researchers.,2021-10-17T07:33:18Z,2021-10-17T07:33:18Z,102
NCT04709172,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-12,NA,NA,2021-10-05,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"January 5, 2021",Actual,2021-01-05,January 2021,2021-01-31,"August 15, 2021",Actual,2021-08-15,"August 15, 2021",Actual,2021-08-15,NA,Interventional,NA,,Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia,"Prospective, Non-controlled Pilot Study to Evaluate the Efficacy and Safety of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia",Completed,NA,Phase 4,20,Actual,Meiji Pharma Spain S.A.,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:33:28Z,2021-10-17T07:33:28Z,25
NCT04707742,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-07,NA,NA,2021-10-06,2021-01-12,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-11,Actual,"June 15, 2020",Actual,2020-06-15,September 2021,2021-09-30,"September 30, 2021",Actual,2021-09-30,"September 18, 2021",Actual,2021-09-18,NA,Interventional,BUCOSARS,,Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients,Clinical Evaluation of Antiseptic Mouth Rinses to Reduce Salivary Viral Load of SARS-CoV-2 in COVID-19 Patients,Completed,NA,N/A,160,Actual,FundaciÃ³n para el Fomento de la InvestigaciÃ³n Sanitaria y BiomÃ©dica de la Comunitat Valenciana,,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:33:41Z,2021-10-17T07:33:41Z,24
NCT04706403,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-05,NA,NA,2021-07-26,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-08-02,Actual,"January 12, 2021",Actual,2021-01-12,July 2021,2021-07-31,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,Views on COVID-19 and Vaccination,"If We Build It, Will They Come? A Pilot Study to Develop and Test Messages to Maximize Uptake of Coronavirus Vaccine When Available",Completed,NA,N/A,1706,Actual,"University of Massachusetts, Worcester",,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:33:54Z,2021-10-17T07:33:54Z,96
NCT04705753,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-06,NA,NA,2021-01-11,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"April 1, 2020",Actual,2020-04-01,January 2021,2021-01-31,"October 15, 2020",Actual,2020-10-15,"October 15, 2020",Actual,2020-10-15,NA,Interventional,COVID-19-IAMA,,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients","Evaluation of the Clinical Outcomes and the Quality of Life of Patients Exhibiting Symptoms Characteristic of Viral Respiratory Infection (VRI), Including Infection by SARS-CoV-2 (COVID-19), and Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in These Patients and the People Cohabiting With Them Via an Open-label, Single-arm Trial",Completed,NA,Phase 2/Phase 3,20,Actual,University of Crete,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:34:00Z,2021-10-17T07:34:00Z,292
NCT04703114,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-30,NA,NA,2021-09-27,2021-01-07,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"February 5, 2021",Actual,2021-02-05,September 2021,2021-09-30,"September 15, 2021",Actual,2021-09-15,"September 15, 2021",Actual,2021-09-15,NA,Interventional,AMBUCOV,,Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV),Study of the Immunological and Virological Response of Patients Infected With SARS-CoV-2 and Presenting an Asymptomatic or Pauci-symptomatic Form,Completed,NA,N/A,57,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:34:22Z,2021-10-17T07:34:22Z,33
NCT04701710,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-07,NA,NA,2021-02-22,2021-01-07,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-23,Actual,"October 15, 2020",Actual,2020-10-15,February 2021,2021-02-28,"December 31, 2020",Actual,2020-12-31,"December 18, 2020",Actual,2020-12-18,NA,Interventional,Ivercar-Tuc,,Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan,A Randomized Trial - Intensive Treatment Based in Ivermectin and Iota-carrageenan as Prophylaxis for Covid-19 In Healthcare Agents,Completed,NA,Phase 1/Phase 2,300,Actual,"Ministry of Public Health, Argentina",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,N/C,2021-10-17T07:34:33Z,2021-10-17T07:34:33Z,250
NCT04701658,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-07,NA,NA,2021-10-06,2021-01-07,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"February 1, 2021",Actual,2021-02-01,October 2021,2021-10-31,"June 22, 2021",Actual,2021-06-22,"June 22, 2021",Actual,2021-06-22,NA,Interventional,BLAZE-5,,A Real World Study of Bamlanivimab in Participants With Mild-to-moderate Coronavirus Disease 2019 (COVID-19),"A Prospective Cohort Study to Evaluate the Real-world Effectiveness of Bamlanivimab in Participants With Mild-to-moderate COVID-19 at High Risk for Progressing to Severe Illness, With Matched Controls",Completed,NA,Phase 2,109,Actual,Eli Lilly and Company,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2021-10-17T07:34:33Z,2021-10-17T07:34:33Z,24
NCT04701489,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-05,NA,NA,2021-06-01,2021-01-06,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-04,Actual,"January 14, 2021",Actual,2021-01-14,June 2021,2021-06-30,"April 7, 2021",Actual,2021-04-07,"March 15, 2021",Actual,2021-03-15,NA,Interventional,NA,,UNITE Study (UMN-GE) for COVID-19,Ultrasound Neural and Immunomodulation Treatment Evaluation Study (UMN-GE) for COVID-19,Completed,NA,N/A,30,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2021-10-17T07:34:35Z,2021-10-17T07:34:35Z,151
NCT04699916,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-06,NA,NA,2021-09-23,2021-01-06,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"January 4, 2021",Actual,2021-01-04,September 2021,2021-09-30,"September 23, 2021",Actual,2021-09-23,"May 23, 2021",Actual,2021-05-23,NA,Interventional,NA,,EEG-based Sedation Protocol for Patients on Mechanical Ventilation Due to SARS-CoV-2 Pneumonia,EEG-based Protocol to Guide Deep Sedation Decreases the Days of Mechanical Ventilation in Patients With SARS-CoV-2 Pneumonia: Randomized Clinical Trial,Completed,NA,N/A,50,Actual,University of Chile,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:34:50Z,2021-10-17T07:34:50Z,37
NCT04698798,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-04,NA,NA,2021-07-07,2021-01-04,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"January 2, 2021",Actual,2021-01-02,July 2021,2021-07-31,"April 3, 2021",Actual,2021-04-03,"April 3, 2021",Actual,2021-04-03,NA,Interventional,SMW,,Skeletal Muscle Wasting in SARS-CoV-2,Skeletal Muscle Wasting in SARS-CoV-2 Infected ICU (Intensive Care Unit) Patients,Completed,NA,N/A,22,Actual,Hasselt University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:35:00Z,2021-10-17T07:35:00Z,115
NCT04691908,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-21,NA,NA,2021-07-23,2020-12-29,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"December 25, 2020",Actual,2020-12-25,December 2020,2020-12-31,"July 11, 2021",Actual,2021-07-11,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,,"Immunogenicity, Efficacy and Safety of QazCovid-inÂ® COVID-19 Vaccine","Multicenter, Randomized, Blind, Placebo-controlled Clinical Study of III Phase on Assessment of Preventive Efficiency, Safety and Immunogenicity QazCovid-inÂ®-Vaccine Against COVID-19 in Healthy Adult Volunteers",Completed,NA,Phase 3,3000,Actual,Research Institute for Biological Safety Problems,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:36:00Z,2021-10-17T07:36:00Z,99
NCT04690920,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-19,NA,NA,2020-12-30,2020-12-30,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-30,2020-12-31,Actual,"July 23, 2020",Actual,2020-07-23,December 2020,2020-12-31,"December 10, 2020",Actual,2020-12-10,"December 10, 2020",Actual,2020-12-10,NA,Interventional,NA,,Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins,Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach,Completed,NA,N/A,200,Actual,University of Lahore,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,"statistical analysis, results",2021-10-17T07:36:08Z,2021-10-17T07:36:08Z,304
NCT04690413,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-31,NA,NA,2021-03-02,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"September 1, 2020",Actual,2020-09-01,March 2021,2021-03-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,,NOWDx Test for the Detection of Antibodies to COVID-19,NOWDx Test for the Detection of Antibodies to COVID-19,Completed,NA,N/A,129,Actual,"NOWDiagnostics, Inc.",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:36:12Z,2021-10-17T07:36:12Z,242
NCT04690387,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-28,NA,NA,2021-07-14,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-07-14,2021-07-20,Actual,"December 7, 2020",Actual,2020-12-07,July 2021,2021-07-31,"January 15, 2021",Actual,2021-01-15,"January 13, 2021",Actual,2021-01-13,NA,Interventional,NA,,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection","Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies",Completed,NA,Phase 1,27,Actual,"Aivita Biomedical, Inc.",,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:36:12Z,2021-10-17T07:36:12Z,108
NCT04689399,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-26,NA,NA,2021-03-25,2020-12-28,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-30,Actual,"December 26, 2020",Actual,2020-12-26,March 2021,2021-03-31,"March 25, 2021",Actual,2021-03-25,"March 25, 2021",Actual,2021-03-25,NA,Interventional,NA,,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test,Completed,NA,N/A,4697,Actual,"Rigshospitalet, Denmark",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:36:20Z,2021-10-17T07:36:20Z,219
NCT04687488,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-03,NA,NA,2020-12-22,2020-12-22,2020-12-29,Actual,NA,NA,NA,NA,NA,NA,2020-12-22,2020-12-29,Actual,"July 23, 2020",Actual,2020-07-23,December 2020,2020-12-31,"November 9, 2020",Actual,2020-11-09,"November 9, 2020",Actual,2020-11-09,NA,Interventional,NA,,Aerosol and Droplet Dispersion During Gastrointestinal Motility Investigations,COVID-19: The Study of Aerosol Generation and Droplet Dispersion and Deposition During Naso-gastric Intubation for Gastrointestinal Motility Investigations,Completed,NA,N/A,15,Actual,Universitaire Ziekenhuizen Leuven,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:36:37Z,2021-10-17T07:36:37Z,312
NCT04685681,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-07,NA,NA,2021-04-30,2020-12-22,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-30,2021-05-04,Actual,"January 7, 2021",Actual,2021-01-07,April 2021,2021-04-30,"April 6, 2021",Actual,2021-04-06,"April 6, 2021",Actual,2021-04-06,NA,Interventional,GO,,The Get Outside Study,Examining Adults' Activity Choices During COVID-19: The UB GO Study,Completed,NA,N/A,53,Actual,State University of New York at Buffalo,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:36:54Z,2021-10-17T07:36:54Z,183
NCT04685512,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-16,NA,NA,2021-06-29,2020-12-24,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-07-01,Actual,"November 18, 2020",Actual,2020-11-18,June 2021,2021-06-30,"May 1, 2021",Actual,2021-05-01,"April 1, 2021",Actual,2021-04-01,NA,Interventional,AR0-CORONA,,Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home,Effect of Tenofovir/Emtricitabine Short Course on Viral Clearance in Patients Recently Infected With SARS-COV2 (Covid-19) Not Requiring Hospitalization: a Phase IIB/III Multicenter Open-label Randomized Controlled Trial,Completed,NA,Phase 2/Phase 3,60,Actual,"University Hospital, Caen",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,We encourage contact the corresponding author for academic IPD sharing,2021-10-17T07:36:56Z,2021-10-17T07:36:56Z,123
NCT04679493,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-18,NA,NA,2021-09-21,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"December 17, 2020",Actual,2020-12-17,September 2021,2021-09-30,"April 9, 2021",Actual,2021-04-09,"April 9, 2021",Actual,2021-04-09,NA,Interventional,NA,,"Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers","Double Blind, Randomized, Placebo-controlled Study of Safety, Tolerability, and Pharmacokinetics of Ascending Doses of XC7 After Single and Multiple Oral Administration in Healthy Volunteers",Completed,NA,Phase 1,16,Actual,NP Therapeutics,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:37:46Z,2021-10-17T07:37:46Z,39
NCT04679415,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-21,NA,NA,2021-08-24,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-26,Actual,"December 17, 2020",Actual,2020-12-17,December 2020,2020-12-31,"August 19, 2021",Actual,2021-08-19,"August 19, 2021",Actual,2021-08-19,NA,Interventional,NA,,Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia,"A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous (IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients",Completed,NA,Phase 2,63,Actual,"ImmuneMed, Inc.",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:37:47Z,2021-10-17T07:37:47Z,67
NCT04678739,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-19,NA,NA,2021-03-31,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-02,Actual,"August 15, 2020",Actual,2020-08-15,March 2021,2021-03-31,"February 10, 2021",Actual,2021-02-10,"January 30, 2021",Actual,2021-01-30,NA,Interventional,NA,,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,Completed,NA,Phase 3,205,Actual,M Abdur Rahim Medical College and Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:37:55Z,2021-10-17T07:37:55Z,213
NCT04678830,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-14,NA,NA,2021-07-30,2020-12-18,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-02,Actual,"March 1, 2021",Actual,2021-03-01,July 2021,2021-07-31,"July 8, 2021",Actual,2021-07-08,"June 5, 2021",Actual,2021-06-05,NA,Interventional,NA,,COVID-19 Long-Haulers Study,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers]",Completed,NA,Phase 2,56,Actual,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:37:54Z,2021-10-17T07:37:54Z,92
NCT04678778,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-11,NA,NA,2021-04-27,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-29,Actual,"March 19, 2019",Actual,2019-03-19,April 2021,2021-04-30,"February 19, 2021",Actual,2021-02-19,"February 19, 2021",Actual,2021-02-19,NA,Interventional,NRVR,,Virtual Reality Study - COVID-19 Protocol,Targeted Physical and Cognitive Activity in a VR Environment - COVID-19 Protocol,Completed,NA,N/A,14,Actual,University of Southern California,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:37:54Z,2021-10-17T07:37:54Z,186
NCT04677270,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-18,NA,NA,2020-12-18,2020-12-18,2020-12-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-18,2020-12-21,Actual,"August 31, 2020",Actual,2020-08-31,December 2020,2020-12-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,COVIDPROBLEM,,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic,Completed,NA,N/A,397,Actual,Karolinska Institutet,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:38:10Z,2021-10-17T07:38:10Z,316
NCT04676867,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-17,NA,NA,2021-06-01,2020-12-18,2020-12-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"January 11, 2021",Actual,2021-01-11,June 2021,2021-06-30,"May 17, 2021",Actual,2021-05-17,"May 17, 2021",Actual,2021-05-17,NA,Interventional,NA,,Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19,"A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19",Completed,NA,Phase 2,227,Actual,DalCor Pharmaceuticals,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:38:13Z,2021-10-17T07:38:13Z,151
NCT04674644,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-16,2021-01-02,NA,2021-01-30,2020-12-17,2020-12-19,Actual,2021-01-27,2021-01-29,Actual,NA,NA,NA,2021-01-30,2021-02-02,Actual,"October 16, 2020",Actual,2020-10-16,January 2021,2021-01-31,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,NA,,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Suleyman Demirel University Faculty of Dentistry Pediatric Dentistry Department,Completed,NA,N/A,850,Actual,Suleyman Demirel University,"The present study has some limitations. Since the stress and anxiety levels of the dentists participating in the study prior to the pandemic are not known, the extent of the increase in these levels is unknown. In addition, because this is a cross-sectional study, the findings reflect only a certain period of the pandemic. Only scales related to COVID-19 were included, as it was thought that participants might be reluctant to participate in a longer survey.",1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:38:32Z,2021-10-17T07:38:32Z,273
NCT04673214,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-16,2021-03-08,NA,2021-08-12,2020-12-16,2020-12-17,Actual,2021-08-12,2021-08-16,Actual,NA,NA,NA,2021-08-12,2021-08-16,Actual,"December 16, 2020",Actual,2020-12-16,August 2021,2021-08-31,"February 25, 2021",Actual,2021-02-25,"February 25, 2021",Actual,2021-02-25,NA,Interventional,NA,"Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis.",Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Prognostic Modification in Patients With COVID-19 Under Early Intervention Treatment at U.M.F 13 and U.M.F 20,Completed,NA,Phase 3,114,Actual,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,SHARED VIA EMAIL IF OTHER RESEARCHERS REQUIRE IT,2021-10-17T07:38:44Z,2021-10-17T07:38:44Z,79
NCT04668625,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-09,NA,NA,2021-02-05,2020-12-14,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-05,2021-02-08,Actual,"November 30, 2020",Actual,2020-11-30,January 2021,2021-01-31,"January 8, 2021",Actual,2021-01-08,"December 20, 2020",Actual,2020-12-20,NA,Interventional,NA,,"Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures",Risk of Infection of SARS-CoV-2 in a Massive Musical Show With Transmission Prevention Measures: Randomized Study,Completed,NA,N/A,1000,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:39:24Z,2021-10-17T07:39:24Z,267
NCT04668469,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-25,NA,NA,2020-12-11,2020-12-11,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-16,Actual,"June 8, 2020",Actual,2020-06-08,December 2020,2020-12-31,"October 30, 2020",Actual,2020-10-30,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Completed,NA,N/A,600,Actual,Benha University,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:39:25Z,2021-10-17T07:39:25Z,323
NCT04667780,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-11,NA,NA,2021-06-19,2020-12-12,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-06-19,2021-06-22,Actual,"December 10, 2020",Actual,2020-12-10,June 2021,2021-06-30,"June 9, 2021",Actual,2021-06-09,"June 9, 2021",Actual,2021-06-09,NA,Interventional,NA,,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Completed,NA,Phase 3,102,Actual,Ayub Teaching Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:39:32Z,2021-10-17T07:39:32Z,133
NCT04666441,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-10,NA,NA,2021-09-30,2020-12-10,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-08,Actual,"December 15, 2020",Actual,2020-12-15,September 2021,2021-09-30,"September 21, 2021",Actual,2021-09-21,"March 4, 2021",Actual,2021-03-04,NA,Interventional,NA,,COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection,A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection,Completed,NA,Phase 2,1164,Actual,Regeneron Pharmaceuticals,,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-10-17T07:39:44Z,2021-10-17T07:39:44Z,30
NCT04666233,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-11,NA,NA,2021-03-27,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-27,2021-04-01,Actual,"March 16, 2021",Actual,2021-03-16,March 2021,2021-03-31,"March 23, 2021",Actual,2021-03-23,"March 23, 2021",Actual,2021-03-23,NA,Interventional,NA,,Personal Protective Equipment for the Prevention of SARS-Cov-2 During Neonatal Resuscitation,Does Personal Protective Equipment for the Prevention of SARS-Cov-2 Infection Impact the Timing of Ventilation in Neonates Needing Resuscitation at Birth? A Crossover Randomized Controlled Trial,Completed,NA,N/A,48,Actual,University Hospital Padova,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:39:46Z,2021-10-17T07:39:46Z,217
NCT04665193,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-08,NA,NA,2021-04-29,2020-12-10,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-05-04,Actual,"November 23, 2020",Actual,2020-11-23,April 2021,2021-04-30,"April 28, 2021",Actual,2021-04-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,,An Approach to Screening for COVID-19 at Vancouver Airport,An Approach to Screening for SARS-CoV-2 at YVR: UBC-PHC-WestJet-YVR COVID-19 Screening Study,Completed,NA,N/A,592,Actual,University of British Columbia,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:39:55Z,2021-10-17T07:39:55Z,184
NCT04663594,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-27,NA,NA,2021-10-01,2020-12-04,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-08,Actual,"December 4, 2020",Actual,2020-12-04,November 2020,2020-11-30,"February 10, 2021",Actual,2021-02-10,"February 10, 2021",Actual,2021-02-10,NA,Interventional,O-ACEPOP,,Online Culture for Mental Health in People Aged 16-24,An Online Cultural Experience to Support Mental Health in People Aged 16-24 During COVID-19: the O-ACEPOP (Online Active Community Engagement Proof of Principle) Study,Completed,NA,N/A,413,Actual,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will be made available on OSF once peer reviewed,NA,NA,Yes,The data will be made available on OSF once peer reviewed,2021-10-17T07:40:08Z,2021-10-17T07:40:08Z,29
NCT04662671,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-09,NA,NA,2021-02-10,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"November 18, 2020",Actual,2020-11-18,February 2021,2021-02-28,"January 30, 2021",Actual,2021-01-30,"December 9, 2020",Actual,2020-12-09,NA,Interventional,NA,,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19","Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19",Completed,NA,Phase 1/Phase 2,31,Actual,KNOWBio Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:40:16Z,2021-10-17T07:40:16Z,262
NCT04661839,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-09,NA,NA,2021-08-16,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"December 24, 2020",Actual,2020-12-24,August 2021,2021-08-31,"July 27, 2021",Actual,2021-07-27,"July 27, 2021",Actual,2021-07-27,NA,Interventional,NA,,A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults,"A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Evaluate Safety and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) Administered as a Single Dose Regimen to Healthy Adults",Completed,NA,Phase 1,28,Actual,Emergent BioSolutions,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Study Protocol, Statistical Analysis Plan, and Informed Consent Form (redacted) to be shared.",2021-10-17T07:40:23Z,2021-10-17T07:40:23Z,75
NCT04659772,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-07,NA,NA,2021-03-02,2020-12-07,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"December 3, 2020",Actual,2020-12-03,March 2021,2021-03-31,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,A Study to Evaluate Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-Controlled Safety And Dose-Finding Study For The Use Of The Il-6 Inhibitor Clazakizumab in Patients With Life-Threatening COVID-19 Infection,Completed,NA,Phase 2,1,Actual,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:40:41Z,2021-10-17T07:40:41Z,242
NCT04659109,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-30,NA,NA,2021-09-10,2020-12-07,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-13,Actual,"December 16, 2020",Actual,2020-12-16,September 2021,2021-09-30,"August 6, 2021",Actual,2021-08-06,"August 6, 2021",Actual,2021-08-06,NA,Interventional,GARDEN,,Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19,"A Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel Group, Exploratory Efficacy and Safety Study of Glenzocimab in SARS-Cov-2-related Acute Respiratory Distress Syndrome",Completed,NA,Phase 2,60,Actual,Acticor Biotech,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:40:47Z,2021-10-17T07:40:47Z,50
NCT04656626,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-04,NA,NA,2020-12-08,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-10,Actual,"July 7, 2020",Actual,2020-07-07,December 2020,2020-12-31,"September 5, 2020",Actual,2020-09-05,"July 21, 2020",Actual,2020-07-21,NA,Interventional,NA,,Brief Mindfulness Based Intervention to Improve Psychological Wellbeing,"Brief Mindfulness Based Intervention for Front-Line Medical Staff in the COVID19 Pandemic to Improve Psychological Wellbeing, a Randomized Controlled Multicenter Trial",Completed,NA,N/A,146,Actual,Imam Abdulrahman Bin Faisal University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:41:10Z,2021-10-17T07:41:10Z,326
NCT04657497,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-09,NA,NA,2021-06-11,2020-12-06,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-14,Actual,"November 9, 2020",Actual,2020-11-09,May 2021,2021-05-31,"April 9, 2021",Actual,2021-04-09,"March 26, 2021",Actual,2021-03-26,NA,Interventional,NA,,A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19),"A Placebo-controlled, Multicenter, Double-blind, Randomized, Parallel-group Comparative Study in SARS-CoV-2 Infection (COVID-19)",Completed,NA,Phase 3,155,Actual,Ono Pharmaceutical Co. Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,https://www.ono.co.jp/eng/rd/policy.html,Yes,NA,2021-10-17T07:41:02Z,2021-10-17T07:41:02Z,141
NCT04657471,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-06,NA,NA,2021-03-12,2020-12-06,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-03-12,2021-03-15,Actual,"December 8, 2020",Actual,2020-12-08,December 2020,2020-12-31,"March 8, 2021",Actual,2021-03-08,"March 8, 2021",Actual,2021-03-08,NA,Interventional,NA,,Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study,Hospitalization or Outpatient ManagEment of Patients With Suspected or Confirmed SRAS-CoV-2 Infection: the Revised HOME-CoV Score Study.,Completed,NA,N/A,1300,Actual,"University Hospital, Angers",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:41:02Z,2021-10-17T07:41:02Z,232
NCT04656691,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-04,NA,NA,2021-04-27,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-29,Actual,"January 4, 2021",Actual,2021-01-04,April 2021,2021-04-30,"April 18, 2021",Actual,2021-04-18,"April 18, 2021",Actual,2021-04-18,NA,Interventional,UNITED,,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,Completed,NA,Phase 4,4000,Actual,UnitedHealth Group,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No plan to share participant level data with other projects or researchers.,2021-10-17T07:41:09Z,2021-10-17T07:41:09Z,186
NCT04652648,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-02,NA,NA,2020-12-02,2020-12-02,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-03,Actual,"May 27, 2020",Actual,2020-05-27,December 2020,2020-12-31,"November 15, 2020",Actual,2020-11-15,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Completed,NA,Phase 4,54,Actual,Bryn Mawr Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:41:45Z,2021-10-17T07:41:45Z,332
NCT04649424,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-27,NA,NA,2021-07-14,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-07-14,2021-07-15,Actual,"December 22, 2020",Actual,2020-12-22,July 2021,2021-07-31,"April 13, 2021",Actual,2021-04-13,"April 13, 2021",Actual,2021-04-13,NA,Interventional,NA,,COVID-19 Nasal Swab Trial,Comparative Evaluation of Nasopharyngeal Swabs for Sampling and Detection of SARS-CoV2,Completed,NA,N/A,169,Actual,Orthopaedic Innovation Centre,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:42:12Z,2021-10-17T07:42:12Z,108
NCT04647305,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-24,NA,NA,2021-04-26,2020-11-25,2020-11-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-27,Actual,"January 16, 2021",Actual,2021-01-16,April 2021,2021-04-30,"March 4, 2021",Actual,2021-03-04,"March 4, 2021",Actual,2021-03-04,NA,Interventional,COVPROSHIELD,,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission: A Randomized Controlled Trial,Completed,NA,N/A,233,Actual,"University of Los Andes, Columbia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,6 months after publication,A formal request sent to the principal investigator.,NA,Yes,"After publication of main results, data will be available for other researchers such as: Study Protocol, Statistical Analysis Plan, Informed Consent Form, Clinical Study Report and Analytic Code.",2021-10-17T07:42:31Z,2021-10-17T07:42:31Z,187
NCT04646109,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-15,2020-12-03,NA,2021-01-25,2020-11-25,2020-11-27,Actual,2021-01-25,2021-01-27,Actual,NA,NA,NA,2021-01-25,2021-01-27,Actual,"May 11, 2020",Actual,2020-05-11,January 2021,2021-01-31,"September 2, 2020",Actual,2020-09-02,"September 2, 2020",Actual,2020-09-02,NA,Interventional,NA,"36 patients were included in the study group. But, 6 patients in the study group were excluded from the study and analysis because ivermectin treatments were terminated due to the detection of a mutation that impairs ivermectin metabolism. As a result, overall number of baseline participants in the study group was 30.",Ivermectin for Severe COVID-19 Management,The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management,Completed,NA,Phase 3,66,Actual,Afyonkarahisar Health Sciences University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:42:42Z,2021-10-17T07:42:42Z,278
NCT04645407,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-15,NA,NA,2020-11-25,2020-11-25,2020-11-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"February 1, 2020",Actual,2020-02-01,November 2020,2020-11-30,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,,Effects of Fuzheng Huayu Tablets on COVID-19,Efficacy of Fuzheng Huayu Tablets for Treating Pulmonary Inflammation in Patients With COVID-19: A Case-Control Study,Completed,NA,Phase 4,66,Actual,ShuGuang Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:42:49Z,2021-10-17T07:42:49Z,339
NCT04644120,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-23,NA,NA,2021-08-30,2020-11-23,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-02,Actual,"December 10, 2020",Actual,2020-12-10,August 2021,2021-08-31,"August 24, 2021",Actual,2021-08-24,"August 24, 2021",Actual,2021-08-24,NA,Interventional,NA,,Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19),"A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ABBV-47D11 and ABBV-2B04 as Monotherapy or Combination Therapy in Adults With COVID-19",Completed,NA,Phase 1,25,Actual,AbbVie,,12,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:43:00Z,2021-10-17T07:43:00Z,61
NCT04643964,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-12,NA,NA,2021-07-15,2020-11-20,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-07-15,2021-07-22,Actual,"November 17, 2020",Actual,2020-11-17,July 2021,2021-07-31,"June 5, 2021",Actual,2021-06-05,"June 5, 2021",Actual,2021-06-05,NA,Interventional,NA,,Brief Video Interventions for Depression,Building Mental Health Resilience in the COVID-19 Pandemic.,Completed,NA,N/A,531,Actual,Ohio State University,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,IPD will be available upon reasonable request within one year of primary outcome manuscript being published.,Proposals should be directed to Daniel R. Strunk at strunk.20@osu.edu,NA,Yes,"Results will be posted to clinicaltrials.gov within one year after completion of the final participant's participation in the clinical trial. Following initial publication, deidentified individual participant data (IPD) that underlie results in the primary outcome data reported will be available on reasonable request for 5 years after study completion.",2021-10-17T07:43:02Z,2021-10-17T07:43:02Z,107
NCT04632368,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-11,NA,NA,2021-08-19,2020-11-16,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-23,Actual,"November 20, 2020",Actual,2020-11-20,May 2021,2021-05-31,"August 16, 2021",Actual,2021-08-16,"August 10, 2021",Actual,2021-08-10,NA,Interventional,NA,,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,Completed,NA,N/A,80,Actual,Duke University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:44:45Z,2021-10-17T07:44:45Z,72
NCT04640181,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-19,NA,NA,2021-06-28,2020-11-19,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-30,Actual,"December 1, 2020",Actual,2020-12-01,June 2021,2021-06-30,"June 28, 2021",Actual,2021-06-28,"June 28, 2021",Actual,2021-06-28,NA,Interventional,XACT,,Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT),"A Phase 2-3, Multi-Center, Randomized Trial to Study the Potential Benefit of Factor Xa Inhibitor (Rivaroxaban) Versus Standard of Care Low Molecular Weight Heparin (Lovenox) in Hospitalized Patients With COVID-19 (XACT)",Completed,NA,Phase 2,150,Actual,St. David's HealthCare,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:43:35Z,2021-10-17T07:43:35Z,124
NCT04638842,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-19,NA,NA,2021-10-12,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Actual,"December 24, 2020",Actual,2020-12-24,October 2021,2021-10-31,"June 1, 2021",Actual,2021-06-01,"June 1, 2021",Actual,2021-06-01,NA,Interventional,NA,,Online Multi-component Psychological Intervention for Prevention of Grief Disorder Due to COVID-19,"Effectiveness of a Self-applied Multi-component Psychological Online Intervention Based on UX, for the Prevention of Complicated Grief Disorder in the Mexican Population During the COVID-19 Outbreak: A Randomized Clinical Trial",Completed,NA,N/A,43,Actual,Universidad Internacional de Valencia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,This data will be available approximately in April 2021 and it will be permanently available. It will be shared in the databases of the journal where the article(s) will be published.,Through the servers of the journal(s) where we will publish the articles.,NA,Yes,"The information will be available in a private server or in a server of the journal(s) that we will publish the articles that will be the result of this study. The protocol of the study is currently in progress to be published, in this article will be included such study protocol, the informed consent is already shared in the register of clinical trials.",2021-10-17T07:43:47Z,2021-10-17T07:43:47Z,18
NCT04637867,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-16,NA,NA,2021-06-03,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-04,Actual,"November 23, 2020",Actual,2020-11-23,June 2021,2021-06-30,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,NA,,COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO),Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study,Completed,NA,N/A,189,Actual,Hospices Civils de Lyon,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:43:55Z,2021-10-17T07:43:55Z,149
NCT04637477,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-06,NA,NA,2021-09-14,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"August 1, 2020",Actual,2020-08-01,September 2021,2021-09-30,"August 25, 2021",Actual,2021-08-25,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,,Virtual Enhanced Lifestyle for Metabolic Syndrome (ELM) Proof-of-Concept Study,Rush Coronavirus Disease Virtual Lifestyle Program to Boost Host Resistance in Patients With Elevated Cardiometabolic Risk: A Proof-of-Concept Study,Completed,NA,N/A,10,Actual,Rush University Medical Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:44:00Z,2021-10-17T07:44:00Z,46
NCT04634903,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-11,2021-05-18,NA,2021-05-21,2020-11-17,2020-11-18,Actual,2021-05-21,2021-05-25,Actual,NA,NA,NA,2021-05-21,2021-05-25,Actual,"November 19, 2020",Actual,2020-11-19,May 2021,2021-05-31,"March 15, 2021",Actual,2021-03-15,"March 15, 2021",Actual,2021-03-15,NA,Interventional,NA,,"Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19",Comparing Two Online Single-Session Interventions for Adolescent Depression: Outcomes of a Randomized Trial,Completed,NA,N/A,2452,Actual,Stony Brook University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Protocol and statistical plan have been posted to Open Science Framework prior to the start of this trial as part of study pre-registration (https://osf.io/kumdv/). Code will be made available upon publication of trial results.,NA,https://osf.io/8mk6x,Yes,NA,2021-10-17T07:44:20Z,2021-10-17T07:44:20Z,162
NCT04632706,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-26,NA,NA,2021-06-16,2020-11-16,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-06-16,2021-06-22,Actual,"September 22, 2020",Actual,2020-09-22,June 2021,2021-06-30,"March 9, 2021",Actual,2021-03-09,"March 9, 2021",Actual,2021-03-09,NA,Interventional,NA,,Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19,"A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Active IMP in Healthy Volunteers",Completed,NA,Early Phase 1,24,Actual,MedinCell S.A,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:44:42Z,2021-10-17T07:44:42Z,136
NCT04632602,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-16,NA,NA,2021-08-12,2020-11-16,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"April 14, 2020",Actual,2020-04-14,August 2021,2021-08-31,"December 31, 2020",Actual,2020-12-31,"November 29, 2020",Actual,2020-11-29,NA,Interventional,ProneSpontCov,,Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure,Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure: a Randomized Cross Over Electrical Impedance Tomography Study,Completed,NA,N/A,20,Actual,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:44:43Z,2021-10-17T07:44:43Z,79
NCT04631666,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-05,NA,NA,2021-08-22,2020-11-14,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-22,2021-08-24,Actual,"December 8, 2020",Actual,2020-12-08,August 2021,2021-08-31,"August 11, 2021",Actual,2021-08-11,"August 11, 2021",Actual,2021-08-11,NA,Interventional,NA,,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion,A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,Completed,NA,Phase 1/Phase 2,57,Actual,University of Cologne,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:44:52Z,2021-10-17T07:44:52Z,69
NCT04630054,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-13,NA,NA,2021-08-05,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-12,Actual,"November 15, 2020",Actual,2020-11-15,August 2021,2021-08-31,"June 29, 2021",Actual,2021-06-29,"June 29, 2021",Actual,2021-06-29,NA,Interventional,NA,,Face Masks to Reduce COVID-19 in Bangladesh,Can Face Masks Reduce Transmission of SARS-CoV-2 in Bangladesh? A Cluster Randomized Controlled Trial,Completed,NA,N/A,350000,Actual,Yale University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,We do not plan to share individual participant data with other researchers,2021-10-17T07:45:10Z,2021-10-17T07:45:10Z,86
NCT04629989,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-13,NA,NA,2021-03-08,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-09,Actual,"November 13, 2020",Actual,2020-11-13,March 2021,2021-03-31,"March 5, 2021",Actual,2021-03-05,"March 5, 2021",Actual,2021-03-05,NA,Interventional,NA,,Comparison of the Surgical Facemask With the Double-trunk Mask on Oxygenation in COVID-19,The Effects of Two Systems Above Low-flow Nasal Cannula on Arterial Oxygen Tension in Patients With COVID-19 : Surgical Face Mask Versus Double-trunk Mask,Completed,NA,N/A,27,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:45:11Z,2021-10-17T07:45:11Z,236
NCT04629157,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-04,NA,NA,2021-08-02,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"November 5, 2020",Actual,2020-11-05,November 2020,2020-11-30,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,LAVA,,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,Completed,NA,N/A,185,Actual,Alder Hey Children's NHS Foundation Trust,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,IPD will not be shared outside of the research team,2021-10-17T07:45:19Z,2021-10-17T07:45:19Z,89
NCT04628143,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-10,NA,NA,2021-08-09,2020-11-10,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-13,Actual,"December 21, 2020",Actual,2020-12-21,April 2021,2021-04-30,"April 5, 2021",Actual,2021-04-05,"April 5, 2021",Actual,2021-04-05,NA,Interventional,NA,,A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,"Open-label, Multi-center, Randomized Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19",Completed,NA,Phase 2,13,Actual,Chong Kun Dang Pharmaceutical,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:45:28Z,2021-10-17T07:45:28Z,82
NCT04627467,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-30,NA,NA,2021-10-05,2020-11-11,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-07,Actual,"March 28, 2020",Actual,2020-03-28,September 2020,2020-09-30,"September 30, 2021",Actual,2021-09-30,"July 9, 2020",Actual,2020-07-09,NA,Interventional,TS-COVID,,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19),Completed,NA,Phase 2,3217,Actual,Fundacion Clinica Valle del Lili,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"We do not plan to share IPD, since we are not allowed to share information concerning medical history of our patients or health workers.",2021-10-17T07:45:34Z,2021-10-17T07:45:34Z,25
NCT04625985,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-23,NA,NA,2021-04-05,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"July 14, 2020",Actual,2020-07-14,April 2021,2021-04-30,"March 18, 2021",Actual,2021-03-18,"March 8, 2021",Actual,2021-03-08,NA,Interventional,DMMETCOV19-2,,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.","Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb",Completed,NA,Phase 2,20,Actual,Laboratorios Silanes S.A. de C.V.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:45:48Z,2021-10-17T07:45:48Z,208
NCT04622891,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-06,NA,NA,2020-11-07,2020-11-07,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"April 1, 2020",Actual,2020-04-01,November 2020,2020-11-30,"July 30, 2020",Actual,2020-07-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,,Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection,"Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial",Completed,NA,N/A,300,Actual,South Valley University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:46:15Z,2021-10-17T07:46:15Z,357
NCT04623021,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-05,NA,NA,2021-01-31,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2021-01-31,2021-02-02,Actual,"September 25, 2020",Actual,2020-09-25,January 2021,2021-01-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,"An Open-label, Randomized, Multicenter, Controlled Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia",Completed,NA,Phase 2,104,Actual,Chong Kun Dang Pharmaceutical,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:46:14Z,2021-10-17T07:46:14Z,272
NCT04621903,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-06,NA,NA,2020-11-18,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-18,2020-11-19,Actual,"October 8, 2020",Actual,2020-10-08,November 2020,2020-11-30,"November 3, 2020",Actual,2020-11-03,"October 27, 2020",Actual,2020-10-27,NA,Interventional,NA,,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19: Community Based Participatory Research,Completed,NA,N/A,26,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:46:25Z,2021-10-17T07:46:25Z,346
NCT04621461,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-06,NA,NA,2021-02-08,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-11,Actual,"December 20, 2020",Actual,2020-12-20,February 2021,2021-02-28,"February 8, 2021",Actual,2021-02-08,"February 8, 2021",Actual,2021-02-08,NA,Interventional,NA,,Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting,"A Randomized, Placebo-Controlled Study Evaluating the Efficacy of Zinc for the Treatment of COVID-19 in the Outpatient Setting",Completed,NA,Phase 4,3,Actual,"St. Francis Hospital, New York",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:46:29Z,2021-10-17T07:46:29Z,264
NCT04621123,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-04,NA,NA,2021-09-04,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-04,2021-09-08,Actual,"November 10, 2020",Actual,2020-11-10,September 2021,2021-09-30,"July 28, 2021",Actual,2021-07-28,"May 31, 2021",Actual,2021-05-31,NA,Interventional,NA,,Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients,Convalescent Methylene Blue Treated (MBT) Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients: a Randomized Double Blind Study (COnV-ert),Completed,NA,Phase 2,384,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:46:31Z,2021-10-17T07:46:31Z,56
NCT04620798,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-04,NA,NA,2021-08-23,2020-11-05,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"September 14, 2020",Actual,2020-09-14,August 2021,2021-08-31,"November 11, 2020",Actual,2020-11-11,"November 11, 2020",Actual,2020-11-11,NA,Interventional,NA,,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,Completed,NA,N/A,1076,Actual,Indiana University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"These study protocol documents will be made available upon completion of the study and the analyses. A de-identified, limited data set and analytic code will be available from the Principal Investigator upon request.","Protocol will be available on clinicaltrials.gov while the other documents, data, and analytic code from the Principal Investigator upon request.",NA,Yes,"The study team will make the following documents available to the public upon completion of the study: (1) Study Protocol, (2) Statistical Analysis Plan (SAP), (3) Informed Consent Form (ICF), and (4) Clinical Study Report (CSR). The individual participant data as well as the analytic code will not be made available to the public due to privacy concerns and in order to protect participants' private health information but will be available from the Principal Investigator upon request.",2021-10-17T07:46:34Z,2021-10-17T07:46:34Z,68
NCT04618042,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-23,NA,NA,2021-06-21,2020-11-04,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"November 13, 2020",Actual,2020-11-13,June 2021,2021-06-30,"June 13, 2021",Actual,2021-06-13,"May 14, 2021",Actual,2021-05-14,NA,Interventional,FX-COVID,,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,Completed,NA,Phase 2,50,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:46:58Z,2021-10-17T07:46:58Z,131
NCT04617483,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-04,NA,NA,2021-07-26,2020-11-04,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"October 31, 2020",Actual,2020-10-31,November 2020,2020-11-30,"May 31, 2021",Actual,2021-05-31,"November 28, 2020",Actual,2020-11-28,NA,Interventional,NA,,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults","A Randomized, Double-Blinded Clinical Trial, to Evaluate the Non-inferiority of the Commercial Scale Inactivated SARS-CoV-2 Vaccine Against That of the Pilot Scale Among Adults Aged 26-45 Years, and the Open-labelled, Bridging Non-inferiority of the Vaccine Induced Immunogenicity in Elderly Against That in Adults",Completed,NA,Phase 3,1040,Actual,"Sinovac Biotech Co., Ltd",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:47:03Z,2021-10-17T07:47:03Z,96
NCT04616989,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-20,NA,NA,2021-06-01,2020-11-03,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"November 1, 2020",Actual,2020-11-01,June 2021,2021-06-30,"January 30, 2021",Actual,2021-01-30,"January 30, 2021",Actual,2021-01-30,NA,Interventional,NA,,Mental Health in Communities Affected by COVID-19 in Uganda,Integration of Mental Health Care in Communities Affected by the COVID-19 Pandemic in Central Uganda,Completed,NA,N/A,814,Actual,Makerere University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:47:07Z,2021-10-17T07:47:07Z,151
NCT04615741,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-29,NA,NA,2021-04-28,2020-10-29,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-29,Actual,"November 9, 2020",Actual,2020-11-09,April 2021,2021-04-30,"April 20, 2021",Actual,2021-04-20,"January 22, 2021",Actual,2021-01-22,NA,Interventional,NA,,Finding Wellness in the Pandemic,Improving Health and Wellness During COVID-19,Completed,NA,N/A,187,Actual,University of Lethbridge,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"After April 2021, for up to 10 years",Researchers must make a reasonable request to the PI,NA,Yes,De-identified data relevant to the researcher's research question may be shared upon a reasonable request,2021-10-17T07:47:18Z,2021-10-17T07:47:18Z,185
NCT04614883,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-02,NA,NA,2021-06-11,2020-11-03,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-16,Actual,"October 21, 2020",Actual,2020-10-21,June 2021,2021-06-30,"February 26, 2021",Actual,2021-02-26,"February 26, 2021",Actual,2021-02-26,NA,Interventional,VOC-COVID-Diag,,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in the Context of Suspicion of COVID-19 Infection,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in Patients Referred to the Emergency Reception Service for Suspected COVID-19 Infection: Diagnostic Value and for Rapid Screening,Completed,NA,N/A,130,Actual,Hopital Foch,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:47:26Z,2021-10-17T07:47:26Z,141
NCT04610502,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-15,NA,NA,2021-03-18,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-18,2021-03-19,Actual,"September 6, 2020",Actual,2020-09-06,March 2021,2021-03-31,"December 6, 2020",Actual,2020-12-06,"October 6, 2020",Actual,2020-10-06,NA,Interventional,SECR-01,,Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients,"Randomized, Controlled, Double-blind, Multicenter Clinical Study to Compare the Efficacy and Safety of the Administration of Two Hyperimmune Equine Anti-Sars-CoV-2 (""S"" and ""M"") Serum Formulations in Hospitalized Patients With COVID-19",Completed,NA,Phase 2,26,Actual,Caja Costarricense de Seguro Social,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:48:05Z,2021-10-17T07:48:05Z,226
NCT04609969,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-28,NA,NA,2020-12-04,2020-10-28,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-04,2020-12-07,Actual,"October 13, 2020",Actual,2020-10-13,December 2020,2020-12-31,"October 17, 2020",Actual,2020-10-17,"October 17, 2020",Actual,2020-10-17,NA,Interventional,COVID-VIRO,,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test on Nasopharyngeal Specimens i,Completed,NA,N/A,200,Actual,Centre Hospitalier RÃ©gional d'OrlÃ©ans,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:48:10Z,2021-10-17T07:48:10Z,330
NCT04609462,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-24,NA,NA,2021-03-26,2020-10-28,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-04-01,Actual,"August 11, 2020",Actual,2020-08-11,March 2021,2021-03-31,"February 10, 2021",Actual,2021-02-10,"January 13, 2021",Actual,2021-01-13,NA,Interventional,HiFlo-COVID,,High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.,A Trial of High-Flow Nasal Cannula vs. Conventional Oxygen Therapy in Patients With SARS-CoV-2-Related Acute Respiratory Failure: the HiFlo-COVID Trial.,Completed,NA,N/A,199,Actual,Fundacion Clinica Valle del Lili,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:48:15Z,2021-10-17T07:48:15Z,218
NCT04609371,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-19,NA,NA,2021-09-20,2020-10-25,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"October 21, 2020",Actual,2020-10-21,September 2021,2021-09-30,"May 1, 2021",Actual,2021-05-01,"March 1, 2021",Actual,2021-03-01,NA,Interventional,NA,,PanDirect: Self-care Tools and Telephone Coaching for Depression and Anxiety During Pandemics,Assisting Family Physicians With Gaps in Mental Health Care Generated by the COVID-19 Pandemic: A Randomized Controlled Trial,Completed,NA,N/A,90,Actual,"St. Mary's Research Center, Canada",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:48:16Z,2021-10-17T07:48:16Z,40
NCT04608097,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-28,NA,NA,2021-04-29,2020-10-28,2020-10-29,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-04-30,Actual,"October 28, 2020",Actual,2020-10-28,April 2021,2021-04-30,"March 12, 2021",Actual,2021-03-12,"March 12, 2021",Actual,2021-03-12,NA,Interventional,NA,,Understanding Reactions to Emotional Material in the Media During COVID-19,Understanding Reactions to Emotional Material in the Media During COVID-19 and the Connections to Cognitive Activities,Completed,NA,N/A,74,Actual,Uppsala University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:48:28Z,2021-10-17T07:48:28Z,184
NCT04604145,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-23,NA,NA,2021-08-24,2020-10-23,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-30,Actual,"February 3, 2021",Actual,2021-02-03,August 2021,2021-08-31,"August 18, 2021",Actual,2021-08-18,"August 18, 2021",Actual,2021-08-18,NA,Interventional,NA,,Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR,Evaluation of Self-Collected Saliva Samples Without Viral Transport Media for SARS-CoV-2 Testing Via RT-PCR,Completed,NA,N/A,60,Actual,David Grant U.S. Air Force Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:49:05Z,2021-10-17T07:49:05Z,67
NCT04603729,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-21,NA,NA,2020-10-24,2020-10-24,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-24,2020-10-27,Actual,"May 30, 2020",Actual,2020-05-30,October 2020,2020-10-31,"July 1, 2020",Actual,2020-07-01,"June 30, 2020",Actual,2020-06-30,NA,Interventional,covid19,,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Completed,NA,Phase 3,100,Actual,Fatima Memorial Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,"patient name and medical record will be confidential, onle the principal investigator will have access to data. Results of study will be shared with other researchers",2021-10-17T07:49:09Z,2021-10-17T07:49:09Z,371
NCT04602871,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-21,NA,NA,2021-04-11,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-11,2021-04-13,Actual,"July 3, 2020",Actual,2020-07-03,October 2020,2020-10-31,"January 30, 2021",Actual,2021-01-30,"January 30, 2021",Actual,2021-01-30,NA,Interventional,COVID-19,,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,Early Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis - Feasibility Study,Completed,NA,N/A,108,Actual,Scentech Medical Technologies Ltd,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No IPDs are to be shared with other researchers.,2021-10-17T07:49:17Z,2021-10-17T07:49:17Z,202
NCT04599959,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-22,2021-07-21,NA,2021-07-21,2020-10-22,2020-10-23,Actual,2021-07-21,2021-07-26,Actual,NA,NA,NA,2021-07-21,2021-07-26,Actual,"October 26, 2020",Actual,2020-10-26,July 2021,2021-07-31,"January 20, 2021",Actual,2021-01-20,"January 20, 2021",Actual,2021-01-20,NA,Interventional,NA,All eligible participants in this study who had been diagnosed with COVID-19 confirmed by polymerase chain reaction (PCR) test within the past 5 days before study entry.,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With SalivetteÂ® Cortisol for Viral RNA Sampling for RT-qPCR,"COVID-19 Tests: a Systematic Comparison of Viral RNA Test Sample Taking for RT-qPCR, in This Case With a Nasopharyngeal Swab or Saliva Collected With SalivetteÂ® Cortisol, to Diagnose SARS-CoV-2 Virus Infection",Completed,NA,N/A,151,Actual,Boehringer Ingelheim,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
For more details refer to: http://trials.boehringer-ingelheim.com/",2021-10-17T07:49:41Z,2021-10-17T07:49:41Z,101
NCT04596839,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-20,NA,NA,2021-08-09,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-10,Actual,"September 4, 2020",Actual,2020-09-04,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,,Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19),"Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19): An Open Label, Multi-Center, Randomized Controlled Trial",Completed,NA,Phase 2,60,Actual,Beximco Pharmaceuticals Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:50:10Z,2021-10-17T07:50:10Z,82
NCT04598594,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-15,NA,NA,2021-06-21,2020-10-21,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"November 6, 2020",Actual,2020-11-06,June 2021,2021-06-30,"June 20, 2021",Actual,2021-06-20,"April 29, 2021",Actual,2021-04-29,NA,Interventional,NICOVID-REA,,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Completed,NA,Phase 3,220,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:49:53Z,2021-10-17T07:49:53Z,131
NCT04598581,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-20,NA,NA,2021-04-14,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-14,2021-04-19,Actual,"November 2, 2020",Actual,2020-11-02,April 2021,2021-04-30,"April 9, 2021",Actual,2021-04-09,"April 9, 2021",Actual,2021-04-09,NA,Interventional,COVID-RT-01,,"Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19",Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2),Completed,NA,N/A,22,Actual,"University Hospital, Basel, Switzerland",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:49:53Z,2021-10-17T07:49:53Z,199
NCT04596085,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-19,2021-07-29,NA,2021-08-11,2020-10-20,2020-10-22,Actual,2021-08-11,2021-08-12,Actual,NA,NA,NA,2021-08-11,2021-08-12,Actual,"September 16, 2020",Actual,2020-09-16,August 2021,2021-08-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)","A Double Blind, Randomized, Placebo Controlled Study to Evaluate Efficacy and Safety of ""VIRACIDE"" in the Management of Corona Virus Disease 2019 (COVID-19)",Completed,NA,N/A,118,Actual,"The Herb, Inc",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:50:17Z,2021-10-17T07:50:17Z,80
NCT04594343,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-18,NA,NA,2021-09-30,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-08,Actual,"November 20, 2020",Actual,2020-11-20,September 2021,2021-09-30,"September 25, 2021",Actual,2021-09-25,"September 10, 2021",Actual,2021-09-10,NA,Interventional,NA,,Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19,"A Randomized, Double-blind, Placebo-controlled Safety and Clinical Outcomes Study of Disulfiram in Subjects With Moderate COVID-19",Completed,NA,Phase 2,140,Actual,ETICA,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2021-10-17T07:50:33Z,2021-10-17T07:50:33Z,30
NCT04593433,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-13,NA,NA,2021-08-23,2020-10-13,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"March 4, 2021",Actual,2021-03-04,August 2021,2021-08-31,"July 4, 2021",Actual,2021-07-04,"July 4, 2021",Actual,2021-07-04,NA,Interventional,VGV,,A 3-month Cycle of Virtual Guided Tours to Promote Health in Older Community Members in a Context of COVID-19 Induced Social Isolation: a Pilot Study,"A 3-month Cycle of Virtual Weekly Montreal Museum of Fine Arts Tours to Promote Social Inclusion, Well-being, Quality of Life and Health in Older Community Members : a Pilot Study",Completed,NA,N/A,44,Actual,Jewish General Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:50:42Z,2021-10-17T07:50:42Z,68
NCT04591158,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-15,NA,NA,2021-07-12,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-14,Actual,"September 15, 2020",Actual,2020-09-15,July 2021,2021-07-31,"June 9, 2021",Actual,2021-06-09,"June 9, 2021",Actual,2021-06-09,NA,Interventional,NA,,COVID-19 and Lung Ultrasound Utility,The Utility of Self-administered Lung Ultrasound in Patients With COVID-19,Completed,NA,N/A,6,Actual,Bridge to Health Medical and Dental USA,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,"Notes pertaining to performance characterization of the device, as well as imaging data for additional quantitative evaluation of the image quality will be collected. This date is recorded for future device development. No IPD will be made available to other researchers.",2021-10-17T07:51:01Z,2021-10-17T07:51:01Z,110
NCT04591600,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-15,NA,NA,2020-10-16,2020-10-16,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"July 1, 2020",Actual,2020-07-01,October 2020,2020-10-31,"October 14, 2020",Actual,2020-10-14,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,"Controlled Randomized Clinical Trial on Using Ivermectin With Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq",Completed,NA,Phase 1/Phase 2,140,Actual,Alkarkh Health Directorate-Baghdad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:50:57Z,2021-10-17T07:50:57Z,379
NCT04590586,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-14,NA,NA,2021-08-12,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"November 24, 2020",Actual,2020-11-24,June 2021,2021-06-30,"August 3, 2021",Actual,2021-08-03,"August 3, 2021",Actual,2021-08-03,NA,Interventional,NA,,Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Completed,NA,Phase 3,516,Actual,Amgen,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.,"Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.",http://www.amgen.com/datasharing,Yes,De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.,2021-10-17T07:51:06Z,2021-10-17T07:51:06Z,79
NCT04589117,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-12,NA,NA,2020-10-14,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"May 27, 2020",Actual,2020-05-27,October 2020,2020-10-31,"August 2, 2020",Actual,2020-08-02,"August 2, 2020",Actual,2020-08-02,NA,Interventional,NA,,Expressive Writing for COVID-19 Resilience for Parents,Expressive Writing for COVID-19 Resilience for Parents,Completed,NA,N/A,11,Actual,Duke University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:51:19Z,2021-10-17T07:51:19Z,381
NCT04589104,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-12,NA,NA,2020-10-14,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"May 26, 2020",Actual,2020-05-26,October 2020,2020-10-31,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,,Expressive Writing for COVID-19 Resilience,Expressive Writing for COVID-19 Resilience,Completed,NA,N/A,63,Actual,Duke University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:51:19Z,2021-10-17T07:51:19Z,381
NCT04583592,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-07,NA,NA,2021-04-01,2020-10-08,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-02,Actual,"November 9, 2020",Actual,2020-11-09,April 2021,2021-04-30,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,,Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for Treatment of COVID-19 in Outpatients",Completed,NA,Phase 2,295,Actual,Sagent Pharmaceuticals Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:52:12Z,2021-10-17T07:52:12Z,212
NCT04583189,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-01,NA,NA,2020-12-01,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-02,Actual,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,"November 25, 2020",Actual,2020-11-25,"November 25, 2020",Actual,2020-11-25,NA,Interventional,NA,,Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department,Evaluation Des Performances du Test Rapide antigÃ©nique Covid-19 Ag BSS Chez l'Enfant Symptomatique Dans un Service d'Urgences pÃ©diatriques,Completed,NA,N/A,500,Actual,Centre Hospitalier Intercommunal Creteil,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:52:17Z,2021-10-17T07:52:17Z,333
NCT04581811,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-07,NA,NA,2021-05-21,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"November 10, 2020",Actual,2020-11-10,May 2021,2021-05-31,"March 20, 2021",Actual,2021-03-20,"March 20, 2021",Actual,2021-03-20,NA,Interventional,NA,,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS): A Pilot Study,Completed,NA,N/A,52,Actual,University of Alabama at Birmingham,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:52:28Z,2021-10-17T07:52:28Z,162
NCT04581291,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-04,NA,NA,2020-10-07,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-09,Actual,"January 1, 2020",Actual,2020-01-01,October 2020,2020-10-31,"October 1, 2020",Actual,2020-10-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,Completed,NA,N/A,30,Actual,Istanbul Gelisim University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:52:32Z,2021-10-17T07:52:32Z,388
NCT04579549,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-06,NA,NA,2021-08-31,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-08,Actual,"September 29, 2020",Actual,2020-09-29,July 2021,2021-07-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,,Repeat Testing for SARS-CoV-2,Repeat Saliva Testing for SARS-CoV-2 Using RT-LAMP Assay,Completed,NA,N/A,464,Actual,"University of Wisconsin, Madison",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,,Data from this study may be requested from other researchers 7 years after the completion of the primary endpoint by contacting David O'Connor at the University of Wisconsin -Madison.,NA,NA,Yes,"Participants will consent to having their data (not their name) and viral sequences shared with the public via manuscripts, presentations and online databases; the study team will share that with other researchers when needed. Samples can be shared with UW researchers internally and non UW researchers through the Material Transfer Agreement process.",2021-10-17T07:52:48Z,2021-10-17T07:52:48Z,60
NCT04578158,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-06,NA,NA,2021-04-21,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-22,Actual,"September 29, 2020",Actual,2020-09-29,April 2021,2021-04-30,"April 15, 2021",Actual,2021-04-15,"March 28, 2021",Actual,2021-03-28,NA,Interventional,NA,,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,"A Prospective, Randomized, Open-labelled, Controlled Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With Diagnosis of COVID-19.",Completed,NA,Phase 3,152,Actual,Liaquat University of Medical & Health Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:53:06Z,2021-10-17T07:53:06Z,192
NCT04579393,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-06,NA,NA,2021-07-09,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"October 8, 2020",Actual,2020-10-08,May 2021,2021-05-31,"April 30, 2021",Actual,2021-04-30,"March 30, 2021",Actual,2021-03-30,NA,Interventional,NA,,Fostamatinib for Hospitalized Adults With COVID-19,A Phase II Study Evaluating Fostamatinib for Hospitalized Adults With COVID-19,Completed,NA,Phase 2,62,Actual,National Institutes of Health Clinical Center (CC),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:52:50Z,2021-10-17T07:52:50Z,113
NCT04577534,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-03,NA,NA,2021-06-17,2020-10-05,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"August 14, 2020",Actual,2020-08-14,June 2021,2021-06-30,"June 16, 2021",Actual,2021-06-16,"June 16, 2021",Actual,2021-06-16,NA,Interventional,COVIDSTORM,,COVID-19: Salvage TOcilizumab as a Rescue Measure,COVID-19: Salvage TOcilizumab as a Rescue Measure. Use of Tocilizumab in the Inflammatory Phase of COVID-19 / New Coronavirus Disease,Completed,NA,Phase 3,88,Actual,Turku University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,plan to investigate if it is possible by law,2021-10-17T07:53:11Z,2021-10-17T07:53:11Z,135
NCT04577235,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-29,NA,NA,2020-10-05,2020-10-05,2020-10-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"June 5, 2020",Actual,2020-06-05,October 2020,2020-10-31,"September 5, 2020",Actual,2020-09-05,"August 5, 2020",Actual,2020-08-05,NA,Interventional,NA,,Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.,Evaluation of the Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores of Patients With Severe COVID 19 Pneumonia in Intensive Care.,Completed,NA,N/A,29,Actual,Gaziosmanpasa Research and Education Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:53:14Z,2021-10-17T07:53:14Z,390
NCT04576312,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-28,NA,NA,2021-08-20,2020-10-05,2020-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-26,Actual,"June 29, 2020",Actual,2020-06-29,August 2021,2021-08-31,"December 4, 2020",Actual,2020-12-04,"December 4, 2020",Actual,2020-12-04,NA,Interventional,NA,,Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers,"Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19",Completed,NA,Phase 1,64,Actual,UNION therapeutics,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:53:22Z,2021-10-17T07:53:22Z,71
NCT04575038,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-01,NA,NA,2021-07-26,2020-10-01,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"November 19, 2020",Actual,2020-11-19,July 2021,2021-07-31,"April 28, 2021",Actual,2021-04-28,"April 28, 2021",Actual,2021-04-28,NA,Interventional,CRISIS2,,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,"The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2",Completed,NA,Phase 2,115,Actual,"Clear Creek Bio, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:53:33Z,2021-10-17T07:53:33Z,96
NCT04573361,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-29,NA,NA,2020-09-30,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"May 2, 2020",Actual,2020-05-02,September 2020,2020-09-30,"May 27, 2020",Actual,2020-05-27,"May 27, 2020",Actual,2020-05-27,NA,Interventional,NA,,Access to Chiropractic Care During the COVID-19 Healthcare Emergency in Spain,Access to Chiropractic Care During the State of Emergency Generated by the COVID-19 Pandemic in Spain: a Pragmatic Controlled Trial,Completed,NA,N/A,723,Actual,Real Centro Universitario Maria Cristina,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"All collected IPD will be shared, though a next phase of the study is being debated, which is why we are still undecided.",2021-10-17T07:53:49Z,2021-10-17T07:53:49Z,395
NCT04573270,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-23,NA,NA,2020-09-30,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"April 24, 2020",Actual,2020-04-24,September 2020,2020-09-30,"September 1, 2020",Actual,2020-09-01,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Mesenchymal Stem Cells for the Treatment of COVID-19,A Pilot Phase Study Evaluating the Effects of a Single Mesenchymal Stem Cell Injection in Patients With Suspected or Confirmed COVID-19 Infection and Healthcare Providers Exposed to Coronavirus Patients,Completed,NA,Phase 1,40,Actual,Thomas Advanced Medical LLC,,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,Data will be blinded and password protected. Research publications will be produced for medical journals. Participating Investigators will have password protected access only.,2021-10-17T07:53:49Z,2021-10-17T07:53:49Z,395
NCT04572399,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-28,NA,NA,2020-12-28,2020-09-29,2020-10-01,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-30,Actual,"October 30, 2020",Actual,2020-10-30,December 2020,2020-12-31,"December 28, 2020",Actual,2020-12-28,"December 28, 2020",Actual,2020-12-28,NA,Interventional,NA,,UVA Light Device to Treat COVID-19,Respiratory Application of a Novel Ultraviolet Light Delivery Device for Patients Infected With COVID-19: A Pilot Study,Completed,NA,N/A,5,Actual,Cedars-Sinai Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:53:57Z,2021-10-17T07:53:57Z,306
NCT04570254,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-26,NA,NA,2021-05-19,2020-09-28,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2021-05-19,2021-05-21,Actual,"August 19, 2020",Actual,2020-08-19,May 2021,2021-05-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,ANTIOX-COVID,,Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19,Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia,Completed,NA,N/A,110,Actual,Unidad Temporal COVID-19 en Centro Citibanamex,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:54:15Z,2021-10-17T07:54:15Z,164
NCT04569188,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-04,NA,NA,2020-09-30,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"May 15, 2020",Actual,2020-05-15,September 2020,2020-09-30,"September 3, 2020",Actual,2020-09-03,"August 15, 2020",Actual,2020-08-15,NA,Interventional,RESCUE,,Convalescent Plasma in COVID-19 Elderly Patients,Real-time Evaluation of Safety and Efficacy of Convalescent Plasma Units Transfused to Elderly Patients With COVID-19,Completed,NA,Phase 2,21,Actual,Azienda Socio Sanitaria Territoriale di Mantova,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:54:23Z,2021-10-17T07:54:23Z,395
NCT04568356,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-27,NA,NA,2020-10-16,2020-09-27,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"April 24, 2020",Actual,2020-04-24,October 2020,2020-10-31,"September 24, 2020",Actual,2020-09-24,"June 12, 2020",Actual,2020-06-12,NA,Interventional,NA,,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,"A Clinical Performance Evaluation of the SARS-COV-2 Direct Antigen Rapid Test ""DART""",Completed,NA,N/A,200,Actual,"E25Bio, Inc.",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,FALSE,NA,,One month after the USA-FDA approval date and for the duration of one year after the date of approval,"via email to: Irene Bosch, PhD at ibosch@e25bio.com",http://www.e25bio.com,Yes,"The sponsor E25Bio, Inc. is in agreement to share the outcome of this Clinical Trial. Because the device product has not been previously approved or cleared by FDA, we will be publicly posting not earlier than the date of FDA approval or clearance.",2021-10-17T07:54:31Z,2021-10-17T07:54:31Z,379
NCT04568876,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-24,NA,NA,2021-08-24,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"October 23, 2020",Actual,2020-10-23,August 2021,2021-08-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,,Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients,"Efficacy of Palmitoylethanolamide, in add-on to Standard Therapy, on Inflammatory Markers of Patients With Interstitial Pneumonia Due to COVID-19. A Pilot Controlled, Randomized, Open Lable Clinical Study",Completed,NA,Phase 4,40,Actual,Epitech Group SpA,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:54:26Z,2021-10-17T07:54:26Z,67
NCT04568863,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-28,NA,NA,2021-03-17,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-18,Actual,"June 20, 2020",Actual,2020-06-20,September 2020,2020-09-30,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,MELCOVID,,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,"A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)",Completed,NA,Phase 2,18,Actual,Pharmamel S.L.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:54:26Z,2021-10-17T07:54:26Z,227
NCT04568525,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-23,NA,NA,2020-09-28,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,"August 1, 2020",Actual,2020-08-01,"July 25, 2020",Actual,2020-07-25,NA,Interventional,NA,,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,Microwave Radiation for Early Diagnostics of Pneumonia in Patients With COVID-19,Completed,NA,N/A,195,Actual,Kyrgyz State Medical Academy,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:54:29Z,2021-10-17T07:54:29Z,397
NCT04567810,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-18,NA,NA,2021-09-16,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-20,Actual,"September 18, 2020",Actual,2020-09-18,September 2021,2021-09-30,"December 14, 2020",Actual,2020-12-14,"December 14, 2020",Actual,2020-12-14,NA,Interventional,NA,,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)","A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single -Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)",Completed,NA,Phase 1,48,Actual,Stanford University,,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:54:35Z,2021-10-17T07:54:35Z,44
NCT04563689,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-22,NA,NA,2020-11-19,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-19,2020-11-20,Actual,"June 18, 2020",Actual,2020-06-18,September 2020,2020-09-30,"October 23, 2020",Actual,2020-10-23,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,,Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients,Efecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado mÃ©dico en Casa en Cali - 2020.,Completed,NA,N/A,23,Actual,Dentaid SL,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:55:15Z,2021-10-17T07:55:15Z,345
NCT04561219,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-22,NA,NA,2021-07-15,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-15,2021-07-22,Actual,"April 19, 2020",Actual,2020-04-19,July 2021,2021-07-31,"October 2, 2020",Actual,2020-10-02,"October 2, 2020",Actual,2020-10-02,NA,Interventional,NA,,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,"Nitazoxanide for Moderate to Severe COVID-19 Pneumonia: a Multicenter, Randomized, Placebo-controlled, Double-Blind Clinical Trial",Completed,NA,Phase 2,500,Actual,Universidade Federal do Rio de Janeiro,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2021-10-17T07:55:35Z,2021-10-17T07:55:35Z,107
NCT04557605,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-09,NA,NA,2020-10-16,2020-09-15,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-20,Actual,"September 14, 2020",Actual,2020-09-14,October 2020,2020-10-31,"October 15, 2020",Actual,2020-10-15,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,,Effects of a Face Mask on Oxygenation During Exercise,The Effects of Wearing a Face Mask During COVID-19 on Blood and Muscle Oxygenation While Performing Exercise,Completed,NA,N/A,14,Actual,University of Saskatchewan,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:56:04Z,2021-10-17T07:56:04Z,379
NCT04558411,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-20,NA,NA,2021-09-23,2020-09-20,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-29,Actual,"September 12, 2020",Actual,2020-09-12,September 2021,2021-09-30,"December 15, 2020",Actual,2020-12-15,"December 15, 2020",Actual,2020-12-15,NA,Interventional,NA,,"Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students","Pilot Study of a Brief, Scaleable Intervention for COVID-19 Mental Health Sequelae in College Students",Completed,NA,N/A,153,Actual,"Rutgers, The State University of New Jersey",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,We will share data after the publication of primary manuscripts.,NA,NA,Yes,We will share data after the publication of primary manuscripts.,2021-10-17T07:55:58Z,2021-10-17T07:55:58Z,37
NCT04558372,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-20,NA,NA,2020-12-28,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"April 1, 2020",Actual,2020-04-01,December 2020,2020-12-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,,Genosvid Diagnostic Test for Early Detection of COVID-19,Genosvid Diagnostic Test for Early Detection of COVID-19: UGM Electronic-Nose Innovation for Indonesia,Completed,NA,N/A,1999,Actual,Gadjah Mada University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:55:58Z,2021-10-17T07:55:58Z,306
NCT04557241,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-16,NA,NA,2021-02-08,2020-09-17,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"January 14, 2020",Actual,2020-01-14,February 2021,2021-02-28,"January 31, 2021",Actual,2021-01-31,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Completed,NA,N/A,1017,Actual,Indiana University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Fully de-identified data will be made available along with the publication of the primary results paper from this study.,NA,NA,Yes,Fully de-identified data (full dataset) will be made available along with the publication of the primary results paper from this study.,2021-10-17T07:56:08Z,2021-10-17T07:56:08Z,264
NCT04555148,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-16,NA,NA,2021-08-17,2020-09-16,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-24,Actual,"September 19, 2020",Actual,2020-09-19,August 2021,2021-08-31,"April 23, 2021",Actual,2021-04-23,"January 22, 2021",Actual,2021-01-22,NA,Interventional,NA,,COVIDIG (COVID-19 Hyper-ImmunoGlobulin),"A Prospective, Open-label, Randomized, Multi-center, Phase 2a Study to Evaluation the Dose Response, Efficacy and Safety of Hyper-Ig (Hyper-immunoglobulin) GC5131 in Patients With COVID-19",Completed,NA,Phase 2,63,Actual,Green Cross Corporation,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:56:26Z,2021-10-17T07:56:26Z,74
NCT04555005,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-11,NA,NA,2020-09-17,2020-09-17,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-17,2020-09-18,Actual,"March 10, 2020",Actual,2020-03-10,March 2020,2020-03-31,"April 26, 2020",Actual,2020-04-26,"April 26, 2020",Actual,2020-04-26,NA,Interventional,NA,,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,"Implementation of a Mindfulness-based Crisis Intervention for Frontline Healthcare Workers During the COVID-19 Outbreak in a Public General Hospital in Madrid, Spain",Completed,NA,N/A,1000,Actual,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:56:27Z,2021-10-17T07:56:27Z,408
NCT04555213,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-16,NA,NA,2021-08-24,2020-09-16,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-26,Actual,"September 30, 2020",Actual,2020-09-30,August 2021,2021-08-31,"August 10, 2021",Actual,2021-08-10,"August 10, 2021",Actual,2021-08-10,NA,Interventional,NOXCOVID,,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID),Completed,NA,Phase 1,41,Actual,Noxopharm Limited,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:56:25Z,2021-10-17T07:56:25Z,67
NCT04552379,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-21,NA,NA,2021-09-02,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-10,Actual,"December 1, 2020",Actual,2020-12-01,December 2020,2020-12-31,"June 30, 2021",Actual,2021-06-30,"May 31, 2021",Actual,2021-05-31,NA,Interventional,ConCorD-19,,The Containing Coronavirus Disease 19 (COVID-19) Trial,A Cluster Randomised Trial of Interferon Versus Standard of Care in the Reduction of Transmission of SARS-Cov-2. The Containing Coronavirus Disease 19 Trial (ConCorD-19),Completed,NA,Phase 3,1173,Actual,Pontificia Universidad Catolica de Chile,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,We are evaluating the best time to share the information.,We are evaluating the best way to share the information.,NA,Yes,We are evaluating the best way to share the information.,2021-10-17T07:56:51Z,2021-10-17T07:56:51Z,58
NCT04551781,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-13,NA,NA,2020-09-14,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"July 30, 2020",Actual,2020-07-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,,Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,Short Term Low Dose Corticosteroids for Management of Post Covid-19 Pulmonary Fibrosis,Completed,NA,N/A,450,Actual,South Valley University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:56:56Z,2021-10-17T07:56:56Z,411
NCT04551768,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-15,NA,NA,2021-08-25,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-26,Actual,"February 10, 2021",Actual,2021-02-10,August 2021,2021-08-31,"August 17, 2021",Actual,2021-08-17,"August 17, 2021",Actual,2021-08-17,NA,Interventional,NA,,Study to Evaluate the Safety and Efficacy of VIRAZOLEÂ® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19,"An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLEÂ® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19",Completed,NA,Phase 1,51,Actual,"Bausch Health Americas, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:56:57Z,2021-10-17T07:56:57Z,66
NCT04551339,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-09,NA,NA,2021-08-07,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-07,2021-08-10,Actual,"September 28, 2020",Actual,2020-09-28,August 2021,2021-08-31,"May 28, 2021",Actual,2021-05-28,"May 28, 2021",Actual,2021-05-28,NA,Interventional,ZnCOVID-19,,Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19,Zinc Versus Multivitamin Micronutrient Supplementation to Support Immune Health in the Setting of COVID-19 Pandemic: A Randomized Study,Completed,NA,N/A,2700,Actual,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:57:01Z,2021-10-17T07:57:01Z,84
NCT04552483,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-09,NA,NA,2020-11-01,2020-09-15,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-01,2020-11-03,Actual,"June 8, 2020",Actual,2020-06-08,November 2020,2020-11-30,"September 5, 2020",Actual,2020-09-05,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Effects of Nitazoxanide Administration to Patients in the Initial Phase of COVID-19,Completed,NA,Phase 2,392,Actual,Universidade Federal do Rio de Janeiro,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2021-10-17T07:56:51Z,2021-10-17T07:56:51Z,363
NCT04551911,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-15,NA,NA,2021-10-14,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"October 26, 2020",Actual,2020-10-26,October 2021,2021-10-31,"October 8, 2021",Actual,2021-10-08,"October 8, 2021",Actual,2021-10-08,NA,Interventional,NA,,Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,"A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)",Completed,NA,Phase 2,171,Actual,"OPKO Health, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:56:55Z,2021-10-17T07:56:55Z,16
NCT04551898,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-10,NA,NA,2021-03-02,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-04,Actual,"December 2, 2020",Actual,2020-12-02,March 2021,2021-03-31,"January 25, 2021",Actual,2021-01-25,"January 25, 2021",Actual,2021-01-25,NA,Interventional,NA,,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients WithMild-to-Moderate COVID-19",Completed,NA,Phase 2,181,Actual,BeiGene,,4,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T07:56:55Z,2021-10-17T07:56:55Z,242
NCT04550325,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-10,NA,NA,2021-01-04,2020-09-13,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-01-04,2021-01-05,Actual,"August 5, 2020",Actual,2020-08-05,January 2021,2021-01-31,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,NA,Interventional,NA,,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19","A Phase 1/2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia",Completed,NA,Phase 1/Phase 2,12,Actual,"Kamada, Ltd.",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:57:09Z,2021-10-17T07:57:09Z,299
NCT04548934,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-02,NA,NA,2021-02-01,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"September 13, 2020",Actual,2020-09-13,September 2020,2020-09-30,"January 31, 2021",Actual,2021-01-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,Completed,NA,N/A,34,Actual,Institute of Mountain Emergency Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:57:22Z,2021-10-17T07:57:22Z,271
NCT04548531,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-09,NA,NA,2021-08-31,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-01,Actual,"September 10, 2020",Actual,2020-09-10,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Completed,NA,N/A,800,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Three months after the end of the funded grant period, the study materials and de-identified data will be available, by request, from the PI. Once data are placed on an open access service such as ICPSR they will be available indefinitely.","The PI will share a de-identified data set with outside investigators at no cost, according to approved Partners and Massachusetts General Hospital policies for data sharing. Investigators from other sites will be able to request the data and will be required to complete a data use agreement that ensures that all local Institutional Review Board requirements are met before using the data, that they will not attempt to identify any data in the dataset, and that they will not share the data set with anyone outside their project team.
On ICPSR, individuals must register and agree to ICPSR's Responsible Use statement prior to accessing datasets.",NA,Yes,"Yes To promote research replicability, transparency and future use of the data, de-identified data sets of the patient survey data will be created and will be available, by request, to outside researchers.
After the main manuscripts have been published, de-identified data sets will also be deposited in an open access service such as, ICPSR (https://www.icpsr.umich.edu/icpsrweb/). Before a dataset is made available for access, ICPSR completes a detailed review of all datasets to assess disclosure risk. If necessary, ICPSR modifies data to reduce disclosure risk or limits access to datasets for which modifying the data would substantially limit their utility or the risk of disclosure remains high. No information that contains identifiers or that could be used to link an individual to the data will be included in the de-identified data set.",2021-10-17T07:57:26Z,2021-10-17T07:57:26Z,60
NCT04547660,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-09,NA,NA,2021-02-08,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"July 16, 2020",Actual,2020-07-16,February 2021,2021-02-28,"January 7, 2021",Actual,2021-01-07,"January 7, 2021",Actual,2021-01-07,NA,Interventional,PLACOVID,,Convalescent Plasma for Severe COVID-19 Patients,"Convalescent Plasma for Severe COVID-19 Patients: a Randomized, Open-label, Phase 3 Trial",Completed,NA,Phase 3,160,Actual,Hospital de Clinicas de Porto Alegre,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:57:33Z,2021-10-17T07:57:33Z,264
NCT04548544,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-11,NA,NA,2020-09-11,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-14,Actual,"October 18, 2019",Actual,2019-10-18,September 2020,2020-09-30,"May 20, 2020",Actual,2020-05-20,"May 20, 2020",Actual,2020-05-20,NA,Interventional,NA,,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During the COVID-19 Pandemic,Completed,NA,N/A,21,Actual,"University of California, San Francisco",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:57:26Z,2021-10-17T07:57:26Z,414
NCT04547283,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-09,NA,NA,2021-07-03,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-03,2021-07-07,Actual,"June 14, 2020",Actual,2020-06-14,July 2021,2021-07-31,"September 30, 2020",Actual,2020-09-30,"September 20, 2020",Actual,2020-09-20,NA,Interventional,NA,,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19: A Pilot Randomized Controlled Trial,Completed,NA,N/A,40,Actual,Atrium Health,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.,Data will be accessible to researchers who provide a methodologically sound proposal After approval by the AtriumHealth Institutional Review Board and the study investigators.,NA,Yes,Individual patient data underlying reported results will be made available with data dictionaries after de-identification.,2021-10-17T07:57:37Z,2021-10-17T07:57:37Z,119
NCT04547127,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-10,NA,NA,2021-03-02,2020-09-10,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"April 29, 2020",Actual,2020-04-29,March 2021,2021-03-31,"February 4, 2021",Actual,2021-02-04,"February 4, 2021",Actual,2021-02-04,NA,Interventional,NA,,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),"A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)",Completed,NA,Phase 2,200,Actual,Grifols Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:57:38Z,2021-10-17T07:57:38Z,242
NCT04546581,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-08,NA,NA,2021-08-09,2020-09-08,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-11,Actual,"October 8, 2020",Actual,2020-10-08,August 2021,2021-08-31,"May 21, 2021",Actual,2021-05-21,"May 21, 2021",Actual,2021-05-21,NA,Interventional,NA,,Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC),"An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19",Completed,NA,Phase 3,593,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,A public data set will be made available at the end of the trial,2021-10-17T07:57:43Z,2021-10-17T07:57:43Z,82
NCT04545749,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-02,NA,NA,2021-06-04,2020-09-10,2020-09-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"September 25, 2020",Actual,2020-09-25,June 2021,2021-06-30,"May 24, 2021",Actual,2021-05-24,"January 18, 2021",Actual,2021-01-18,NA,Interventional,NA,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Completed,NA,Phase 1,60,Actual,"United Biomedical Inc., Asia",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:57:52Z,2021-10-17T07:57:52Z,148
NCT04545060,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-04,NA,NA,2021-09-24,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-27,Actual,"August 27, 2020",Actual,2020-08-27,September 2021,2021-09-30,"September 2, 2021",Actual,2021-09-02,"April 8, 2021",Actual,2021-04-08,NA,Interventional,COMET-ICE,,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,"A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients",Completed,NA,Phase 2/Phase 3,1057,Actual,"Vir Biotechnology, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:57:58Z,2021-10-17T07:57:58Z,36
NCT04543760,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-08,NA,NA,2021-05-18,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-19,Actual,"October 1, 2020",Actual,2020-10-01,May 2021,2021-05-31,"March 14, 2021",Actual,2021-03-14,"January 15, 2021",Actual,2021-01-15,NA,Interventional,DeCOPO,,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to Sars-covid-2: a Randomized Crossover Trial.,Completed,NA,N/A,18,Actual,"Hospital St. Joseph, Marseille, France",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:58:12Z,2021-10-17T07:58:12Z,165
NCT04542967,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-04,NA,NA,2021-05-06,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,"June 23, 2020",Actual,2020-06-23,September 2020,2020-09-30,"September 30, 2020",Actual,2020-09-30,"September 2, 2020",Actual,2020-09-02,NA,Interventional,PC-COVID-HCM,,Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,Convalescent Plasma as a Treatment for Patients With Severe COVID-19 Disease,Completed,NA,Phase 2,150,Actual,Hospital Central Militar,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,From 6 months after publication,PRIOR APPLICATION,NA,Yes,Plan to make IPD still not decided and would need approval by regulatory authorities,2021-10-17T07:58:19Z,2021-10-17T07:58:19Z,177
NCT04542941,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-31,NA,NA,2021-01-13,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-15,Actual,"June 16, 2020",Actual,2020-06-16,January 2021,2021-01-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,COVIDIT,,Assessment of Safety and Efficacy of CCP,Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial,Completed,NA,N/A,136,Actual,Makerere University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Arrangments to enable sharing of de-identified data will be instituted by the research team.,2021-10-17T07:58:19Z,2021-10-17T07:58:19Z,290
NCT04542876,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-08,NA,NA,2020-09-08,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-09,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"August 18, 2020",Actual,2020-08-18,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection: An Open Label Feasibility Study,Completed,NA,N/A,46,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:58:20Z,2021-10-17T07:58:20Z,417
NCT04542694,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-04,2020-10-11,NA,2020-11-03,2020-09-04,2020-09-09,Actual,2020-11-03,2020-11-05,Actual,NA,NA,NA,2020-11-03,2020-11-05,Actual,"May 21, 2020",Actual,2020-05-21,November 2020,2020-11-30,"August 20, 2020",Actual,2020-08-20,"August 10, 2020",Actual,2020-08-10,NA,Interventional,NA,,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19",Completed,NA,Phase 3,200,Actual,"Promomed, LLC",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:58:22Z,2021-10-17T07:58:22Z,361
NCT04542213,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-03,NA,NA,2021-03-19,2020-09-04,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-19,2021-03-23,Actual,"August 1, 2020",Actual,2020-08-01,March 2021,2021-03-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,Covid19DPP4i,,Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19,Completed,NA,Phase 3,70,Actual,Hospital Regional de Alta Especialidad del Bajio,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Data will be available once the main results of the study are published, and in accordance with the journal",Direct contact with the principal investigator,NA,Yes,"Sharing of the data can be done, depending on the requested purposes",2021-10-17T07:58:27Z,2021-10-17T07:58:27Z,225
NCT04539821,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-03,NA,NA,2021-08-13,2020-09-03,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-13,2021-08-16,Actual,"October 1, 2020",Actual,2020-10-01,August 2021,2021-08-31,"August 12, 2021",Actual,2021-08-12,"May 31, 2021",Actual,2021-05-31,NA,Interventional,VCPM,,Virtual Pain Care Management (COVID-19),Virtual Pain Care for High Risk Veterans on Opioids During COVID19 (and Beyond),Completed,NA,N/A,51,Actual,VA Office of Research and Development,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:58:49Z,2021-10-17T07:58:49Z,78
NCT04539275,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-27,NA,NA,2021-10-05,2020-09-03,2020-09-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-14,Actual,"November 16, 2020",Actual,2020-11-16,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,VA CURES-1,,COVID-19 (VA CURES-1),VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1),Completed,NA,Phase 3,75,Actual,VA Office of Research and Development,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:58:54Z,2021-10-17T07:58:54Z,25
NCT04539262,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-26,NA,NA,2021-04-08,2020-09-03,2020-09-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-09,Actual,"September 14, 2020",Actual,2020-09-14,April 2021,2021-04-30,"March 22, 2021",Actual,2021-03-22,"February 26, 2021",Actual,2021-02-26,NA,Interventional,NA,,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation","A Phase 1b/2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",Completed,NA,Phase 1/Phase 2,156,Actual,Gilead Sciences,,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:58:54Z,2021-10-17T07:58:54Z,205
NCT04535856,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-28,NA,NA,2021-01-25,2020-08-31,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"November 14, 2020",Actual,2020-11-14,January 2021,2021-01-31,"January 14, 2021",Actual,2021-01-14,"January 14, 2021",Actual,2021-01-14,NA,Interventional,DW-MSC,,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,"Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients: Randomized, Double-blind, and Placebo-controlled",Completed,NA,Phase 1,9,Actual,Ina-Respond,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:59:22Z,2021-10-17T07:59:22Z,278
NCT04536935,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-22,NA,NA,2021-06-28,2020-08-27,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"November 30, 2020",Actual,2020-11-30,June 2021,2021-06-30,"June 20, 2021",Actual,2021-06-20,"June 20, 2021",Actual,2021-06-20,NA,Interventional,NA,,Mobile Mental Health Apps for Suicide Prevention,"Acceptability, Usability and Effectiveness of Mental Health Apps for Suicide Prevention in Essential Workers and the Unemployed During SARS-CoV-2",Completed,NA,N/A,3000,Actual,University of Washington,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:59:14Z,2021-10-17T07:59:14Z,124
NCT04536441,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-26,NA,NA,2020-09-01,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"June 30, 2020",Actual,2020-06-30,"May 30, 2020",Actual,2020-05-30,NA,Interventional,NA,,Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order,Effects of an Ultra-brief Online Mindfulness-based Intervention on Mental Health During the Coronavirus Disease (COVID-19) Outbreak in Malaysia: A Randomised Controlled Trial,Completed,NA,N/A,161,Actual,Universiti Tunku Abdul Rahman,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"The data will be become available once the study is being published, for 5 years.",The data will be made available upon request to the corresponding author.,NA,Yes,NA,2021-10-17T07:59:18Z,2021-10-17T07:59:18Z,424
NCT04535167,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-21,NA,NA,2021-06-23,2020-08-31,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-23,2021-06-24,Actual,"September 9, 2020",Actual,2020-09-09,June 2021,2021-06-30,"June 7, 2021",Actual,2021-06-07,"June 7, 2021",Actual,2021-06-07,NA,Interventional,NA,,"First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.","A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND MULTIPLE ASCENDING (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID-19",Completed,NA,Phase 1,26,Actual,Pfizer,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-17T07:59:28Z,2021-10-17T07:59:28Z,129
NCT04534790,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-05,NA,NA,2021-02-08,2020-08-30,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"July 24, 2020",Actual,2020-07-24,February 2021,2021-02-28,"January 8, 2021",Actual,2021-01-08,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,,Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,"Randomized Trial, Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia",Completed,NA,N/A,30,Actual,Instituto Mexicano del Seguro Social,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:59:31Z,2021-10-17T07:59:31Z,264
NCT04532931,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-26,NA,NA,2021-09-16,2020-08-28,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-20,Actual,"September 3, 2020",Actual,2020-09-03,September 2021,2021-09-30,"August 23, 2021",Actual,2021-08-23,"August 5, 2021",Actual,2021-08-05,NA,Interventional,NA,,COVID-19 Treatment in South Africa,"Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19",Completed,NA,Phase 2,192,Actual,Shin Poong Pharmaceutical Co. Ltd.,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:59:50Z,2021-10-17T07:59:50Z,44
NCT04532294,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-27,NA,NA,2021-05-17,2020-08-27,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-18,Actual,"September 8, 2020",Actual,2020-09-08,May 2021,2021-05-31,"February 13, 2021",Actual,2021-02-13,"January 15, 2021",Actual,2021-01-15,NA,Interventional,NA,,"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants","A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy Subjects",Completed,NA,Phase 1,18,Actual,BeiGene,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T07:59:57Z,2021-10-17T07:59:57Z,166
NCT04530422,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-26,NA,NA,2020-08-27,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-28,Actual,"April 15, 2020",Actual,2020-04-15,August 2020,2020-08-31,"July 23, 2020",Actual,2020-07-23,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Completed,NA,Phase 3,250,Actual,Almaza Military Fever Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:00:20Z,2021-10-17T08:00:20Z,429
NCT04530357,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-26,NA,NA,2021-05-01,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-04,Actual,"September 19, 2020",Actual,2020-09-19,February 2021,2021-02-28,"April 25, 2021",Actual,2021-04-25,"November 25, 2020",Actual,2020-11-25,NA,Interventional,NA,,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine","Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-INÂ®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder",Completed,NA,Phase 1/Phase 2,244,Actual,Research Institute for Biological Safety Problems,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:00:20Z,2021-10-17T08:00:20Z,182
NCT04529525,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-21,NA,NA,2021-07-04,2020-08-26,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-04,2021-07-07,Actual,"August 19, 2020",Actual,2020-08-19,September 2020,2020-09-30,"February 22, 2021",Actual,2021-02-22,"February 22, 2021",Actual,2021-02-22,NA,Interventional,IVERCORCOVID19,,Ivermectin to Prevent Hospitalizations in COVID-19,"Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled",Completed,NA,Phase 2/Phase 3,501,Actual,Instituto de CardiologÃ­a de Corrientes,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:00:28Z,2021-10-17T08:00:28Z,118
NCT04528641,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-19,NA,NA,2021-07-09,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"August 10, 2020",Actual,2020-08-10,August 2020,2020-08-31,"May 19, 2021",Actual,2021-05-19,"May 19, 2021",Actual,2021-05-19,NA,Interventional,NA,,GRAd-COV2 Vaccine Against COVID-19,"A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects",Completed,NA,Phase 1,90,Actual,ReiThera Srl,,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:00:36Z,2021-10-17T08:00:36Z,113
NCT04527562,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-25,NA,NA,2021-01-07,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-11,Actual,"July 14, 2020",Actual,2020-07-14,January 2021,2021-01-31,"December 10, 2020",Actual,2020-12-10,"November 15, 2020",Actual,2020-11-15,NA,Interventional,COLCOVIDBD,,Colchicine in Moderate Symptomatic COVID-19 Patients,"Colchicine in Moderate Symptomatic COVID-19 Patients: Double Blind, Randomized, Placebo Controlled Trial to Observe the Efficacy",Completed,NA,N/A,299,Actual,Dhaka Medical College,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:00:45Z,2021-10-17T08:00:45Z,296
NCT04527354,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-24,NA,NA,2021-04-02,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-05,Actual,"September 1, 2020",Actual,2020-09-01,March 2021,2021-03-31,"February 10, 2021",Actual,2021-02-10,"February 10, 2021",Actual,2021-02-10,NA,Interventional,NA,,Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,"Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study of Treamid Efficacy and Safety in the Rehabilitation of Patients After COVID-19 Pneumonia",Completed,NA,Phase 2,60,Actual,PHARMENTERPRISES LLC,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:00:47Z,2021-10-17T08:00:47Z,211
NCT04527081,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-24,NA,NA,2021-10-01,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"August 31, 2020",Actual,2020-08-31,October 2021,2021-10-31,"September 24, 2021",Actual,2021-09-24,"November 9, 2020",Actual,2020-11-09,NA,Interventional,NA,,Study of COVID-19 DNA Vaccine (AG0302-COVID19),"A Randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults",Completed,NA,Phase 1/Phase 2,30,Actual,"AnGes, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:00:51Z,2021-10-17T08:00:51Z,29
NCT04525742,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-28,NA,NA,2020-10-31,2020-08-23,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2020-10-31,2020-11-03,Actual,"July 5, 2020",Actual,2020-07-05,October 2020,2020-10-31,"September 15, 2020",Actual,2020-09-15,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,,COVID-19 Pandemic and Parents of Disabled Children,COVID-19 Pandemic From the Perspective of Parents of Disabled Children,Completed,NA,N/A,309,Actual,Gaziosmanpasa Research and Education Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Research is planned to bu conducted between June 15 th and July 15 th 2020. After 15 th of July in 1 week coming statistical analysis will be finished and than in 3 weeks article will be written,In necessary cases colleced data from the research will be shared with the local ethical committe,NA,Yes,Study protocol was established by Berrin Huner and Ebru Yilmaz YalcÄ±nkaya Statistical analysis (Power analysis) was established by Ozden Ozyemisci Taskiran Informed consent was written by Berrin Huner,2021-10-17T08:01:05Z,2021-10-17T08:01:05Z,364
NCT04525417,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-21,NA,NA,2021-02-02,2020-08-22,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"April 25, 2020",Actual,2020-04-25,August 2020,2020-08-31,"October 25, 2020",Actual,2020-10-25,"September 25, 2020",Actual,2020-09-25,NA,Interventional,NA,,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,Use of Rapid Covid-19 Antibody Test Marketed by AAZ Laboratories in Healthcare Workers Presumably Being Infected by SARS-CoV-2,Completed,NA,N/A,75,Actual,Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:01:12Z,2021-10-17T08:01:12Z,270
NCT04524507,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-21,NA,NA,2021-06-04,2020-08-21,2020-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"August 27, 2020",Actual,2020-08-27,June 2021,2021-06-30,"June 4, 2021",Actual,2021-06-04,"June 4, 2021",Actual,2021-06-04,NA,Interventional,UNC CCP RCT,,COVID-19 Antibody Plasma Research Study in Hospitalized Patients,"IGHID 12021 - A Randomized, Phase II Study Comparing the Efficacy and Safety of Standard Versus High-Titer Anti-SARS-CoV2 Neutralizing Antibody Plasma in Hospitalized Patients With COVID-19",Completed,NA,Phase 2,56,Actual,"University of North Carolina, Chapel Hill",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,12-24 months after publication,"Investigators/researchers who propose to use study data will need to have IRB, IEC, or REB approval and an executed data use/sharing agreement with UNC.",NA,Yes,"De-identified individual data that supports the results will be shared beginning 12 to 24 months following publication provided the investigator/researcher who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2021-10-17T08:01:21Z,2021-10-17T08:01:21Z,148
NCT04524663,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-10,NA,NA,2021-06-08,2020-08-20,2020-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-11,Actual,"December 19, 2020",Actual,2020-12-19,June 2021,2021-06-30,"May 15, 2021",Actual,2021-05-15,"May 15, 2021",Actual,2021-05-15,NA,Interventional,COPS-2003,,Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients,"A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild-Moderate COVID-19",Completed,NA,Phase 2,48,Actual,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:01:19Z,2021-10-17T08:01:19Z,144
NCT04523831,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-19,2020-09-30,NA,2020-10-07,2020-08-20,2020-08-24,Actual,2020-10-07,2020-10-09,Actual,NA,NA,NA,2020-10-07,2020-10-09,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"September 10, 2020",Actual,2020-09-10,"August 22, 2020",Actual,2020-08-22,NA,Interventional,NA,We followed intention to treat analysis; SPSS (Statistical Package for Social Sciences) version 20 was used to analyze data. To compare mean of the two group chi square test was done.,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care,Completed,NA,Phase 3,400,Actual,Dhaka Medical College,"We followed up the patients by telephonic (video) interview, which has some inherent drawback for the study. we could not assess viral clearance directly. Only single dose regimen was used. Efficacy might higher if the different regimen would use.",2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,September 2020 to December 2020,Person who are investigating covid-19 in various aspects,NA,Yes,"Patients age, sex, Date of covid positive report, Symtoms,Date of covid negative report, post covid symptoms, time to recover.",2021-10-17T08:01:27Z,2021-10-17T08:01:27Z,388
NCT04522986,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-20,NA,NA,2021-03-16,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-18,Actual,"August 21, 2020",Actual,2020-08-21,March 2021,2021-03-31,"February 2, 2021",Actual,2021-02-02,"February 2, 2021",Actual,2021-02-02,NA,Interventional,COVID-19,,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,Completed,NA,Phase 1,6,Actual,"Rohto Pharmaceutical Co., Ltd.",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:01:35Z,2021-10-17T08:01:35Z,228
NCT04522128,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-12,NA,NA,2021-09-29,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-09-30,Actual,"May 22, 2020",Actual,2020-05-22,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"September 1, 2021",Actual,2021-09-01,NA,Interventional,NA,,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Completed,NA,N/A,274,Actual,University of Manchester,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,WHOQOL COMBI data cannot be shared with researchers outside of the research team.,2021-10-17T08:01:42Z,2021-10-17T08:01:42Z,31
NCT04522830,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-18,NA,NA,2021-04-09,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-13,Actual,"July 30, 2020",Actual,2020-07-30,April 2021,2021-04-30,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,BTL-TML-COVID,,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,"A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 Infection",Completed,NA,Phase 2,28,Actual,"Beech Tree Labs, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:01:36Z,2021-10-17T08:01:36Z,204
NCT04521309,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-03-21,2020-08-19,2020-08-20,Actual,NA,NA,NA,NA,NA,NA,2021-03-21,2021-03-24,Actual,"June 19, 2020",Actual,2020-06-19,March 2021,2021-03-31,"February 8, 2021",Actual,2021-02-08,"January 26, 2021",Actual,2021-01-26,NA,Interventional,NA,,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 Patients,Completed,NA,Phase 1/Phase 2,50,Actual,Dow University of Health Sciences,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:01:51Z,2021-10-17T08:01:51Z,223
NCT04519385,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-17,NA,NA,2020-08-21,2020-08-17,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-21,2020-08-25,Actual,"March 1, 2020",Actual,2020-03-01,August 2020,2020-08-31,"August 5, 2020",Actual,2020-08-05,"July 1, 2020",Actual,2020-07-01,NA,Interventional,NA,,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Completed,NA,N/A,69,Actual,South Valley University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:02:08Z,2021-10-17T08:02:08Z,435
NCT04517422,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-16,NA,NA,2021-05-02,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-06,Actual,"August 19, 2020",Actual,2020-08-19,May 2021,2021-05-31,"February 2, 2021",Actual,2021-02-02,"February 2, 2021",Actual,2021-02-02,NA,Interventional,NA,,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Efficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota: A Randomized Clinical Trial,Completed,NA,N/A,300,Actual,"AB Biotics, SA",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"From the moment of manuscript publication, without time limit.",Formal request with a defined analysis plan. Please contact espadaler@ab-biotics.com or medical@ab-biotics.com,NA,Yes,"Deidentified individual patient data (IPD), together with data dictionary defining each field in the set, will be made public upon any formal requests with a defined analysis plan.",2021-10-17T08:02:25Z,2021-10-17T08:02:25Z,181
NCT04517006,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-14,NA,NA,2021-05-25,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-26,Actual,"January 31, 2021",Actual,2021-01-31,May 2021,2021-05-31,"April 4, 2021",Actual,2021-04-04,"April 4, 2021",Actual,2021-04-04,NA,Interventional,NA,,Prosocial Behavior Can Safeguard Mental Health and Foster Emotional Well-being During the COVID-19 Pandemic,Prosocial Behavior Can Safeguard Mental Health and Foster Emotional Well-being During the COVID-19 Pandemic: A Randomized Clinical Trial,Completed,NA,N/A,1328,Actual,University of Toronto,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"After the publication of the paper and perpetually. The investigators plan to publish the study as a registered report, so study information will also be available as part of the report protocol.",NA,https://osf.io/63yg9/,Yes,"Using an OSF repository, other researchers and readers of the published study will have access to the IPD.",2021-10-17T08:02:28Z,2021-10-17T08:02:28Z,158
NCT04516759,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-14,NA,NA,2021-09-09,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-16,Actual,"August 12, 2020",Actual,2020-08-12,September 2021,2021-09-30,"May 12, 2021",Actual,2021-05-12,"April 25, 2021",Actual,2021-04-25,NA,Interventional,ARCADIA,,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,"A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19",Completed,NA,Phase 2,156,Actual,St George Street Capital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,Requests for access to the data will be accepted beginning 6 months after article publication and will continue to be accepted for up to 5 years after publication.,Researchers must submit a methodologically sound research proposal to St George Street using the contact details provided on our website. See link below.,http://www.sgscapital.org,Yes,Qualified researchers can request access to deidentified individual participant data (IDP) that underlie the published clinical trial results.,2021-10-17T08:02:30Z,2021-10-17T08:02:30Z,51
NCT04514900,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-20,NA,NA,2021-04-27,2020-08-12,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-30,Actual,"September 23, 2020",Actual,2020-09-23,April 2021,2021-04-30,"March 8, 2021",Actual,2021-03-08,"March 8, 2021",Actual,2021-03-08,NA,Interventional,iREACH,,Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program,Exploring the Optimal Treatment Components for a Contactless Online Group-based Behavioral Weight Loss Program for the COVID 19 Pandemic,Completed,NA,N/A,73,Actual,University of South Carolina,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:02:47Z,2021-10-17T08:02:47Z,186
NCT04512027,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-11,NA,NA,2020-10-16,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"September 15, 2020",Actual,2020-09-15,October 2020,2020-10-31,"October 16, 2020",Actual,2020-10-16,"September 19, 2020",Actual,2020-09-19,NA,Interventional,Prolectin-M,,Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,"Effect of Prolectin-M; a (1-6)-Alpha-D-Mannopyranose on SarsCoV2 Viral Copy Numbers: A Proof of Concept, Open Label Randomized Controlled Trial",Completed,NA,N/A,10,Actual,Composite Interceptive Med Science,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:03:13Z,2021-10-17T08:03:13Z,379
NCT04511949,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-12,NA,NA,2021-02-02,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"July 12, 2020",Actual,2020-07-12,February 2021,2021-02-28,"November 30, 2020",Actual,2020-11-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,FAMICOV,,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Completed,NA,N/A,500,Actual,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:03:14Z,2021-10-17T08:03:14Z,270
NCT04510493,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-11,NA,NA,2021-09-07,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"October 23, 2020",Actual,2020-10-23,September 2021,2021-09-30,"August 17, 2021",Actual,2021-08-17,"August 17, 2021",Actual,2021-08-17,NA,Interventional,CanCovDia,,Canakinumab in Patients With COVID-19 and Type 2 Diabetes,Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial,Completed,NA,Phase 3,116,Actual,"University Hospital, Basel, Switzerland",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:03:27Z,2021-10-17T08:03:27Z,53
NCT04508075,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-07,NA,NA,2021-09-06,2020-08-08,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"August 10, 2020",Actual,2020-08-10,September 2021,2021-09-30,"August 31, 2021",Actual,2021-08-31,"January 9, 2021",Actual,2021-01-09,NA,Interventional,COVID-19,,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine","A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia",Completed,NA,Phase 3,1620,Actual,PT Bio Farma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:03:48Z,2021-10-17T08:03:48Z,54
NCT04507867,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-06,2021-09-22,NA,2021-10-13,2020-08-09,2020-08-11,Actual,2021-10-13,2021-10-15,Estimate,NA,NA,NA,2021-10-13,2021-10-15,Estimate,"September 7, 2020",Actual,2020-09-07,October 2021,2021-10-31,"April 10, 2021",Actual,2021-04-10,"April 10, 2021",Actual,2021-04-10,NA,Interventional,NA,"all participants enrolled in the study, a total of 80 patients were compared.",Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Effect of a Nutritional Support System to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Completed,NA,N/A,80,Actual,Anahuac University,"Restriction of resources for laboratory tests, small number of subjects analyzed and restriction of access of measuring instruments to the COVID-19 area.",2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:03:50Z,2021-10-17T08:03:50Z,17
NCT04506268,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-07,NA,NA,2021-03-10,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-03-10,2021-03-11,Actual,"September 9, 2020",Actual,2020-09-09,March 2021,2021-03-31,"October 30, 2020",Actual,2020-10-30,"October 30, 2020",Actual,2020-10-30,NA,Interventional,COVID SAFE,,COVID-19 SAFE Enrollment,Opt-In Versus Opt-Out for COVID Screening Assessment for Exposure,Completed,NA,N/A,412,Actual,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:04:05Z,2021-10-17T08:04:05Z,234
NCT04505761,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-03,NA,NA,2021-04-05,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-06,Actual,"August 1, 2020",Actual,2020-08-01,June 2020,2020-06-30,"March 31, 2021",Actual,2021-03-31,"February 1, 2021",Actual,2021-02-01,NA,Interventional,COVRehab,,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19","The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19: An Explorative Study",Completed,NA,N/A,48,Actual,Radboud University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Only upon asking.,2021-10-17T08:04:10Z,2021-10-17T08:04:10Z,208
NCT04504877,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-04,NA,NA,2021-09-27,2020-08-06,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"June 16, 2020",Actual,2020-06-16,September 2021,2021-09-30,"December 16, 2020",Actual,2020-12-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,BONSAI,,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling (Bonsai Study) wIth COVID-19: a Randomised Controlled Trial,Completed,NA,Phase 2/Phase 3,120,Actual,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Immediately the following publication. No end date,"Researchers who provide a methodologically sound proposal. Depending on the level of the proposed use of data, approval by an independent review committee will be required for the identified purpose.",NA,Yes,"All of the individual participant data collected during the trial, after deidentification",2021-10-17T08:04:18Z,2021-10-17T08:04:18Z,33
NCT04502056,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-02,2021-05-28,NA,2021-07-24,2020-08-04,2020-08-06,Actual,2021-07-24,2021-07-27,Actual,NA,NA,NA,2021-07-24,2021-07-27,Actual,"August 7, 2020",Actual,2020-08-07,July 2021,2021-07-31,"September 6, 2020",Actual,2020-09-06,"September 6, 2020",Actual,2020-09-06,NA,Interventional,NA,Any intervention was indeed an arm that included each sub arm of different types of message that we tested against a control and pre-specified in our study protocol and analysis plan to combine arms for analysis.,Covid-19 Messaging to Underserved Communities - 2nd Experiment,Covid-19 Messaging to Underserved Communities - 2nd Experiment,Completed,NA,N/A,20460,Actual,"National Bureau of Economic Research, Inc.","1. It was conducted online, and the participants may not be representative of the population with less than a college degree, since they have access to the internet and are used to participating in online studies; 2. Participants' preventive health behaviors were not directly observed; 3. Outcomes might be subject to social desirability bias.",12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:04:43Z,2021-10-17T08:04:43Z,98
NCT04501445,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-04,NA,NA,2021-09-15,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"September 14, 2020",Actual,2020-09-14,September 2021,2021-09-30,"July 31, 2021",Actual,2021-07-31,"April 8, 2021",Actual,2021-04-08,NA,Interventional,NA,,Psychological Symptoms and Families of COVID-19 Patients,Relieving the Burden of Psychological Symptoms Among Families of Critically Ill Patients With COVID-19,Completed,NA,N/A,90,Actual,Rush University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:04:51Z,2021-10-17T08:04:51Z,45
NCT04500067,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-15,NA,NA,2020-10-12,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"May 7, 2020",Actual,2020-05-07,October 2020,2020-10-31,"September 15, 2020",Actual,2020-09-15,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment","An Open-label Multicenter Randomized Trial to Evaluate the Efficacy of Bioven, Manufactured by Biopharma Plasma, LLC, in Complex Therapy of Patients With Pneumonia Induced by COVID-19 / SARS-CoV-2",Completed,NA,Phase 3,76,Actual,Biopharma Plasma LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After trial result publication 3 months later,"For specialists in medicine, pharmacy, scientists",NA,Yes,"After completion of the trial, results will be published. Access to parts CSR planned after the release of scientific publications",2021-10-17T08:05:03Z,2021-10-17T08:05:03Z,383
NCT04498936,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2020-11-10,2020-08-03,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"July 15, 2020",Actual,2020-07-15,November 2020,2020-11-30,"October 30, 2020",Actual,2020-10-30,"October 30, 2020",Actual,2020-10-30,NA,Interventional,NA,,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,"Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial",Completed,NA,Phase 4,240,Actual,Assiut University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:05:13Z,2021-10-17T08:05:13Z,354
NCT04498442,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-03,NA,NA,2021-09-23,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"May 22, 2020",Actual,2020-05-22,September 2021,2021-09-30,"October 22, 2020",Actual,2020-10-22,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls","A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",Completed,NA,N/A,8519,Actual,Beth Israel Deaconess Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:05:17Z,2021-10-17T08:05:17Z,37
NCT04497987,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-31,NA,NA,2021-07-02,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-06,Actual,"August 2, 2020",Actual,2020-08-02,July 2021,2021-07-31,"May 20, 2021",Actual,2021-05-20,"January 16, 2021",Actual,2021-01-16,NA,Interventional,BLAZE-2,,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 Alone and in Combination With LY3832479 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff; a NIAID and Lilly Collaborative Study",Completed,NA,Phase 3,1374,Actual,Eli Lilly and Company,,9,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2021-10-17T08:05:22Z,2021-10-17T08:05:22Z,120
NCT04497415,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-02,NA,NA,2021-10-05,2020-08-02,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-13,Actual,"October 21, 2020",Actual,2020-10-21,October 2021,2021-10-31,"January 30, 2021",Actual,2021-01-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,,The COVID-19 and Healthcare Workers: An Active Intervention,The COVID-19 and Healthcare Workers: An Active Intervention,Completed,NA,N/A,350,Actual,"Research Foundation for Mental Hygiene, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:05:28Z,2021-10-17T08:05:28Z,25
NCT04497623,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-27,NA,NA,2020-09-22,2020-08-01,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-24,Actual,"July 28, 2020",Actual,2020-07-28,September 2020,2020-09-30,"September 20, 2020",Actual,2020-09-20,"August 13, 2020",Actual,2020-08-13,NA,Interventional,SabanaHerons,,"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.","Clinical Evaluation of Ventilator Innovation Product in Colombia in the SARS Pandemic Covid 19, Unisabana Herons - A Cohort Study - Phase 1",Completed,NA,N/A,5,Actual,FundaciÃ³n Neumologica Colombiana,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The clinical and ventilatory data of the patients will be entered into an anonymized database hosted on the RedCap platform with which the University of La Sabana has an agreement.,2021-10-17T08:05:26Z,2021-10-17T08:05:26Z,403
NCT04497298,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-31,NA,NA,2021-07-06,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-09,Actual,"August 10, 2020",Actual,2020-08-10,July 2021,2021-07-31,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,COVID-19-101,,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,"A Randomized, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, a Measles Vector-based Vaccine Candidate Against COVID-19 in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase",Completed,NA,Phase 1,90,Actual,Institut Pasteur,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:05:29Z,2021-10-17T08:05:29Z,116
NCT04494984,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-29,NA,NA,2021-02-09,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-11,Actual,"July 27, 2020",Actual,2020-07-27,February 2021,2021-02-28,"December 30, 2020",Actual,2020-12-30,"November 23, 2020",Actual,2020-11-23,NA,Interventional,NA,,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.","A Stage 2/3, Adaptive, Randomized, Controlled, Double-blind Study to Investigate the Pharmacokinetics, Efficacy and Safety of the Hyperimmune Equine Serum (INM005) in Adult Patients With Moderate to Severe Confirmed SARS-CoV2 Disease.",Completed,NA,Phase 2/Phase 3,242,Actual,Inmunova S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:05:50Z,2021-10-17T08:05:50Z,263
NCT04495101,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-28,NA,NA,2021-07-07,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"July 29, 2020",Actual,2020-07-29,July 2021,2021-07-31,"June 10, 2021",Actual,2021-06-10,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,,Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19,"A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19",Completed,NA,Phase 2,100,Actual,Grifols Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:05:49Z,2021-10-17T08:05:49Z,115
NCT04494646,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-29,NA,NA,2021-05-11,2020-07-29,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-12,Actual,"September 8, 2020",Actual,2020-09-08,May 2021,2021-05-31,"January 8, 2021",Actual,2021-01-08,"January 8, 2021",Actual,2021-01-08,NA,Interventional,NA,,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),"BARCONA: A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)",Completed,NA,Phase 2,40,Actual,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Data will become available beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Sripal.Bangalore@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices) will be shared upon reasonable request.",2021-10-17T08:05:53Z,2021-10-17T08:05:53Z,172
NCT04492527,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-28,NA,NA,2021-08-26,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-30,Actual,"July 28, 2020",Actual,2020-07-28,August 2021,2021-08-31,"June 30, 2021",Actual,2021-06-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,,Student-delivered Telehealth Program for COVID-19 Education and Health Promotion,A Student-delivered Community Outreach teleheAlth Program for Covid Education and Health Promotion (COACH),Completed,NA,N/A,75,Actual,University of British Columbia,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:06:13Z,2021-10-17T08:06:13Z,65
NCT04494204,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-28,NA,NA,2020-12-19,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-19,2020-12-22,Actual,"August 7, 2020",Actual,2020-08-07,December 2020,2020-12-31,"December 20, 2020",Actual,2020-12-20,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,"An Open Label, Multicenter, Randomized, Controlled, Clinical Study to Evaluate the Efficacy and Safety of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets Compared With Standard Treatment Protocol in the Treatment of Mild to Moderate COVID-19 Patients.",Completed,NA,Phase 2/Phase 3,100,Actual,Nutrin GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"The trial is meant for pandemic, and any data is fruitful to the society will be shared with researchers only, without compromising personal data of the participant.",2021-10-17T08:05:57Z,2021-10-17T08:05:57Z,315
NCT04493242,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-29,NA,NA,2021-07-07,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-14,Actual,"September 24, 2020",Actual,2020-09-24,July 2021,2021-07-31,"May 22, 2021",Actual,2021-05-22,"May 1, 2021",Actual,2021-05-01,NA,Interventional,EXIT-COVID19,,Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Phase II Clinical Trial,Completed,NA,Phase 2,120,Actual,"Direct Biologics, LLC",,3,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:06:07Z,2021-10-17T08:06:07Z,115
NCT04492501,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-28,NA,NA,2020-07-28,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-30,Actual,"April 1, 2020",Actual,2020-04-01,July 2020,2020-07-31,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,NA,Interventional,NA,,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,"Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19",Completed,NA,N/A,600,Actual,UNICEF,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,6 months from completion of study,email,NA,Yes,data can be shared on demand in SPSS sheet,2021-10-17T08:06:14Z,2021-10-17T08:06:14Z,459
NCT04492475,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-28,NA,NA,2021-02-04,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-02-04,2021-02-09,Actual,"August 5, 2020",Actual,2020-08-05,November 2020,2020-11-30,"December 21, 2020",Actual,2020-12-21,"December 21, 2020",Actual,2020-12-21,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)",Completed,NA,Phase 3,969,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:06:14Z,2021-10-17T08:06:14Z,268
NCT04491994,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-28,2020-07-31,NA,2020-08-18,2020-07-28,2020-07-30,Actual,2020-08-18,2020-08-21,Actual,NA,NA,NA,2020-08-18,2020-08-21,Actual,"April 10, 2020",Actual,2020-04-10,August 2020,2020-08-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,COVID-19,sample size calculation was done and 540 patients enrolled,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial,Completed,NA,Phase 3,540,Actual,UNICEF,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,any time when asked,by email,NA,Yes,data can be shared on demand in SPSS sheet,2021-10-17T08:06:19Z,2021-10-17T08:06:19Z,438
NCT04491240,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-27,2020-10-21,NA,2020-10-28,2020-07-27,2020-07-29,Actual,2020-10-28,2020-11-04,Actual,NA,NA,NA,2020-10-28,2020-11-04,Actual,"July 20, 2020",Actual,2020-07-20,October 2020,2020-10-31,"October 20, 2020",Actual,2020-10-20,"October 1, 2020",Actual,2020-10-01,NA,Interventional,COVID-19EXO,,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,The Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Two-Sided Pneumonia,Completed,NA,Phase 1/Phase 2,30,Actual,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:06:25Z,2021-10-17T08:06:25Z,367
NCT04490278,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-23,NA,NA,2021-10-04,2020-07-23,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-06,Actual,"September 29, 2020",Actual,2020-09-29,October 2021,2021-10-31,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,,CoV-PICS: A Virtual Post-ICU Clinic,"COVID-19 Virtual Post Intensive Care Syndrome (CoV-PICS) Clinic: Modern, Convenient and Practical Recovery Care",Completed,NA,N/A,23,Actual,Washington University School of Medicine,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:06:34Z,2021-10-17T08:06:34Z,26
NCT04489446,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-25,NA,NA,2021-09-27,2020-07-25,2020-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"August 19, 2020",Actual,2020-08-19,September 2021,2021-09-30,"June 30, 2021",Actual,2021-06-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,,Sildenafil in COVID-19,Sildenafil for Treating Patients With COVID-19 and Perfusion Mismatch: A Pilot Randomised Trial,Completed,NA,Phase 1/Phase 2,40,Actual,Universidad Nacional Andres Bello,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:06:41Z,2021-10-17T08:06:41Z,33
NCT04488796,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-22,NA,NA,2021-04-06,2020-07-26,2020-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"September 7, 2020",Actual,2020-09-07,April 2021,2021-04-30,"December 16, 2020",Actual,2020-12-16,"December 16, 2020",Actual,2020-12-16,NA,Interventional,NA,,STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,"STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers, a Pilot Randomized Controlled Trial",Completed,NA,N/A,148,Actual,"Western University, Canada",,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:06:47Z,2021-10-17T08:06:47Z,207
NCT04487574,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-22,NA,NA,2020-11-11,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"July 25, 2020",Actual,2020-07-25,November 2020,2020-11-30,"October 29, 2020",Actual,2020-10-29,"October 29, 2020",Actual,2020-10-29,NA,Interventional,NA,,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,"A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With COVID-19",Completed,NA,Phase 3,118,Actual,RSV Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:06:59Z,2021-10-17T08:06:59Z,353
NCT04486482,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-23,NA,NA,2021-08-12,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"January 12, 2021",Actual,2021-01-12,August 2021,2021-08-31,"March 30, 2021",Actual,2021-03-30,"March 30, 2021",Actual,2021-03-30,NA,Interventional,NA,,A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function,"An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients With Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting",Completed,NA,N/A,49,Actual,Kaleido Biosciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:07:09Z,2021-10-17T08:07:09Z,79
NCT04486313,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-23,NA,NA,2021-03-31,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-01,Actual,"August 13, 2020",Actual,2020-08-13,March 2021,2021-03-31,"February 8, 2021",Actual,2021-02-08,"February 8, 2021",Actual,2021-02-08,NA,Interventional,NA,,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,"Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19",Completed,NA,Phase 3,1092,Actual,Romark Laboratories L.C.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:07:10Z,2021-10-17T08:07:10Z,213
NCT04486508,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-22,NA,NA,2021-08-14,2020-07-22,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-14,2021-08-17,Actual,"July 30, 2020",Actual,2020-07-30,August 2021,2021-08-31,"July 5, 2021",Actual,2021-07-05,"April 4, 2021",Actual,2021-04-04,NA,Interventional,INSPIRATION,,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19,Completed,NA,Phase 3,600,Actual,Rajaie Cardiovascular Medical and Research Center,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:07:09Z,2021-10-17T08:07:09Z,77
NCT04484493,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-22,NA,NA,2020-11-11,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"August 8, 2020",Actual,2020-08-08,November 2020,2020-11-30,"November 3, 2020",Actual,2020-11-03,"October 25, 2020",Actual,2020-10-25,NA,Interventional,NA,,Corticosteroid Nasal Spray in COVID-19 Anosmia,Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients,Completed,NA,Phase 3,100,Actual,Benha University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:07:26Z,2021-10-17T08:07:26Z,353
NCT04485169,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-21,NA,NA,2020-09-24,2020-07-22,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,Plex,,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm; a Retrospective Propensity Matched Control Study,Completed,NA,N/A,280,Actual,UNICEF,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Data is available right now and will remain available (6 months),By email,NA,Yes,data can be shared on demand in SPSS sheet,2021-10-17T08:07:20Z,2021-10-17T08:07:20Z,401
NCT04483375,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-17,NA,NA,2021-03-21,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-21,2021-03-23,Actual,"July 24, 2020",Actual,2020-07-24,July 2020,2020-07-31,"November 17, 2020",Actual,2020-11-17,"November 17, 2020",Actual,2020-11-17,NA,Interventional,NA,,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects","A Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of SCTA01 in Healthy Subjects",Completed,NA,Phase 1,33,Actual,Sinocelltech Ltd.,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:07:36Z,2021-10-17T08:07:36Z,223
NCT04483830,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-22,NA,NA,2020-09-07,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-09,Actual,"June 5, 2020",Actual,2020-06-05,September 2020,2020-09-30,"September 7, 2020",Actual,2020-09-07,"August 6, 2020",Actual,2020-08-06,NA,Interventional,SulES-COVID,,Suloexide in the Treatment of Early Stages of COVID-19,Sulodexide in the Treatment of Early Stages of COVID-19,Completed,NA,Phase 2/Phase 3,243,Actual,Clinedem,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,individual participant data will be confidential,2021-10-17T08:07:33Z,2021-10-17T08:07:33Z,418
NCT04481685,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-15,NA,NA,2021-06-22,2020-07-20,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-23,Actual,"July 20, 2020",Actual,2020-07-20,May 2020,2020-05-31,"June 1, 2021",Actual,2021-06-01,"February 25, 2021",Actual,2021-02-25,NA,Interventional,NA,,"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)","A Double-blind, Randomized, Controlled Trial of ATI-450 in Patients With Moderate-severe COVID-19",Completed,NA,Phase 2,20,Actual,University of Kansas Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:07:52Z,2021-10-17T08:07:52Z,130
NCT04480957,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-17,NA,NA,2021-08-12,2020-07-17,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-18,Actual,"August 4, 2020",Actual,2020-08-04,August 2021,2021-08-31,"January 29, 2021",Actual,2021-01-29,"January 29, 2021",Actual,2021-01-29,NA,Interventional,NA,,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,"A Phase 1/2 Randomised, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Immunogenicity of ARCT-021 in Healthy Adult Subjects",Completed,NA,Phase 1/Phase 2,106,Actual,"Arcturus Therapeutics, Inc.",,8,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:07:58Z,2021-10-17T08:07:58Z,79
NCT04480593,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-12,NA,NA,2020-09-28,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"June 2, 2020",Actual,2020-06-02,September 2020,2020-09-30,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,Bee-Covid,,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,"The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.",Completed,NA,Phase 2/Phase 3,120,Actual,D'Or Institute for Research and Education,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:08:02Z,2021-10-17T08:08:02Z,397
NCT04480112,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-19,NA,NA,2021-08-27,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"June 2, 2020",Actual,2020-06-02,August 2021,2021-08-31,"June 11, 2021",Actual,2021-06-11,"June 11, 2021",Actual,2021-06-11,NA,Interventional,NA,,Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults,Impact of Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults With and Without Cognitive Impairment,Completed,NA,N/A,196,Actual,Boston University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:08:06Z,2021-10-17T08:08:06Z,64
NCT04479202,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-13,NA,NA,2020-07-19,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-19,2020-07-21,Actual,"February 8, 2020",Actual,2020-02-08,May 2020,2020-05-31,"April 23, 2020",Actual,2020-04-23,"April 18, 2020",Actual,2020-04-18,NA,Interventional,BOIFIM,,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,NA,Phase 4,76,Actual,Chinese Medical Association,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,We have other articles about covid-19 yet to be published,2021-10-17T08:08:14Z,2021-10-17T08:08:14Z,468
NCT04479163,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-29,NA,NA,2020-12-19,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-19,2020-12-22,Actual,"June 4, 2020",Actual,2020-06-04,December 2020,2020-12-31,"October 25, 2020",Actual,2020-10-25,"October 25, 2020",Actual,2020-10-25,NA,Interventional,NA,,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2.,Completed,NA,N/A,165,Actual,Fundacion Infant,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:08:14Z,2021-10-17T08:08:14Z,315
NCT04477655,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-15,NA,NA,2021-04-12,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-13,Actual,"May 3, 2020",Actual,2020-05-03,April 2021,2021-04-30,"January 26, 2021",Actual,2021-01-26,"January 26, 2021",Actual,2021-01-26,NA,Interventional,PRO-CARF,,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Prone Positioning in Non-intubated Patients With Severe COVID-19: a Randomized Controlled Trial,Completed,NA,N/A,430,Actual,Hospital Civil de Guadalajara,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:08:26Z,2021-10-17T08:08:26Z,201
NCT04476888,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-16,NA,NA,2021-01-18,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-18,2021-01-20,Actual,"April 26, 2020",Actual,2020-04-26,January 2021,2021-01-31,"October 10, 2020",Actual,2020-10-10,"September 15, 2020",Actual,2020-09-15,NA,Interventional,COLLATE,,Convalescent Plasma Treatment in COVID-19,Convalescent Plasma Treatment in COVID-19 Patients at a Tertiary Care Center in Pakistan,Completed,NA,N/A,110,Actual,Aga Khan University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:08:33Z,2021-10-17T08:08:33Z,285
NCT04476667,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-13,NA,NA,2021-09-07,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-09,Actual,"June 15, 2020",Actual,2020-06-15,September 2021,2021-09-30,"May 1, 2021",Actual,2021-05-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,NA,,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19","Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Completed,NA,N/A,80,Actual,Queen's University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Ethics and Data Privacy: Only care providers involved in care of participant will have access to charts. Patients will only be identifiable by ID number on OPTT platform and real identity and consent forms will be stored locally in locked file cabinet and destroyed 5 years after study completion date. Only anonymized data will be provided to analysis team members.
OPTT is HIPAA, PIPEDA and SOC-2 compliant and all servers and databases are hosted in AWS Canada cloud infrastructure which is managed by Medstack to assure all provincial and federal privacy and security regulations are met. OPTT will not collect any identifiable personal information or IP addresses for privacy purposes. OPTT will only collect anonymized metadata to improve its service quality and provide advanced analytics to the clinician team. All data is encrypted by OPTT and no employee has direct access to patient data. All encrypted backups are kept in the S3 storage that is dedicated to Queen's University.",2021-10-17T08:08:35Z,2021-10-17T08:08:35Z,53
NCT04475120,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-16,NA,NA,2021-05-12,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-14,Actual,"April 15, 2020",Actual,2020-04-15,May 2021,2021-05-31,"July 2, 2020",Actual,2020-07-02,"July 2, 2020",Actual,2020-07-02,NA,Interventional,NA,,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Interventional Pilot Study to Assess the Use of Oral and Intra-nasal Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Completed,NA,Phase 2/Phase 3,92,Actual,University of Rome Tor Vergata,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:08:49Z,2021-10-17T08:08:49Z,171
NCT04475588,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-16,2020-08-02,NA,2021-06-10,2020-07-16,2020-07-17,Actual,2021-05-17,2021-05-20,Actual,NA,NA,NA,2021-06-10,2021-06-14,Actual,"May 1, 2020",Actual,2020-05-01,June 2021,2021-06-30,"July 7, 2020",Actual,2020-07-07,"July 7, 2020",Actual,2020-07-07,NA,Interventional,NA,,Efficacy and Safety of Itolizumab in COVID-19 Complications,"A Multi-Centre, Open Label, Two Arm Randomized, Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications",Completed,NA,Phase 2,32,Actual,Biocon Limited,Due to current pandemic situation few datapoints not available for ptxs who got discharged earlier basis clinical status & bed shortage. As time to discharge was influenced by load on the hospital it was not an evaluable parameter after the trial.,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:08:45Z,2021-10-17T08:08:45Z,142
NCT04475575,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-15,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 6, 2020",Actual,2020-04-06,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Can the Electronic Nose Smell COVID-19 Antibodies?,Can the Electronic Nose Smell COVID-19 Antibodies? A Proof-of-principle Study,Completed,NA,N/A,222,Actual,Maastricht University Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:08:45Z,2021-10-17T08:08:45Z,471
NCT04475562,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-15,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 6, 2020",Actual,2020-04-06,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"May 6, 2020",Actual,2020-05-06,NA,Interventional,NA,,Can the Electronic Nose Smell COVID-19?,Can the Electronic Nose Smell COVID-19? A Proof-of-principle Study,Completed,NA,N/A,219,Actual,Maastricht University Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:08:45Z,2021-10-17T08:08:45Z,471
NCT04475913,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-14,NA,NA,2021-02-24,2020-07-14,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-24,2021-03-01,Actual,"July 11, 2018",Actual,2018-07-11,July 2020,2020-07-31,"August 20, 2020",Actual,2020-08-20,"July 11, 2020",Actual,2020-07-11,NA,Interventional,NA,,Digital vs Analog Impression in Cases of All-on-4 - Prosthesis,"In a Post -Covid-19 World, What is the Clinical Influence of Digital vs Analog Impression in Cases of All-on-4 - Prosthesis ?",Completed,NA,N/A,56,Actual,October University for Modern Sciences and Arts,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:08:42Z,2021-10-17T08:08:42Z,248
NCT04475107,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-14,NA,NA,2021-05-27,2020-07-15,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"July 9, 2020",Actual,2020-07-09,April 2021,2021-04-30,"April 15, 2021",Actual,2021-04-15,"March 25, 2021",Actual,2021-03-25,NA,Interventional,NA,,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,"A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase â…¡ Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients",Completed,NA,Phase 2,113,Actual,Shin Poong Pharmaceutical Co. Ltd.,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:08:49Z,2021-10-17T08:08:49Z,156
NCT04473898,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-14,NA,NA,2021-02-17,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"June 19, 2020",Actual,2020-06-19,July 2020,2020-07-31,"February 17, 2021",Actual,2021-02-17,"October 19, 2020",Actual,2020-10-19,NA,Interventional,NA,,Telerehabilitation After Coronavirus,Telerehabilitation After Covid-19: Effectiveness of Respiratory and Aerobic Training,Completed,NA,N/A,35,Actual,KTO Karatay University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:09:01Z,2021-10-17T08:09:01Z,255
NCT04473170,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-14,NA,NA,2020-07-15,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"April 4, 2020",Actual,2020-04-04,July 2020,2020-07-31,"July 14, 2020",Actual,2020-07-14,"May 20, 2020",Actual,2020-05-20,NA,Interventional,SENTAD-COVID,,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,"Adaptive Open-label Study Evaluating the Safety and Efficacy of Autologous Non- Hematopoietic Peripheral Blood Stem Cells Therapy in COVID-19 Outbreak in Abu Dhabi, 2020 (SENTAD-COVID Study)",Completed,NA,Phase 1/Phase 2,146,Actual,Abu Dhabi Stem Cells Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:09:07Z,2021-10-17T08:09:07Z,472
NCT04473274,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-22,NA,NA,2020-12-02,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-04,Actual,"May 21, 2020",Actual,2020-05-21,December 2020,2020-12-31,"December 1, 2020",Actual,2020-12-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,GOTCHA,,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study","GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Completed,NA,Phase 4,10,Actual,Samaritan Health Services,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:09:06Z,2021-10-17T08:09:06Z,332
NCT04473248,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-14,NA,NA,2020-11-11,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"June 28, 2020",Actual,2020-06-28,July 2020,2020-07-31,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,,Spartan COVID-19 System: Evaluation of Clinical Sample Collection,Evaluation of Clinical Sample Collection Project: Spartan COVID-19,Completed,NA,N/A,27,Actual,Spartan Bioscience Inc.,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:09:07Z,2021-10-17T08:09:07Z,353
NCT04470258,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-10,NA,NA,2021-04-18,2020-07-11,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-18,2021-04-20,Actual,"June 25, 2020",Actual,2020-06-25,April 2021,2021-04-30,"November 30, 2020",Actual,2020-11-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,,Elmo Respiratory Support Project - COVID-19,Elmo Respiratory Support Project for Patients With Hypoxemic Respiratory Insufficiency in Covid-19: Proof Of Concept and Usability,Completed,NA,N/A,10,Actual,Escola de SaÃºde PÃºblica do CearÃ¡,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:09:40Z,2021-10-17T08:09:40Z,195
NCT04469621,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-28,NA,NA,2020-11-10,2020-07-12,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-13,Actual,"July 17, 2020",Actual,2020-07-17,November 2020,2020-11-30,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,NA,,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19",Completed,NA,Phase 1,68,Actual,Sanofi,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-17T08:09:58Z,2021-10-17T08:09:58Z,354
NCT04468893,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-10,NA,NA,2021-10-12,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Actual,"May 20, 2020",Actual,2020-05-20,October 2021,2021-10-31,"July 31, 2021",Actual,2021-07-31,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,"Effectiveness of a Self-applied Positive Psychology Online Intervention Program ""Mental Health COVID-19"" in Mexican Population: A Randomized Controlled Trial.",Completed,NA,N/A,35,Actual,Universidad Internacional de Valencia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,This data will be available approximately in december 2020 and it will be permanently available. It will be shared in the databases of the journal where the article(s) will be published,Through the servers of the journal(s) where we will publish the articles.,NA,Yes,"The information will be available in a private server or in a server of the journal(s) that we will publish the articles that will be the result of this study. The protocol of the study is currently in progress to be published, in this article will be included such study protocol, the informed consent is already shared in the register of clinical trials.",2021-10-17T08:10:08Z,2021-10-17T08:10:08Z,18
NCT04469114,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-10,NA,NA,2021-08-02,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-09,Actual,"September 16, 2020",Actual,2020-09-16,July 2020,2020-07-31,"January 9, 2021",Actual,2021-01-09,"January 9, 2021",Actual,2021-01-09,NA,Interventional,NA,,Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia",Completed,NA,Phase 3,289,Actual,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:10:06Z,2021-10-17T08:10:06Z,89
NCT04468009,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-09,NA,NA,2021-08-23,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-25,Actual,"June 25, 2020",Actual,2020-06-25,August 2021,2021-08-31,"June 19, 2021",Actual,2021-06-19,"January 19, 2021",Actual,2021-01-19,NA,Interventional,NA,,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Completed,NA,Phase 2,134,Actual,Hospital de Infecciosas Francisco Javier Muniz,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:10:17Z,2021-10-17T08:10:17Z,68
NCT04467840,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-09,NA,NA,2021-07-19,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"August 21, 2020",Actual,2020-08-21,July 2021,2021-07-31,"July 18, 2021",Actual,2021-07-18,"July 18, 2021",Actual,2021-07-18,NA,Interventional,NA,,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia","Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia",Completed,NA,Phase 2/Phase 3,475,Actual,RedHill Biopharma Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:10:18Z,2021-10-17T08:10:18Z,103
NCT04466605,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-09,NA,NA,2020-07-09,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-10,Actual,"March 30, 2020",Actual,2020-03-30,July 2020,2020-07-31,"July 6, 2020",Actual,2020-07-06,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown: Randomized Clinical Trial,Completed,NA,N/A,64,Actual,Aarogyam UK,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:10:29Z,2021-10-17T08:10:29Z,478
NCT04465513,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-08,NA,NA,2021-10-04,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"August 31, 2020",Actual,2020-08-31,June 2021,2021-06-30,"October 4, 2021",Actual,2021-10-04,"October 4, 2021",Actual,2021-10-04,NA,Interventional,NA,,Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19,"A Randomized, Open-label, Parallel Study to Investigate the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19 Who Are Hospitalized as Well as Patients Following the Guidance From Public Health",Completed,NA,N/A,14,Actual,Hofseth Biocare ASA,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:10:38Z,2021-10-17T08:10:38Z,26
NCT04464395,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-07,NA,NA,2021-07-20,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"July 1, 2020",Actual,2020-07-01,July 2021,2021-07-31,"July 9, 2021",Actual,2021-07-09,"March 1, 2021",Actual,2021-03-01,NA,Interventional,NA,,Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,Immunotherapy of COVID-19 With B-Cell Activating CPI-006 Monoclonal Antibody,Completed,NA,Phase 1,30,Actual,"Corvus Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:11:01Z,2021-10-17T08:11:01Z,102
NCT04463472,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-08,NA,NA,2021-08-17,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"June 29, 2020",Actual,2020-06-29,August 2021,2021-08-31,"August 12, 2021",Actual,2021-08-12,"September 28, 2020",Actual,2020-09-28,NA,Interventional,NA,,Study of COVID-19 DNA Vaccine (AG0301-COVID19),"A Non-randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Two Doses of Intramuscular AG0301-COVID19 (1mg/2mg) in Healthy Adults",Completed,NA,Phase 1/Phase 2,30,Actual,"AnGes, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:11:17Z,2021-10-17T08:11:17Z,74
NCT04463602,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-07,NA,NA,2021-04-22,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-23,Actual,"July 25, 2020",Actual,2020-07-25,April 2021,2021-04-30,"March 31, 2021",Actual,2021-03-31,"January 25, 2021",Actual,2021-01-25,NA,Interventional,NA,,Desidustat in the Management of COVID-19 Patients,"A Phase 2b, Multicenter, Open-label, Randomized, Comparator-Controlled, Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of COVID-19 Patients",Completed,NA,Phase 2,24,Actual,Cadila Healthcare Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:11:16Z,2021-10-17T08:11:16Z,191
NCT04463004,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-07,2021-08-04,NA,2021-08-04,2020-07-07,2020-07-09,Actual,2021-08-04,2021-08-11,Actual,NA,NA,NA,2021-08-04,2021-08-11,Actual,"September 2, 2020",Actual,2020-09-02,August 2021,2021-08-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,NA,Phase 2,2,Actual,Virginia Commonwealth University,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:11:21Z,2021-10-17T08:11:21Z,87
NCT04460534,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-02,NA,NA,2021-08-16,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"May 7, 2020",Actual,2020-05-07,August 2021,2021-08-31,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,COVISPERM,,Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Detection of SARS-CoV-2 in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Completed,NA,N/A,52,Actual,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:12:04Z,2021-10-17T08:12:04Z,75
NCT04460027,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-01,NA,NA,2021-04-26,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-28,Actual,"June 22, 2020",Actual,2020-06-22,April 2021,2021-04-30,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,,W-SUDs for COVID-19,Woebot for Substance Use Disorders During COVID-19,Completed,NA,Phase 1,180,Actual,"Woebot Labs, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:12:12Z,2021-10-17T08:12:12Z,187
NCT04459962,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-03,NA,NA,2021-01-28,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"June 29, 2020",Actual,2020-06-29,July 2020,2020-07-31,"January 7, 2021",Actual,2021-01-07,"January 7, 2021",Actual,2021-01-07,NA,Interventional,NA,,Covid-19 Breath Test,Breath Test Feasibility Trial for Covid-19 Infection Diagnosis,Completed,NA,N/A,330,Actual,Ancon Technologies Ltd,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:12:14Z,2021-10-17T08:12:14Z,275
NCT04460703,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-02,NA,NA,2020-07-18,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-18,2020-07-21,Actual,"July 3, 2020",Actual,2020-07-03,July 2020,2020-07-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,,"COVID-19 Vaccine Messaging, Part 1","Persuasive Messages for COVID-19 Vaccine Uptake: a Randomized Controlled Trial, Part 1",Completed,NA,N/A,4000,Actual,Yale University,,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After publication,Anonymized data and analysis code will be posted in a public replication archive,NA,Yes,Anonymized data and analysis code will be posted in a public replication archive after publication.,2021-10-17T08:12:01Z,2021-10-17T08:12:01Z,469
NCT04460690,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-06,NA,NA,2021-08-31,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-08,Actual,"July 13, 2020",Actual,2020-07-13,July 2021,2021-07-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,,"Rapid, Onsite COVID-19 Detection","Rapid, Onsite COVID-19 Detection",Completed,NA,N/A,93,Actual,"University of Wisconsin, Madison",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,NA,NA,,Data from this study may be requested from other researchers 7 years after the completion of the primary endpoint by contacting David O'Connor at the University of Wisconsin - Madison.,NA,NA,Yes,"Participants will consent to having their data (not their name) and viral sequences shared with the public via manuscripts, presentations and online databases; the study team will share that with other researchers when needed. Samples can be shared with UW researchers internally and non UW researchers through the Material Transfer Agreement process.",2021-10-17T08:12:01Z,2021-10-17T08:12:01Z,60
NCT04460651,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-02,NA,NA,2021-09-10,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-17,Actual,"August 14, 2020",Actual,2020-08-14,August 2021,2021-08-31,"August 30, 2021",Actual,2021-08-30,"August 30, 2021",Actual,2021-08-30,NA,Interventional,PREPARE-IT,,PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial,PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial,Completed,NA,Phase 3,4093,Actual,Estudios ClÃ­nicos Latino AmÃ©rica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:12:02Z,2021-10-17T08:12:02Z,50
NCT04458363,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-25,NA,NA,2021-01-14,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-19,Actual,"July 4, 2020",Actual,2020-07-04,January 2021,2021-01-31,"September 1, 2020",Actual,2020-09-01,"September 1, 2020",Actual,2020-09-01,NA,Interventional,NA,,Convalescent Plasma in Pediatric COVID-19,Convalescent Plasma to Optimize Treatment of COVID-19 Disease in Pediatric Patients: A Feasibility Study,Completed,NA,Early Phase 1,3,Actual,Emory University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:12:51Z,2021-10-17T08:12:51Z,289
NCT04459520,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-05,NA,NA,2020-08-19,2020-07-05,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-20,Actual,"July 23, 2020",Actual,2020-07-23,August 2020,2020-08-31,"July 29, 2020",Actual,2020-07-29,"July 28, 2020",Actual,2020-07-28,NA,Interventional,NA,,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Completed,NA,N/A,1400,Actual,"University of California, Los Angeles",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:12:24Z,2021-10-17T08:12:24Z,437
NCT04459455,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-29,NA,NA,2020-10-19,2020-07-05,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"August 19, 2020",Actual,2020-08-19,October 2020,2020-10-31,"October 15, 2020",Actual,2020-10-15,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,,"Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic","Project HF-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",Completed,NA,N/A,500,Actual,Stony Brook University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:12:24Z,2021-10-17T08:12:24Z,376
NCT04459325,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-03,NA,NA,2020-10-13,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,NA,Interventional,NA,,TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,A Prospective Open-label Study of the TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,Completed,NA,Phase 3,100,Actual,AO GENERIUM,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:12:27Z,2021-10-17T08:12:27Z,382
NCT04458519,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-01,NA,NA,2021-05-27,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"July 16, 2020",Actual,2020-07-16,July 2020,2020-07-31,"May 27, 2021",Actual,2021-05-27,"May 27, 2021",Actual,2021-05-27,NA,Interventional,NA,,Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Randomised Single Blinded Clinical Study of Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Completed,NA,N/A,23,Actual,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:12:47Z,2021-10-17T08:12:47Z,156
NCT04457388,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-30,NA,NA,2020-07-07,2020-06-30,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"March 25, 2020",Actual,2020-03-25,July 2020,2020-07-31,"June 15, 2020",Actual,2020-06-15,"June 15, 2020",Actual,2020-06-15,NA,Interventional,NA,,Tele-Yoga Therapy for Chronic Pain,Tele- Yoga Therapy for Patients With Chronic Pain During Covid-19 Lockdown: A Prospective Non-randomized Single Arm Clinical Trial,Completed,NA,N/A,18,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:13:06Z,2021-10-17T08:13:06Z,480
NCT04456452,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-30,NA,NA,2021-01-12,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-12,2021-01-13,Actual,"July 27, 2020",Actual,2020-07-27,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"September 8, 2020",Actual,2020-09-08,NA,Interventional,NA,,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,A Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampionâ„¢ in Adult COVID-19 Patients Requiring Oxygen Supplementation,Completed,NA,Phase 1,10,Actual,Ampio Pharmaceuticals. Inc.,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:13:16Z,2021-10-17T08:13:16Z,291
NCT04456153,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-30,NA,NA,2021-02-16,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-21,Actual,"July 22, 2020",Actual,2020-07-22,February 2021,2021-02-28,"January 31, 2021",Actual,2021-01-31,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NA,,Atovaquone for Treatment of COVID-19,Atovaquone for Treatment of COVID-19,Completed,NA,Phase 2,61,Actual,University of Texas Southwestern Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:13:19Z,2021-10-17T08:13:19Z,256
NCT04455360,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-26,NA,NA,2021-09-28,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"October 1, 2020",Actual,2020-10-01,September 2021,2021-09-30,"September 20, 2021",Actual,2021-09-20,"September 20, 2021",Actual,2021-09-20,NA,Interventional,Cov-EMERALD,,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,EMERALD: Can a Virtual Eye Movement Desensitisation and Reprocessing Intervention Improve Psychological Outcome Following Covid-19 Related Critical Illness: A Feasibility Trial,Completed,NA,N/A,26,Actual,University Hospital Southampton NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:13:27Z,2021-10-17T08:13:27Z,32
NCT04455308,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-30,NA,NA,2020-11-03,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"July 21, 2020",Actual,2020-07-21,November 2020,2020-11-30,"October 19, 2020",Actual,2020-10-19,"October 19, 2020",Actual,2020-10-19,NA,Interventional,ECCES,,COVID-19 and Chilblains,"Chilblains, COVID-19 and Lockdown: Epidemiologic Study",Completed,NA,N/A,269,Actual,Rennes University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:13:27Z,2021-10-17T08:13:27Z,361
NCT04454606,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-26,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"May 31, 2020",Actual,2020-05-31,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,,The New Silicone N99 Half-Piece Respirator,The New Silicone N99 Half-Piece Respirator:VJR-NMU N99:New and Effective Tool to Prevent COVID-19,Completed,NA,N/A,43,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:13:33Z,2021-10-17T08:13:33Z,487
NCT04453852,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-03,NA,NA,2021-05-05,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"June 30, 2020",Actual,2020-06-30,May 2021,2021-05-31,"April 14, 2021",Actual,2021-04-14,"February 1, 2021",Actual,2021-02-01,NA,Interventional,COVAX19,,Monovalent Recombinant COVID19 Vaccine,"A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects",Completed,NA,Phase 1,40,Actual,Vaxine Pty Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:13:39Z,2021-10-17T08:13:39Z,178
NCT04453514,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-30,NA,NA,2021-07-20,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"July 21, 2020",Actual,2020-07-21,July 2021,2021-07-31,"June 19, 2021",Actual,2021-06-19,"June 19, 2021",Actual,2021-06-19,NA,Interventional,NA,,Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic,Cultivating Calm During COVID-19: A Feasibility Study of Video-based Trauma-informed Yoga,Completed,NA,N/A,212,Actual,National University of Natural Medicine,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:13:42Z,2021-10-17T08:13:42Z,102
NCT04452669,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-29,NA,NA,2021-08-04,2020-06-29,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"September 15, 2020",Actual,2020-09-15,August 2021,2021-08-31,"June 29, 2021",Actual,2021-06-29,"June 29, 2021",Actual,2021-06-29,NA,Interventional,VPCOVID,,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,"Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation",Completed,NA,Phase 2,11,Actual,Aerogen Pharma Limited,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:13:50Z,2021-10-17T08:13:50Z,87
NCT04452435,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-29,2021-03-24,NA,2021-06-21,2020-06-29,2020-06-30,Actual,2021-04-28,2021-04-30,Actual,NA,NA,NA,2021-06-21,2021-06-23,Actual,"July 21, 2020",Actual,2020-07-21,June 2021,2021-06-30,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Interventional,NA,,Safety and Efficacy of C21 in Subjects With COVID-19,"A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial Investigating the Safety and Efficacy of C21 in Hospitalised Subjects With COVID-19 Infection Not Requiring Mechanical Ventilation",Completed,NA,Phase 2,206,Actual,Vicore Pharma AB,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:13:53Z,2021-10-17T08:13:53Z,131
NCT04452318,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-26,NA,NA,2021-10-06,2020-06-26,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-07,Actual,"July 13, 2020",Actual,2020-07-13,October 2021,2021-10-31,"October 4, 2021",Actual,2021-10-04,"October 4, 2021",Actual,2021-10-04,NA,Interventional,NA,,COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2",Completed,NA,Phase 3,3303,Actual,Regeneron Pharmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-10-17T08:13:54Z,2021-10-17T08:13:54Z,24
NCT04449718,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-16,NA,NA,2020-11-16,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-16,2020-11-17,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"October 7, 2020",Actual,2020-10-07,"October 7, 2020",Actual,2020-10-07,NA,Interventional,NA,,Vitamin D Supplementation in Patients With COVID-19,"Vitamin D Supplementation in Patients With COVID-19: A Randomized, Double-blind, Placebo-controlled Trial",Completed,NA,N/A,240,Actual,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:14:51Z,2021-10-17T08:14:51Z,348
NCT04448769,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-23,NA,NA,2020-08-18,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"June 26, 2020",Actual,2020-06-26,August 2020,2020-08-31,"July 24, 2020",Actual,2020-07-24,"July 24, 2020",Actual,2020-07-24,NA,Interventional,COVAL-NANCY,,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19) in the Population of the Grand Nancy Metropolitan Area,Completed,NA,N/A,2006,Actual,"Central Hospital, Nancy, France",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:15:07Z,2021-10-17T08:15:07Z,438
NCT04448756,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-25,NA,NA,2021-09-05,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2021-09-05,2021-09-08,Actual,"July 29, 2020",Actual,2020-07-29,September 2021,2021-09-30,"August 16, 2021",Actual,2021-08-16,"August 16, 2021",Actual,2021-08-16,NA,Interventional,NA,,Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE),"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia (ANEMONE)",Completed,NA,Phase 2,151,Actual,EMD Serono,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html",2021-10-17T08:15:07Z,2021-10-17T08:15:07Z,55
NCT04446429,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-22,2021-01-22,NA,2021-06-14,2020-06-23,2020-06-24,Actual,2021-01-29,2021-02-03,Actual,NA,NA,NA,2021-06-14,2021-06-16,Actual,"September 15, 2020",Actual,2020-09-15,June 2021,2021-06-30,"January 21, 2021",Actual,2021-01-21,"December 24, 2020",Actual,2020-12-24,NA,Interventional,NA,,Anti-Androgen Treatment for COVID-19,Anti-Androgen Treatment for COVID-19,Completed,NA,N/A,268,Actual,"Applied Biology, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:15:29Z,2021-10-17T08:15:29Z,138
NCT04446104,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-11,NA,NA,2020-10-13,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-19,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,NA,,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial),Completed,NA,Phase 3,4257,Actual,"National University Hospital, Singapore",,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:15:32Z,2021-10-17T08:15:32Z,382
NCT04445272,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-13,NA,NA,2021-05-31,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-31,2021-06-02,Actual,"May 22, 2020",Actual,2020-05-22,June 2020,2020-06-30,"December 23, 2020",Actual,2020-12-23,"December 23, 2020",Actual,2020-12-23,NA,Interventional,NA,,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,"A Multicentre, Open-label Clinical Trial to Evaluate the Effectiveness and Safety of Intravenous Tocilizumab for Treating Patients With COVID-19 Pneumonia: the BREATH-19 Study",Completed,NA,Phase 2,495,Actual,Fundacion SEIMC-GESIDA,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:15:39Z,2021-10-17T08:15:39Z,152
NCT04445376,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-22,NA,NA,2020-10-06,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"July 3, 2020",Actual,2020-07-03,October 2020,2020-10-31,"October 3, 2020",Actual,2020-10-03,"September 10, 2020",Actual,2020-09-10,NA,Interventional,NA,,Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,Effect of Aerobic Exercises on Cardio-respiratory Fitness and Quality of Life in Recovered COVID 19 Recovered Patients.,Completed,NA,N/A,20,Actual,Government College University Faisalabad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:15:38Z,2021-10-17T08:15:38Z,389
NCT04443881,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-18,NA,NA,2021-05-27,2020-06-20,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"May 8, 2020",Actual,2020-05-08,May 2021,2021-05-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,ANA-COVID-GEAS,,Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS),"Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2/3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS- CoV-2 Infection",Completed,NA,Phase 2/Phase 3,179,Actual,Fundacion Miguel Servet,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,"All collected IPD will be available for exploitation in future research projects. This statement also includes the availability of the study protocol, the statistical analysis plan, the informed consent form, the clinical study report and the analytic code.",2021-10-17T08:15:54Z,2021-10-17T08:15:54Z,156
NCT04442958,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-17,NA,NA,2020-06-30,2020-06-19,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,"June 17, 2020",Actual,2020-06-17,"June 15, 2020",Actual,2020-06-15,NA,Interventional,NA,,Effectiveness of Convalescent Immune Plasma Therapy,Effectiveness of Convalescent Immune Plasma Therapy in Severe COVID-19 Patients With Acute Respiratory Distress Syndrome,Completed,NA,N/A,60,Actual,Bagcilar Training and Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:16:02Z,2021-10-17T08:16:02Z,487
NCT04441632,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-18,NA,NA,2020-08-11,2020-06-18,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 15, 2020",Actual,2020-06-15,August 2020,2020-08-31,"July 30, 2020",Actual,2020-07-30,"July 26, 2020",Actual,2020-07-26,NA,Interventional,TEAM-ICU,,Effect of Positive Attitudes on Behavior and Wellness,"The Impact of Positive Reinforcement on Teamwork Climate, Resiliency, and Burnout During the COVID-19 Pandemic: the TEAM-ICU Study (Transforming Employee Attitudes Via Messaging Strengthens Interconnection, Communication, and Unity)",Completed,NA,N/A,24,Actual,Cedars-Sinai Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:16:14Z,2021-10-17T08:16:14Z,445
NCT04441996,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-19,NA,NA,2021-03-25,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-29,Actual,"July 17, 2020",Actual,2020-07-17,March 2021,2021-03-31,"March 18, 2021",Actual,2021-03-18,"March 18, 2021",Actual,2021-03-18,NA,Interventional,NA,,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Completed,NA,Phase 4,20,Actual,Emory University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:16:11Z,2021-10-17T08:16:11Z,219
NCT04441424,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-12,NA,NA,2020-06-20,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-20,2020-06-23,Actual,"April 3, 2020",Actual,2020-04-03,June 2020,2020-06-30,"June 1, 2020",Actual,2020-06-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,"The Therapeutic Potential of Convalescent Plasma Therapy on Treating Critically-ill COVID-19 Patients Residing in Respiratory Care Units in Hospitals in Baghdad, Iraq",Completed,NA,N/A,49,Actual,Alkarkh Health Directorate-Baghdad,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:16:16Z,2021-10-17T08:16:16Z,497
NCT04441684,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-20,NA,NA,2021-07-26,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"April 17, 2020",Actual,2020-04-17,July 2021,2021-07-31,"July 16, 2021",Actual,2021-07-16,"May 7, 2020",Actual,2020-05-07,NA,Interventional,SeroCoV-HUS,,"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)","Study of the Seroprevalence of SARS-CoV-2 in Hospital Staff in Strasbourg University Hospital, Strasbourg, France",Completed,NA,N/A,1466,Actual,"University Hospital, Strasbourg, France",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:16:14Z,2021-10-17T08:16:14Z,96
NCT04439825,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-18,NA,NA,2021-03-11,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-15,Actual,"July 20, 2020",Actual,2020-07-20,March 2021,2021-03-31,"December 1, 2020",Actual,2020-12-01,"September 3, 2020",Actual,2020-09-03,NA,Interventional,NA,,Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction,Randomized Controlled Single Blind Cross Over Trial Evaluating the Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction in a Post Covid Period.,Completed,NA,Phase 1,45,Actual,DeNova Research,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:16:30Z,2021-10-17T08:16:30Z,233
NCT04438980,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-18,NA,NA,2021-05-14,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-17,Actual,"May 15, 2020",Actual,2020-05-15,May 2021,2021-05-31,"April 9, 2021",Actual,2021-04-09,"March 12, 2021",Actual,2021-03-12,NA,Interventional,CORTIVID,,Glucocorticoids in COVID-19 (CORTIVID),Treatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled Trial,Completed,NA,Phase 3,72,Actual,Fundacion Miguel Servet,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"All collected IPD will be available for exploitation in future research projects. This statement also includes the availability of the study protocol, the statistical analysis plan, the informed consent form, the clinical study report and the analytic code.",2021-10-17T08:16:39Z,2021-10-17T08:16:39Z,169
NCT04319445,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-20,NA,NA,2021-04-30,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-30,2021-05-06,Actual,"March 22, 2020",Actual,2020-03-22,March 2021,2021-03-31,"March 30, 2021",Actual,2021-03-30,"August 31, 2020",Actual,2020-08-31,NA,Interventional,NA,,Mindfulness During COVID-19,Mindfulness During COVID-19 - Remote Mindfulness Sessions,Completed,NA,N/A,233,Actual,Wake Forest University Health Sciences,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:34:59Z,2021-10-17T08:34:59Z,183
NCT04437875,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac Lyo"" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:16:49Z,2021-10-17T08:16:49Z,445
NCT04436471,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:17:02Z,2021-10-17T08:17:02Z,445
NCT04435184,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-16,NA,NA,2021-01-14,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-19,Actual,"July 9, 2020",Actual,2020-07-09,January 2021,2021-01-31,"January 4, 2021",Actual,2021-01-04,"November 28, 2020",Actual,2020-11-28,NA,Interventional,CRITICAL,,Crizanlizumab for Treating COVID-19 Vasculopathy,Crizanlizumab for Treating COVID-19 Vasculopathy,Completed,NA,Phase 2,50,Actual,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:17:16Z,2021-10-17T08:17:16Z,289
NCT04435522,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-15,NA,NA,2021-02-02,2020-06-15,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-04,Actual,"October 1, 2020",Actual,2020-10-01,June 2020,2020-06-30,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,,Maraviroc in Patients With Moderate and Severe COVID-19,Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2,Completed,NA,Phase 1,9,Actual,Rhode Island Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:17:13Z,2021-10-17T08:17:13Z,270
NCT04433910,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-06,NA,NA,2021-03-16,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-17,Actual,"August 30, 2020",Actual,2020-08-30,March 2021,2021-03-31,"February 22, 2021",Actual,2021-02-22,"January 21, 2021",Actual,2021-01-21,NA,Interventional,CAPSID,,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,"A Randomized, Prospective, Open Label Clinical Trial on the Use of Convalescent Plasma Compared to Best Supportive Care in Patients With Severe COVID-19",Completed,NA,Phase 2,106,Actual,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:17:27Z,2021-10-17T08:17:27Z,228
NCT04432324,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-12,NA,NA,2021-03-09,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-10,Actual,"June 2, 2020",Actual,2020-06-02,March 2021,2021-03-31,"March 3, 2021",Actual,2021-03-03,"March 3, 2021",Actual,2021-03-03,NA,Interventional,NA,,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),"A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19",Completed,NA,Phase 2,100,Actual,Grifols Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:17:41Z,2021-10-17T08:17:41Z,235
NCT04432272,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-12,NA,NA,2021-05-05,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"July 16, 2020",Actual,2020-07-16,May 2021,2021-05-31,"November 28, 2020",Actual,2020-11-28,"November 13, 2020",Actual,2020-11-13,NA,Interventional,ABACCuS,,ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),Completed,NA,Phase 2,71,Actual,William Beaumont Hospitals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:17:41Z,2021-10-17T08:17:41Z,178
NCT04431856,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-12,NA,NA,2020-11-30,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-01,Actual,"May 15, 2020",Actual,2020-05-15,November 2020,2020-11-30,"November 17, 2020",Actual,2020-11-17,"November 17, 2020",Actual,2020-11-17,NA,Interventional,Co-PARENT,,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,Completed,NA,N/A,80,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:17:45Z,2021-10-17T08:17:45Z,334
NCT04390477,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-07-20,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"May 4, 2020",Actual,2020-05-04,July 2021,2021-07-31,"April 30, 2021",Actual,2021-04-30,"March 21, 2021",Actual,2021-03-21,NA,Interventional,NA,,Study to Evaluate the Effect of a Probiotic in COVID-19,The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection,Completed,NA,N/A,41,Actual,Bioithas SL,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:05Z,2021-10-17T08:24:05Z,102
NCT04431297,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-12,NA,NA,2021-08-19,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"March 22, 2021",Actual,2021-03-22,August 2021,2021-08-31,"May 14, 2021",Actual,2021-05-14,"May 14, 2021",Actual,2021-05-14,NA,Interventional,NA,,Virtual Mindfulness Rounds in the Time of COVID-19 Pandemic,The Impact of Virtual Mindfulness Education Sessions on Staff Perceived Stress During COVID-19,Completed,NA,N/A,15,Actual,Icahn School of Medicine at Mount Sinai,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:17:50Z,2021-10-17T08:17:50Z,72
NCT04429828,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-11,NA,NA,2021-08-26,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-27,Actual,"June 13, 2020",Actual,2020-06-13,August 2021,2021-08-31,"December 30, 2020",Actual,2020-12-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,PoWerS,,COVID-19 Psychological Wellbeing for Healthcare Students,PoWerS Study: Psychological Wellbeing for Healthcare Students: Evaluation of a COVID-19 Digital Learning Package,Completed,NA,N/A,42,Actual,University of Nottingham,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Interview data will be available on request at study end (after publication of findings).,On request.,NA,Yes,Interview data will be made available on request (after study end).,2021-10-17T08:18:04Z,2021-10-17T08:18:04Z,65
NCT04429529,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-09,NA,NA,2021-04-06,2020-06-10,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"June 9, 2020",Actual,2020-06-09,September 2020,2020-09-30,"January 20, 2021",Actual,2021-01-20,"November 19, 2020",Actual,2020-11-19,NA,Interventional,NA,,"Safety of TY027, a Treatment for COVID-19, in Humans","Phase 1 First-in-Human, Time Lagged, Randomised, Placebo Controlled, Double Blind, Single Ascending Dose Study of TY027 in Healthy Adult Volunteers",Completed,NA,Phase 1,32,Actual,Tychan Pte Ltd.,,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:06Z,2021-10-17T08:18:06Z,207
NCT04426695,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-08,NA,NA,2021-08-20,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-26,Actual,"June 10, 2020",Actual,2020-06-10,August 2021,2021-08-31,"June 4, 2021",Actual,2021-06-04,"May 7, 2021",Actual,2021-05-07,NA,Interventional,NA,,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19","A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19",Completed,NA,Phase 1/Phase 2,2252,Actual,Regeneron Pharmaceuticals,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-10-17T08:18:30Z,2021-10-17T08:18:30Z,71
NCT04426318,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-09,NA,NA,2021-01-22,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-26,Actual,"June 14, 2020",Actual,2020-06-14,November 2020,2020-11-30,"January 12, 2021",Actual,2021-01-12,"January 12, 2021",Actual,2021-01-12,NA,Interventional,CAHMP-ED,,COVID-19 and the Healthy Minds Program for Educators,COVID-19 and the Healthy Minds Program for Educators,Completed,NA,N/A,733,Actual,"University of Wisconsin, Madison",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Data will be de-identified and made publicly available based on the publication of preregistered study hypotheses following peer review.,Researcher consent. Any reasonable request will be granted.,NA,Yes,"Data will be de-identified and listed in public data registries (i.e., osf) based on the publication of preregistered study hypotheses on a manuscript by manuscript basis.",2021-10-17T08:18:33Z,2021-10-17T08:18:33Z,281
NCT04426305,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-03,NA,NA,2021-06-07,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-08,Actual,"May 21, 2020",Actual,2020-05-21,May 2020,2020-05-31,"October 30, 2020",Actual,2020-10-30,"June 20, 2020",Actual,2020-06-20,NA,Interventional,NA,,Community Health Workers Against COVID19,Community Health Workers Against COVID19 Tackling Psychosocial Suffering Due to Physical Distancing,Completed,NA,N/A,140,Actual,University Ghent,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:18:33Z,2021-10-17T08:18:33Z,145
NCT04425915,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-07,NA,NA,2021-10-06,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"June 14, 2020",Actual,2020-06-14,June 2021,2021-06-30,"December 15, 2020",Actual,2020-12-15,"December 15, 2020",Actual,2020-12-15,NA,Interventional,NA,,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19: A Randomized Control Trial,Completed,NA,Phase 3,400,Actual,"Institute of Liver and Biliary Sciences, India",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,After publication till 5 years,It will be available for researcher scientist & government agencies.,NA,Yes,NA,2021-10-17T08:18:36Z,2021-10-17T08:18:36Z,24
NCT04425538,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-08,NA,NA,2021-02-17,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"June 1, 2020",Actual,2020-06-01,February 2021,2021-02-28,"January 22, 2021",Actual,2021-01-22,"January 22, 2021",Actual,2021-01-22,NA,Interventional,NA,,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,Completed,NA,Phase 2,17,Actual,Tufts Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:40Z,2021-10-17T08:18:40Z,255
NCT04425252,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-09,NA,NA,2021-01-15,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-19,Actual,"August 1, 2020",Actual,2020-08-01,January 2021,2021-01-31,"December 29, 2020",Actual,2020-12-29,"December 29, 2020",Actual,2020-12-29,NA,Interventional,CRISIS,,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,The CRISIS Study: A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19),Completed,NA,Phase 1/Phase 2,23,Actual,"Clear Creek Bio, Inc.",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:42Z,2021-10-17T08:18:42Z,288
NCT04425005,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-08,NA,NA,2021-01-18,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-18,2021-01-22,Actual,"May 10, 2020",Actual,2020-05-10,January 2021,2021-01-31,"December 7, 2020",Actual,2020-12-07,"December 7, 2020",Actual,2020-12-07,NA,Interventional,NA,,Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric,Effect of Home-based Exercise Training Program During the Covid-19 Pandemic in Post-bariatric Patients: A Randomized Controlled Trial,Completed,NA,N/A,55,Actual,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:44Z,2021-10-17T08:18:44Z,285
NCT04424953,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-01,NA,NA,2021-03-16,2020-06-05,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-17,Actual,"June 1, 2020",Actual,2020-06-01,March 2021,2021-03-31,"September 25, 2020",Actual,2020-09-25,"September 25, 2020",Actual,2020-09-25,NA,Interventional,NA,,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,A Randomised Controlled Trial to Compare McGrath Videolaryngoscope Against Direct Laryngoscope for Endotracheal Intubation When Powered Air Purifying Respirator is Worn During the Current Coronavirus Disease 2019 Pandemic,Completed,NA,N/A,28,Actual,Singapore General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:45Z,2021-10-17T08:18:45Z,228
NCT04424082,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-07,NA,NA,2021-05-27,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-05-28,Actual,"June 9, 2020",Actual,2020-06-09,May 2021,2021-05-31,"May 27, 2021",Actual,2021-05-27,"June 25, 2020",Actual,2020-06-25,NA,Interventional,NA,,External Dead Space in Ventilated COVID-19 Patients,Influence of External Dead Space on Volumetric Capnography Derived Parameters in Mechanically Ventilated COVID-19 Patients,Completed,NA,N/A,10,Actual,Karolinska Institutet,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:54Z,2021-10-17T08:18:54Z,156
NCT04423289,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-06,NA,NA,2020-06-08,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"March 31, 2020",Actual,2020-03-31,June 2020,2020-06-30,"May 18, 2020",Actual,2020-05-18,"May 4, 2020",Actual,2020-05-04,NA,Interventional,NA,,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,COVID Follow-App: Telematic Monitoring Through a Mobile Application of Patients With COVID-19: A Randomized Clinical Trial,Completed,NA,N/A,150,Actual,Hospital Universitari Vall d'Hebron Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:19:02Z,2021-10-17T08:19:02Z,509
NCT04422561,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-06,2020-08-23,NA,2020-08-23,2020-06-06,2020-06-09,Actual,2020-08-23,2020-08-27,Actual,NA,NA,NA,2020-08-23,2020-08-27,Actual,"May 31, 2020",Actual,2020-05-31,August 2020,2020-08-31,"July 27, 2020",Actual,2020-07-27,"July 14, 2020",Actual,2020-07-14,NA,Interventional,NA,,Prophylactic Ivermectin in COVID-19 Contacts,Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19,Completed,NA,Phase 2/Phase 3,340,Actual,Zagazig University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:19:07Z,2021-10-17T08:19:07Z,433
NCT04422509,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-03,NA,NA,2021-07-11,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-11,2021-07-13,Actual,"October 30, 2020",Actual,2020-10-30,July 2021,2021-07-31,"April 30, 2021",Actual,2021-04-30,"February 25, 2021",Actual,2021-02-25,NA,Interventional,COVID_LAN,,Lanadelumab for Treatment of COVID-19 Disease,Lanadelumab for Treatment of COVID-19 Disease,Completed,NA,Phase 1/Phase 2,43,Actual,Radboud University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,this has not yet been decided,2021-10-17T08:19:08Z,2021-10-17T08:19:08Z,111
NCT04421612,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-04,NA,NA,2021-05-05,2020-06-04,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"April 2, 2020",Actual,2020-04-02,August 2020,2020-08-31,"January 1, 2021",Actual,2021-01-01,"January 1, 2021",Actual,2021-01-01,NA,Interventional,Co-COVID-19,,COVID-19 - No Health Without Mental Health,COVID-19 - No Health Without Mental Health,Completed,NA,N/A,91,Actual,Haukeland University Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,There is a plan to share anonymous interaction-data. Health data are undecided,2021-10-17T08:19:15Z,2021-10-17T08:19:15Z,178
NCT04421027,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-05,NA,NA,2021-07-15,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-15,2021-07-19,Actual,"June 12, 2020",Actual,2020-06-12,July 2021,2021-07-31,"June 10, 2021",Actual,2021-06-10,"February 12, 2021",Actual,2021-02-12,NA,Interventional,COV-BARRIER,,A Study of Baricitinib (LY3009104) in Participants With COVID-19,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection",Completed,NA,Phase 3,1585,Actual,Eli Lilly and Company,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement,2021-10-17T08:19:20Z,2021-10-17T08:19:20Z,107
NCT04420273,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-03,NA,NA,2021-03-01,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-03,Actual,"July 2, 2020",Actual,2020-07-02,March 2021,2021-03-31,"March 1, 2021",Actual,2021-03-01,"March 1, 2021",Actual,2021-03-01,NA,Interventional,TMD,,Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access,Targeted Melanoma Detection With Skin Self-examination: Leveraging the Mammogram Encounter,Completed,NA,N/A,1000,Actual,Northwestern University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:19:27Z,2021-10-17T08:19:27Z,243
NCT04420260,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-25,NA,NA,2021-07-08,2020-06-04,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-08,2021-07-15,Actual,"March 18, 2021",Actual,2021-03-18,July 2021,2021-07-31,"July 5, 2021",Actual,2021-07-05,"June 23, 2021",Actual,2021-06-23,NA,Interventional,PI-Covid-19,,Primary Prevention of Infection by COVID-19 in Workers,"Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in MedellÃ­n-Antioquia",Completed,NA,N/A,152,Actual,Unidad de InvestigaciÃ³n GenÃ©tica Molecular,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:19:27Z,2021-10-17T08:19:27Z,114
NCT04420247,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-02,NA,NA,2021-05-10,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,"April 16, 2020",Actual,2020-04-16,May 2021,2021-05-31,"September 3, 2020",Actual,2020-09-03,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Completed,NA,Phase 3,142,Actual,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:19:27Z,2021-10-17T08:19:27Z,173
NCT04419623,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-03,NA,NA,2021-05-10,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,"July 9, 2020",Actual,2020-07-09,May 2021,2021-05-31,"December 15, 2020",Actual,2020-12-15,"September 22, 2020",Actual,2020-09-22,NA,Interventional,NA,,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,"A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer",Completed,NA,Phase 1,7,Actual,"Telios Pharma, Inc.",,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:19:33Z,2021-10-17T08:19:33Z,173
NCT04419610,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-16,NA,NA,2021-05-25,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-27,Actual,"October 9, 2020",Actual,2020-10-09,May 2021,2021-05-31,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,NA,,RAS and Coagulopathy in COVID19,Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19,Completed,NA,Early Phase 1,30,Actual,Imperial College London,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:19:33Z,2021-10-17T08:19:33Z,158
NCT04423991,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-08,NA,NA,2020-06-08,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"March 10, 2020",Actual,2020-03-10,June 2020,2020-06-30,"June 4, 2020",Actual,2020-06-04,"June 4, 2020",Actual,2020-06-04,NA,Interventional,IDENTIFY,,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning: the IDENTIFY Trial,Completed,NA,N/A,290,Actual,Dascena,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:18:55Z,2021-10-17T08:18:55Z,509
NCT04421404,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-03,2021-05-18,NA,2021-08-23,2020-06-05,2020-06-09,Actual,2021-08-23,2021-08-25,Actual,NA,NA,NA,2021-08-23,2021-08-25,Actual,"June 9, 2020",Actual,2020-06-09,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,CAPRI,,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,A Randomized Controlled Adaptive Study Comparing COVID-19 Convalescent Plasma (CCP) to Non-immune Plasma to Limit Coronavirus-associated Complications in Hospitalized Patients,Completed,NA,Phase 2,34,Actual,"University of California, San Francisco","This study was limited by the small sample of hospitalized, hypoxic patients, limiting the generalizability of the results. Most participants were beyond 72 hours of symptom onset, the period when studies suggest CCP is most likely to be beneficial.",2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:19:17Z,2021-10-17T08:19:17Z,68
NCT04420806,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-05,NA,NA,2020-11-12,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Actual,"March 14, 2020",Actual,2020-03-14,November 2020,2020-11-30,"October 30, 2020",Actual,2020-10-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Effects of Three Months of COVID-19 Lockdown Induced Deconditioning After 13 Months of High Intensity Exercise Training in Early Postmenopausal Women,Completed,NA,N/A,21,Actual,University of Erlangen-NÃ¼rnberg Medical School,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:19:22Z,2021-10-17T08:19:22Z,352
NCT04420741,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-04,NA,NA,2021-08-20,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"June 15, 2020",Actual,2020-06-15,August 2021,2021-08-31,"April 23, 2021",Actual,2021-04-23,"February 23, 2021",Actual,2021-02-23,NA,Interventional,COMBAT-COVID,,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng)/ Kilo(kg)/Minute(Min)) in Patients With COVID-19 Induced Pulmonary Endotheliopathy,Completed,NA,Phase 2,80,Actual,"Rigshospitalet, Denmark",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:19:23Z,2021-10-17T08:19:23Z,71
NCT04419025,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-03,NA,NA,2021-05-26,2020-06-03,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-28,Actual,"September 23, 2020",Actual,2020-09-23,May 2021,2021-05-31,"May 14, 2021",Actual,2021-05-14,"May 14, 2021",Actual,2021-05-14,NA,Interventional,NA,,Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease,Completed,NA,Phase 2,165,Actual,Cambridge Health Alliance,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,Six months after publication available for a year,Written request; to be reviewed by the PI,http://www.NACinCOVID.info,Yes,Information that underlies results in published data,2021-10-17T08:19:39Z,2021-10-17T08:19:39Z,157
NCT04417270,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-01,NA,NA,2021-03-01,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-02,Actual,"June 12, 2020",Actual,2020-06-12,March 2021,2021-03-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Completed,NA,N/A,52,Actual,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,The team has not decided whether to share the results with other researchers. The team will consider publishing results after study completion,2021-10-17T08:19:54Z,2021-10-17T08:19:54Z,243
NCT04417257,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-28,NA,NA,2021-10-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-03,2021-10-05,Actual,"June 29, 2020",Actual,2020-06-29,October 2021,2021-10-31,"July 15, 2021",Actual,2021-07-15,"July 15, 2021",Actual,2021-07-15,NA,Interventional,RESOLUTION,,Study of LAU-7b for the Treatment of COVID-19 Disease in Adults,"RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Pilot Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease",Completed,NA,Phase 2,240,Actual,Laurent Pharmaceuticals Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:19:54Z,2021-10-17T08:19:54Z,27
NCT04416308,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-27,NA,NA,2021-04-13,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-14,Actual,"May 29, 2020",Actual,2020-05-29,April 2021,2021-04-30,"October 12, 2020",Actual,2020-10-12,"July 10, 2020",Actual,2020-07-10,NA,Interventional,AntiCoV-HB,,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne,Completed,NA,N/A,9453,Actual,Rennes University Hospital,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:20:04Z,2021-10-17T08:20:04Z,200
NCT04414618,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-26,NA,NA,2021-03-08,2020-05-29,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-10,Actual,"July 2, 2020",Actual,2020-07-02,March 2021,2021-03-31,"December 23, 2020",Actual,2020-12-23,"November 26, 2020",Actual,2020-11-26,NA,Interventional,COVID-19,,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia",Completed,NA,Phase 2,42,Actual,RedHill Biopharma Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:18Z,2021-10-17T08:20:18Z,236
NCT04414124,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-01,NA,NA,2021-08-12,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"August 2, 2020",Actual,2020-08-02,August 2021,2021-08-31,"February 2, 2021",Actual,2021-02-02,"February 2, 2021",Actual,2021-02-02,NA,Interventional,NA,,A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,"A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19",Completed,NA,N/A,350,Actual,Kaleido Biosciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:20:23Z,2021-10-17T08:20:23Z,79
NCT04414267,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-01,NA,NA,2021-05-09,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"May 26, 2020",Actual,2020-05-26,May 2021,2021-05-31,"May 7, 2021",Actual,2021-05-07,"April 28, 2021",Actual,2021-04-28,NA,Interventional,ACTIVATEII,,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial,Completed,NA,Phase 4,301,Actual,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:22Z,2021-10-17T08:20:22Z,174
NCT04413968,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-02,NA,NA,2020-10-23,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"June 2, 2020",Actual,2020-06-02,May 2020,2020-05-31,"October 2, 2020",Actual,2020-10-02,"July 2, 2020",Actual,2020-07-02,NA,Interventional,COVIDOCRECHE,,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants","Contamination and Transmission of the SARS-CoV-2 Virus in Exposed, Confined and Community-based Infants: A Cross-sectional, Multicentre, Interventional Seroprevalence Study",Completed,NA,N/A,600,Actual,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:20:24Z,2021-10-17T08:20:24Z,372
NCT04412668,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-01,NA,NA,2021-01-28,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"June 12, 2020",Actual,2020-06-12,January 2021,2021-01-31,"December 21, 2020",Actual,2020-12-21,"December 21, 2020",Actual,2020-12-21,NA,Interventional,NA,,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,A Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19),Completed,NA,Phase 2,32,Actual,"aTyr Pharma, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:35Z,2021-10-17T08:20:35Z,275
NCT04412343,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-29,NA,NA,2020-11-02,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"May 23, 2020",Actual,2020-05-23,November 2020,2020-11-30,"October 5, 2020",Actual,2020-10-05,"October 5, 2020",Actual,2020-10-05,NA,Interventional,SCOPE,,The Seniors COvid-19 Pandemic and Exercise Study,The Seniors COvid-19 Pandemic and Exercise Study: A Randomized Controlled Trial,Completed,NA,N/A,241,Actual,University of British Columbia,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available from this trial 1 year after completion of the study. The data will remain available indefinitely.,"The nature of the request for sharing access will be reviewed by the PI (Beauchamp, M) and the data management team. Data will be shared via secure platforms (Redcap). Contact for data access can be done through personal communications (e.g., email) with PI Beauchamp.",https://osf.io/xw9gm,Yes,"The protocol for this study will be available on Open Science Framework (after 4 months to allow for study completion). The Statistical Analysis Plan will also be available on Open Science Framework. The Consent form is freely available if requested from the Primary Investigator (PI: Beauchamp, M.).",2021-10-17T08:20:38Z,2021-10-17T08:20:38Z,362
NCT04412330,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-12,NA,NA,2021-06-08,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-11,Actual,"May 1, 2020",Actual,2020-05-01,June 2021,2021-06-30,"May 5, 2021",Actual,2021-05-05,"May 5, 2021",Actual,2021-05-05,NA,Interventional,OPTIMAL,,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19 (OPTImAL) - a Single Center Prospective Study,Completed,NA,N/A,32,Actual,University of Kentucky,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:38Z,2021-10-17T08:20:38Z,144
NCT04412356,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-24,NA,NA,2021-09-20,2020-05-31,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-22,Actual,"June 6, 2020",Actual,2020-06-06,September 2021,2021-09-30,"September 20, 2021",Actual,2021-09-20,"June 1, 2021",Actual,2021-06-01,NA,Interventional,TTCOV19,,Timing of Tracheotomy in Covid-19 Patients,"Timing of Tracheotomy in Covid-19 Positive Patients: a Randomized, Controlled Trial",Completed,NA,N/A,150,Actual,"Sahlgrenska University Hospital, Sweden",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:20:38Z,2021-10-17T08:20:38Z,40
NCT04412057,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-29,NA,NA,2021-03-01,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-02,Actual,"June 9, 2020",Actual,2020-06-09,September 2020,2020-09-30,"January 19, 2021",Actual,2021-01-19,"December 2, 2020",Actual,2020-12-02,NA,Interventional,NA,,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CERC-002 in Adults With COVID 19 Pneumonia and Acute Lung Injury",Completed,NA,Phase 2,83,Actual,Cerecor Inc,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:40Z,2021-10-17T08:20:40Z,243
NCT04411680,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-29,NA,NA,2021-06-17,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"August 18, 2020",Actual,2020-08-18,June 2021,2021-06-30,"May 19, 2021",Actual,2021-05-19,"March 2, 2021",Actual,2021-03-02,NA,Interventional,iLeukPulm,,Study of Sargramostim in Patients With COVID-19,A Phase 2 Trial Evaluating Sargramostim in Patients With COVID-19 Associated Acute Hypoxemia,Completed,NA,Phase 2,122,Actual,"Partner Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:20:43Z,2021-10-17T08:20:43Z,135
NCT04411667,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-29,2021-06-10,NA,2021-06-23,2020-06-01,2020-06-02,Actual,2021-06-23,2021-06-25,Actual,NA,NA,NA,2021-06-23,2021-06-25,Actual,"April 28, 2020",Actual,2020-04-28,June 2021,2021-06-30,"June 23, 2020",Actual,2020-06-23,"June 23, 2020",Actual,2020-06-23,NA,Interventional,NA,,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection,Completed,NA,Phase 4,34,Actual,Sharp HealthCare,"Study limited to two hospitals in one US city. Resulted in a homogenous population of younger Hispanic/Latino patients.
Study was not blinded.
Methylprednisolone was used as a pre-medication for each dose of IVIG which may have confounded the results.
Small sample size.",2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:43Z,2021-10-17T08:20:43Z,129
NCT04411628,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-29,NA,NA,2020-10-29,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"May 28, 2020",Actual,2020-05-28,October 2020,2020-10-31,"August 26, 2020",Actual,2020-08-26,"August 26, 2020",Actual,2020-08-26,NA,Interventional,NA,,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,"A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19",Completed,NA,Phase 1,24,Actual,Eli Lilly and Company,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:44Z,2021-10-17T08:20:44Z,366
NCT04411446,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-26,NA,NA,2021-07-28,2020-05-31,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-30,Actual,"August 11, 2020",Actual,2020-08-11,March 2021,2021-03-31,"July 28, 2021",Actual,2021-07-28,"July 28, 2021",Actual,2021-07-28,NA,Interventional,CARED,,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients,Completed,NA,Phase 4,218,Actual,Vitamin D Study Group,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:46Z,2021-10-17T08:20:46Z,94
NCT04410692,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-27,NA,NA,2020-05-30,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"May 17, 2020",Actual,2020-05-17,"May 16, 2020",Actual,2020-05-16,NA,Interventional,NA,,Can the Prediction Market Improve Predictions of COVID-19?,Can the Prediction Market Improve Predictions of COVID-19?,Completed,NA,N/A,560,Actual,"National University, Singapore",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,After completion of all analysis. It will be made available in the supporting documentation.,It will be made available in the supporting documentation.,NA,Yes,"Investigators will not be storing or sharing any personal identifiers. All individual level data will be anonymized, and only anonymized data will be shared with other researchers, upon request.",2021-10-17T08:20:54Z,2021-10-17T08:20:54Z,518
NCT04410016,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-22,NA,NA,2021-08-26,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-30,Actual,"May 25, 2020",Actual,2020-05-25,August 2021,2021-08-31,"October 30, 2020",Actual,2020-10-30,"July 31, 2020",Actual,2020-07-31,NA,Interventional,COVID-WELL,,Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study,Evaluation of a Workplace Intervention to Implement Supported COVID-19 Wellbeing Centres in a Healthcare Workplace During and After the Coronavirus Pandemic: The COVID-WELL Study,Completed,NA,N/A,819,Actual,University of Nottingham,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Interview data will be available on request at study end (after publication of findings).,On request.,NA,Yes,Interview data will be made available on request (after study end).,2021-10-17T08:21:01Z,2021-10-17T08:21:01Z,65
NCT04410159,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-27,2020-07-08,NA,2020-07-17,2020-05-28,2020-06-01,Actual,2020-07-17,2020-07-21,Actual,NA,NA,NA,2020-07-17,2020-07-21,Actual,"June 22, 2020",Actual,2020-06-22,July 2020,2020-07-31,"July 6, 2020",Actual,2020-07-06,"June 29, 2020",Actual,2020-06-29,NA,Interventional,GARGLES,,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,"A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients",Completed,NA,Phase 2,20,Actual,Universiti Sains Islam Malaysia,Inadequate budget for laboratory test lead to small numbers of subjects analyzed,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,September to December 2020,email to drnurul@usim.edu.my,NA,Yes,The participant data from the final research dataset used in the published manuscript will be shared upon reasonable request. The protocol and data analysis will be shared in clinicaltrial,2021-10-17T08:21:00Z,2021-10-17T08:21:00Z,470
NCT04409509,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-28,NA,NA,2021-01-21,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"July 1, 2020",Actual,2020-07-01,January 2021,2021-01-31,"January 12, 2021",Actual,2021-01-12,"January 12, 2021",Actual,2021-01-12,NA,Interventional,NA,,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),"A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)",Completed,NA,Phase 2,124,Actual,CSL Behring,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.,"Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.
An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.
The requesting party must execute an appropriate data sharing agreement before IPD will be made available.",NA,Yes,"CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.
If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.",2021-10-17T08:21:06Z,2021-10-17T08:21:06Z,282
NCT04409496,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-26,NA,NA,2021-03-02,2020-05-26,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-04,Actual,"June 2, 2020",Actual,2020-06-02,March 2021,2021-03-31,"January 22, 2021",Actual,2021-01-22,"January 22, 2021",Actual,2021-01-22,NA,Interventional,NA,,Chat-based Support for Preventing Smoking Relapse,Chat-based Instant Messaging Support for Preventing Smoking Relapse in the Context of COVID-19 Outbreak: a Pilot Randomised Clinical Trial,Completed,NA,N/A,108,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:21:06Z,2021-10-17T08:21:06Z,242
NCT04409262,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-28,NA,NA,2021-03-09,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"June 16, 2020",Actual,2020-06-16,March 2021,2021-03-31,"March 8, 2021",Actual,2021-03-08,"February 1, 2021",Actual,2021-02-01,NA,Interventional,REMDACTA,,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,"A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 3,649,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-10-17T08:21:08Z,2021-10-17T08:21:08Z,235
NCT04408456,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-24,NA,NA,2020-08-01,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-08-01,2020-08-04,Actual,"March 1, 2020",Actual,2020-03-01,August 2020,2020-08-31,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,PEP-CQ,,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Open Level Control Clinical Trial,Completed,NA,Phase 3,325,Actual,Postgraduate Institute of Medical Education and Research,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Data will be shared with the concerned authority and Institutional Ethics committee as and when required.,2021-10-17T08:21:15Z,2021-10-17T08:21:15Z,455
NCT04407507,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-27,2021-05-10,NA,2021-05-19,2020-05-27,2020-05-29,Actual,2021-05-19,2021-05-21,Actual,NA,NA,NA,2021-05-19,2021-05-21,Actual,"July 1, 2020",Actual,2020-07-01,May 2021,2021-05-31,"January 29, 2021",Actual,2021-01-29,"January 29, 2021",Actual,2021-01-29,NA,Interventional,SILVERBULLET,,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms","Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms",Completed,NA,Phase 2,66,Actual,Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:21:23Z,2021-10-17T08:21:23Z,164
NCT04407182,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-25,NA,NA,2021-01-07,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"October 1, 2020",Actual,2020-10-01,"August 1, 2020",Actual,2020-08-01,NA,Interventional,NA,,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19,Completed,NA,Phase 2,60,Actual,Catalysis SL,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:21:26Z,2021-10-17T08:21:26Z,296
NCT04407130,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-17,NA,NA,2021-02-01,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-04,Actual,"June 16, 2020",Actual,2020-06-16,June 2020,2020-06-30,"November 20, 2020",Actual,2020-11-20,"October 30, 2020",Actual,2020-10-30,NA,Interventional,NA,,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,"Ivermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19: a Randomised, Double-blind, Placebo-controlled Trial.",Completed,NA,Phase 2,72,Actual,"International Centre for Diarrhoeal Disease Research, Bangladesh",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:21:27Z,2021-10-17T08:21:27Z,271
NCT04407286,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-19,NA,NA,2020-11-30,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-02,Actual,"May 19, 2020",Actual,2020-05-19,November 2020,2020-11-30,"November 30, 2020",Actual,2020-11-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,,Vitamin D Testing and Treatment for COVID 19,Vitamin D Testing and Treatment for Adults With COVID 19,Completed,NA,Phase 1,41,Actual,Arizona State University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Contact us if you wish to discuss sharing of de-identified data,2021-10-17T08:21:25Z,2021-10-17T08:21:25Z,334
NCT04407208,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-16,NA,NA,2020-06-27,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-27,2020-06-30,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"June 22, 2020",Actual,2020-06-22,"June 22, 2020",Actual,2020-06-22,NA,Interventional,NA,,Convalescent Plasma Therapy in Patients With COVID-19,Convalescent Plasma Therapy in Patients With COVID-19,Completed,NA,Phase 1,10,Actual,Biofarma,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:21:26Z,2021-10-17T08:21:26Z,490
NCT04406246,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-24,NA,NA,2021-03-29,2020-05-27,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-03-30,Actual,"May 21, 2020",Actual,2020-05-21,March 2021,2021-03-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide,Completed,NA,Phase 4,150,Actual,Materno-Perinatal Hospital of the State of Mexico,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,The Data will be available upon request after a publication is reached.,2021-10-17T08:21:34Z,2021-10-17T08:21:34Z,215
NCT04405999,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-18,NA,NA,2020-09-02,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-03,Actual,"May 14, 2020",Actual,2020-05-14,September 2020,2020-09-30,"August 31, 2020",Actual,2020-08-31,"August 9, 2020",Actual,2020-08-09,NA,Interventional,NA,,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial,Completed,NA,Phase 4,50,Actual,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:21:37Z,2021-10-17T08:21:37Z,423
NCT04405986,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-08,NA,NA,2021-04-07,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-08,Actual,"May 19, 2020",Actual,2020-05-19,April 2021,2021-04-30,"March 10, 2021",Actual,2021-03-10,"March 10, 2021",Actual,2021-03-10,NA,Interventional,BRAINCOV,,Exploring Brain Damages After COVID-19 Infection,Exploring Brain Damages After COVID-19 Infection,Completed,NA,N/A,38,Actual,"University Hospital, Bordeaux",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:21:37Z,2021-10-17T08:21:37Z,206
NCT04405843,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-23,NA,NA,2020-12-24,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-24,2020-12-28,Actual,"July 14, 2020",Actual,2020-07-14,December 2020,2020-12-31,"December 21, 2020",Actual,2020-12-21,"December 21, 2020",Actual,2020-12-21,NA,Interventional,EPIC,,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),"Randomized, Placebo Controlled, Double Blind Clinical Trial to Evaluate the Efficacy of Molecule D11AX22 in Adults Patients From Valle Del Cauca, Colombia With Early Stages of SARS COV2 / COVID-19",Completed,NA,Phase 2/Phase 3,476,Actual,Centro de Estudios en InfectogÃ­a Pediatrica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:21:38Z,2021-10-17T08:21:38Z,310
NCT04405310,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-26,NA,NA,2020-12-16,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-16,2020-12-21,Actual,"May 20, 2020",Actual,2020-05-20,December 2020,2020-12-31,"December 10, 2020",Actual,2020-12-10,"November 20, 2020",Actual,2020-11-20,NA,Interventional,CPC-SARS,,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,"Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial",Completed,NA,Phase 2,42,Actual,Grupo Mexicano para el Estudio de la Medicina Intensiva,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,3 months after completion up to five years,"proposal should be directed to gmemiinv@gmails.com, to gain access, requestor will need to sign a data access agreement",NA,Yes,IPD will be shared by petition.,2021-10-17T08:21:42Z,2021-10-17T08:21:42Z,318
NCT04405570,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-26,NA,NA,2021-02-22,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-23,Actual,"June 16, 2020",Actual,2020-06-16,February 2021,2021-02-28,"February 21, 2021",Actual,2021-02-21,"February 21, 2021",Actual,2021-02-21,NA,Interventional,NA,,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19","A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19",Completed,NA,Phase 2,204,Actual,"Ridgeback Biotherapeutics, LP",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:21:40Z,2021-10-17T08:21:40Z,250
NCT04405544,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-26,NA,NA,2020-10-29,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"May 22, 2020",Actual,2020-05-22,October 2020,2020-10-31,"October 29, 2020",Actual,2020-10-29,"July 22, 2020",Actual,2020-07-22,NA,Interventional,NA,,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Completed,NA,N/A,51,Actual,"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:21:40Z,2021-10-17T08:21:40Z,366
NCT04404426,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-22,NA,NA,2021-05-28,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-28,2021-06-02,Actual,"November 4, 2020",Actual,2020-11-04,May 2021,2021-05-31,"May 28, 2021",Actual,2021-05-28,"March 25, 2021",Actual,2021-03-25,NA,Interventional,CACOLAC,,CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,CACOLAC : Randomized Trial of Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,Completed,NA,N/A,33,Actual,Rennes University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:21:52Z,2021-10-17T08:21:52Z,155
NCT04403555,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-23,NA,NA,2021-07-29,2020-05-23,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-02,Actual,"June 1, 2020",Actual,2020-06-01,July 2021,2021-07-31,"December 1, 2020",Actual,2020-12-01,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,,Ivermectin as a Novel Therapy in COVID-19 Treatment,The Efficacy of Ivermectin in COVID-19 Treatment,Completed,NA,Phase 2/Phase 3,164,Actual,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:01Z,2021-10-17T08:22:01Z,93
NCT04402970,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-20,2021-03-12,NA,2021-04-12,2020-05-22,2020-05-27,Actual,2021-04-12,2021-04-14,Actual,NA,NA,NA,2021-04-12,2021-04-14,Actual,"June 19, 2020",Actual,2020-06-19,April 2021,2021-04-30,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,DORNASESARS2,,Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2,Completed,NA,Phase 3,30,Actual,University of Missouri-Columbia,Study was performed in non-randomized trial as there were initial concerns for low recruitment and difficulty with randomization. Study was also not powered for most secondary outcome analyses as it was designed in a pilot/feasibility status to determine drug effects.,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:06Z,2021-10-17T08:22:06Z,201
NCT04402983,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-22,NA,NA,2020-12-11,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"May 27, 2020",Actual,2020-05-27,May 2020,2020-05-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,Completed,NA,N/A,34,Actual,Istanbul Medipol University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:22:06Z,2021-10-17T08:22:06Z,323
NCT04402918,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-18,NA,NA,2021-08-02,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"May 17, 2020",Actual,2020-05-17,July 2021,2021-07-31,"August 2, 2021",Actual,2021-08-02,"May 19, 2020",Actual,2020-05-19,NA,Interventional,TRANSCOVID,,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 During Pregnancy,Completed,NA,N/A,160,Actual,Centre Hospitalier Universitaire de Besancon,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:07Z,2021-10-17T08:22:07Z,89
NCT04402866,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-22,NA,NA,2021-05-17,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-19,Actual,"June 24, 2020",Actual,2020-06-24,May 2021,2021-05-31,"April 21, 2021",Actual,2021-04-21,"April 21, 2021",Actual,2021-04-21,NA,Interventional,NA,,TD-0903 for ALI Associated With COVID-19,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated With COVID-19",Completed,NA,Phase 2,235,Actual,Theravance Biopharma,,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2021-10-17T08:22:07Z,2021-10-17T08:22:07Z,166
NCT04401579,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-22,2021-02-25,NA,2021-04-22,2020-05-22,2020-05-26,Actual,2021-04-22,2021-04-26,Actual,NA,NA,NA,2021-04-22,2021-04-26,Actual,"May 8, 2020",Actual,2020-05-08,April 2020,2020-04-30,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)",Completed,NA,Phase 3,1033,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:22:19Z,2021-10-17T08:22:19Z,191
NCT04402060,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-22,NA,NA,2021-08-30,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"May 28, 2020",Actual,2020-05-28,August 2021,2021-08-31,"February 19, 2021",Actual,2021-02-19,"February 19, 2021",Actual,2021-02-19,NA,Interventional,NA,,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,"A Randomized, Double-Blinded, Vehicle-Controlled, Multicenter, Parallel-Group Study of APL-9 in Mild to Moderate Acute Respiratory Distress Syndrome Due to COVID-19",Completed,NA,Phase 1/Phase 2,65,Actual,"Apellis Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:22:15Z,2021-10-17T08:22:15Z,61
NCT04401423,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-21,NA,NA,2021-07-27,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-29,Actual,"February 10, 2021",Actual,2021-02-10,July 2021,2021-07-31,"June 10, 2021",Actual,2021-06-10,"June 10, 2021",Actual,2021-06-10,NA,Interventional,NA,,TXA127 for the Treatment of Severe COVID-19,Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19,Completed,NA,Phase 2,22,Actual,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:22:22Z,2021-10-17T08:22:22Z,95
NCT04401202,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-21,2021-05-23,NA,2021-05-25,2020-05-22,2020-05-26,Actual,2021-05-25,2021-05-26,Actual,NA,NA,NA,2021-05-25,2021-05-26,Actual,"May 21, 2020",Actual,2020-05-21,May 2021,2021-05-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,,Nigella Sativa in COVID-19,"Effects of Nigella Sativa as a Treatment of Patients With Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study",Completed,NA,Phase 2,183,Actual,King Abdulaziz University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:22:24Z,2021-10-17T08:22:24Z,158
NCT04401046,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-22,NA,NA,2021-07-21,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"May 20, 2020",Actual,2020-05-20,July 2021,2021-07-31,"February 2, 2021",Actual,2021-02-02,"November 26, 2020",Actual,2020-11-26,NA,Interventional,COVID-TRAUMA,,COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,COVID-19 EPIDEMIC Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,Completed,NA,N/A,1096,Actual,Institut Paoli-Calmettes,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:22:26Z,2021-10-17T08:22:26Z,101
NCT04401293,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-20,NA,NA,2021-08-03,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-05,Actual,"April 26, 2020",Actual,2020-04-26,August 2021,2021-08-31,"May 14, 2021",Actual,2021-05-14,"May 14, 2021",Actual,2021-05-14,NA,Interventional,NA,,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial),Completed,NA,Phase 3,257,Actual,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:23Z,2021-10-17T08:22:23Z,88
NCT04400279,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-21,NA,NA,2021-01-08,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"June 1, 2020",Actual,2020-06-01,January 2021,2021-01-31,"November 28, 2020",Actual,2020-11-28,"November 28, 2020",Actual,2020-11-28,NA,Interventional,COPE,,The COVID-19 Pandemic and Exercise Study,COvid-19 Pandemic and Exercise (COPE) Trial: A Randomized Study Examining Physical Activities and Wellbeing in Individuals Mandated to Stay at Home,Completed,NA,N/A,334,Actual,University of British Columbia,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"4 months following trial's end, materials will be made available. following publication, all data will be made available.",Investigators whose proposed use of the data has been approved by an independent review committee identified for the purpose for the purpose of meta-analyses and to achieve aims in the approved proposal. Investigators of the study need to approve the proposals. Proposals should be directed to eli.puterman@Ubc.ca,https://osf.io/g9xqp,Yes,"All of the individual participant data collected during the trial, after de-identification upon request and cleared for approval by principal investigator.
All of the protocols, statistical analysis plan, informed consent form, analytic code.",2021-10-17T08:22:33Z,2021-10-17T08:22:33Z,295
NCT04400032,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-27,NA,NA,2021-04-23,2020-05-20,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-26,Actual,"May 15, 2020",Actual,2020-05-15,April 2021,2021-04-30,"April 22, 2021",Actual,2021-04-22,"April 22, 2021",Actual,2021-04-22,NA,Interventional,CIRCA-19,,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome,Cellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19),Completed,NA,Phase 1/Phase 2,15,Actual,Ottawa Hospital Research Institute,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:35Z,2021-10-17T08:22:35Z,190
NCT04399980,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-21,2021-05-06,NA,2021-05-11,2020-05-21,2020-05-22,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"May 20, 2020",Actual,2020-05-20,May 2021,2021-05-31,"April 23, 2021",Actual,2021-04-23,"April 23, 2021",Actual,2021-04-23,NA,Interventional,NA,,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,NA,Phase 2,40,Actual,The Cleveland Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:35Z,2021-10-17T08:22:35Z,172
NCT04399252,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-19,NA,NA,2021-07-12,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-14,Actual,"June 24, 2020",Actual,2020-06-24,July 2021,2021-07-31,"July 8, 2021",Actual,2021-07-08,"July 8, 2021",Actual,2021-07-08,NA,Interventional,NA,,Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,A Randomized Trial of the Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,Completed,NA,N/A,182,Actual,Duke University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:42Z,2021-10-17T08:22:42Z,110
NCT04399005,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-19,NA,NA,2020-06-23,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"June 10, 2020",Actual,2020-06-10,"June 5, 2020",Actual,2020-06-05,NA,Interventional,NA,,The Efficacy Comparing Daily and After-each-case Room Disinfection.,The Efficacy Comparing Daily and After-each-case Room Disinfection in the Endoscopy Unit During the COVID-19 Pandemic.,Completed,NA,N/A,240,Actual,The First Affiliated Hospital of Zhejiang Chinese Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,individual participant data sharing will be consider after study,2021-10-17T08:22:44Z,2021-10-17T08:22:44Z,494
NCT04398004,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-17,NA,NA,2021-01-08,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"May 6, 2020",Actual,2020-05-06,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,ACHIEVE,,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early: The ACHIEVE Open-label Non-randomized Clinical Trial,Completed,NA,Phase 2,90,Actual,Hellenic Institute for the Study of Sepsis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:55Z,2021-10-17T08:22:55Z,295
NCT04397757,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-19,NA,NA,2021-06-09,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-10,Actual,"May 13, 2020",Actual,2020-05-13,June 2021,2021-06-30,"March 8, 2021",Actual,2021-03-08,"February 6, 2021",Actual,2021-02-06,NA,Interventional,NA,,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,"An Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2.",Completed,NA,Phase 1,80,Actual,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:22:57Z,2021-10-17T08:22:57Z,143
NCT04397718,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-14,NA,NA,2021-06-30,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-30,2021-07-02,Actual,"July 6, 2020",Actual,2020-07-06,June 2021,2021-06-30,"June 8, 2021",Actual,2021-06-08,"June 8, 2021",Actual,2021-06-08,NA,Interventional,HITCH,,Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization,"Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH): A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus Degarelix",Completed,NA,Phase 2,96,Actual,VA Office of Research and Development,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:57Z,2021-10-17T08:22:57Z,122
NCT04397523,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-20,NA,NA,2021-05-10,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-11,Actual,"April 30, 2020",Actual,2020-04-30,February 2021,2021-02-28,"May 10, 2021",Actual,2021-05-10,"May 10, 2021",Actual,2021-05-10,NA,Interventional,NA,,Efficacy and Safety of COVID-19 Convalescent Plasma,Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety,Completed,NA,N/A,200,Actual,Institute for Transfusion Medicine of RNM,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:22:59Z,2021-10-17T08:22:59Z,173
NCT04397562,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-19,NA,NA,2020-11-17,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-17,2020-11-18,Actual,"April 29, 2020",Actual,2020-04-29,November 2020,2020-11-30,"August 3, 2020",Actual,2020-08-03,"July 3, 2020",Actual,2020-07-03,NA,Interventional,CORONA,,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19",Completed,NA,Phase 3,206,Actual,Biocad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:22:58Z,2021-10-17T08:22:58Z,347
NCT04395911,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-17,NA,NA,2021-08-04,2020-05-18,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"September 10, 2020",Actual,2020-09-10,August 2021,2021-08-31,"July 21, 2021",Actual,2021-07-21,"July 5, 2021",Actual,2021-07-05,NA,Interventional,NA,,Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,A Multi-Center Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Patients Developing Acute Kidney Injury (AKI) or Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 Infection,Completed,NA,N/A,22,Actual,SeaStar Medical,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,,Data will be collected throughout the study conduct.,Participant data will be accessible to the Investigational Site and CRO through a secured electronic data capture system. CRO personnel will be responsible for data verification. De-identified Participant information will be accessible to the CRO and the Sponsor.,NA,Yes,Unidentified participant data collected for this study will be submitted to a CRO for data analysis. All data will be submitted to the Sponsor.,2021-10-17T08:23:15Z,2021-10-17T08:23:15Z,87
NCT04395144,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-15,NA,NA,2021-03-21,2020-05-18,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-03-21,2021-03-23,Actual,"May 15, 2020",Actual,2020-05-15,March 2021,2021-03-31,"March 15, 2021",Actual,2021-03-15,"March 15, 2021",Actual,2021-03-15,NA,Interventional,COVAYDE,,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Randomized-controlled Trial of HFNC Alone vs HFNC and Awake Self-proning for Treatment of Severe COVID-19,Completed,NA,N/A,13,Actual,HÃ´pital de Verdun,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:21Z,2021-10-17T08:23:21Z,223
NCT04394377,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-08,NA,NA,2021-06-08,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-10,Actual,"June 21, 2020",Actual,2020-06-21,May 2020,2020-05-31,"May 30, 2021",Actual,2021-05-30,"March 26, 2021",Actual,2021-03-26,NA,Interventional,ACTION,,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial,Completed,NA,Phase 4,615,Actual,Brazilian Clinical Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,All data provided during study is anonymized to respect the privacy of patients who have participated in the trial in line with applicable regulations.,2021-10-17T08:23:28Z,2021-10-17T08:23:28Z,144
NCT04394039,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-13,NA,NA,2021-07-09,2020-05-13,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-15,Actual,"June 1, 2020",Actual,2020-06-01,July 2021,2021-07-31,"December 31, 2020",Actual,2020-12-31,"August 1, 2020",Actual,2020-08-01,NA,Interventional,NA,,Post-Pandemic Perception of Public Space in Singapore,Effects of COVID-19-Related Self-isolation on Psychological Response to Different Outdoor Environments in Singapore - Before & After Brain and Behavior Study,Completed,NA,N/A,34,Actual,"National University, Singapore",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:31Z,2021-10-17T08:23:31Z,113
NCT04394013,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-18,NA,NA,2021-02-22,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-24,Actual,"August 26, 2020",Actual,2020-08-26,February 2021,2021-02-28,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,Completed,NA,N/A,70,Actual,Monash University Malaysia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Upon request via direct contact to researcher,2021-10-17T08:23:31Z,2021-10-17T08:23:31Z,250
NCT04393818,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-18,NA,NA,2020-09-09,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-10,Actual,"May 5, 2020",Actual,2020-05-05,August 2020,2020-08-31,"August 24, 2020",Actual,2020-08-24,"August 24, 2020",Actual,2020-08-24,NA,Interventional,PsyCovid_App,,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,A Double-blinded Randomized Controlled Trial to Examine the Effectiveness of a Mobile-based Intervention to Reduce Mental Health Problems in Healthcare Workers at the Frontline Against COVID-19 in Spain: the PsyCovidApp Trial,Completed,NA,Phase 3,560,Actual,FundaciÃ³ d'investigaciÃ³ SanitÃ ria de les Illes Balears,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:23:32Z,2021-10-17T08:23:32Z,416
NCT04392778,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-25,NA,NA,2021-05-22,2020-05-17,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-22,2021-05-25,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"November 30, 2020",Actual,2020-11-30,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,,Clinical Use of Stem Cells for the Treatment of Covid-19,What is the Effect of Mesenchymal Stem Cell Therapy on Seriously Ill Patients With Covid 19 in Intensive Care? (Prospective Double Controlled Study),Completed,NA,Phase 1/Phase 2,30,Actual,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:42Z,2021-10-17T08:23:42Z,161
NCT04393077,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-11,NA,NA,2020-11-20,2020-05-15,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-11-20,2020-11-24,Actual,"May 10, 2020",Actual,2020-05-10,November 2020,2020-11-30,"May 20, 2020",Actual,2020-05-20,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,,Emotional Freedom Technique (EFT) Effect on Nurses,"Emotional Freedom Technique (EFT) Effect on Nurses' Stress, Anxiety and Burnout Levels During the COVID-19 Pandemic Process: A Randomized Controlled Study",Completed,NA,N/A,80,Actual,Istanbul Saglik Bilimleri University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:39Z,2021-10-17T08:23:39Z,344
NCT04392973,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-10,NA,NA,2021-08-19,2020-05-13,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"May 21, 2020",Actual,2020-05-21,August 2021,2021-08-31,"April 26, 2021",Actual,2021-04-26,"January 26, 2021",Actual,2021-01-26,NA,Interventional,FACCT,,FAvipiravir and HydroxyChloroquine Combination Therapy,A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19,Completed,NA,N/A,268,Actual,King Abdullah International Medical Research Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:40Z,2021-10-17T08:23:40Z,72
NCT04392531,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-03,NA,NA,2021-08-26,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-27,Actual,"April 16, 2020",Actual,2020-04-16,August 2021,2021-08-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,,Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,"Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection",Completed,NA,Phase 4,111,Actual,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:23:44Z,2021-10-17T08:23:44Z,65
NCT04392414,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-13,NA,NA,2020-09-23,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"September 23, 2020",Actual,2020-09-23,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,"Randomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease",Completed,NA,Phase 2,60,Actual,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is no current plan to share individual participant data (IPD).,2021-10-17T08:23:45Z,2021-10-17T08:23:45Z,402
NCT04392219,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-29,2021-06-15,NA,2021-07-15,2020-05-15,2020-05-18,Actual,2021-07-15,2021-07-19,Actual,NA,NA,NA,2021-07-15,2021-07-19,Actual,"April 10, 2020",Actual,2020-04-10,July 2021,2021-07-31,"August 11, 2020",Actual,2020-08-11,"August 11, 2020",Actual,2020-08-11,NA,Interventional,NA,Safety population,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers","A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers",Completed,NA,Phase 1,130,Actual,"Ridgeback Biotherapeutics, LP",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:47Z,2021-10-17T08:23:47Z,107
NCT04392141,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-15,2020-11-25,NA,2021-04-16,2020-05-15,2020-05-18,Actual,2021-04-16,2021-04-20,Actual,NA,NA,NA,2021-04-16,2021-04-20,Actual,"April 1, 2020",Actual,2020-04-01,April 2021,2021-04-30,"November 1, 2020",Actual,2020-11-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Application of Colchicine Plus Herbal Phenolic Monoterpene Fractions to Treat COVID-19,Completed,NA,Phase 1/Phase 2,120,Actual,Kermanshah University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:51Z,2021-10-17T08:23:51Z,197
NCT04391712,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-04,NA,NA,2020-08-03,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-05,Actual,"April 30, 2020",Actual,2020-04-30,August 2020,2020-08-31,"July 16, 2020",Actual,2020-07-16,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Multiwave Locked System (MLS) Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Completed,NA,Phase 2,10,Actual,Lowell General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:23:54Z,2021-10-17T08:23:54Z,453
NCT04391179,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-15,NA,NA,2021-03-16,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-18,Actual,"May 31, 2020",Actual,2020-05-31,March 2021,2021-03-31,"February 22, 2021",Actual,2021-02-22,"February 22, 2021",Actual,2021-02-22,NA,Interventional,DICER,,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Completed,NA,Phase 2,100,Actual,University of Michigan,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:59Z,2021-10-17T08:23:59Z,228
NCT04391127,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-12,NA,NA,2020-11-06,2020-05-14,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"May 4, 2020",Actual,2020-05-04,November 2020,2020-11-30,"November 6, 2020",Actual,2020-11-06,"November 6, 2020",Actual,2020-11-06,NA,Interventional,NA,,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial,Completed,NA,Phase 3,108,Actual,Centenario Hospital Miguel Hidalgo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:59Z,2021-10-17T08:23:59Z,358
NCT04390516,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-14,NA,NA,2020-06-10,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"March 24, 2020",Actual,2020-03-24,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"May 4, 2020",Actual,2020-05-04,NA,Interventional,READY,,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Prediction Of Respiratory Decompensation In Covid-19 Patients Using Machine Learning: The READY Trial,Completed,NA,N/A,197,Actual,Dascena,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:04Z,2021-10-17T08:24:04Z,507
NCT04389710,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-27,NA,NA,2021-06-03,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-04,Actual,"April 15, 2020",Actual,2020-04-15,June 2021,2021-06-30,"December 7, 2020",Actual,2020-12-07,"November 3, 2020",Actual,2020-11-03,NA,Interventional,NA,,Convalescent Plasma for the Treatment of COVID-19,Convalescent Plasma for the Treatment of Patients With COVID-19,Completed,NA,Phase 2,52,Actual,Thomas Jefferson University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:11Z,2021-10-17T08:24:11Z,149
NCT04390022,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,2020-12-09,NA,2020-12-10,2020-05-14,2020-05-15,Actual,2020-12-10,2020-12-17,Actual,NA,NA,NA,2020-12-10,2020-12-17,Actual,"July 31, 2020",Actual,2020-07-31,December 2020,2020-12-31,"October 9, 2020",Actual,2020-10-09,"September 17, 2020",Actual,2020-09-17,NA,Interventional,SAINT,,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission,Completed,NA,Phase 2,24,Actual,"Clinica Universidad de Navarra, Universidad de Navarra",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:09Z,2021-10-17T08:24:09Z,324
NCT04389944,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-12,NA,NA,2020-08-03,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-04,Actual,"March 31, 2020",Actual,2020-03-31,August 2020,2020-08-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe Coronavirus Disease 2019 Infectious Disease (COVID-19),Completed,NA,N/A,15,Actual,"University Hospital, Basel, Switzerland",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:10Z,2021-10-17T08:24:10Z,453
NCT04389333,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-09,NA,NA,2020-07-19,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-07-19,2020-07-21,Actual,"March 26, 2020",Actual,2020-03-26,July 2020,2020-07-31,"May 20, 2020",Actual,2020-05-20,"April 26, 2020",Actual,2020-04-26,NA,Interventional,NA,,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,"Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic: a Prospective, Open-label, Pilot, Randomized Trial",Completed,NA,N/A,40,Actual,Changhai Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:24:15Z,2021-10-17T08:24:15Z,468
NCT04389294,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-08,NA,NA,2021-02-10,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"May 5, 2020",Actual,2020-05-05,February 2021,2021-02-28,"September 4, 2020",Actual,2020-09-04,"June 16, 2020",Actual,2020-06-16,NA,Interventional,NA,,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,Hospital for Special Surgery COVID-19 Antibody Serology Among Anesthesiologists and Surgeons 2020,Completed,NA,N/A,143,Actual,"Hospital for Special Surgery, New York",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:15Z,2021-10-17T08:24:15Z,262
NCT04388527,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-04,NA,NA,2021-06-09,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-10,Actual,"April 30, 2020",Actual,2020-04-30,June 2021,2021-06-30,"January 30, 2021",Actual,2021-01-30,"January 25, 2021",Actual,2021-01-25,NA,Interventional,NA,,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,"An Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2",Completed,NA,Phase 1,32,Actual,University of Pennsylvania,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:21Z,2021-10-17T08:24:21Z,143
NCT04387292,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-12,NA,NA,2021-08-02,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"September 7, 2020",Actual,2020-09-07,August 2021,2021-08-31,"May 15, 2021",Actual,2021-05-15,"January 21, 2021",Actual,2021-01-21,NA,Interventional,SOCOVID,,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Completed,NA,N/A,34,Actual,Fondation Ophtalmologique Adolphe de Rothschild,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:34Z,2021-10-17T08:24:34Z,89
NCT04386694,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-08,NA,NA,2020-10-28,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"May 18, 2020",Actual,2020-05-18,October 2020,2020-10-31,"September 17, 2020",Actual,2020-09-17,"September 17, 2020",Actual,2020-09-17,NA,Interventional,NA,,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,Is Photobiomodulation Therapy (PBMT) Combined With Static Magnetic Field (sMF) Able to Decrease the Intensive Care Unit (ICU) Length of Stay for Patients With COVID-19?,Completed,NA,N/A,30,Actual,University of Nove de Julho,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:38Z,2021-10-17T08:24:38Z,367
NCT04386616,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-11,NA,NA,2021-08-16,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-18,Actual,"June 2, 2020",Actual,2020-06-02,August 2021,2021-08-31,"February 12, 2021",Actual,2021-02-12,"January 8, 2021",Actual,2021-01-08,NA,Interventional,COVASTIL,,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 2,410,Actual,"Genentech, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-10-17T08:24:39Z,2021-10-17T08:24:39Z,75
NCT04385810,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-29,NA,NA,2020-11-13,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-13,2020-11-16,Actual,"April 27, 2020",Actual,2020-04-27,November 2020,2020-11-30,"July 29, 2020",Actual,2020-07-29,"July 29, 2020",Actual,2020-07-29,NA,Interventional,DOCOV,,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Completed,NA,N/A,23,Actual,Fondation Ophtalmologique Adolphe de Rothschild,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:46Z,2021-10-17T08:24:46Z,351
NCT04385901,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-06,NA,NA,2021-02-04,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-04,2021-02-08,Actual,"May 19, 2020",Actual,2020-05-19,February 2021,2021-02-28,"September 19, 2020",Actual,2020-09-19,"September 19, 2020",Actual,2020-09-19,NA,Interventional,NA,,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Completed,NA,N/A,26,Actual,University of Missouri-Columbia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:24:45Z,2021-10-17T08:24:45Z,268
NCT04385199,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-09,NA,NA,2021-05-26,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"May 4, 2020",Actual,2020-05-04,May 2021,2021-05-31,"August 1, 2020",Actual,2020-08-01,"August 1, 2020",Actual,2020-08-01,NA,Interventional,NA,,Convalescent Plasma for Patients With COVID-19,The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease,Completed,NA,Phase 2,30,Actual,Henry Ford Health System,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:24:52Z,2021-10-17T08:24:52Z,157
NCT04384380,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2020-07-31,2020-05-10,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"April 1, 2020",Actual,2020-04-01,March 2020,2020-03-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,"A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",Completed,NA,N/A,33,Actual,Taoyuan General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The study outcome will be shared with the experts and persons interested in this field.,2021-10-17T08:25:00Z,2021-10-17T08:25:00Z,456
NCT04383535,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-06,NA,NA,2020-09-29,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"May 15, 2020",Actual,2020-05-15,September 2020,2020-09-30,"September 27, 2020",Actual,2020-09-27,"September 27, 2020",Actual,2020-09-27,NA,Interventional,PLASM-AR,,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,"Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria",Completed,NA,N/A,333,Actual,Hospital Italiano de Buenos Aires,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:09Z,2021-10-17T08:25:09Z,396
NCT04382755,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-07-01,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-02,Actual,"May 22, 2020",Actual,2020-05-22,July 2021,2021-07-31,"April 9, 2021",Actual,2021-04-09,"December 29, 2020",Actual,2020-12-29,NA,Interventional,ZILU-COV,,ZilucoplanÂ® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With ZilucoplanÂ® in Improving Oxygenation and short-and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure",Completed,NA,Phase 2,81,Actual,"University Hospital, Ghent",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:16Z,2021-10-17T08:25:16Z,121
NCT04382924,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-08,NA,NA,2021-07-19,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-21,Actual,"August 5, 2020",Actual,2020-08-05,July 2021,2021-07-31,"January 26, 2021",Actual,2021-01-26,"December 24, 2020",Actual,2020-12-24,NA,Interventional,NA,,Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,Completed,NA,Phase 2/Phase 3,168,Actual,Algernon Pharmaceuticals,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:25:14Z,2021-10-17T08:25:14Z,103
NCT04382651,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-08,NA,2021-07-07,2021-07-07,2020-05-08,2020-05-11,Actual,NA,NA,NA,2021-07-07,2021-07-08,Actual,2021-07-07,2021-07-08,Actual,"June 11, 2020",Actual,2020-06-11,July 2021,2021-07-31,"April 21, 2021",Actual,2021-04-21,"January 6, 2021",Actual,2021-01-06,NA,Interventional,MAS-COVID,,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,"A Phase 2, Randomized, Placebo-controlled, Participant and Investigator Blinded, Multi-center Study to Assess Efficacy and Safety of MAS825 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function",Completed,NA,Phase 2,140,Actual,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-10-17T08:25:17Z,2021-10-17T08:25:17Z,115
NCT04382586,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-06-15,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-15,2021-06-16,Actual,"July 6, 2020",Actual,2020-07-06,June 2021,2021-06-30,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,"A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress",Completed,NA,Phase 2,67,Actual,BeiGene,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:25:17Z,2021-10-17T08:25:17Z,137
NCT04382560,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-05,NA,NA,2021-03-30,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-01,Actual,"May 2, 2020",Actual,2020-05-02,March 2021,2021-03-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,Resting Heart Rate Variability as a Predictor of Coping Strategies and Responsiveness to a Brief Online Intervention During Forced Quarantine,Completed,NA,N/A,69,Actual,University of Parma,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:18Z,2021-10-17T08:25:18Z,214
NCT04382547,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-08,NA,NA,2021-08-20,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"May 11, 2020",Actual,2020-05-11,August 2021,2021-08-31,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Completed,NA,Phase 1/Phase 2,32,Actual,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:18Z,2021-10-17T08:25:18Z,71
NCT04382092,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-06,NA,NA,2020-05-08,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"March 23, 2020",Actual,2020-03-23,May 2020,2020-05-31,"April 24, 2020",Actual,2020-04-24,"April 24, 2020",Actual,2020-04-24,NA,Interventional,NA,,Co-infection Management in COVID-19 Critically Ill,Co-infections in COVID-19 Critically Ill and Antibiotic Management,Completed,NA,N/A,32,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:22Z,2021-10-17T08:25:22Z,540
NCT04382066,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,2021-08-02,NA,2021-09-22,2020-05-08,2020-05-11,Actual,2021-09-22,2021-09-24,Actual,NA,NA,NA,2021-09-22,2021-09-24,Actual,"May 12, 2020",Actual,2020-05-12,September 2021,2021-09-30,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,NA,Interventional,APLICOV-PC,,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,"Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization",Completed,NA,Phase 1,46,Actual,PharmaMar,Small number of patients. No control group.,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,Data of the final publication of the study will be shared upon request.,2021-10-17T08:25:22Z,2021-10-17T08:25:22Z,38
NCT04382053,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-08,NA,NA,2021-05-03,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-04,Actual,"May 27, 2020",Actual,2020-05-27,May 2021,2021-05-31,"December 24, 2020",Actual,2020-12-24,"December 10, 2020",Actual,2020-12-10,NA,Interventional,NA,,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,"Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia and Impaired Respiratory Function",Completed,NA,Phase 2,143,Actual,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-10-17T08:25:24Z,2021-10-17T08:25:24Z,180
NCT04382040,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-08-25,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-31,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"December 21, 2020",Actual,2020-12-21,"November 5, 2020",Actual,2020-11-05,NA,Interventional,NA,,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19","A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",Completed,NA,Phase 2,50,Actual,MGC Pharmaceuticals d.o.o,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:24Z,2021-10-17T08:25:24Z,66
NCT04381962,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-05-04,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-04,2021-05-06,Actual,"June 3, 2020",Actual,2020-06-03,May 2020,2020-05-31,"April 20, 2021",Actual,2021-04-20,"January 29, 2021",Actual,2021-01-29,NA,Interventional,ATOMIC2,,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),A Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2),Completed,NA,Phase 3,298,Actual,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:25:24Z,2021-10-17T08:25:24Z,179
NCT04381884,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-05,NA,NA,2020-10-01,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"May 18, 2020",Actual,2020-05-18,October 2020,2020-10-31,"September 29, 2020",Actual,2020-09-29,"September 29, 2020",Actual,2020-09-29,NA,Interventional,NA,,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,"A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19",Completed,NA,Phase 2,45,Actual,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:25:25Z,2021-10-17T08:25:25Z,394
NCT04381858,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-06,NA,NA,2020-11-26,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,NA,Interventional,NA,,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial,Completed,NA,Phase 3,196,Actual,Centenario Hospital Miguel Hidalgo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:25Z,2021-10-17T08:25:25Z,338
